<SEC-DOCUMENT>0001126234-19-000142.txt : 20191106
<SEC-HEADER>0001126234-19-000142.hdr.sgml : 20191106
<ACCEPTANCE-DATETIME>20191106162312
ACCESSION NUMBER:		0001126234-19-000142
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191106
DATE AS OF CHANGE:		20191106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEWLINK GENETICS CORP
		CENTRAL INDEX KEY:			0001126234
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				421491350
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35342
		FILM NUMBER:		191196639

	BUSINESS ADDRESS:	
		STREET 1:		2503 SOUTH LOOP DRIVE
		STREET 2:		SUITE 5100
		CITY:			AMES
		STATE:			IA
		ZIP:			50010
		BUSINESS PHONE:		515-296-5555

	MAIL ADDRESS:	
		STREET 1:		2503 SOUTH LOOP DRIVE
		STREET 2:		SUITE 5100
		CITY:			AMES
		STATE:			IA
		ZIP:			50010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nlnk-20190930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2019 Workiva--><!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08,d:da7719d876044622bc66aeb4ea910318--><html xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nlnk="http://www.linkp.com/20190930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl80LTEtMS0xLTA_ae96c667-4000-4373-a343-b0d149184c53">0001126234</ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl85LTEtMS0xLTA_84d1eb4c-888e-432e-8671-e24b2e9e49f6">2019</ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl8xMC0xLTEtMS0w_b697d582-3e1b-40da-9003-2874a268d0a7">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl8xMS0xLTEtMS0w_81354d4a-49f3-47a2-ad97-3fbd1d5e9d7d">false</ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGV4dHJlZ2lvbjowODJiMmIxMmU5ZTg0ZjZkOWRiMDA5ZTc2ZDIxYjkwMV80NA_2d11377e-78a7-4fce-87e7-d4966c3dcf4d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i75260a9b71b248a180be746c764bb685_D20190101-20190930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ia903a4bd9a7147489f1eee7dc6293440_D20190731-20190731" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjQ5OQ_eda0d1de-291e-4724-9f3d-24d63817ed19">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i9a2c4b2e6e974786a12caa1d58429adb_D20190731-20190731" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjUxMw_1e2e5b28-e0fd-452d-9a2f-63613413e197">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iea28de91b41343fda8f542de215d493f_I20190930" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i531e62c5dc1b43ee9e14641d30401d86_I20190930" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nlnk-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idc0e4827406f4f73ae9067857e0f0115_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9ace74c0019743fe88745f618d835f4e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2743af692cc2469faa69ffc8ef0a9673_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4664525312404d1b94728c50760da2a4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if704753e5c8a46528426b0f8ea5dfb41_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c515a2dbfdb4d1595a67d09c00d6655_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d82dd02a58c4c18a9a60caa4785696e_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9151d1bccda84d16ba78784a7225722a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a287cf3281c476b98eed454958f2277_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ebbfa104374f4d9aa9a287ba8b999e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb50f6d464f41209ad8d692ff7fbf39_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d751ee6c76466fb5eb60f4019c30a5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25aea5b67dc4615836b71f7ec170110_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505afb318e1146129e9c7d51a2e1dd64_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf470515d3af40d1b502950814a2820d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743bdaaa5b21446bbc814722f648cd49_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59db6466a5d48b5a06237c225e6a257_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d41031c4b440719ab7602de06c798e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f04576fbb64c32a7733ec82cee0caf_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d697c19fe5e4fa58ef31272011cf521_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6330f627e2f84026b002dd0309e55153_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f28d90376cb4de3827920363100e946_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d872755c9d49bead485135d03d139a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de8dfc9265f4814a10af285b763d500_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf3bbd0ea44455a821a356b26309749_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie307d6d5bcea4b01bff357ad51555c41_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i183f47689ec84868ab9f6b72e3f7e433_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8364331140614060a05ae248ab045408_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ea5410251564fd6a62a198b8e5f4009_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab97d107e9549eb8b271ae98baea406_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b974929d044217aed5ac3c4be73ea8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3dd401368e49a4ad4de2abc0db6cb6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52ffe662b424bbb88ce5417c24c5166_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5715e9adfac45a8b83e8d40a69664d9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a75e769cc224d6298f34cd36e25d43a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i351b47f7af6542ac9248452c834d8455_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a81768f87d40cca900412fadac8d87_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118a4632bd23467da06fa77e0c2bb1f1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4c804c8dac4cfd990183466fd9ad56_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acd99c8b887434880292fb731fadbdf_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e1400b763c49568b5cacb45201ccaa_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a22af9c5264e37834b47db5e74b120_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d603373292d4142b02b4ad42398d206_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288a43aa7f8440249689de817a189731_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d85a484cbcd4b0abfadd3bc26932841_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5534a41e53449b97133e968328f9a5_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140b485706b14058a26125a6cce6a765_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a934ace4c946c28093a195503e156f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cdc44a40d049039d180bc48b94bf7f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a400765af1e4295a589ad235b0bb229_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7921dfa4bf484fbd69745528d65347_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d417601e8ed469ba93c08f508e5c6cb_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife35f142e8d74a338ff0bcaccfa25ad0_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef502f9d9d44723b54dcbb9a8c41982_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29c7d068b9374823b5c5345eb272ce77_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d6f7ba47da4441ace39e0c4364b8cd_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied703d3a9b144f7399e282419ab70c09_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64eda74baf5476a8141082fd8f23afa_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088d0c7eb2e542868a81a509f658724c_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18061ceabd14d7cbfa7e44c6aa37ff3_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8fe32be617d48f8b264cb18a8de74d1_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida83887e682745b687c7e89ab3d035f6_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i11f2bdb36ed64cb5b8001849d4dad9df_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:LumosPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib799a2a817e04b59aab49144acc02919_D20190930-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75260a9b71b248a180be746c764bb685_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9fcb41ebd843cfa2f5be0b9a6e54c6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5dd96d6f28439094a7f5c566181c4f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3288156e044e1ea7072638951290c4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nlnk:ContractManufacturingOrganizationEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42832590af241ccbfc792218e48761d_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f327bd7ef245e79de2f37014c6d665_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d3bfeeceed429b9919afe16c36b882_D20150201-20150228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-01</xbrli:startDate><xbrli:endDate>2015-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a8e9aa761347babed3658ff5c9a4d6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4778bd47a7ba44e880bf6a0a6262fcd0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0068a8d71d2412c8b3c5bc4e29bbc32_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af278cb3284478691a305bda935ae58_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f6713f23084b77b9f014a1385b3370_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie54c7721636a4a35b6a388e0c9fa5e67_D20100515-20100515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-05-15</xbrli:startDate><xbrli:endDate>2010-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bebf0fb283644b1b4fa4191fa81d9e9_D20110107-20110107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-07</xbrli:startDate><xbrli:endDate>2011-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i614cfc319ae4417e821a813bf2a85f20_D20120101-20120101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab1db675dee4e5da76fe81774a8552b_D20130101-20130101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0760fc05764fa1a60a9c9d11289a14_D20140101-20140101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c98279781c9463f806811bc0a673a4d_D20150101-20150101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff1b4bb134b4e37a54c3394f117eb6b_D20160101-20160101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33b56d22b074f6897659805507c8fd1_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4016611a1eab4f25b572395001428c52_D20180101-20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f210ec5feb14d6589ee87904ff50298_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic06e3556e29342f9b22ed68a8c5b9967_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36cc09bb5c5d4dd48310b49ce7bfd13b_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107fa001f84543fa888d506c91a7babb_D20190509-20190509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-09</xbrli:startDate><xbrli:endDate>2019-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba61dd7590642d3b68ea5be9247b3d3_I20111110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db880b71be843cf9fa1297dd718c0fb_D20130509-20130509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-09</xbrli:startDate><xbrli:endDate>2013-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb329194fab14e95927fc78307847e9a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019744478ea04e56985668e5cb38d38d_I20111110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5956af200be14c239393954a2fd95c97_D20130509-20130509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-09</xbrli:startDate><xbrli:endDate>2013-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1bc3c99884466aba07355633ce5f0e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7f9677e03e45f3a98571e955061cad_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef382a4e2574d5795c997701aaa5ba2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1b201dcccc48339b02bb8bb2870d0e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22dbb1e99d54346b14b3c0916a4c37a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f55c0e897664d23bff3a32fd6ca9f5a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a2953b237a4956bb04a2ba877036e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57817203713c4925802ca15e17d5adaa_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257055a317c4463eb42d9ef38312b06f_I20190620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e071305c5974ee088653329c9314097_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6344520fdce4afb87589a3d00b3e720_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370c9ff0ce304ee3974eceb8f6074b8c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f4cfa3cbf241ec8c3640a53481c862_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0476f147a0a46768f18d7f62d1b188a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acd55e388054c249dd813ea270ac6b8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1655708734471499ed19001400af44_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169a1b92c3e548cc86648a4bb5aae559_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d00499345b541a7874a4e149b9f52ef_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>nlnk:employee</xbrli:measure></xbrli:unit><xbrli:context id="i008f25566c8b40b295668c906960417d_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>nlnk:director</xbrli:measure></xbrli:unit><xbrli:context id="id606702fb4024e63b1d691ef77f26589_D20190731-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia903a4bd9a7147489f1eee7dc6293440_D20190731-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2c4b2e6e974786a12caa1d58429adb_D20190731-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db96647bdad4850a6a856796387bea0_D20190731-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea28de91b41343fda8f542de215d493f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531e62c5dc1b43ee9e14641d30401d86_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b905d67ed264c328656baba2a4db384_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3f948dc1734160ad119b9960b9d13b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39cb87fc9300480f802ea9c680a0f776_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ae389b9e2b4cae9570b2523f80048b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347cb4a8f93f4834925abbdb2c22d273_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f20a25e4d646fdb0ce1a7190c7639a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14e8601ef3249db99d27585927dca67_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55705cb9c17045b2b56549f7969a9968_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia427f2113ccc4110bc882b22d38777fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic490d40b023c41d2b5ba726dbee45eb8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001126234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">   </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN184OA_057c0849-3215-4b5a-b475-4a1e0073015e">10-Q</ix:nonNumeric></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:12pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN185MQ_5f0a777d-8c7c-4367-8d87-7100b78462b9">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Quarterly report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18yMTQ_786563e9-a092-4dd2-9975-d146dd294e92">September&#160;30, 2019</ix:nonNumeric>.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:12pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18yMTg_36069a74-a99e-42cd-a13e-88aa55d396ef">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Transition report pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Commission File Number</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180MTI_954e0cab-83df-4d1c-bf7a-f12f0e734c40">001-35342</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180MTU_e82b6d8b-afd1-4542-86b6-3e601d234df4">NEWLINK GENETICS CORP</ix:nonNumeric>ORATION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(Exact name of Registrant as specified in Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:48.584795%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.801170%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.584795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6MjQyZmJiMzU3NmRmNDk1ZmI0ZDIyYzExZGViMzFlODkvdGFibGVyYW5nZToyNDJmYmIzNTc2ZGY0OTVmYjRkMjJjMTFkZWIzMWU4OV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDBlMGJhOTRmMWQ0MTkyYWNkM2RkNTJmNWM3MmJmNV80_101d97f7-d03d-4aa4-b26d-2c4d7740ed3b">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6MjQyZmJiMzU3NmRmNDk1ZmI0ZDIyYzExZGViMzFlODkvdGFibGVyYW5nZToyNDJmYmIzNTc2ZGY0OTVmYjRkMjJjMTFkZWIzMWU4OV8wLTItMS0xLTAvdGV4dHJlZ2lvbjphMTdjNjM5NDdlNzI0NDRkOTU5Yjc2OWNmNGFhMTcxM180_7e8c32fb-bb1f-4a6e-b33f-74879cb5a2e6">42-1491350</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODI_f49a11fd-a75e-48a2-9fbc-642c8c6a1bd8">2503 South Loop Drive</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODU_9e1d4694-4354-423f-ba4c-cbfd7142c8eb">Ames</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODk_b1c1e337-9ca9-4669-9844-81b2bf679e40">Iowa</ix:nonNumeric> <ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180OTI_539a481b-0071-4c34-b807-3ecd58f70eb9">50010</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180OTY_ad53cc04-50b8-4286-8954-a0fa3d72c495">515</ix:nonNumeric>) <ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN181MDA_1cb88d34-ccd8-4483-baaa-6d0fbf075cf8">296-5555</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(Address, including zip code, and telephone number, including area code, of principal executive offices)</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.935673%;"><tr><td style="width:1.0%;"></td><td style="width:28.868167%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.421222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.710611%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTAtMS0xLTA_123b3026-40df-4b59-b00d-ecfc4f635565">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTEtMS0xLTA_c9282f43-eb44-45b1-9be5-99dc394a7e0f">NLNK</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTItMS0xLTA_de200377-a321-4b96-8e5a-9ab920fd60cf">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:14pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xMDE4_e59935c2-e044-40a7-bcdc-979aab08d256">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;">o</span></div><div style="text-indent:14pt;text-align:justify;"><span><br/></span></div><div style="text-indent:14pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xMzUw_3c016da0-3c73-4ea3-974b-9c0331b26860">Yes</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;">o</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.093842%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.665689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.240469%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Large accelerated filer&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">o  </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accelerated filer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;"> o  </span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M18yLTAtMS0xLTAvdGV4dHJlZ2lvbjplY2M5MDU4ODk5N2I0MzZkYTkyMWIxY2NjNzc0ZGQxYl81_e4b8d901-fd23-48e6-8f32-9531b45e162f">Non-accelerated filer</ix:nonNumeric>&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Smaller reporting company&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M18yLTItMS0xLTAvdGV4dHJlZ2lvbjo3NjA5OWM1YTI2YjA0ZDNmYTZjYmU0OTMwYmJhYjkyMF8zMQ_caaf73d4-b620-4cbb-987c-886d7e4262d9">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Emerging growth company&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M180LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTA4ZWIyZmFjM2U0YzU3OTVkZjYwMzcyNWQ5NTg0OF8yOQ_8f7b466a-7116-412c-8e64-a56afa5d8cef">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:100%;">o</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xODQz_5938f2fe-c9ae-4f8d-ab25-913599d261ae">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:10pt;font-weight:400;line-height:120%;">&#253;</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As of October&#160;31, 2019, there were <ix:nonFraction unitRef="shares" contextRef="idc0e4827406f4f73ae9067857e0f0115_I20191031" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xODc1_41bd5ac8-1a9c-4a87-bd59-58c03b2e5073">37,314,076</ix:nonFraction> shares of the registrant&#8217;s Common Stock, par value $0.01&#160;per share, outstanding.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_7"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><img src="nlnk-20190930_g1.jpg" alt="nlnk-20190930_g1.jpg" style="height:138px;width:277px;"/></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">FORM 10-Q</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:6.479532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:84.695906%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">Page</span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i_0_10">PART&#160;I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_13">ITEM 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_13">Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_16">Condensed Consolidated Balance Sheets as of </a>September 30, 2019 and December 31, 2018</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_19">Condensed Consolidated Statements of Operations for the </a>Three and Nine Months Ended September 30, 2019 and 2018</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_22">Condensed Consolidated Statement of Stockholders&#8217; Equity for the </a>Nine Months Ended September 30, 2019 and 2018</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_25">Condensed Consolidated Statements of Cash Flows for the </a>Nine Months Ended September 30, 2019 and 2018</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_76">ITEM 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_76">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_76">17</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_94">ITEM 3</a>.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_94">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_94">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_97">ITEM 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_97">23</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i_0_103">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_106">ITEM 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_106">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_106">25</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_109">ITEM 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_109">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_109">26</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_112">ITEM 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_112">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#51a57cabe8384bc59387580c3e091ea1_0">ITEM 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_115">57</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_118">ITEM 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_118">57</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_121">ITEM 5</a>.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_121">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_121">57</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_124">ITEM 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_124">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_124">58</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_127">INDEX OF EXHIBITS</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_127">58</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_130">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i_0_130">60</a></span></div></td></tr></table></div><div style="text-align:center;margin-bottom:15pt;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:27pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART&#160;I</span></div><div id="i_0_13"></div><div><span><br/></span></div><div id="i_0_16"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share data)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.390805%;"><tr><td style="width:1.0%;"></td><td style="width:69.538462%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.569231%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.230769%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.569231%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.692308%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNC0yLTEtMS0w_a97d6fe0-7685-4927-8596-f1fe8a0cc240">98,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNC00LTEtMS0w_7a73713b-358a-40c2-9d02-7699c03f2b12">120,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNS0yLTEtMS0w_7358e081-2bdf-4fee-9d7e-b7afd81836c3">3,311</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNS00LTEtMS0w_1c857512-41af-4330-8a9e-515e67a9b686">5,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Income tax receivable</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNi0yLTEtMS0w_03df40c9-435c-41d6-9014-ebc5b28ad3c8">76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNi00LTEtMS0w_29fbef5d-6678-4e5d-bcf1-0bf69539ced4">339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Other receivables</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNy0yLTEtMS0w_2d5fca32-20ba-42fd-a2d5-9cde82c8e28c">740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNy00LTEtMS0w_9caba568-b883-45a8-b02f-689123e3ab80">459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total current assets</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOC0yLTEtMS0w_567d871e-a3b1-4a19-898d-5558eabff548">102,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOC00LTEtMS0w_74be43cf-afec-4fe8-aa41-286de32dd13f">127,072</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOS0yLTEtMS0w_3bec1613-92f0-4869-97f9-614265e7c1ad">2,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOS00LTEtMS0w_1c11f8b6-d0d6-4548-9c41-a120bca83df9">3,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Right-of-use asset</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:OperatingLeaseRightofUseAssetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTAtMi0xLTEtMA_902fd70e-a1ef-4f66-90eb-fdf20569a47a">1,042</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:zerodash" name="nlnk:OperatingLeaseRightofUseAssetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTAtNC0xLTEtMA_1fb90ff8-970d-4bd8-8d40-d98e4ca5052e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Income tax receivable</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTEtMi0xLTEtMA_98026d21-42fe-4dcc-97db-0c05363c5e2e">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTEtNC0xLTEtMA_2c3b0a5a-4a53-4155-9143-f12cd453fd08">140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total non-current assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTItMi0xLTEtMA_0b7e53f8-055f-4902-8d1d-cc17dc686dab">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTItNC0xLTEtMA_49bd4e3a-429e-4ad8-a443-cb23aaeb0166">3,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTMtMi0xLTEtMA_cb4d42d5-2d7c-4a44-ae6a-2f0dce64fa2f">106,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTMtNC0xLTEtMA_a3737d1c-cdb8-4680-baeb-0dea63b13e64">130,939</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accounts payable</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTYtMi0xLTEtMA_32ffb52d-d196-426f-8912-c17afe4e5702">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTYtNC0xLTEtMA_a9063ea9-0610-4b64-9a24-a19f67fd2233">555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accrued expenses</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTctMi0xLTEtMA_04f85039-56c4-4330-b068-fffbd94d51f1">12,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTctNC0xLTEtMA_932e94d6-4bdf-4192-8431-42218cb2b03b">8,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Current portion of deferred rent</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTgtMi0xLTEtMA_df91dcaa-3a29-4bcb-a9b2-46a82468ff0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTgtNC0xLTEtMA_260c3992-600b-4a29-aac8-3b87ce63b38b">92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Current portion of lease liability</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTktMi0xLTEtMA_6efe1618-df48-408d-84ac-5bfa9d1fa07b">1,712</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTktNC0xLTEtMA_284305a9-c7fd-4f2e-b054-ed93e5804ac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Current portion of notes payable</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjAtMi0xLTEtMA_868ca264-9214-479b-b13b-1fd3e94eea76">58</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjAtNC0xLTEtMA_3bdaac86-f97c-420f-92a5-609406452911">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjEtMi0xLTEtMA_c03dd1ad-6bad-4612-88fb-ab368901ee96">14,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjEtNC0xLTEtMA_46a09fe6-65fd-4631-a50c-e3629025bfe5">8,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Royalty obligation payable to Iowa Economic Development Authority</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:DeferredGovernmentGrantsObligationsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjMtMi0xLTEtMA_c9d6f984-f5fd-43ac-95ff-42d92f892151">6,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="nlnk:DeferredGovernmentGrantsObligationsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjMtNC0xLTEtMA_e4d79779-c7a1-4139-bc9c-6dc40fa16258">6,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Notes payable</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjQtMi0xLTEtMA_f614ada9-cc9e-42c9-8b23-5ff39345343d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjQtNC0xLTEtMA_3ae0ea51-da3e-4d98-879b-955995e2f7a6">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Lease liability</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjUtMi0xLTEtMA_617ab977-d0fa-4d6f-87d7-375ced9ae339">217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjUtNC0xLTEtMA_77cbeeb3-c4bf-4593-9096-c4af74781fe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Deferred rent</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjYtMi0xLTEtMA_48fb031d-d58b-4abf-8f05-2f894ec12bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjYtNC0xLTEtMA_0c713400-13a5-42e8-b375-a40d2a7e61b4">906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjctMi0xLTEtMA_bc3c972d-16bb-41e2-ab15-bf14ec789c5c">6,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjctNC0xLTEtMA_c73086f1-1c34-40ad-b92b-7961d98db85c">6,949</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjgtMi0xLTEtMA_c680154c-1efe-47c0-8850-04b942ae2735">20,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjgtNC0xLTEtMA_51fb7a5a-fe95-4f19-b68b-724f5c23071b">15,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Blank check preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzMz_42fad464-df06-4379-bc0c-b26079661a3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzMz_6f025580-02a8-41f9-ae68-f91a7a8a411b">0.01</ix:nonFraction></ix:nonFraction> par value: Authorized shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzY3_9583e963-dcee-427c-8367-6eb4d7aa503c"><ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzY3_abfd3526-6244-4b2a-86bf-e512096d0f13">5,000,000</ix:nonFraction></ix:nonFraction> at September&#160;30, 2019 and December&#160;31, 2018; issued and outstanding shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_07203fca-5f4b-4b67-8016-156ff32fb0a0"><ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_277a4d77-0b09-4539-b378-707f302fd32d"><ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_eb4eae3d-ab03-4420-b0e8-c4de0dd713ea"><ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_f2a42bd5-cd5e-4744-a8c7-e8b172c16bb1">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at September&#160;30, 2019 and December&#160;31, 2018</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMi0xLTEtMA_d03b6518-68c0-4958-a685-33088794dae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtNC0xLTEtMA_1a8ca786-5896-4601-b34b-370719bb2e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzE4_247d4070-9988-4d18-96d2-0a6647912d72"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzE4_3d3537ed-16af-4633-b9d8-291472098d40">0.01</ix:nonFraction></ix:nonFraction> par value: Authorized shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzUy_145e4182-7cd4-4445-afd1-b32e613a385d"><ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzUy_efaeac2c-adfb-46dc-a856-f1f0a09676a1">75,000,000</ix:nonFraction></ix:nonFraction> at September&#160;30, 2019 and December&#160;31, 2018;  issued <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzc3_9cc90d49-9384-4169-86e2-5486924eec90">37,426,844</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzg0_d7b3ca37-88a4-4fde-85b9-aed9a9fb5087">37,343,547</ix:nonFraction> at September&#160;30, 2019 and December&#160;31, 2018, respectively; and outstanding <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzEzMQ_15d9c2d8-5834-4b5d-9ca9-3e352397fc7e">37,314,076</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzEzOA_138638f9-3215-4628-ac22-85ac2d1ba38d">37,251,220</ix:nonFraction> at September&#160;30, 2019 and December&#160;31, 2018, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMi0xLTEtMA_317485e4-7cf3-46d9-9de4-b299929bb1f2">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtNC0xLTEtMA_2c1b7861-d594-4129-a5db-8b46f4b81fda">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzItMi0xLTEtMA_78122dd8-e1d9-4499-a439-63a127bb4c6a">413,205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzItNC0xLTEtMA_dc9ee810-342e-4236-b90e-1f4b27f7e12a">407,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Treasury stock, at cost: <ix:nonFraction unitRef="shares" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjcyMWYzZDc5MTIzNTRjYWQ5MTQ1ZTQ5ZmM0ZmEwNmJhXzI5_4109de0d-cb02-47aa-99aa-957911885022">112,768</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjcyMWYzZDc5MTIzNTRjYWQ5MTQ1ZTQ5ZmM0ZmEwNmJhXzM2_cb7af4bf-c85e-407e-aa3a-a520287e414e">92,327</ix:nonFraction> shares at September&#160;30, 2019 and December&#160;31, 2018, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMi0xLTEtMA_6722ec88-da6f-4b7b-a1ae-61c618014a06">1,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtNC0xLTEtMA_0f6794a7-5878-4bbe-ba02-a03cd3227e78">1,417</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Accumulated deficit</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzQtMi0xLTEtMA_28b953c7-1e5e-4bd6-844c-e4e01d4d096c">325,730</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzQtNC0xLTEtMA_83680215-c588-44d9-be5c-e89d62d547e4">291,012</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total stockholders' equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzUtMi0xLTEtMA_143db1bb-5275-47c1-9da4-10e9b9faf899">86,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzUtNC0xLTEtMA_fe92ea36-8a89-4483-8c46-6c481bb052bb">115,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzYtMi0xLTEtMA_141fbb7c-076b-4682-83f0-fc7aa5ada5fb">106,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzYtNC0xLTEtMA_2278f784-845d-4f4c-b06f-067d0ff3664b">130,939</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">See accompanying notes to condensed consolidated financial statements.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div id="i_0_19"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:27pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:39.202346%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.782991%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.782991%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.782991%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.782991%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533138%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Grant revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4664525312404d1b94728c50760da2a4_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC0yLTEtMS0w_961e0965-4eae-4152-944d-7bcc839f834c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if704753e5c8a46528426b0f8ea5dfb41_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC00LTEtMS0w_c16cd805-e68a-481b-91d8-5b1e69d554b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c515a2dbfdb4d1595a67d09c00d6655_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC02LTEtMS0w_30c908bc-616c-4aea-a95c-5b79ad1c3923">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d82dd02a58c4c18a9a60caa4785696e_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC04LTEtMS0w_82300e1e-58e7-4242-87a8-cb99bebd1705">11,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Licensing and collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9151d1bccda84d16ba78784a7225722a_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS0yLTEtMS0w_f09389a2-b24e-491c-a402-aae8ecbfc6ac">246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a287cf3281c476b98eed454958f2277_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS00LTEtMS0w_2edcd898-48dc-4eea-a0b9-89f360bb7ad6">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98ebbfa104374f4d9aa9a287ba8b999e_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS02LTEtMS0w_aca19417-a0d4-47ea-9357-27ac5555366f">503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cb50f6d464f41209ad8d692ff7fbf39_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS04LTEtMS0w_61cdc5b6-ecb6-410d-886a-217db6624895">1,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total operating revenues</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi0yLTEtMS0w_16dfdfa6-4006-4ce1-b442-755f30ff58ea">246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi00LTEtMS0w_795581bd-8f82-42be-9733-82963c2b55e7">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi02LTEtMS0w_47f85e2c-69df-4854-9a77-c61739d2d5b6">503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi04LTEtMS0w_f4cfcaba-d1ef-426d-9649-ed7c200e6ba0">12,272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC0yLTEtMS0w_e834b7e6-2447-4cd7-b2bd-505da46ed03e">7,024</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC00LTEtMS0w_61a9461f-36c9-4068-96bd-cc4fc253026c">7,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC02LTEtMS0w_32f01945-7daf-4d40-b726-e400e26c731b">17,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC04LTEtMS0w_9df71db4-313e-466b-aa5f-499e1fdc6379">39,972</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">General and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS0yLTEtMS0w_5796c384-ab5c-49bd-bfdc-d7d023bf7425">8,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS00LTEtMS0w_15188fde-ea5b-4c33-9052-2e1e596c98d5">7,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS02LTEtMS0w_a562928c-b584-4242-8b30-ba4b87409862">19,484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS04LTEtMS0w_c0e64456-396e-4596-b2f9-2f2b98550e6f">23,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtMi0xLTEtMA_34605658-a766-45d5-b00d-31b4894ce644">15,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtNC0xLTEtMA_75553869-3441-4b2c-8551-f10e01489ad0">15,158</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtNi0xLTEtMA_d6faf758-920f-4401-b43c-28148b99304b">36,948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtOC0xLTEtMA_7deb6121-9f5a-4f19-be25-b3bc0cfceb06">63,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtMi0xLTEtMA_2d75d787-1afd-4125-bcc7-f98c55ddd8bc">15,057</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtNC0xLTEtMA_e80e9497-8eb6-471a-b9dc-dd70d3ebba24">15,038</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtNi0xLTEtMA_ff6ad30c-f621-4efe-8a08-d11506a2b415">36,445</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtOC0xLTEtMA_7aa30459-aa77-4416-924a-89f521411353">51,492</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income and expense:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Miscellaneous (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtMi0xLTEtMA_1dbb652d-0c2a-44f6-be5a-2f71894182f7">33</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtNC0xLTEtMA_e0601d3f-2433-4d67-bb3a-41686bd83c2d">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtNi0xLTEtMA_92b3afae-75c6-4c7b-a362-2651958a39c3">38</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtOC0xLTEtMA_2eabdff4-a8f5-4931-85c4-4c50c70b199d">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Interest income</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtMi0xLTEtMA_3a21c4c2-b6a7-495b-b70e-4067e4b0ba05">567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtNC0xLTEtMA_15bf0ac1-1918-4e05-b2b1-3ce5cc8a2a75">664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtNi0xLTEtMA_bd77a1bf-4821-4379-8643-62efa42ed4ef">1,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtOC0xLTEtMA_6133990d-7f42-43ce-95d9-0b6353e67db4">1,510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtMi0xLTEtMA_5e2be3cf-e906-4e43-a26d-9f3c1759cde4">25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtNC0xLTEtMA_d037e612-24c9-4801-a33b-c8ced4b0057a">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtNi0xLTEtMA_47627166-e627-481a-a109-e488a073127b">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtOC0xLTEtMA_9a08049a-335b-4f0a-92fc-5df5584dc595">51</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Other income, net</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtMi0xLTEtMA_85df196d-9c84-4711-bba2-d82a66aa7c38">509</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtNC0xLTEtMA_9f09afb8-3b69-4114-a018-2e3430b9d2cb">644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtNi0xLTEtMA_79f33ec3-6680-4239-b069-23a018786b81">1,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtOC0xLTEtMA_f36a11d1-5ed4-493a-9faa-1770f3aee096">1,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss before taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctMi0xLTEtMA_55b27c29-e45b-41cc-8b92-495d741b9ea9">14,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctNC0xLTEtMA_3096e8bd-4f29-4574-8199-831b9b8d0ac8">14,394</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctNi0xLTEtMA_159b92d7-0f5f-4fe9-90ef-ad7533b8700f">34,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctOC0xLTEtMA_6336e805-8cdf-42a8-b56d-65d4dccc28bd">50,017</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtMi0xLTEtMA_e1f41d77-d93e-4cbd-ac7b-8e019da6c696">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtNC0xLTEtMA_743ccb91-3b4d-4143-b89f-73632c679a53">6,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtNi0xLTEtMA_29e8703a-17da-4a7b-8204-f7ab4f0ee844">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtOC0xLTEtMA_c420623c-5ab5-494e-8088-12f36a094740">6,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktMi0xLTEtMA_791d6f8d-9d5c-4825-99da-c43cb2181f91">14,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktNC0xLTEtMA_2421aac9-4c68-473f-8c5b-6fb4864d2ffe">7,403</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktNi0xLTEtMA_df87f03e-3e39-4454-8ea0-6ae404dcd8da">34,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktOC0xLTEtMA_6e43ff13-f2ef-4324-8eb9-84afdab08289">43,026</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtMi0xLTEtMA_6ef84dac-0210-4a9e-bac9-4258e112f043">0.39</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtNC0xLTEtMA_bf30ac39-a4ca-45ff-84ec-6496da96b13d">0.20</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtNi0xLTEtMA_a77b6794-3d71-4daa-ab63-d9d9db8bf8b7">0.93</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtOC0xLTEtMA_2ae379cd-1dd6-4509-9c45-6bd0a0a8b0f5">1.16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtMi0xLTEtMA_6db34284-c1ad-4043-a12e-3b5beb96f78c">37,308,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtNC0xLTEtMA_e31637be-08d8-424b-80d3-d501fd60b5f0">37,214,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtNi0xLTEtMA_3df268bd-f687-4755-b621-45f84ff9a757">37,286,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtOC0xLTEtMA_b80621c3-79fa-42c4-bbb8-8f159c298d54">37,178,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="30" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">See accompanying notes to condensed consolidated financial statements.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div><span><br/></span></div><div id="i_0_22"></div><div style="text-align:justify;margin-top:3pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statement of Stockholders' Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:42.542773%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.849558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.669617%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.374631%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.997050%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.144543%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Month Period ended September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Common</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Common</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Stock</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Paid-in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Treasury Stock</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Accumulated Deficit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Stockholders' Equity</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i03d751ee6c76466fb5eb60f4019c30a5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0yLTEtMS0w_89a42cea-3ae0-4732-b4ca-9b3d70ec368b">37,251,220</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03d751ee6c76466fb5eb60f4019c30a5_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi00LTEtMS0w_04e2f332-c570-4370-bb9f-30fafad2d37d">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic25aea5b67dc4615836b71f7ec170110_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi02LTEtMS0w_a32c42f0-e637-43d6-8454-d65a3316cc22">407,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i505afb318e1146129e9c7d51a2e1dd64_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi04LTEtMS0w_58aa5524-7324-4dec-baed-40da2116dd3a">1,417</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaf470515d3af40d1b502950814a2820d_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0xMC0xLTEtMA_789b72c4-8568-4f92-b05d-69cc54b0d4c8">291,012</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0xMi0xLTEtMA_4cfdd5be-d949-46ce-8314-147830e83b29">115,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:100%;">Share-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i743bdaaa5b21446bbc814722f648cd49_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMy02LTEtMS0w_0b599ba4-4d07-459c-a52b-661a41b4570f">1,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMy0xMi0xLTEtMA_65f2d8b8-cf81-4eeb-9f53-58bed5afa43b">1,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNC0yLTEtMS0w_2316d60d-b458-4669-9eb3-5a9bf9dfc527">44,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNC0xMi0xLTEtMA_4d5e7fcb-25f2-4325-9a52-ec5132742b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS0yLTEtMS0w_6d7c7491-a3c4-4945-a6ef-0bc417f27908">19,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id59db6466a5d48b5a06237c225e6a257_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS04LTEtMS0w_a36a1947-2d3e-4660-89a2-ea0a06e285af">32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS0xMi0xLTEtMA_6e0f0dd8-6231-4563-a12f-9cd0c8782995">32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if9d41031c4b440719ab7602de06c798e_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNi0xMC0xLTEtMA_bfb093ca-de09-4023-84d7-4e1f379b8a91">10,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNi0xMi0xLTEtMA_1f035e10-c831-4cac-80a0-825fe9d328cb">10,036</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0yLTEtMS0w_fb6625cc-26d4-428b-80a9-ef883a92f8cb">37,276,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy00LTEtMS0w_3ea60361-ab95-44c1-b622-13cab90c4fc8">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83f04576fbb64c32a7733ec82cee0caf_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy02LTEtMS0w_546c531a-f6e4-4540-beda-a1206a70bd78">409,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5d697c19fe5e4fa58ef31272011cf521_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy04LTEtMS0w_4a862771-a037-4311-aba8-16b98778a86c">1,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6330f627e2f84026b002dd0309e55153_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0xMC0xLTEtMA_2c79d6e6-d1e6-4933-830b-9616f10dbcf1">301,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f28d90376cb4de3827920363100e946_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0xMi0xLTEtMA_f42670d6-c890-45cc-b9ca-97175a00d239">107,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53d872755c9d49bead485135d03d139a_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOC02LTEtMS0w_b437204b-d93d-4656-b7d3-426eaa5834cb">1,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOC0xMi0xLTEtMA_349b4a4d-6679-4c85-b992-b28a86471964">1,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOS0yLTEtMS0w_02066f0f-6e93-486a-986d-2373e2e12f5c">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOS0xMi0xLTEtMA_a03f9362-d1f5-4f0c-9c80-886740eeae67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sales of shares under stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtMi0xLTEtMA_1def31c0-ba5a-425b-91e2-9b7255fa29e8">23,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53d872755c9d49bead485135d03d139a_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtNi0xLTEtMA_e2a88841-56d5-42f0-b7a9-b27c30e20206">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtMTItMS0xLTA_ce501dd7-80b7-4398-a045-80bbe560e640">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtMi0xLTEtMA_a2c2148c-7d85-4c99-826a-57c802f5d129">359</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8de8dfc9265f4814a10af285b763d500_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtOC0xLTEtMA_6bc5b4d3-6367-46a1-8425-766348371add">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtMTItMS0xLTA_a9ebe739-0844-43b9-b337-9249d5608aee">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iacf3bbd0ea44455a821a356b26309749_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTItMTAtMS0xLTA_65d28398-b690-40d9-9c3a-759b48e1e5d0">10,134</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTItMTItMS0xLTA_5d1a278d-758d-4e0d-af1c-142779ae7972">10,134</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie307d6d5bcea4b01bff357ad51555c41_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMi0xLTEtMA_24f2d8ef-8739-43f0-87f4-260cf9d7fe90">37,300,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie307d6d5bcea4b01bff357ad51555c41_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtNC0xLTEtMA_80ac4c74-4e2c-450e-987b-21b971e68e3f">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i183f47689ec84868ab9f6b72e3f7e433_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtNi0xLTEtMA_3cf44a63-eea7-4de0-8fb4-a91c1b8cafe1">410,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8364331140614060a05ae248ab045408_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtOC0xLTEtMA_21c2e083-89d3-41fd-a908-78e3cd4c5053">1,450</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ea5410251564fd6a62a198b8e5f4009_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMTAtMS0xLTA_a903b938-742b-4e8d-b23b-94ee5059f776">311,182</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifab97d107e9549eb8b271ae98baea406_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMTItMS0xLTA_e562dd51-b6f3-4fef-981e-ed345e438d50">98,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24b974929d044217aed5ac3c4be73ea8_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTQtNi0xLTEtMjE0_757433af-8b87-4893-86e4-4d53dc6a2a67">2,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTQtMTItMS0xLTIyMg_4f3aa305-6b0e-4e44-829c-8f46f256c3bf">2,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTUtMi0xLTEtMjE2_14eaf1cf-4d54-457e-a84c-5d05938e1f5d">13,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTUtMTItMS0xLTIyMg_0b1854ba-4ae3-4518-bc38-241a18c5f752">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtMi0xLTEtMjE2_3d271f36-717e-47d7-a00c-3c53a4905241">635</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a3dd401368e49a4ad4de2abc0db6cb6_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtOC0xLTEtMjE4_028ac407-018b-4d40-8360-de816312572b">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtMTItMS0xLTIyMg_b706814b-822d-43b4-b572-d07991849eee">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id52ffe662b424bbb88ce5417c24c5166_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTAtMS0xLTIyMA_54b5bd50-9b71-43ae-ba99-7a9b723a3f1c">14,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTItMS0xLTIyMg_35beae7f-621b-4264-a043-da0b512d8e98">14,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMi0xLTEtMzYy_98d2095b-f964-46ff-a556-003014917b40">37,314,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNC0xLTEtMzYy_92d0cddf-3ab9-4d6d-8e6c-716311f14a36">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5715e9adfac45a8b83e8d40a69664d9_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNi0xLTEtMzYy_db9ace65-7e83-44d9-9588-c27b4522cb45">413,205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a75e769cc224d6298f34cd36e25d43a_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtOC0xLTEtMzYy_c5a9d045-1b1a-4cd6-b7ff-6bbd5b58970d">1,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i351b47f7af6542ac9248452c834d8455_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTAtMS0xLTM2Mg_56f4557b-0080-449d-b1dc-2f8547cc0852">325,730</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTItMS0xLTM2Mg_77207ce1-75ed-446d-9b0e-4a5d0cfbdbc5">86,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Month Period ended September 30, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Number of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Common</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Outstanding</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Common</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Stock</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Additional</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Paid-in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Treasury Stock</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Accumulated Deficit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:7pt;font-weight:700;line-height:100%;">Stockholders' Equity</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i45a81768f87d40cca900412fadac8d87_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMi0xLTEtMA_160e9ad7-f492-4a36-b3d2-e4082dcc9af1">37,109,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45a81768f87d40cca900412fadac8d87_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctNC0xLTEtMA_66a275b2-6f87-4aaa-9bb6-24cd4ae0c9f2">372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i118a4632bd23467da06fa77e0c2bb1f1_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctNi0xLTEtMA_6d988a71-09d8-4d55-88e4-1e60628f553b">389,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a4c804c8dac4cfd990183466fd9ad56_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctOC0xLTEtMA_789d5b5d-1a70-45f8-99d0-a327b6ac4cba">1,142</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9acd99c8b887434880292fb731fadbdf_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTAtMS0xLTA_28a62ab9-2ddc-45f2-8b54-91b8afc680aa">237,459</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72e1400b763c49568b5cacb45201ccaa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTItMS0xLTA_89587139-a40c-4607-a77b-e0f7086c6207">151,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNi0xLTEtMA_fcd98943-541a-482b-8b25-3bdb89fea808">4,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTItMS0xLTA_36666084-475c-4a00-8be6-1fe3f4bfbfe0">4,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktMi0xLTEtMA_b43ef4d9-769a-4557-9456-1e7be73ce47f">84,262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktNC0xLTEtMA_5825748f-ce96-478a-9973-10c7225b328c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktNi0xLTEtMA_53a7ab9d-0307-4814-9ff4-cf69995196ee">105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktMTItMS0xLTA_e76e7236-aeda-4c62-a223-eba28223ef60">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtMi0xLTEtMA_52cbabf9-cfe4-49a4-baa1-b619ddad52a2">28,720</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5a22af9c5264e37834b47db5e74b120_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtOC0xLTEtMA_445f6508-087a-478f-96f5-73d26a07d904">261</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtMTItMS0xLTA_14b860c0-8fbe-46db-92a2-1118a7174399">261</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect of accounting change</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d603373292d4142b02b4ad42398d206_D20180101-20180331" decimals="-3" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjItMTAtMS0xLTA_c209171d-39ba-4c32-9b22-e6a3c8ee047a">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331" decimals="-3" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjItMTItMS0xLTA_3926f0ef-a8b2-4bad-aece-c5b92096dcaa">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4d603373292d4142b02b4ad42398d206_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjMtMTAtMS0xLTA_51148b01-3d05-4fb7-bbdb-e11afb297659">18,310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjMtMTItMS0xLTA_b97ded4c-036c-4fd2-b282-1d93aa458245">18,310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMi0xLTEtMA_6f1f754f-c49d-4daa-9260-11fb52d24697">37,165,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtNC0xLTEtMA_6d3548f6-f83a-4967-852e-f06e1ecc839f">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i288a43aa7f8440249689de817a189731_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtNi0xLTEtMA_13a1a603-068f-4b56-b144-0a00aa522b62">394,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d85a484cbcd4b0abfadd3bc26932841_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtOC0xLTEtMA_d85d3ec8-3e3a-4cf8-8822-5596612df2ad">1,403</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idf5534a41e53449b97133e968328f9a5_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMTAtMS0xLTA_3f7b1ba5-3e36-4c8d-b74b-1afd586c9300">255,727</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i140b485706b14058a26125a6cce6a765_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMTItMS0xLTA_b9488613-9544-4afe-9283-ea3b9acefb7f">137,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5a934ace4c946c28093a195503e156f_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjUtNi0xLTEtMA_6f71d937-d14e-4608-99bb-f7cedab09318">4,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjUtMTItMS0xLTA_35cba31f-9aaf-4f48-a3ff-fb4d5c3d3b96">4,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjYtMi0xLTEtMA_b695e660-01f9-439a-a3b7-03c97546452a">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjYtMTItMS0xLTA_72e17465-bd58-410a-ab17-5bdb75afc62d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Sales of shares under stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctMi0xLTEtMA_b5eb31cf-cc59-4ed5-870c-a1dd178baaf5">32,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5a934ace4c946c28093a195503e156f_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctNi0xLTEtMA_85928f76-0e6f-4ee6-94fc-e7c4da449194">130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctMTItMS0xLTA_6ce47119-cdca-42f4-a40c-47ddb6d64af7">130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtMi0xLTEtMA_702639e6-ab8e-4396-ab50-1576de206245">359</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i63cdc44a40d049039d180bc48b94bf7f_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtOC0xLTEtMA_9d2bcae8-1919-450e-abeb-efd05983e8bc">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtMTItMS0xLTA_3048df6e-a92c-4ead-82d0-2becdc270eb6">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3a400765af1e4295a589ad235b0bb229_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjktMTAtMS0xLTA_be20f1c6-09da-434d-8f3a-0501b40fc4f3">17,313</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjktMTItMS0xLTA_a27b7e94-4ec9-4ec2-be2f-778d23ec3921">17,313</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0e7921dfa4bf484fbd69745528d65347_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMi0xLTEtMA_18a14fba-b892-4bf6-a3b8-e8f8c96dac7f">37,198,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e7921dfa4bf484fbd69745528d65347_I20180630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtNC0xLTEtMA_36fb9740-480b-41f8-9e1f-afecac413f48">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d417601e8ed469ba93c08f508e5c6cb_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtNi0xLTEtMA_99c03a28-b4c9-47ee-911e-e9855ebe47bb">399,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ife35f142e8d74a338ff0bcaccfa25ad0_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtOC0xLTEtMA_b5821424-0224-4ebe-a7ea-52a3e134e0ce">1,405</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8ef502f9d9d44723b54dcbb9a8c41982_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMTAtMS0xLTA_42c07f9f-c54e-4a63-9d64-90a50c98e377">273,040</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i29c7d068b9374823b5c5345eb272ce77_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMTItMS0xLTA_f4e33a45-a10d-41d1-be9e-d39783571f69">124,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzgtNi0xLTEtMTI2_a21488f5-44a3-459a-b2c4-d9bba9b49b68">4,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzgtMTItMS0xLTEyOQ_80ec0655-4800-451f-b08e-cdd20f92006f">4,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktMi0xLTEtMTMy_58f5e719-3314-48ee-b08f-2335c6c8588d">19,881</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktNi0xLTEtMTM1_53aae108-5071-4f2e-8dd8-f59a8b2cfa75">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktMTItMS0xLTE0NA_b9df6bfa-6921-483a-8021-38f9bb61ea72">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtMi0xLTEtMTMy_bcf69310-f09d-4739-8c4b-4c280c77d894">1,089</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if7d6f7ba47da4441ace39e0c4364b8cd_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtOC0xLTEtMTM4_28f7895c-795d-4110-b6bd-d4b3174fff67">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtMTItMS0xLTE0NA_d65e1c89-ed61-4ce9-8010-6c9650fdd547">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied703d3a9b144f7399e282419ab70c09_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDEtMTAtMS0xLTE0MQ_690e87bf-baf5-4770-afef-ef450b10c083">7,403</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDEtMTItMS0xLTE0NA_a520592d-5415-427e-ae0e-78eadbd3de30">7,403</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id64eda74baf5476a8141082fd8f23afa_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMi0xLTEtMTU3_7c48cc5f-fcd5-4af4-9de3-803cf08af7b8">37,216,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id64eda74baf5476a8141082fd8f23afa_I20180930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItNC0xLTEtMTY3_69323396-8151-4c38-93b3-c6cc3e82c7f4">373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i088d0c7eb2e542868a81a509f658724c_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItNi0xLTEtMTU4_c63e26dc-e1c0-4c52-aef3-41527050b5b5">403,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie18061ceabd14d7cbfa7e44c6aa37ff3_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItOC0xLTEtMTYy_1cfa278d-a3af-4946-809a-cf51d44f8cd6">1,409</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie8fe32be617d48f8b264cb18a8de74d1_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMTAtMS0xLTE2NA_4b9b573e-d6e2-4c2c-9350-0a3ac45aed4a">280,443</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida83887e682745b687c7e89ab3d035f6_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMTItMS0xLTE2Ng_3c89e55b-31bb-4fa1-8aef-6e00bdd28b31">122,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div id="i_0_25"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:40.5pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:65.794118%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.705882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.029412%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Cash Flows From Operating Activities</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMy0yLTEtMS0w_f3144681-f8e6-4c50-b69a-c207b84695a6">34,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMy00LTEtMS0w_dcd8eac2-cf8a-4eae-82dc-01c974c8a537">43,026</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNS0yLTEtMS0w_abb7789e-39b8-405e-a81a-e5a91f07ecb8">5,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNS00LTEtMS0w_c34612f5-21fc-4802-bccf-054d861b79af">13,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNi0yLTEtMS0w_53275e3b-c9ff-4a7e-83f9-28dc0c6943f2">432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNi00LTEtMS0w_4b913b3c-4108-4706-82af-bc3c56e31c8f">901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Impairment of fixed assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtMi0xLTEtMTg5Nw_60e5c012-bed0-4201-977c-5be6cc1b32c6">351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtNC0xLTEtMTg5OQ_b5198b63-c01c-456c-a0b2-1d928a0e81c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Gain on sale of fixed assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtMi0xLTEtMA_645c0dfb-d09b-4956-921e-374497528a39">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtNC0xLTEtMA_a33f5a99-065e-4930-a4e8-905c61d75001">16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Amortization of right-of-use asset and change in operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTEtMi0xLTEtMA_99c8260d-7dc6-42ba-8998-dc72ef44be10">111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTEtNC0xLTEtMA_48f879f5-7cae-40ff-9e18-b331576aae2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTMtMi0xLTEtMA_b2d5c8a7-178e-41ac-a9dd-5d3cc3e90a24">2,225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTMtNC0xLTEtMA_df5ad0ce-53af-4aa9-b225-41caa00cf25a">842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Other receivables</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTQtMi0xLTEtMA_f6fb8171-81dd-4993-b507-18dd80139383">281</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTQtNC0xLTEtMA_25c95f8a-baf6-4cad-aaff-cb48ff54794d">9,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTUtMi0xLTEtMA_a62d3c8f-2fb2-4d00-9ef3-8d0c6cd41efe">3,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTUtNC0xLTEtMA_2944365c-71a9-45b4-a326-97c34e0b2794">11,749</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Income taxes receivable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTYtMi0xLTEtMA_4c2238cc-88ae-4a61-89dc-43a64675232b">334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTYtNC0xLTEtMA_d750b88f-06e7-42f2-a917-6045f9d14cea">7,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Unearned revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTctMi0xLTEtMA_ae304bfb-df48-4b82-8933-b51cee4f38d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTctNC0xLTEtMA_1da9ce14-0fbd-47e9-8d84-91e8bba860ea">56</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Deferred rent</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTgtMi0xLTEtMA_b44ac86c-ed2a-464a-bc81-53b450da4b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTgtNC0xLTEtMA_884aebb1-a519-4cff-893a-75f1773758f6">78</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTktMi0xLTEtMA_9819c2cb-c50b-4395-b471-01e2904beaad">22,176</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTktNC0xLTEtMA_11cced94-5ab4-4880-a07f-8654f1788bef">36,622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Purchase of equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjItMi0xLTEtMA_0beb2d2f-9489-4be9-bfb7-33e21d5d6095">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjItNC0xLTEtMA_2a97e964-b85d-4ace-b143-aed569223e5c">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Proceeds on sale of equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjMtMi0xLTEtMA_671d8732-595a-464e-82b7-26fc487ee30e">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjMtNC0xLTEtMA_4beeef64-6931-4945-bbc2-67fa26397bef">118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjQtMi0xLTEtMA_4fadd540-8006-494e-98cf-8fc1a32aa8dc">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjQtNC0xLTEtMA_b45bd8f0-a0e4-4e68-8d18-ab619a642716">111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Issuance of common stock, net of offering costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjYtMi0xLTEtMA_c85e087d-1dff-42ab-807b-fcca2a34f3df">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjYtNC0xLTEtMA_09420667-89ef-4540-b5c9-2593cb6100ab">269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Repurchase of common stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjctMi0xLTEtMA_d0be3166-905c-4df5-ac23-fb33b0acd63e">34</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjctNC0xLTEtMA_601041f3-210c-4d92-b24d-4d13e95db4ed">267</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Principal payments on notes payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjgtMi0xLTEtMA_82130cfc-4a76-4f1d-88db-e795ded9daa7">46</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjgtNC0xLTEtMA_86977fa1-1115-47cd-a4c8-9ef6d0f6c3d9">138</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjktMi0xLTEtMA_4d53f9f7-c096-4bef-a553-2db2bea4b801">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjktNC0xLTEtMA_4dc34977-7d9e-463d-b8ff-57b3db9427fa">136</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzAtMi0xLTEtMA_42e49c90-0e94-4d56-90fd-d32735e93f94">22,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzAtNC0xLTEtMA_d1cba743-16f2-49f8-bcfb-e62574139a43">36,647</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzEtMi0xLTEtMA_933dffef-74fc-4032-bd32-60212f2e61df">120,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72e1400b763c49568b5cacb45201ccaa_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzEtNC0xLTEtMA_dbdd46e6-6481-4261-baa1-16d6fd7d33b4">158,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzItMi0xLTEtMA_32cbc8ad-2853-4200-8481-42af56ad605a">98,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida83887e682745b687c7e89ab3d035f6_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzItNC0xLTEtMA_81d9393e-e751-4fc4-a7f8-38f0473787af">122,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flows information:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzQtMi0xLTEtMA_4184ab28-82c6-4152-ad60-2b605bd4af11">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzQtNC0xLTEtMA_f47ba431-31ea-4420-bc0c-7936c818b1ff">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for taxes, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzUtMi0xLTEtMA_361672c9-f8ab-414a-b544-417165f75484">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzUtNC0xLTEtMA_86b6431e-106f-4af0-8edf-7c06c088a855">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash refunds received for taxes, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzctMi0xLTEtMjAyNg_af3d6fa9-0aba-4c1c-a298-c19e5bbfc0fa">348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzctNC0xLTEtMjAzNA_c833fc9c-832b-4743-9d76-c2d9c702f5e6">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div id="i_0_28"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:40.5pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div id="i_0_31"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">1.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMjE2OA_4229ec4b-89a5-43e9-9385-fa8fc358a6c3" continuedAt="i142072f09cd148e8ae6cc2e77b062afe" escape="true">D</ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:continuation id="i142072f09cd148e8ae6cc2e77b062afe" continuedAt="ib775662ab04d44abbe3edccd67104648">escription of Business</ix:continuation></span></div><ix:continuation id="ib775662ab04d44abbe3edccd67104648"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June&#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed to develop treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NewLink and its subsidiaries (the Company) have historically devoted substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements as of September&#160;30, 2019 and for the three and nine months ended September&#160;30, 2019 have been prepared assuming the Company will continue as a going concern. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s cash and cash equivalents as of September&#160;30, 2019 are expected to be adequate to satisfy the Company&#8217;s liquidity requirements through 2021. If available liquidity becomes insufficient to meet the Company&#8217;s operating obligations as they come due, the Company&#8217;s plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position and may materially affect the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Proposed Merger with Lumos Pharma</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, the Company, Cyclone Merger Sub, Inc., a wholly-owned subsidiary of the Company (Merger Sub), and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as a wholly-owned subsidiary of NewLink (the Merger). Following the Merger, NewLink will change its name to &#8220;Lumos Pharma, Inc.&#8221; and Lumos will change its name to a name mutually agreed upon by the Company and Lumos. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the effective time of the Merger (Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of NewLink&#8217;s common stock equal to the amount determined pursuant to a charter amendment to Lumos&#8217; certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock.  Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately <ix:nonFraction unitRef="number" contextRef="i11f2bdb36ed64cb5b8001849d4dad9df_D20190930-20190930" decimals="2" name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMzg0ODI5MDcxOTI1MQ_f2c3ceca-13be-48bc-aa84-beecb8f21474">50</ix:nonFraction>% of the aggregate number of shares of Company common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and the stockholders of the Company as of immediately prior to the Merger are expected to own approximately <ix:nonFraction unitRef="number" contextRef="ib799a2a817e04b59aab49144acc02919_D20190930-20190930" decimals="2" name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMzg0ODI5MDcxOTI1Ng_eddbc7b8-eff9-499e-a889-75f7664ff924">50</ix:nonFraction>% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by NewLink and converted into options to purchase a number of shares of NewLink&#8217;s common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for NewLink&#8217;s common stock.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company's and Lumos' conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger.  Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos.  Lumos stockholders approved the Merger in September 2019.  The Merger Agreement contains certain termination rights for both the Company and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company or Lumos, as applicable, may be required to pay the other party a termination fee of $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:MergerAgreementCovenantsTerminationFeePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfNjU5NzA2OTc4Njk5OA_52d51892-05e9-4da6-a0bc-71cddcd27dc3">2.0</ix:nonFraction> million.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split, with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time. The Merger is expected to close in the first quarter of 2020.</span></div></ix:continuation><div id="i_0_34"></div><div style="text-indent:-22pt;padding-left:22pt;margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-indent:-22pt;padding-left:22pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">2.&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNC9mcmFnOjBmMGY1OWI5MGY3OTQyN2E5MTJmZDBiMGZmNGVlNmI2L3RleHRyZWdpb246MGYwZjU5YjkwZjc5NDI3YTkxMmZkMGIwZmY0ZWU2YjZfOTcy_f789a966-e633-443d-8301-e5ad25f310f6" continuedAt="i59957709fafe4603a19f27a0340c4b33" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i59957709fafe4603a19f27a0340c4b33"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&#160;GAAP) and the rules&#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&#8217;s opinion, reflect all adjustments necessary to present fairly the Company&#8217;s interim condensed financial information.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2018, included in the Company&#8217;s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div></ix:continuation><div id="i_0_37"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc4OA_e80e562b-246a-43db-ab21-3a1fd536c414" continuedAt="i6f9d809602204fa18354c8ba5bd61974" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6f9d809602204fa18354c8ba5bd61974" continuedAt="i905403199b6c4bd1a40c271f85856835"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc4OQ_87a45c6c-e8e2-4fa7-b629-4ccde171dbfe" escape="true"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5MA_819eef65-f47b-4580-8963-060acb5d0d72" escape="true"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly-owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5MQ_6429bbf9-f059-4c77-adb2-ac9980db14ec" continuedAt="ib3be4ed3be6043b4a03703a2514892a7" escape="true">Financial Instruments and Concentrations of Credit Risk</ix:nonNumeric></span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib3be4ed3be6043b4a03703a2514892a7">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable was $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMTAzNg_68f7f60f-0e00-4eb4-b71c-ad73f269b654">58,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMTA0Mw_89001efe-b645-4f02-b4fc-75b9ab8d6bea">104,000</ix:nonFraction> as of September&#160;30, 2019 and December&#160;31, 2018, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.</ix:continuation>  </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5Mg_11c15605-dcc1-4aa2-a05a-cf33c3eb8ffe" escape="true">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</ix:nonNumeric></span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5Mw_6c424b86-6dca-4765-af68-2cee799a05fa" continuedAt="ic772a37f82664df09f2726889ac41c7c" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic772a37f82664df09f2726889ac41c7c">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjAwMA_df463cbc-3289-4426-a4a2-88055cb0e17a">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjAwNw_c3147c5d-b632-4e0d-90b8-fcd7ab2d6c1b">7.0</ix:nonFraction> million as of September&#160;30, 2019 and December&#160;31, 2018, respectively.  Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e">three</span> to <ix:nonNumeric contextRef="ibf9fcb41ebd843cfa2f5be0b9a6e54c6_D20190101-20190930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0Ng_112c86f3-6b5c-47b7-8afd-a974084b8ccd">five years</ix:nonNumeric>, lab equipment has a useful life of <ix:nonNumeric contextRef="i2c5dd96d6f28439094a7f5c566181c4f_D20190101-20190930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI4NQ_f4fd105d-187a-4055-b0c1-239a50c6e651">five years</ix:nonNumeric>, and contract manufacturing organization equipment has a useful life of <ix:nonNumeric contextRef="idc3288156e044e1ea7072638951290c4_D20190101-20190930" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjM2MA_adbe12bf-6a71-469b-8c52-fc3e1120b28a">five years</ix:nonNumeric>.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5NA_4271b550-36be-4882-8ad4-63fccc32ee21" continuedAt="i378358fe655045d797d3833681aea710" escape="true"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases, to improve financial reporting for leasing transactions. The Company adopted the standard on January 1, 2019 using the modified retrospective method, as required, applying the new standard to all leases existing as of the date of initial application. The Company has elected that the date of the initial application, January 1, 2019, will be the effective date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to apply the use-of-hindsight or the practical expedient pertaining to land easements; as the latter is not applicable to the Company.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i905403199b6c4bd1a40c271f85856835"><ix:continuation id="i378358fe655045d797d3833681aea710">Upon adoption of the standard, the Company recorded a lease liability of $<ix:nonFraction unitRef="usd" contextRef="if42832590af241ccbfc792218e48761d_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzQ3Mg_e4a8f51d-37d7-4d05-95cc-1556eeaa2a60">8.5</ix:nonFraction>&#160;million and a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="if42832590af241ccbfc792218e48761d_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzUwMw_9a933d31-590b-4b3c-a071-c49d90e5d47f">7.5</ix:nonFraction>&#160;million associated with these leases. Included in the right-of-use asset are lease incentives that were previously recorded as deferred rent liability of $<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRentReceivablesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzY1Mg_e11cb3d6-a75a-480d-bc44-d00cd9017b47">1.0</ix:nonFraction>&#160;million as of December 31, 2018 on the consolidated balance sheet.  There was no material impact to the consolidated statement of operations. Refer to Note 7 within for additional discussion around the lease liability and right of use asset as of September&#160;30, 2019.</ix:continuation></ix:continuation> </span></div><div id="i_0_43"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">4.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTgyNA_70e080fc-941e-4548-a99b-02249f21334b" continuedAt="i92c0a82495e249b7912477b1caef6d85" escape="true">Revenues </ix:nonNumeric></span></div><ix:continuation id="i92c0a82495e249b7912477b1caef6d85" continuedAt="if1eda3f617064f3ea041c377cc12268a"><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTgyNg_3863987c-d78d-41e9-a44e-aefe49d4dd84" continuedAt="i9171a0c782974cbb833d406825285086" escape="true">Revenue Recognition </ix:nonNumeric></span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9171a0c782974cbb833d406825285086">Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Prior to transferring the government contracts over to Merck Sharp &amp; Dohme Corp. (Merck) in June 2018, the Company received payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services (HHS). These agreements provided the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues were recognized over time and measured using the input method. The Company used labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. Under this method, the Company recognized revenue generally in the period during which the related costs were incurred, in an amount that reflected the consideration the Company expected to be entitled to in exchange for those goods or services transferred to the government entities due to the government entities' control over the research and development activities.</ix:continuation> </span></div></ix:continuation><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if1eda3f617064f3ea041c377cc12268a">The grants and contracts with government entities were fully transferred to Merck as of June 2018. Accordingly, during the nine months ended September&#160;30, 2019, the Company recognized no grant revenue. The Company had $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GovernmentContractReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMjc0ODc3OTA3MTI2OQ_38e07065-e991-498d-a523-5a5787d161ee">520,000</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GovernmentContractReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTU3OA_840f6006-1183-460c-95b1-f42864b2d3bc">309,000</ix:nonFraction> of receivables relating to the government contracts on the balance sheet as of September&#160;30, 2019 and December&#160;31, 2018, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:GovernmentContractAccruedSubcontractorFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMjc0ODc3OTA3MTI3Mw_92be670d-d4f7-4534-a18c-35ac98deb3ad">24,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="nlnk:GovernmentContractAccruedSubcontractorFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTcwOA_e32f7ccb-7733-4a16-bf23-b701d932249e">54,000</ix:nonFraction> of accrued expenses for subcontractor fees incurred under the government contracts as of September&#160;30, 2019 and December&#160;31, 2018, respectively.</ix:continuation> </span></div><div id="i_0_46"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">5.&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjkwOA_3aade098-2ce3-4c70-a650-cc90eea3b573" continuedAt="i21d4c463379e4ebaaae4b58b1b0af169" escape="true">License and Research Collaboration Agreement</ix:nonNumeric></span></div><ix:continuation id="i21d4c463379e4ebaaae4b58b1b0af169" continuedAt="ib61bb9a43a954be6828b96274050fc6b"><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merck Sharp &amp; Dohme Corp. </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2014, the Company entered into a licensing and collaboration agreement (the Merck Agreement) with Merck to develop, manufacture and commercialize rVSV-ZEBOV-GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada (PHAC). Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV-GP and related technology. Under the Merck Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ib8f327bd7ef245e79de2f37014c6d665_D20141201-20141231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfNTM2_580cbd69-8f08-41fd-a024-a178f2e2ec3c">30.0</ix:nonFraction> million non-refundable, upfront payment in December 2014, and a one-time $<ix:nonFraction unitRef="usd" contextRef="i09d3bfeeceed429b9919afe16c36b882_D20150201-20150228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfNjA0_8e72a101-7a8e-44a8-87a2-a839c1a2e2b7">20.0</ix:nonFraction> million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV-GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV-GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&#8217;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck is expected to lead the development of rVSV-ZEBOV-GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.</span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation (BPS), from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC&#8217;s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck&#8217;s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018, the Company entered into an agreement with Merck, the U.S. BioMedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA) to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants.</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September&#160;30, 2019, the Company recognized revenues under the amended Merck Agreement of $<ix:nonFraction unitRef="usd" contextRef="i12a8e9aa761347babed3658ff5c9a4d6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjU1Ng_eaeb206a-2b0c-4e00-a0a5-ecc360b4e66c">246,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4778bd47a7ba44e880bf6a0a6262fcd0_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjU2Mw_1ea5f80b-3f60-44f4-a0a8-efbfe5cbbe13">503,000</ix:nonFraction>, respectively, for work the Company performed as a subcontractor of Merck under the government contracts that were transferred to Merck.  For the three and nine months ended September&#160;30, 2018, the Company </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><ix:continuation id="ib61bb9a43a954be6828b96274050fc6b" continuedAt="ie303720937cd4817b4fe65c1175f62d8"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">recognized license and collaboration revenue under the amended Merck Agreement of $<ix:nonFraction unitRef="usd" contextRef="ie0068a8d71d2412c8b3c5bc4e29bbc32_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjgxMw_b76221e3-26c1-40df-a21c-3a19d35007d3">120,000</ix:nonFraction> and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> $<ix:nonFraction unitRef="usd" contextRef="i1af278cb3284478691a305bda935ae58_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjgyMA_6a7683a2-a5e2-44d7-8752-d5f521dea23c">949,000</ix:nonFraction>, respectively, </span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie303720937cd4817b4fe65c1175f62d8">for the reimbursement of costs not covered under government contracts.</ix:continuation> </span></div><div id="i_0_49"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">6.&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxMw_782106b5-43ab-4eb4-b108-2eb284f904d2" continuedAt="i304ab7e9dd6b4947b16b4ae4f393ea0d" escape="true">Common Stock Equity Incentive Plan</ix:nonNumeric></span></div><ix:continuation id="i304ab7e9dd6b4947b16b4ae4f393ea0d" continuedAt="i20f20cd6061c42c1833674a952c830f1"><div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2009 Equity Incentive Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan (the 2000 Plan), in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan (the 2009 Plan), and in May 2019, the stockholders approved to amend and extend the Company's 2009 Equity Incentive Plan (the 2019 Plan). Following the approval of the 2019 Plan, no additional stock awards will be granted under the 2009 Plan. Shares that remained available for issuance pursuant to the exercise of options or issuance or settlement of stock awards under the 2009 Plan became available for issuance pursuant to the 2019 Plan and all shares that would have otherwise returned to the 2009 Plan became available for issuance pursuant to the 2019 Plan. Under the provisions of the 2019 Plan, the Company may grant the following types of common stock awards:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Incentive Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Nonstatutory Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Restricted Stock Awards</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock Appreciation Rights</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Awards under the 2019 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of September&#160;30, 2019, there were <ix:nonFraction unitRef="shares" contextRef="i93f6713f23084b77b9f014a1385b3370_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTE5OA_ddb87518-895c-490f-a5d2-3437a53467e1">12,400,653</ix:nonFraction> shares of common stock authorized for the 2019 Plan and <ix:nonFraction unitRef="shares" contextRef="i93f6713f23084b77b9f014a1385b3370_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTI1Nw_19dd09d5-1282-4739-b05f-8df625846a76">5,271,904</ix:nonFraction> shares remained available for issuance.</span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxOQ_d0c3c9a3-afb1-4f2a-aefb-f2b9552adf55" escape="true"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"><tr><td style="width:1.0%;"></td><td style="width:40.199488%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.078772%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:54.521739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Date Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Authorized Shares Added</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2010</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie54c7721636a4a35b6a388e0c9fa5e67_D20100515-20100515" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMS0yLTEtMS0w_129689f9-466c-47a7-940b-2b4499bc94a8">1,238,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 7, 2011</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3bebf0fb283644b1b4fa4191fa81d9e9_D20110107-20110107" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMi0yLTEtMS0w_7e043fa6-ef8d-4b94-b0fb-3ea755d9a381">714,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2012</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i614cfc319ae4417e821a813bf2a85f20_D20120101-20120101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMy0yLTEtMS0w_ce20a08a-e788-4c57-8df8-1d0eacbb8a8e">823,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2013</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieab1db675dee4e5da76fe81774a8552b_D20130101-20130101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNC0yLTEtMS0w_b884b7b0-5e59-40e8-8655-0fae47f50e51">839,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2014</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icd0760fc05764fa1a60a9c9d11289a14_D20140101-20140101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNS0yLTEtMS0w_5ace90c9-6c9d-4db5-a29d-56f1f7044cb7">1,062,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1c98279781c9463f806811bc0a673a4d_D20150101-20150101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNi0yLTEtMS0w_9a0fe44e-95f7-4698-8c13-f15a368af234">1,119,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6ff1b4bb134b4e37a54c3394f117eb6b_D20160101-20160101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNy0yLTEtMS0w_590a2225-778a-45ab-9cc1-ec0be06e5c1e">1,152,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if33b56d22b074f6897659805507c8fd1_D20170101-20170101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfOC0yLTEtMS0w_f66c05ca-1272-4c19-9495-426e886c111e">1,166,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4016611a1eab4f25b572395001428c52_D20180101-20180101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfOS0yLTEtMS0w_82a333c7-54d7-4489-8d54-12037fbfe3c1">1,484,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f210ec5feb14d6589ee87904ff50298_D20190101-20190101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMTAtMi0xLTEtMA_d0e1c683-a069-4c86-9eca-9d59f9eb067c">1,490,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&#8217;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2019 were made pursuant to an &#8220;evergreen provision,&#8221; in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to <ix:nonFraction unitRef="number" contextRef="ic06e3556e29342f9b22ed68a8c5b9967_D20190101-20190930" decimals="2" name="nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTgyMQ_ab8f9186-6639-46d6-9ff2-c6c06c3fdd62">4</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </span></div><div style="text-indent:24pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On May 9, 2019, the Company&#8217;s stockholders approved an amendment to the 2009 Plan which, among other modifications, included decreasing the automatic annual &#8220;evergreen provision&#8221; from <ix:nonFraction unitRef="number" contextRef="i36cc09bb5c5d4dd48310b49ce7bfd13b_D20190508-20190508" decimals="INF" name="nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjI3OA_80fcd86f-302f-47f9-bbab-aa6096ec31e3">4</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i107fa001f84543fa888d506c91a7babb_D20190509-20190509" decimals="INF" name="nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjI4NA_4c240825-08c7-4b94-9a19-26eefaf3da6b">3</ix:nonFraction>%, in accordance with which, on January 1 of each year, from 2020 to (and including) 2029, a number of shares of common stock in an amount equal to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"><ix:nonFraction unitRef="number" contextRef="i107fa001f84543fa888d506c91a7babb_D20190509-20190509" decimals="INF" name="nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjQzMw_46028a64-7b6e-4588-8c01-af0f8de775fa">3</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Non-Employee Directors' Stock Award Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Company&#8217;s 2010 Non-Employee Directors&#8217; Stock Award Plan (the Directors&#8217; Plan) which became effective on November 10, 2011, <ix:nonFraction unitRef="shares" contextRef="i7ba61dd7590642d3b68ea5be9247b3d3_I20111110" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjg5OA_83189ce8-fe56-4a6a-a790-5685b9e95622">238,095</ix:nonFraction> shares of common stock were reserved for future issuance. On May&#160;9, 2013, an </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i20f20cd6061c42c1833674a952c830f1" continuedAt="i63915ba539ee442d927f293f96b4ddb8"><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">additional <ix:nonFraction unitRef="shares" contextRef="i5db880b71be843cf9fa1297dd718c0fb_D20130509-20130509" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjk4OQ_07f0bbd8-c565-43b7-b67a-9bc21bbc6c47">161,905</ix:nonFraction> shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of September&#160;30, 2019, <ix:nonFraction unitRef="shares" contextRef="ieb329194fab14e95927fc78307847e9a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzEwNw_d56db801-4ddd-4737-99a8-17e5ccd218be">268,902</ix:nonFraction> shares remain available for issuance under the Directors' Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Employee Stock Purchase Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Company&#8217;s 2010 Employee Stock Purchase Plan (the 2010 Purchase Plan), which became effective on November 10, 2011, <ix:nonFraction unitRef="shares" contextRef="i019744478ea04e56985668e5cb38d38d_I20111110" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzM0Ng_476248dd-1e39-4bae-b443-4601b5502aa1">214,285</ix:nonFraction> shares of common stock were reserved for future issuance. On May&#160;9, 2013, an additional <ix:nonFraction unitRef="shares" contextRef="i5956af200be14c239393954a2fd95c97_D20130509-20130509" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzQzNw_080bd796-df32-4ab5-a7cc-c6b22b76d2ff">185,715</ix:nonFraction> shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September&#160;30, 2019, <ix:nonFraction unitRef="shares" contextRef="i7a1bc3c99884466aba07355633ce5f0e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzU1Nw_356c0136-2d5a-4515-8f9e-a3fa17dc088c">29,542</ix:nonFraction> shares remained available for issuance under the 2010 Purchase Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense for the three months ended September&#160;30, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzcxMg_e9483250-9fac-4319-b0ae-401f0ba799f8">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzcxOQ_24416c29-828c-45fc-9a86-41e946aacffd">4.6</ix:nonFraction> million, respectively. Share-based compensation expense for the nine months ended September&#160;30, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzc5NQ_12988dbf-8a33-457d-9457-83dce3110eb4">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzgwMg_ad07f4d9-432f-4df5-8dca-65431d642f94">13.6</ix:nonFraction> million, respectively.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the total compensation cost related to nonvested option awards not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDA5Nw_5a280458-4909-474f-994f-545228ac8f20">4.7</ix:nonFraction> million and the weighted-average period over which it is expected to be recognized is <ix:nonNumeric contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDE3OA_e7fa6aa0-c3c8-4521-942b-8ce5377be17e">2.7</ix:nonNumeric> years.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options and Performance Stock Options</span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxNQ_c16fa813-c833-4569-9190-79766a523041" escape="true"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity, including options with market and performance conditions and options granted and forfeited in conjunction with the option exchange program, for the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"><tr><td style="width:1.0%;"></td><td style="width:39.090909%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.709091%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.818182%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.709091%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.636364%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.709091%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.727273%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">of options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">remaining contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">term (years)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2ef382a4e2574d5795c997701aaa5ba2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS0yLTEtMS0w_38ec3652-fa01-4e54-beda-17c16d8cbadb">7,978,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ef382a4e2574d5795c997701aaa5ba2_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS00LTEtMS0w_02de2141-992a-4c03-a0c1-6b5665db8afd">11.86</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ief1b201dcccc48339b02bb8bb2870d0e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS02LTEtMS0w_f3c760cb-e93d-42fd-b053-4db5cca61795">4.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMi0yLTEtMS0w_b170c7dd-5ab3-4dce-9382-66dfdf51fc26">3,753,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMi00LTEtMS0w_4969e104-db12-44f7-b2da-d501b66e08c5">1.77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMy0yLTEtMS0w_23b1a739-2586-4277-81ca-dacca0319521">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMy00LTEtMS0w_c8a5a35f-897b-4d94-ae8b-95b6a54b50c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNC0yLTEtMS0w_b26e1944-5b94-4e54-a67e-f247cae615f8">4,696,520</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNC00LTEtMS0w_7688f324-0aae-4683-bb67-2eb78db0a106">11.43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options expired</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNS0yLTEtMS0w_2f7dfc2b-b91f-4a35-afb8-6856986d0a6f">1,318,698</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNS00LTEtMS0w_1563ae7d-b8cf-4f4a-9684-f4d90701b0be">5.93</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at end of period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi0yLTEtMS0w_a1227383-00bc-4c8c-a9a8-bc1355223bb5">5,716,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi00LTEtMS0w_2f7cf03e-9d8a-46a5-9687-5679db366bf6">6.96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi02LTEtMS0w_9ce66dca-e36c-495c-b62f-3aba7bb25950">4.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercisable at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy0yLTEtMS0w_41fae093-e51f-4ea1-8d6c-4690814db13c">3,165,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy00LTEtMS0w_d52b6e2c-5692-465e-bdbd-3ad29a608ef6">11.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy02LTEtMS0w_65a6c936-b3fa-49fa-9680-e9582b7b49ee">0.9</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. </span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAyMg_087646f1-8c89-470f-be93-ba809da87740" escape="true"><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"><tr><td style="width:1.0%;"></td><td style="width:66.139535%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.962791%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.697674%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMC0yLTEtMS0wL3RleHRyZWdpb246ZDg1Y2M2NjdiMjE5NDBlZmI2ZmEwMTA4ZDc4MTJkM2FfMzg0ODI5MDY5NzIzNg_8a4e8a7d-d8fb-4297-9350-26220b3a6929">1.8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMC0yLTEtMS0wL3RleHRyZWdpb246ZDg1Y2M2NjdiMjE5NDBlZmI2ZmEwMTA4ZDc4MTJkM2FfMzg0ODI5MDY5NzI0Mg_d2cbd2c1-b772-44a7-aaad-d5360bf7d9a2">2.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMS0yLTEtMS0wL3RleHRyZWdpb246MTdjZjI0NTJmY2E0NDllNmE4Yjg5NjdmYTcxNGZlMjVfMzg0ODI5MDY5NzIyMw_b0e91ee4-4e66-444a-ae88-ea666fa3d1d8">&#8212;</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMi0yLTEtMS0wL3RleHRyZWdpb246M2JjOGRlMGViNzBkNDcwYmJkMTFkYjcyMTM1YmU3NDVfMzg0ODI5MDY5NzIzOQ_db8c456f-e21c-43b3-88ab-e3d72e287d76">77.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMi0yLTEtMS0wL3RleHRyZWdpb246M2JjOGRlMGViNzBkNDcwYmJkMTFkYjcyMTM1YmU3NDVfMzg0ODI5MDY5NzI0Ng_b39536c2-fa71-4336-9ebb-2ffe444250b2">86.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="id22dbb1e99d54346b14b3c0916a4c37a_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMy0yLTEtMS0wL3RleHRyZWdpb246ZmFlNTkwZTM4ZTVmNDMwN2JiY2QzZmY3NGQ0NmE0M2JfMzg0ODI5MDY5NzIzMw_42fe548d-c48d-4b1a-84ed-ad3b3eb90d88">4</ix:nonNumeric> to <ix:nonNumeric contextRef="i8f55c0e897664d23bff3a32fd6ca9f5a_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMy0yLTEtMS0wL3RleHRyZWdpb246ZmFlNTkwZTM4ZTVmNDMwN2JiY2QzZmY3NGQ0NmE0M2JfMzg0ODI5MDY5NzIzOA_2c98eeca-2096-4e88-aed5-a7c0bcdd89d6">7.7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Weighted-average grant-date fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfNC0yLTEtMS0wL3RleHRyZWdpb246YWI3NWVkYmMyYjkwNDU1ZTljN2Q4OTVmMDZhOTNjZmFfMzg0ODI5MDY5NzIyOA_b17eb2b1-8956-4041-a0d7-c95fc9e13d69">1.89</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="usd" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDgzNA_62b22035-7b82-46a0-938d-2f004da9df61">No</ix:nonFraction> options were exercised during the nine months ended September&#160;30, 2019. The fair value of awards vested during the nine months ended September&#160;30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDkzMQ_257c8e5b-f066-4c85-a257-76b650124b90">2.7</ix:nonFraction> million. </span></div></ix:continuation><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i63915ba539ee442d927f293f96b4ddb8"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September&#160;30, 2019, the Company&#8217;s Board of Directors approved and granted <ix:nonFraction unitRef="shares" contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTAwOA_90f0dd70-c55e-43c5-8aad-4c672b517b79">650,000</ix:nonFraction> shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTE4MA_f78f04e0-3e23-46e4-bf94-744d4f45252d">1.24</ix:nonFraction>.  The equity awards vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2017 were met during the three and nine months ended September&#160;30, 2019 and <ix:nonFraction unitRef="shares" contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTM3MQ_b0819eaf-20a4-4b65-be34-a54f886c4078">79,849</ix:nonFraction> shares vested.  None of the targets for 2019 equity awards have been met.  </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock and Performance Restricted Stock</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the planning committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant.</span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAyMw_cc7e6736-cc8a-4c1d-8c00-cd534964fce1" escape="true"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September&#160;30, 2019 and changes during the nine months ended September&#160;30, 2019 are as follows:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"><tr><td style="width:1.0%;"></td><td style="width:54.235828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.933787%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.954649%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.933787%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.933787%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.933787%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.140590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.933787%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number of restricted stock shares</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average grant date fair value</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib4a2953b237a4956bb04a2ba877036e8_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMS0yLTEtMS0w_f94ea5e0-313d-4856-8a59-a56be583aea7">68,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4a2953b237a4956bb04a2ba877036e8_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMS02LTEtMS0w_4e89d319-7df5-4cd6-9dd0-fa9d430b4d17">37.75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMi0yLTEtMS0w_dff0b695-6346-4f36-b44d-8f3f3e25263b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMi02LTEtMS0w_d6382a13-eddb-4da2-a677-0878dc2aab92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMy0yLTEtMS0w_cca3e44f-1655-46be-8c1e-d0b99fce17fe">59,330</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMy02LTEtMS0w_e3d139f6-0d54-4508-b26d-bb4abebacfad">38.22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Forfeited/cancelled</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNC0yLTEtMS0w_28b29d29-3ff9-477f-bd2a-48774f624dcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNC02LTEtMS0w_48e75f3d-38d5-4357-a7ce-dd983f2b989d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i57817203713c4925802ca15e17d5adaa_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNS0yLTEtMS0w_fcc22245-8905-4e1c-be9d-3eb44f985c9f">9,255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i57817203713c4925802ca15e17d5adaa_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNS02LTEtMS0w_a540286a-dca6-4854-abda-a5299e046b26">34.73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the total remaining unrecognized compensation cost related to restricted stock was approximately $<ix:nonFraction unitRef="usd" contextRef="i57817203713c4925802ca15e17d5adaa_I20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNjQ3MA_36b01d89-938f-4959-a784-1c3bc18b1f60">124,963</ix:nonFraction> and is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNjU0MA_f621e33e-1077-41a5-bf58-b73a72f027c1">0.3</ix:nonNumeric> years. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Option Exchange Program</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company commenced an option exchange program (Option Exchange) for its officers and employees to exchange eligible stock options to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i257055a317c4463eb42d9ef38312b06f_I20190620" decimals="INF" format="ixt:numdotdecimal" name="nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzAyOA_834d6d81-6eb7-490c-a968-dc4cc22a484d">5,849,059</ix:nonFraction> shares of the Company's common stock that had been granted to eligible holders, for a lesser number of new stock options with a lower exercise price. Stock options granted prior to December 31, 2018 with an exercise price equal to or greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e071305c5974ee088653329c9314097_I20181231" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzI3OA_4729c96e-9da2-4da6-9a7a-690706da9f39">2.97</ix:nonFraction> and held by eligible holders in continuous service through the termination of the Option Exchange were eligible for exchange in the Option Exchange. </span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxOA_f5de9e73-8aa0-4f60-8a16-c27e801d2ffb" escape="true"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The eligible shares were exercisable for a reduced number of shares based on the following exchange ratios:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"><tr><td style="width:1.0%;"></td><td style="width:23.559105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.598722%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:23.559105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.598722%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.284345%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price Range per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Outstanding Eligible Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exchange Ratio (Surrendered Stock Options to New Stock Options)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia6344520fdce4afb87589a3d00b3e720_I20190930" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0wLTEtMS0wL3RleHRyZWdpb246Mzk2YWIyZjVhNGIzNDMwYzgwZjYzZGIxMjYwMWNiMDBfMzg0ODI5MDY5NzI1OQ_9dc416fa-b18a-484b-93ab-23d7f7d8c02e">2.97</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i370c9ff0ce304ee3974eceb8f6074b8c_I20190930" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0wLTEtMS0wL3RleHRyZWdpb246Mzk2YWIyZjVhNGIzNDMwYzgwZjYzZGIxMjYwMWNiMDBfNTQ5NzU1ODEzODkxNw_ff5c334d-57f6-4b02-a834-f5bffcf19935">10.99</ix:nonFraction></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i35f4cfa3cbf241ec8c3640a53481c862_I20190930" decimals="INF" format="ixt:numdotdecimal" name="nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0yLTEtMS0w_81af62f4-85b6-4d48-9304-a6536a5b56ab">2,725,812</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i35f4cfa3cbf241ec8c3640a53481c862_I20190930" decimals="2" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS00LTEtMS0wL3RleHRyZWdpb246ZTIwMGIxNDg2OGEzNGVjYWFmOTk4NGYzZTZkZGM0YzJfMzg0ODI5MDY5NzIyNw_55f960f9-101b-4d8a-bd9b-df448e859fe6">2</ix:nonFraction> to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib0476f147a0a46768f18d7f62d1b188a_I20190930" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0wLTEtMS0wL3RleHRyZWdpb246ZTE5ZjZmNmVjOTcwNDdkYmE0ZDg5Y2NmZDI2NDA4MTRfMzg0ODI5MDY5NzI0NQ_4c640541-61e5-4642-931b-162f35f1ac9e">11.00</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i5acd55e388054c249dd813ea270ac6b8_I20190930" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0wLTEtMS0wL3RleHRyZWdpb246ZTE5ZjZmNmVjOTcwNDdkYmE0ZDg5Y2NmZDI2NDA4MTRfNTQ5NzU1ODEzODkwMg_6fe39c81-cd2d-4f4d-a437-bf31bb862583">24.99</ix:nonFraction></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibe1655708734471499ed19001400af44_I20190930" decimals="INF" format="ixt:numdotdecimal" name="nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0yLTEtMS0w_b920d6b5-0374-470e-b98c-fc437bdae4c3">720,373</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="ibe1655708734471499ed19001400af44_I20190930" decimals="2" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi00LTEtMS0wL3RleHRyZWdpb246M2ZlNTIwM2NhZWRhNGIxNmI4M2I5NDc4NThiOGM5OWZfMzg0ODI5MDY5NzIyNw_7c09c6a4-f806-4339-82e2-d309a1a0f105">3</ix:nonFraction> to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i169a1b92c3e548cc86648a4bb5aae559_I20190930" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy0wLTEtMS0wL3RleHRyZWdpb246MzFmZGJiYTE2ZmM1NGQ1Y2IwZTkyMDA0NzQ2ODhmZWVfMzg0ODI5MDY5NzIzOA_50cceb2f-3d59-4a45-9369-2214de682c85">25.00</ix:nonFraction>-And Up</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4d00499345b541a7874a4e149b9f52ef_I20190930" decimals="INF" format="ixt:numdotdecimal" name="nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy0yLTEtMS0w_fec5a7c6-cf13-4db9-8d49-c97ae8fa9af2">468,671</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i4d00499345b541a7874a4e149b9f52ef_I20190930" decimals="2" name="nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy00LTEtMS0wL3RleHRyZWdpb246ZGYzMjc3OTJlNzQyNDIwNjk1NjU1ZDJmMjgwZWE2MGRfMzg0ODI5MDY5NzIyNw_9d4e40bf-f76d-491e-a0d0-e0076b347fb3">4</ix:nonFraction> to 1</span></div></td></tr></table></div></ix:nonNumeric><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Upon the expiration of the Option Exchange on July 31, 2019, <ix:nonFraction unitRef="employee" contextRef="i008f25566c8b40b295668c906960417d_I20190731" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzU5OQ_2fbbc09f-266b-469c-8f9e-9f8917bd1c7e">45</ix:nonFraction> eligible employees and <ix:nonFraction unitRef="director" contextRef="i008f25566c8b40b295668c906960417d_I20190731" decimals="INF" name="nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzYyNQ_c5361e68-ceca-4e57-8b8a-3f6337b6b78c">5</ix:nonFraction> eligible directors had tendered an aggregate of <ix:nonFraction unitRef="shares" contextRef="i008f25566c8b40b295668c906960417d_I20190731" decimals="INF" format="ixt:numdotdecimal" name="nlnk:ShareBasedPaymentArrangementOptionExchangeOptionsConverted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzY3Ng_baf36305-5233-41c1-8594-6637ea700809">3,914,856</ix:nonFraction> options, representing <ix:nonFraction unitRef="number" contextRef="i008f25566c8b40b295668c906960417d_I20190731" decimals="2" name="nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzcwMQ_54c126d4-f6b3-46f7-9f6e-333f17c68fb6">67</ix:nonFraction>% of the total eligible options, for <ix:nonFraction unitRef="shares" contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzczOQ_57a3646e-827d-4f17-9411-571801e51abf">1,720,341</ix:nonFraction> new options to purchase shares of common stock (New Awards). Each New Award was granted on July 31, 2019, pursuant to the Company's 2009 Plan, with an exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzkyNw_76095ca7-7445-4e6a-b37d-86464115e4e1">1.77</ix:nonFraction> per share, the closing price on the grant date of the New Awards.  Each New Award has a maximum term of <ix:nonNumeric contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjE5OTAyMzI2NTU1Mw_f1c4a09c-4a06-40cf-bcaf-4828dd482911">seven years</ix:nonNumeric>.  The New Awards will vest in equal annual amounts over either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjQ5OQ_eda0d1de-291e-4724-9f3d-24d63817ed19">two</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjUxMw_1e2e5b28-e0fd-452d-9a2f-63613413e197">three</span> years, depending on whether the tendered eligible option was vested as of the exchange date. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As a result of this transaction the Company will recognize additional stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i0db96647bdad4850a6a856796387bea0_D20190731-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzE0NjgyNTU4ODgzMA_f0760bec-7876-40ed-9825-4b23f2b963c2">1.0</ix:nonFraction> million over the vesting schedule of the New Awards.</span></div></ix:continuation><div id="i_0_55"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">7.&#160;   <ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyMw_1f06a6df-aeaf-47b7-92aa-4cb448de2699" continuedAt="ie71e746a1715426bb79d626bc97ba723" escape="true"><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyNA_b44eaf83-70a3-4a42-ab9b-ba173c1871ef" continuedAt="i2ed4981fd6724ae7b5ffa02941d3f4d4" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ie71e746a1715426bb79d626bc97ba723"><ix:continuation id="i2ed4981fd6724ae7b5ffa02941d3f4d4"><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has certain facility leases with non-cancellable terms ranging between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7">one</span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6">three</span> years, with certain renewal options. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company records lease liabilities based on the present value of lease payments over the lease term using an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. To compute the present value of the lease liability, the Company used a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfNTAy_f08a6a18-de9e-464a-ab3f-3524bb1f6f00">5</ix:nonFraction>%. Certain lease agreements include renewal options that are under the Company's control. The Company includes optional renewal periods in the lease term only when it is reasonably certain that the Company will exercise its option. Prior to September&#160;30, 2019, the Company had asserted it would renew the lease terms through expiry of the lease renewal option periods. At September&#160;30, 2019, as part of the Company's efforts to reduce costs and conserve resources, the Company concluded it would not be seeking renewal of the leased facilities in Ames, Iowa and upon termination of the lease agreements, it would identify a new space for the Company. As a result of this decision, the Company remeasured the right-of-use assets and lease liabilities using the shorter term. The weighted-average remaining lease term as of September&#160;30, 2019 is <ix:nonNumeric contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfNzkw_b7ce93a1-679a-4df4-a2d8-de787d456f26">1.0</ix:nonNumeric> year. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not separate lease components from non-lease components. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The Company's lease agreements do not contain any residual value guarantees or restrictive covenants.</span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyNQ_261af0cc-cf0a-4b50-af60-df637c5f06aa" escape="true"><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: </span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"></td><td style="width:61.112392%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.887608%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMS0xLTEtMS0w_06ed2892-dea2-4cc0-995c-c718026f7160">255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMi0xLTEtMS0w_25d4df09-d1da-4b4e-bed5-a546c202da46">599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMy0xLTEtMS0w_2926fea9-6124-4b5f-aca2-268a4629599d">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNC0xLTEtMS0w_bb3e0d83-d468-4d10-98da-80070b0433ef">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNS0xLTEtMS0w_dc7b0c24-41de-428c-bb30-d2012d3ecfd2">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNi0xLTEtMS0w_92e014b1-9c63-4448-8d01-4589f2b7cab6">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNy0xLTEtMS0w_cb2525a0-f093-415f-aeb0-54665ea1f0c2">987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOC0xLTEtMS0yNTAz_a788e669-1966-4b2f-bf0d-ea68e1e87aaf">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" name="nlnk:LesseeOperatingLeaseLiabilityUnamortizedIncentives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOC0xLTEtMS0w_3cfab903-66aa-4945-b42c-c06c74328c9c">951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOS0xLTEtMS0w_1a5e9915-12ad-42c8-892e-5f5d6628c594">1,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyMg_fb6583bd-a227-4635-b501-cd162d44f7c9" escape="true"><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"></td><td style="width:61.112392%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.887608%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMS0xLTEtMS0w_d4b95915-8944-4cbc-9bc4-b279dd709a06">1,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMi0xLTEtMS0w_40afbc18-7b24-4ab8-b3c8-85b97afb0e4a">1,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMy0xLTEtMS0w_fbe9cee5-ee5d-4a57-af27-6e55992f3abd">923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNC0xLTEtMS0w_0fc01f16-32ae-4c8b-a56c-c5ff1c0ff557">906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNS0xLTEtMS0w_09a14ea1-05d1-444d-aa7f-17039bd3ac22">909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNi0xLTEtMS0w_ff296c89-3d78-4fc2-8bef-4f2511750fc6">6,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNy0xLTEtMS0w_1cdd4f0f-cbd1-448e-a587-c706988d53ef">11,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-indent:36pt;text-align:center;margin-top:9pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_58"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">8.&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMTg0MQ_bed0fedd-8ae1-48d6-846f-b9c089f6d187" continuedAt="i9897fb3f68f94ff88839d06ba2af2f69" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i9897fb3f68f94ff88839d06ba2af2f69"><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September&#160;30, 2019 and 2018, the Company has recorded</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> <ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfOTQ_1c77e909-2ed6-48a8-9863-09f8d529ed29"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfOTQ_f9620ce8-1654-471f-9af1-aac7f77a01f8">no</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMjc0ODc3OTA3MTU2NQ_27d6aa96-b945-4e9c-95f2-3b02d752e1f4"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMjc0ODc3OTA3MTU2NQ_5c82f50e-7f6b-42be-9a5d-0916eccba5f4">7.0</ix:nonFraction></ix:nonFraction> million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> income tax benefit (expense). The income tax amount for the three and nine months ended  September&#160;30, 2019 and 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to a full valuation allowance recorded against anticipated net operating loss carryforwards.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has an income tax receivable as of September&#160;30, 2019 for $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNDcw_49a79479-7434-4f11-af72-9903917021fa">140,000</ix:nonFraction> of which $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNjU5NzA2OTc2ODc0NA_ad78badc-bf21-4246-8266-18da6d426d97">71,000</ix:nonFraction> is recorded within short term receivables and $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNjU5NzA2OTc2ODc0Nw_ba73b9b5-d2b4-4a92-9d7d-05297b4659f0">69,000</ix:nonFraction> is recorded in long-term. The full amount was recorded as an income tax benefit in 2017 and is for the receipt of alternative minimum tax (AMT) credit carryovers. The Tax Cuts and Jobs Act of 2017 (the Tax Act), provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability.  The Company expects the amount to be fully refunded by 2021.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September&#160;30, 2019 and December&#160;31, 2018, respectively, due to the uncertainty of future recoverability.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has a reserve for uncertain tax positions related to state tax matters of $<ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMTYwOQ_e2c6d5aa-d2bf-4477-b99c-d0da41d67f0e">653,000</ix:nonFraction> as of September&#160;30, 2019 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.</span></div></ix:continuation><div id="i_0_61"></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">9.&#160;&#160;&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTA0Mg_be064e5b-3ea1-40a6-b6a2-719eee029365" continuedAt="i88153f73ff8540b6bd2f7ff45d90870b" escape="true">Net Loss per Share of Common Stock</ix:nonNumeric></span></div><ix:continuation id="i88153f73ff8540b6bd2f7ff45d90870b" continuedAt="i6eb4906011764577878c11415e5606cb"><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Basic loss per share is based upon the weighted-average number of shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.</span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTA0MQ_f495fd7f-a86c-4ed0-981a-d432c6749e0f" escape="true"><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data):</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"></td><td style="width:42.709389%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545156%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.141282%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.588376%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.667660%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Loss attributable to common stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi0yLTEtMS0w_220d9085-7098-408a-8737-31697a1f0950">14,548</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi00LTEtMS0w_866f45f0-911e-4571-ae57-08b55078db42">7,403</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi02LTEtMS0w_df87f03e-3e39-4454-8ea0-6ae404dcd8da">34,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi04LTEtMS0w_6e43ff13-f2ef-4324-8eb9-84afdab08289">43,026</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC0yLTEtMS0w_d21695bd-2fcd-4457-8ad2-7736de49452b">37,308,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC00LTEtMS0w_4388f019-a622-449d-9afe-841fe86303e9">37,214,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC02LTEtMS0w_3df268bd-f687-4755-b621-45f84ff9a757">37,286,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC04LTEtMS0w_ba5a2b49-5a0c-4d2d-a0a9-48240caa8cc1">37,178,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Basic and diluted loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC0yLTEtMS0w_357bbf5e-7072-4c80-b190-acd605957fb8">0.39</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC00LTEtMS0w_117269fe-ab92-4075-98cc-dd11b7d4e00a">0.20</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC02LTEtMS0w_c40223a4-f031-48c0-978c-7208d7793929">0.93</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC04LTEtMS0w_6d39bcb0-653e-40a4-8726-caddfa77b11e">1.16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6eb4906011764577878c11415e5606cb">All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September&#160;30, 2019, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled <ix:nonFraction unitRef="shares" contextRef="if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfODg0_e981bf8b-ba7c-49fa-8276-b21014b2f9b9">5,716,086</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b905d67ed264c328656baba2a4db384_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfODkx_dac8aae1-ec57-43a3-b9b7-9f3f1126574f">9,255</ix:nonFraction>, respectively.  As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled <ix:nonFraction unitRef="shares" contextRef="i7b3f948dc1734160ad119b9960b9d13b_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTAxNg_90d86741-8aa9-4720-bd5c-23d52c5d810d">8,371,005</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i39cb87fc9300480f802ea9c680a0f776_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTAyMw_82948ac8-bff5-4c3c-acf4-c67aa8142b0b">89,053</ix:nonFraction>, respectively.</ix:continuation> </span></div><div id="i_0_67"></div><div style="margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">10.&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfMTEyMQ_a29f0a51-d639-4366-b218-76a79d4656da" continuedAt="i08fe90a6893446f199116aee5ce7bd36" escape="true">Restructuring and Severance Charges</ix:nonNumeric></span></div><ix:continuation id="i08fe90a6893446f199116aee5ce7bd36"><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&#160;restructuring&#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, is recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&#160;activities. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, the Company adopted a restructuring plan to reduce its headcount by approximately <ix:nonFraction unitRef="number" contextRef="ib799a2a817e04b59aab49144acc02919_D20190930-20190930" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc2OTc5MQ_de822ffc-551a-4bd0-961e-e2204d1f84ba">60</ix:nonFraction>%, which consisted primarily of clinical and research and development staff, and made several changes to senior leadership in order to conserve resources. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the restructuring, Charles J. Link, Jr, M.D. retired from the Company and the Board of Directors, effective August 3, 2019 and Nicholas Vahanian retired from his position as the President and member of the Board of Directors, effective September 27, 2019, and will remain an employee of the Company through a transition period ending November 11, 2019.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the restructuring and departure of Company executives, the Company recorded restructuring and severance charges of $<ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzMQ_be89cc4e-83ee-407b-a819-97b03c215086"><ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzMQ_eb2bd911-601c-44e6-a88e-059de32a7f66">4.5</ix:nonFraction></ix:nonFraction> million during the three and nine months ended September&#160;30, 2019 of which $<ix:nonFraction unitRef="usd" contextRef="ie7ae389b9e2b4cae9570b2523f80048b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzNg_269366a5-844c-49e6-acba-0c202d915d72"><ix:nonFraction unitRef="usd" contextRef="i347cb4a8f93f4834925abbdb2c22d273_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzNg_7ccf361c-f6d7-4736-a947-98eafb538d6c">2.9</ix:nonFraction></ix:nonFraction>&#160;million is included within general and administrative expenses and $<ix:nonFraction unitRef="usd" contextRef="i79f20a25e4d646fdb0ce1a7190c7639a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3Mjk0NQ_47bb69bd-642f-4c2b-a842-a51f2642236a"><ix:nonFraction unitRef="usd" contextRef="ia14e8601ef3249db99d27585927dca67_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3Mjk0NQ_4a29fb1c-d025-432c-83bc-db1d285aae23">1.6</ix:nonFraction></ix:nonFraction>&#160;million is included within research and development expenses. As a result of the restructuring, the Company also recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkyNQ_95f3af01-623c-4f8f-b19c-02fe925a609a"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkyNQ_aec1ce3f-1d30-4489-a4e7-1bdee8f44f0f">351,000</ix:nonFraction></ix:nonFraction> relating to fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#8217;s estimate of market resale value.  </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In July 2018, the Company reduced its headcount by approximately <ix:nonFraction unitRef="number" contextRef="i55705cb9c17045b2b56549f7969a9968_D20180701-20180731" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzAx_a03eb44e-7818-4610-93fc-1eba8e1c30dc">30</ix:nonFraction>% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to advance its clinical development programs. Restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzE0NjgyNTU4NTE3MA_22a1643f-391e-40b2-a4d1-7845b24f084d"><ix:nonFraction unitRef="usd" contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzE0NjgyNTU4NTE3MA_8aae1a5d-6418-43a5-adde-67da7c8c8f84">1.3</ix:nonFraction></ix:nonFraction> million were recorded during the three and nine months ended September&#160;30, 2018.</span></div><ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfMTEyNA_b33f9428-b2f3-46a3-88d8-2a10f30e79fe" escape="true"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table shows the amount accrued for restructuring and severance activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"><tr><td style="width:1.0%;"></td><td style="width:44.838407%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.205152%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.824356%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.205152%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:23.526932%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Employee Severance Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia427f2113ccc4110bc882b22d38777fe_I20181231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMS0yLTEtMS0w_9d76a60d-a1cc-4013-9ce2-f671c73984e7">649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMS00LTEtMS0w_b5f9eba7-be2d-46a2-86d8-b30617c1bf83">649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expensed</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMi0yLTEtMS0w_6d8fc247-ca45-4a7d-98eb-8c29bdbf74ea">4,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMi00LTEtMS0w_ff8baa24-5801-403c-ae16-170ad666eaa6">4,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash Payments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMy0yLTEtMS0w_cdaf2dfa-dd65-4df2-a241-99e5be296956">554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMy00LTEtMS0w_76edc7d5-14d7-4b90-8503-dffe12a12415">554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic490d40b023c41d2b5ba726dbee45eb8_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfNC0yLTEtMS0w_b6cf3094-d6c9-4681-b25a-1b82670175d0">4,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfNC00LTEtMS0w_eb1c06d4-eaa8-4490-bfa3-0b8b5a6c47fe">4,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24pt;text-align:center;margin-top:9pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_70"></div><div style="text-indent:-22pt;padding-left:22pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">11.&#160;<ix:nonNumeric contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF83MC9mcmFnOmNmM2JkNzE5NGNhYTQ4Yzc5YzU2M2Q0Y2U0Mjk3MTc0L3RleHRyZWdpb246Y2YzYmQ3MTk0Y2FhNDhjNzljNTYzZDRjZTQyOTcxNzRfNjAxNg_05fb5ce2-3753-4706-905b-8b8e0eb0e4fe" continuedAt="i04015fdc9a02460199c380abb46aeb41" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i04015fdc9a02460199c380abb46aeb41" continuedAt="i5697319cc64b47e9806864dd664e8991"><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York (the Court), captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545 (the Securities Action).  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, (collectively, the Defendants).  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors.  The Defendants filed a motion to dismiss the amended complaint on July 14, 2017.  On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:81pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents </a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><ix:continuation id="i5697319cc64b47e9806864dd664e8991"><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company&#8217;s investors.  The lead plaintiffs do not quantify any alleged damages in the second amended complaint but, in addition to attorneys&#8217; fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018.   On February 13, 2019, the Court dismissed the second amended complaint for failure to state a claim, with prejudice, and closed the case.  On March 14, 2019, lead plaintiffs filed a notice of appeal. The briefing on lead plaintiffs' appeal was completed in early July 2019 and oral argument before the Second Circuit Court of Appeals was held on October 21, 2019. The Company intends to continue defending the Securities Action vigorously.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth (collectively, the Morrow Defendants), captioned Morrow v. Link., et al., Case 1:17-cv-03039 (the Morrow Action).  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action has until March 15, 2019 (30 days after dismissal of the Securities Action with prejudice) to file an amended derivative complaint or rest upon the current derivative complaint.  By further agreement of the parties, dated March 15, 2019, the Ely Action will continue to be stayed pending the outcome of the appeal in the Securities Action. If the Securities Action continues to be dismissed in its entirety following its appeal plaintiff in the Ely Action has agreed to withdraw or dismiss the action, with prejudice.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</span></div></ix:continuation><div id="i_0_76"></div><div></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, Section&#160;21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and such statements are subject to the &#8220;safe harbor&#8221; created by those sections. &#160;Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information available to our management as of the date hereof. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: the expected completion and timing of the proposed merger with Lumos Pharma; the expected solicitation of and the actual stockholders&#8217; approval of issuance of NewLink&#8217;s common stock pursuant to the merger agreement and reverse stock split; the expected focus of the combined company post consummation of the proposed merger; the development plan for LUM-201; the development plan for our existing pipeline and potential partnership and out-licensing opportunities; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">our ongoing and planned preclinical studies and clinical trials; the timing of the release of the results of data from ongoing preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the clinical utility of our product candidates; our plans to leverage our existing technologies to discover and develop additional product candidates; our ability to quickly and efficiently identify and develop product candidates; our intellectual property position; the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; plans to develop, commercialize, market and manufacture our product candidates; and other risks and uncertainties, including those described in Part&#160;II,&#160;Item&#160;1A, &#8220;Risk Factors&#8221; of this Quarterly Report and in our other periodic reports filed from time to time with the Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K for the year ended December 31, 2018.&#160; Our actual results could differ materially from those discussed in our forward-looking statements for many reasons, including those risks. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form&#160;10-Q. You should read this Quarterly Report on Form&#160;10-Q completely. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part&#160;I,&#160;Item&#160;1 of this Quarterly Report on Form&#160;10-Q.</span></div><div><span><br/></span></div><div id="i_0_79"></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NewLink Genetics Corporation (the Company, NewLink, we, our or us) is a clinical-stage company that has historically focused on developing novel immunotherapeutic products for the treatment of patients with cancer. Our leading small-molecule product candidates currently in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway, which is one of the key pathways for cancer immune escape. These product candidates, indoximod and NLG802 (a prodrug of indoximod), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system&#8217;s tolerance to cancer. We also have an additional small molecule product candidate, NLG207 (formerly CRLX101), which is a nanoparticle-drug conjugate (NDC) consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on early clinical data from our Phase 1/2 clinical trials, our clinical program to date has been focused on targeted indications with great unmet need where indoximod, NLG802, and NLG207 have produced encouraging early data. Updated Phase 1b data for indoximod for the cohort of pediatric patients with newly diagnosed treatment-na&#239;ve diffuse intrinsic pontine glioma (DIPG) has been accepted for presentation at the upcoming ESMO Immuno-Oncology Congress 2019, 11-14 December 2019, Geneva, Switzerland. </span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Events</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On September 30, 2019, we entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Cyclone Merger Sub, Inc., a wholly-owned subsidiary of NewLink (Merger Sub) and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as our wholly-owned subsidiary (the Merger). Following the Merger, we will change our name to &#8220;Lumos Pharma, Inc.&#8221; and Lumos will change its name to a name mutually agreed upon by us and Lumos. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the effective time of the Merger (Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of our common stock equal to the amount determined pursuant to a charter amendment to Lumos&#8217; certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock.  Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately 50% of the aggregate number of shares of our common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and our stockholders as of immediately prior to the Merger will own approximately 50% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by us and converted into options to purchase a number of shares of our common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for our common stock.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company&#8217;s and Lumos&#8217; conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos.  Lumos stockholders approved the Merger in September 2019.  The Merger Agreement contains certain termination rights for both NewLink and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, NewLink or Lumos, as applicable, may be required to pay the other party a termination fee of $2.0 million.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement contemplates that we will also seek approval from our stockholders to effect a reverse stock split,  with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time. The Merger is expected to close in the first quarter of 2020.</span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">After the consummation of the Merger, the combined company expects to focus its efforts on the development of Lumos&#8217; sole product candidate, LUM-201 (ibutamoren), a potential oral therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. Our management does not intend to pursue further internal development of its existing pipeline upon consummation of the Merger, but will continue to evaluate our pipeline pending results of the DIPG cohort of our Phase 1b clinical trial for indoximod and, depending on such results, may seek to identify potential partnerships and out-licensing opportunities. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We have prepared this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and the forward-looking statements contained in this report as if the Merger will not be consummated. If the Merger is consummated, many of the forward-looking statements related to our current product candidates and contained in this report would no longer be applicable.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">IDO Pathway Inhibitors</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In cancer, the IDO pathway regulates immune response by suppressing T-cell activation, which enables cancer to avoid immune response. IDO is overexpressed in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor-draining lymph nodes, thereby promoting peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The IDO pathway refers to a series of reactions initiated by IDO that result in the reduction of the amino acid tryptophan in the local tumor environment. We believe the local presence of tryptophan in adequate concentrations promotes antitumor T-cells, and the local reduction of tryptophan combined with the presence of the breakdown product of tryptophan metabolism, kynurenine, is understood to suppress the activation of T-cells. Preclinical and, increasingly, clinical data suggest that IDO pathway inhibitors may also enhance the anti-tumor effects of other immunotherapies, chemotherapies and radiation when used as a combination therapy for patients with cancer.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Currently, we have a clinical development program primarily focused on the IDO pathway. Our small-molecule IDO pathway inhibitor product candidates currently in clinical development include indoximod and NLG802. Our product candidates are designed to counteract immunosuppressive effects of the IDO pathway, a fundamental mechanism regulating immune response. Indoximod acts as a tryptophan mimetic, thereby signaling the activation of antitumor T-cells by the activation of mammalian target of rapamycin (mTOR), acts directly on T-cells, and modulates aryl hydrocarbon receptor (AhR)-mediated effects.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have observed an encouraging safety profile for our IDO pathway inhibitors. They are also orally bioavailable and we believe they offer the potential to be synergistic with other therapies such as radiation, chemotherapy, vaccination and immunotherapies involving other checkpoint inhibitors such as anti-PD-1, anti-programmed cell death ligand-1 (PD-L1), or </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">anti-cytotoxic T-lymphocyte antigen 4 (CLTA4). Clinical data suggest an increase in clinical activity without adding significant toxicity.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indoximod</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indoximod, our lead IDO pathway inhibitor, is currently in clinical development in combination with other cancer therapeutics for patients with DIPG. We believe there may be future opportunities to apply indoximod to a broader set of cancer indications based upon clinical data generated by the Company and potentially resulting from data generated by others with ongoing IDO clinical development programs. More than 900 patients have been treated with indoximod to date and it has generally been well-tolerated, including in combination with PD-1 checkpoint inhibitors, various chemotherapy agents, radiation, and a cancer vaccine.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">A tablet formulation of indoximod hydrochloride has been developed for adult patients and a sprinkle formulation is being developed for pediatric indications.   We plan to use our new tablet formulation of indoximod in any future clinical trials.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Two U.S. patents covering both the salt and prodrug formulations of indoximod were issued in the U.S. on August 15, 2017 and February 19, 2019 providing exclusivity until at least 2036. We are currently pursuing international patent coverage for these formulations.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NLG802</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NLG802 is a prodrug of indoximod. NLG802 is intended to increase bioavailability and exposure to indoximod above levels currently achievable by direct oral administration of indoximod. We filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), in the first quarter of 2017 and the first patient was dosed with NLG802 in a Phase 1 clinical trial in July 2017. The purpose of this Phase 1 trial is to assess preliminary safety and to determine the recommended dose for subsequent Phase 2 evaluations. NLG802 is a new chemical entity with patent coverage into 2036. We are also pursuing international patent coverage for NLG802.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In May 2019, we presented updated results for the Phase 1 dose escalation trial for NLG802 at the Immuno-Oncology 2019 World Congress. Pharmacokinetics (PK) results were also reported from this study. After continuous twice-daily dosing with NLG802 at all levels, significantly higher PK exposure as compared to indoximod was observed. At 1452 mg twice daily, the highest dose administered, NLG802 produced a 6-fold increase in Cmax and a 4.7-fold increase in AUC compared with molar equivalent indoximod dosing.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The treatment regimen was well tolerated with no NLG802-related serious adverse events reported. The recommended Phase 2 dose was established at 1452 mg BID based on achieving preclinical exposure levels required for pharmacodynamic effects of indoximod. </span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NLG919</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NLG919, a direct IDO enzymatic inhibitor, was previously in clinical development as part of our collaboration with Genentech, Inc. (Genentech). In October 2014, we entered into an exclusive worldwide license and collaboration agreement with Genentech (the Genentech Agreement). The Genentech Agreement provided for the development and commercialization of NLG919. On December 6, 2017, the Genentech Agreement with respect to NLG919 was terminated. As part of the partial termination, worldwide rights to NLG919 reverted to us and Genentech granted us a license under certain of Genentech&#8217;s intellectual property to develop and commercialize NLG919. We continue to explore the potential for further development and licensing opportunities but do not have an active program for the drug product candidate as of September 30, 2019.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Additional Product Candidates</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NLG207</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NLG207 is a NDC consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase-1, or top-1, inhibitor. Because the vasculature in tumors is more permeable than normal tissue, we believe NDCs have the potential to enhance drug delivery to tumors by enabling gradual payload release inside cancer cells to augment antitumor activity while reducing off-target toxicity. NLG207 has been studied in more than 400 patients as monotherapy or in combination with other anticancer agents for patients with solid tumors.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A Phase 2 trial evaluating NLG207 plus paclitaxel for patients with recurrent ovarian, fallopian tube or primary peritoneal cancer was completed in collaboration with the Gynecological Oncology Group and the results of the trial were presented at the annual meeting for the American Association for Cancer Research on April 2, 2019. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are exploring the potential for further development through out-licensing opportunities for the drug product candidate as of September 30, 2019.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ebola Vaccine Candidate</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2014, we entered into the Merck Agreement to develop and potentially commercialize our rVSV&#8710;G-ZEBOV-GP vaccine product candidate and other aspects of our vaccine technology. The rVSV&#8710;G-ZEBOV-GP vaccine product candidate was originally developed by the Public Health Agency of Canada (PHAC) and is designed to utilize the rVSV vector to induce immunity against Ebola virus when replacing the VSV glycoprotein with corresponding glycoproteins from filoviruses. Under the Merck Agreement, we received an upfront payment of $30.0 million in October 2014, and in February 2015 we received a milestone payment of $20.0 million. We have the potential to earn royalties on sales of the vaccine in certain countries, if the vaccine is approved by the FDA and successfully commercialized by Merck. rVSV&#8710;G-ZEBOV-GP is also eligible to receive a priority review voucher and we are entitled to a portion of the value of the voucher if it is granted. In addition to milestone payments from Merck, we were awarded contracts for development of the rVSV&#8710;G-ZEBOV-GP from the U.S. BioMedical Advanced Research &amp; Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA), totaling $52.1 million during 2016 and $67.0 million during 2014 and 2015. Funds of $2.1 million were de-obligated from the DTRA grant awards in 2017. We have received total awards of $118.8 million.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On April 26, 2018 we entered into an agreement with Merck, DTRA and BARDA to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced us as the prime contractor on all such grants.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Merck announced in September 2019 that the FDA had accepted its biologics license application (BLA) filing and granted priority review for the Ebola vaccination. The Prescription Drug User Fee Act, or target action date, is set for March 14, 2020. </span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Restructuring Charges</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, we adopted a restructuring plan to reduce our headcount by approximately 60%, which consisted primarily of clinical and research and development staff, and made several changes to senior leadership in order to conserve resources. </span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In addition to the restructuring, effective August 3, 2019, Charles J. Link, Jr, M.D. retired from his position as the Chairman, Chief Executive Officer and Chief Scientific Officer and a member of the Board of Directors of the Company, and Nicholas Vahanian retired from his position as the President and member of the Board of the Company, effective September 27, 2019, and will remain an employee of the Company through a transition period ending November 11, 2019.  </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the restructuring and departure of our executives, we recorded restructuring and severance charges of $4.5 million during the three and nine months ended September&#160;30, 2019 of which $2.9&#160;million is included within general and administrative expenses and $1.6&#160;million is included within research and development expenses. As a result of the restructuring, we also recorded an impairment charge of $351,000 relating to fixed assets for which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#8217;s estimate of market resale value.  </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In July 2018, we reduced our headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September&#160;30, 2018.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Amounts accrued for restructuring and severance activities is recorded within Accrued Expenses in the condensed consolidated balance sheet.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Corporate Information</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Founded in 1999, our executive offices are located in the Iowa State University Research Park in Ames, Iowa. We have approximately 50,160 square feet, comprising executive office space and space available for manufacturing, testing and product storage, leased with the Iowa State University Research Park Corporation. At the earlier of the entry into a sublease agreement with a tenant or termination of these lease agreements, with the last to terminate in March 2021, we will seek to lease an office space in the Ames, Iowa area with a smaller footprint.  We have additional executive and administrative space in Austin, Texas, with the lease ending in December 2019, and clinical, regulatory and executive offices in Wayne, Pennsylvania.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We incurred a net loss of $34.7 million for the nine months ended September&#160;30, 2019.  We expect to continue to incur losses over the next several years as we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates.</span></div><div id="i_0_82"></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have prepared our financial statements in accordance with U.S. GAAP which requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenues and expenses during the reporting periods. As such, to understand our financial statements, it is important to understand our critical accounting policies.  A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results could, therefore, differ materially from these estimates under different assumptions or conditions.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our Annual Report on Form 10-K for the year ended December&#160;31, 2018 discusses our most critical accounting policies. Since December&#160;31, 2018, there have been no material changes in the critical accounting policies discussed in our 2018 Annual Report.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We adopted ASC Topic 842 on January 1, 2019 and have disclosed the impact adoption had on our condensed consolidated financial statements within Note 3 of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; of this Form 10-Q. We do not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.</span></div><div id="i_0_85"></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three Months Ended September&#160;30, 2019 and 2018</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Revenues for the three months ended September&#160;30, 2019 were $246,000, a increase of $126,000 from $120,000 for the same period in 2018. The increase in revenue was attributable to an increase of $126,000 in licensing revenue, attributable to higher billings to Merck. We recognized licensing revenue during the three months ended September&#160;30, 2019 for work we performed as a subcontractor of Merck.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. Research and development expenses for the three months ended September&#160;30, 2019 were $7.0 million, a decrease of $546,000 from $7.6 million for the same period in 2018.  The decrease was primarily due to reductions of $1.1 million in personnel-related and stock compensation expense, $255,000 in contract research and manufacturing spend, and $333,000 in legal and consulting and supplies expense, offset by increases of $1.1 million in restructuring and severance expenses and $87,000 in clinical trial and licensing expense.  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> General and administrative expenses for the three months ended September&#160;30, 2019 were $8.3 million, an increase of $691,000 from $7.6&#160;million for the same period in 2018. The increase was due primarily to increases of $2.0 million in restructuring and severance expenses, and $1.2 million in legal and consulting expense, offset by decreases of $1.7 million in stock compensation expense,  $431,000 in personnel-related expense, and $353,000 in supplies.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Tax Benefit.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We recorded no income tax benefit for the three months ended September&#160;30, 2019. We recorded an income tax benefit of $7.0&#160;million for the three months ended September&#160;30, 2018. The income tax benefit differs from the three months ended September 30, 2018 due to a refund received in 2018 as a result of amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Loss.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The net loss for the three months ended September&#160;30, 2019 was $14.5 million compared to a net loss of $7.4 million for the same period in 2018.  The basic and diluted weighted-average shares of common stock outstanding for the three months ended September&#160;30, 2019 were 37,308,523, resulting in a basic and diluted loss per share of $0.39.  For the three months ended September&#160;30, 2018, the basic and diluted weighted-average shares of common stock outstanding were 37,214,363, resulting in basic and diluted loss per share of $0.20.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Nine Months Ended September&#160;30, 2019 and 2018</span></div><div><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Revenues for the nine months ended September&#160;30, 2019 were $503,000, a decrease of $11.8 million from $12.3 million for the same period in 2018. The decrease in revenue was due to a decrease in grant revenue of $11.3 million, primarily attributable to a decrease in billings under the government grant contracts which were fully transferred to Merck in June 2018, and a decrease of $501,000 in licensing revenue, attributable to lower billings to Merck. We recognized licensing revenue during the nine months ended September&#160;30, 2019 for work we performed as a subcontractor of Merck.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. Research and development expenses for the nine months ended September&#160;30, 2019 were $17.5 million, a decrease of $22.5 million from $40.0 million for the same period in 2018.   The decrease was primarily </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">due to reductions of $12.5 million in contract research and manufacturing spend, $5.2 million in personnel-related and stock compensation expense, $4.0 million in clinical trial expense, $961,000 in supplies and licensing, and $945,000 in legal and consulting expenses, offset by an increase of $1.1 million in restructuring and severance expenses. .</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expenses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> General and administrative expenses for the nine months ended September&#160;30, 2019 were $19.5 million, a decrease of $4.3 million from $23.8 million for the same period in 2018. The decrease was due primarily to reductions of $6.0 million in personnel-related and stock compensation expense, and $1.2 million in supplies expense, offset by increases of $2.0 million in restructuring and severance expenses and $988,000 in legal and consulting expense.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Tax Benefit.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We recorded no income tax benefit for the nine months ended September&#160;30, 2019 and a $7.0 million income tax benefit for the nine months ended September&#160;30, 2018. The income tax benefit differs from the nine months ended September 30, 2018 due to a refund received in 2018 as a result of amendments filed to change the allocation of income for certain states for the years ending December 31, 2014 and 2015. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Loss.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The net loss for the nine months ended September&#160;30, 2019 was $34.7 million compared to a net loss of $43.0 million for the same period in 2018.  The basic and diluted weighted-average shares of common stock outstanding for the nine months ended September&#160;30, 2019 were 37,286,930, resulting in a basic and diluted loss per share of $0.93.  For the nine months ended September&#160;30, 2018, the basic and diluted weighted-average shares of common stock outstanding were 37,178,542, resulting in basic and diluted loss per share of $1.16.</span></div><div id="i_0_88"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_91"></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, we had cash and cash equivalents of $98.5 million. We have historically funded our operations principally through the private placement of equity securities, public offerings of common stock, and license and milestone payments received under our collaboration agreements. We believe that our cash and cash equivalents on hand will be sufficient to fund our operations through 2021. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">With the exception of fiscal year 2014, we have incurred operating losses and an accumulated deficit as a result of ongoing research and development spending since inception. We anticipate that we will continue to generate operating losses to the extent that we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may seek to sell additional equity or debt securities or obtain a credit facility if our available cash and cash equivalents are insufficient to satisfy our liquidity requirements or if we develop additional opportunities to do so. The sale of additional equity and debt securities may result in additional dilution to our stockholders. If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned research and development activities, which could harm our business.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Because of the numerous risks and uncertainties associated with the research and development of our product candidates, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the scope, progress, results, and costs of clinical trials for our product candidates, and discovery and development activities related to new product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales, facilities, and distribution costs;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the cost of manufacturing our product candidates and any products we commercialize;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">whether, and to what extent, we are required to repay our outstanding government provided loans;</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:8pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:73.099415%;"><tr><td style="width:0.1%;"></td><td style="width:1.400000%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:56.800000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.800000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.800000%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.800000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.800000%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net cash used in operating activities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(22,176)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(36,622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Net cash provided by investing activities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(136)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(22,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(36,647)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September&#160;30, 2019 and 2018, we used cash of $22.2 million and $36.6 million, respectively, for our operating activities. The decrease in cash used in operating activities was primarily due to the decrease in research and development activity and changes in working capital for the nine months ended September&#160;30, 2019 as compared to the nine months ended September&#160;30, 2018.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September&#160;30, 2019 and 2018, our investing activities provided cash of $15,000 and $111,000, respectively. The cash provided by investing activities during the nine months ended September&#160;30, 2019 was due to proceeds received from sales of property and equipment of $15,000. The cash provided by investing activities during the nine months ended September&#160;30, 2018 was due to proceeds received from sales of property and equipment of $118,000, offset by $7,000 used in the purchase of equipment. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September&#160;30, 2019 and 2018, our financing activities used cash of $50,000 and $136,000, respectively. The cash used in financing activities during the nine months ended September&#160;30, 2019 was due to the net payments made on long-term obligations and notes payable of $46,000 and repurchases of common stock of $34,000, offset by the issuance of shares of common stock of $30,000. The cash provided by financing activities during the nine months ended September&#160;30, 2018 was primarily due to the issuance of shares of common stock for net proceeds of $269,000, offset by net payments on long-term obligations and notes payable of $138,000, and repurchase of common stock of $267,000. </span></div><div id="i_0_94"></div><div><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates. As of September&#160;30, 2019 and December&#160;31, 2018, we had cash and cash equivalents of $98.5 million and $120.7 million, respectively, consisting primarily of money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. Due to the short-term duration of our investment portfolio and the low-risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our long-term debt bears interest at fixed rates. Any change in interest rates would have an immaterial impact on our financial statements.</span></div><div id="i_0_97"></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company&#8217;s principal executive officer and principal financial officer have concluded, based on an evaluation of the Company&#8217;s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934, as amended (Exchange Act), Rules 13a-15(e) or 15d-15(e)) as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15 that, as of September&#160;30, 2019, the Company&#8217;s disclosure controls and procedures were effective. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;"> </span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In connection with the evaluation of the Company's internal control over financial reporting that occurred during the quarter ended September&#160;30, 2019, which is required under the Exchange Act by paragraph (d) of Exchange Rules 13a-15 or </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">15d-15 (as defined in paragraph (f) of Rule 13a-15), management determined that there was no change that materially affected or is reasonably likely to materially affect internal control over financial reporting. </span></div><div id="i_0_100"></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="i_0_103"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART&#160;II. OTHER INFORMATION</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_106"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;LEGAL PROCEEDINGS</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York (the Court), captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545 (the Securities Action).  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian (collectively, the Defendants).  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors.  The Defendants filed a motion to dismiss the amended complaint on July 14, 2017.  On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company&#8217;s investors.  The lead plaintiffs do not quantify any alleged damages in the second amended complaint but, in addition to attorneys&#8217; fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018.   On February 13, 2019, the Court dismissed the second amended complaint for failure to state a claim, with prejudice, and closed the case.  On March 14, 2019, lead plaintiffs filed a notice of appeal. The briefing on lead plaintiffs' appeal was completed in early July 2019 and oral argument before the Second Circuit Court of Appeals is currently scheduled for the week of October 21, 2019. The Company intends to continue defending the Securities Action vigorously.</span></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth (collectively, the Morrow Defendants), captioned Morrow v. Link., et al., Case 1:17-cv-03039 (the Morrow Action).  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action has until March 15, 2019 (30 days after dismissal of the Securities Action with prejudice) to file an amended derivative complaint or rest upon the current derivative complaint.  By further agreement of the parties, dated March 15, 2019, the Ely Action will continue to be stayed pending the outcome of the appeal in the Securities Action. If the Securities Action continues to be dismissed in its entirety following its appeal plaintiff in the Ely Action has agreed to withdraw or dismiss the action, with prejudice.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</span></div><div id="i_0_109"></div><div style="margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Item 1A. &#160;RISK FACTORS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">RISK FACTORS</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Investing in our common stock involves significant risks, some of which are described below. In evaluating our business, investors should carefully consider the following risk factors. These risk factors contain, in addition to historical information, forward-looking statements that involve substantial risks and uncertainties. Our actual results could differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below. The order in which the following risks are presented is not intended to reflect the magnitude of the risks described. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.  Except for the important risk factors relating to consummation of the proposed Merger with Lumos, the following risk factors have been prepared as if the Merger will not be consummated.  However, many of the same risks identified below will continue to apply to the combined company if the Merger is consummated. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to the Merger </span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If the proposed Merger with Lumos is not consummated, our business could suffer materially and our stock price could decline.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The consummation of the proposed Merger with Lumos is subject to a number of closing conditions, including the approval by NewLink stockholders and other customary closing conditions. We are targeting a closing of the Merger by the first quarter of 2020.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">If the proposed Merger is not consummated, we may be subject to a number of material risks, and our business and stock price could be materially adversely affected, as follows:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">we have incurred and expect to continue to incur significant expenses related to the proposed Merger with Lumos even if the Merger is not consummated;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the Merger Agreement contains covenants relating to our solicitation of competing acquisition proposals and the conduct of our business between the date of signing the Merger Agreement and the closing of the Merger. Accordingly, we may be unable to pursue business opportunities that would otherwise be in our best interest as a standalone company; </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">we may be obligated to pay Lumos a $2.0 million termination fee in connection with the termination of the Merger Agreement;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our customers, manufacturers, partners and other investors in general may view the failure to consummate the Merger as a poor reflection on our business or prospects;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">some of our manufacturers and other business partners may seek to change or terminate their relationships with us as a result of the proposed Merger;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">as a result of the proposed Merger, current and prospective employees could experience uncertainty about their future roles within the combined company. This uncertainty may adversely affect our ability to retain our key employees, who may seek other employment opportunities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on our development activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our management team may be distracted from day to day operations as a result of the proposed Merger; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the market price of our common stock may decline to the extent that the current market price reflects a market assumption that the proposed Merger will be completed.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In addition, if the Merger Agreement is terminated and the NewLink Board determines to seek another business combination, it may not be able to find a third party willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the Merger. In such circumstances, the NewLink Board may elect to, among other things, seek to out-</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">license or partner with respect to our product candidates, divest all or a portion of our business, or take the steps necessary to liquidate all of our business and assets, and in either such case, the consideration that we receive may be less attractive than the consideration to be received by us pursuant to the Merger Agreement.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The exchange ratios are not adjustable based on the market price of NewLink&#8217;s common stock so the merger consideration at the closing may have a greater or lesser value than at the time the Merger Agreement was signed.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the Merger Agreement, the applicable exchange ratios are included in Lumos&#8217; amended and restated certificate of incorporation, which does not include a price-based termination right and there will be no adjustment to the total number of shares of NewLink&#8217;s common stock that Lumos stockholders and optionholders will be entitled to receive for changes in the market price of NewLink&#8217;s common stock. Any changes in the market price of NewLink&#8217;s common stock before the completion of the Merger will not affect the number of shares Lumos stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the Merger the market price of NewLink&#8217;s common stock increases from the market price on the date of the Merger Agreement, then Lumos stockholders could receive merger consideration with substantially more value for their shares of Lumos capital stock than the parties had negotiated for in the establishment of the exchange ratios.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Failure to complete the Merger may result in NewLink paying a termination fee or expenses to Lumos and could harm the common stock price of NewLink and future business and operations of NewLink.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">If the Merger is not completed, we are subject to the following risks:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">if the Merger Agreement is terminated under certain circumstances, we may be required to pay a termination fee to Lumos of $2,000,000;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the price of our stock may decline and remain volatile; and</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">significant costs related to the Merger, such as legal and accounting fees which must be paid even if the Merger is not completed.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In addition, if the Merger Agreement is terminated and the NewLink Board determines to seek another business combination, there can be no assurance that we will be able to find a partner willing to provide equivalent or more attractive consideration than the consideration to be provided by Lumos.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If the conditions to the Merger are not met, the Merger may not occur.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Even if the Merger is approved by the NewLink stockholders, specified conditions must be satisfied or waived to complete the Merger. These conditions are set forth in the Merger Agreement. We cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or will be delayed, and we may lose some or all of the intended benefits of the Merger.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">During the pendency of the Merger, NewLink may not be able to enter into a business combination with another party and will be subject to contractual limitations on certain actions because of restrictions in the Merger Agreement.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Covenants in the Merger Agreement impede the ability of NewLink to make acquisitions or complete other transactions that are not in the ordinary course of business pending completion of the Merger. As a result, if the Merger is not completed, NewLink may be at a disadvantage to its competitors. In addition, while the Merger Agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting, initiating, encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead to the entering into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition of NewLink&#8217;s common stock, a tender offer for NewLink&#8217;s common stock or a merger or other business combination outside the ordinary course of business. Any such transactions could be favorable to NewLink stockholders.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may become involved in securities litigation or stockholder derivative litigation in connection with the Merger, and this could divert the attention of management and harm the combined company&#8217;s business, and insurance coverage may not be sufficient to cover all related costs and damages.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Securities litigation or stockholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale of a business division or announcement of a business combination transaction. We may become involved in this type of litigation in connection with the Merger, and the combined company may become involved in this type of litigation in the future. Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect the business of NewLink and the combined company.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;"> </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-style:italic;font-weight:700;line-height:95%;">We</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:95%;"> are substantially dependent on our remaining employees to facilitate the consummation of the Merger.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have substantially reduced our workforce since September 2019. Our ability to successfully complete the proposed merger depends in large part on our ability to retain our remaining personnel. Despite our efforts to retain these employees, one or more may terminate their employment with us on short notice. The loss of the services of any of these employees could potentially harm our ability to consummate the proposed merger, to run our day-to-day business operations, as well as to fulfill our reporting obligations as a public company.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Business Risks </span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Clinical Development and Commercialization of Our Product Candidates</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them. We have not completed testing of any of our product candidates in controlled clinical trials.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The clinical development and regulatory approval process is expensive and time-consuming. The timing of any future product approval cannot be accurately predicted. If we fail to obtain regulatory approval for our current or future product candidates, we will be unable to market and sell them, and therefore we may never be profitable.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As part of the regulatory process, we must conduct clinical trials for each product candidate to demonstrate safety and efficacy to the satisfaction of the FDA and other regulatory authorities abroad. The number and design of clinical trials that will be required varies depending on the product candidate, the condition being evaluated, the trial results and regulations applicable to any particular product candidate. Any inability to successfully complete preclinical and clinical development could result in additional costs to us.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Prior clinical trial program designs and results are not necessarily predictive of future clinical trial designs or results. Initial results may not be confirmed upon full analysis of the detailed results of a trial. Product candidates in later-stage clinical trials may fail to show the desired safety and efficacy despite having progressed through initial clinical trials with acceptable endpoints. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will remain heavily dependent on the success of the clinical development of our drug product candidates, and if we fail to complete clinical trials, fail to demonstrate safety and efficacy in those clinical trials, fail to obtain regulatory approval or fail to commercialize any of our current or future drug product candidates successfully, our business, financial condition and results of operations would be harmed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our clinical development program currently encompasses a number of Phase 1 and 2 combination trials across multiple cancer indications. If we fail to complete any of these trials or fail to obtain regulatory approval, our ability to commercialize indoximod will be materially and adversely affected and our business, financial condition and results of operations would be harmed. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we make changes to any of our product candidates, additional clinical trials may be required resulting in additional costs and delays.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have an ongoing research program to investigate potential opportunities to improve the potency, efficacy and/or safety profile of some of our product candidates through modifications to their formulations or chemical compositions. &#160;These efforts may not be successful.&#160; If a new formulation or composition appears promising, we may decide to undertake clinical development of such formulation or composition even if an existing product candidate has shown acceptable safety and efficacy in clinical trials.&#160; The nature and extent of additional clinical trials that might be required for a new formulation or composition would depend on many factors.&#160; If we were to decide to pursue clinical development of a new formulation or composition, we would incur additional costs and the timeline for potential commercialization would be delayed.&#160; There can be no assurance that any new formulation or composition would prove to be safe or effective or superior to an existing product candidate.&#160; Any delay in commercialization of a new formulation or composition may adversely affect our competitive position.</span></div><div style="text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because we have limited financial and managerial resources, we must focus on research programs and product candidates for the specific indications that we believe are the most scientifically and commercially promising. As a result, we have in the past determined to let certain of our development projects remain idle, including by allowing IND applications to lapse into inactive status, and we may in the future decide to forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater scientific or commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable scientific or commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial and financial resources on research programs and product candidates for specific indications that ultimately do not yield any scientifically or commercially viable products. Furthermore, our resource allocation decisions and our decisions about whether and how to develop or commercialize any particular product candidate may be based on evaluations of the scientific and commercial potential or target market for the product candidate that later prove to be materially inaccurate. If we enter into collaborations, licensing or other royalty arrangements to develop or commercialize a particular product candidate, we may relinquish valuable rights to that product candidate in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may face delays in completing our clinical trials, or we may not be able to complete them at all.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have not completed all of the clinical trials necessary to support an application with the FDA for approval to market any of our product candidates. Our current and future clinical trials may be delayed or terminated as a result of many factors, including:</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may experience delays or failure in reaching agreement on acceptable clinical trial contracts or clinical trial protocols with prospective sites;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulators or institutional review boards may not authorize us to commence a clinical trial;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or concerns about patient safety;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may suspend or terminate our clinical trials if we believe that they expose the participating patients to unacceptable health risks;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may need to reformulate or change the dosing of our product candidates;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our clinical trials may have slower than expected patient enrollment or lack of a sufficient number of patients that meet their enrollment criteria;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">patients may not complete clinical trials due to safety issues, side effects, dissatisfaction with the product candidate, or other reasons;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may experience difficulty in maintaining contact with patients after treatment, preventing us from collecting the data required by our clinical trial protocol;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">product candidates may demonstrate a lack of efficacy during clinical trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our third-party contractors, including those manufacturing our product candidates or components of ingredients thereof or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner or at all;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may experience governmental or regulatory delays, failure to obtain regulatory approval or changes in regulatory requirements, policy and guidelines;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">enrollment in and conduct of our clinical trials may be adversely affected by the regulatory approval of competing agents in this class, competition with ongoing clinical trials or scheduling conflicts with participating clinicians; and</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may experience delays in achieving clinical trial endpoints and completing data analysis for a trial.</span></div><div style="text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, we rely on academic institutions, physician practices and clinical research organizations to conduct, supervise or monitor some or all aspects of clinical trials involving our product candidates. We have less control over the timing and other aspects of these clinical trials than if we conducted the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities for our clinical trials on our anticipated schedule or consistent with a clinical trial protocol or applicable regulations. We also may rely on clinical research organizations to perform our data management and analysis. They may not provide these services as required or in a timely or compliant manner.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Moreover, our development costs will increase if we are required to complete additional or larger clinical trials for our product candidates prior to FDA approval. If the delays or costs are significant, our financial results and ability to commercialize our product candidates will be adversely affected.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we encounter difficulties enrolling patients in our clinical trials, our clinical trials could be delayed or otherwise adversely affected.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Clinical trials for our product candidates require us to identify and enroll a large number of patients with the disease under investigation, or healthy volunteers willing to participate in certain trials. We may not be able to enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a clinical trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:</span></div><div style="text-indent:45pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">severity of the disease under investigation;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">design of the trial protocol;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">size of the patient population;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">eligibility criteria for the clinical trial in question;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">changes in the standard of care that make the trial as designed less attractive to clinicians and patients;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">availability of competing therapies and clinical trials, including announced clinical trials evaluating potentially competing IDO pathway inhibitors in clinical settings similar to our clinical trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the results of clinical trials of other IDO pathway inhibitors;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">patient referral practices of physicians;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">ability to monitor patients adequately during and after treatment; and</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have discussions with and obtain guidance from regulatory authorities regarding certain aspects of our clinical development activities. These discussions are not binding commitments on the part of regulatory authorities. Under certain circumstances, regulatory authorities may revise or retract previous guidance during the course of our clinical activities or after the completion of our clinical trials. A regulatory authority may also disqualify a clinical trial in whole or in part from consideration in support of approval of a potential product for commercial sale or otherwise deny approval of that product. Prior to regulatory approval, a regulatory authority may elect to obtain advice from outside experts regarding scientific issues and/or marketing applications under a regulatory authority review. In the United States, these outside experts are convened through the FDA&#8217;s Advisory Committee process, which would report to the FDA and make recommendations that may differ from the views of the FDA. The FDA is not bound by the recommendations of an Advisory Committee, but it typically follows such recommendations.  In addition, should an Advisory Committee be convened, it would be expected to lengthen the time for obtaining regulatory approval, if such approval is obtained at all.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The FDA and other foreign regulatory agencies can delay, limit or deny marketing approval for many reasons, including:</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">a product candidate may not be considered safe or effective;</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">our manufacturing processes or facilities may not meet the applicable requirements; and</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">changes in their approval policies or adoption of new regulations may require additional work on our part.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from ever generating meaningful revenues or achieving profitability in future years.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our product candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA, or their advisors may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may change requirements for approval even after a clinical trial design has been approved. Regulatory agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, which may result in greater costs and a longer timeframe for regulatory approval than we estimate, yet we will receive limited revenues, if any, from any future sales of our Ebola vaccine product candidate. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Merck Agreement, we have ongoing obligations related to the development of our Ebola vaccine product candidate, including obligations related to clinical trials, government contracting and licensing of the vaccine technology, which may cause us to incur costs or losses materially larger than we expect. However, because we have exclusively licensed the right to research, develop, manufacture and distribute our Ebola vaccine product candidate to Merck and we are only entitled to certain royalty and other payments under the Merck Agreement, we will receive limited revenues, if any, even if we or Merck are successful in developing and commercializing our Ebola vaccine product candidate. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The time and cost of product development and the timeframe for regulatory approval of any Ebola vaccine product candidate are uncertain and may be longer and more costly than we estimate. Our Ebola vaccine product candidate is a live virus based on vesicular stomatitis virus (VSV). There are no commercial vaccines based upon this virus, and unforeseen problems related to the use of our live virus vaccine may prevent or materially increase costs and delays of further development or approval of our Ebola vaccine product candidate. There may be unknown safety risks associated with the vaccine, and regulatory agencies such as the FDA may require us to conduct extensive safety testing prior to approval to demonstrate a low-risk of rare and severe adverse events caused by the vaccine. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Public perception of vaccine safety issues, including adoption of novel vaccines based upon VSV, may adversely influence willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe, and of patients to receive, novel vaccines. For example, our Ebola vaccine product candidate is currently being developed for the prevention of, and may later be developed for the treatment of patients infected with, Ebola, and public aversion to vaccines for Ebola or vaccines in general may adversely influence later-stage clinical trials of this product candidate or, if approved, its commercial success. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Even if approved, a number of factors may adversely affect commercial sales. Lack of familiarity with the viral vaccine and potential adverse events associated with vaccination may adversely affect physician and patient perception and uptake of our potential product. Furthermore, there are no assurances that the vaccine will be approved for inclusion in government stockpile programs, which may be material to the commercial success of the product candidate, either in the United States or abroad. If our Ebola vaccine product candidate eventually is approved and sold commercially, we will receive limited revenues under the Merck Agreement. Finally, in certain cases, our obligations to pay royalties to PHAC may exceed the royalties we receive from Merck. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Clinical trials must be conducted in accordance with the FDA&#8217;s Good Clinical Practice (GCP) requirements, or other applicable foreign government guidelines and are subject to oversight by the FDA, other foreign governmental agencies and Institutional Review Boards at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice (cGMP) requirements and may require large numbers of test subjects. Clinical trials may be suspended by the FDA, other foreign governmental agencies, or us for various reasons, including:</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the product candidate may have unforeseen adverse side effects;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the time required to determine whether the product candidate is effective may be longer than expected;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">fatalities or other adverse events arising during a clinical trial due to medical problems that may not be related to clinical trial treatments;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">failure to demonstrate a benefit from using a drug;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the quality or stability of the product candidate may fall below acceptable standards; or</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">insufficient quantities of the product candidate to complete the trials.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to Institutional Review Boards for reexamination, which may impact the costs, timing or successful completion of a clinical trial. Due to these and other factors indoximod, NLG802, NLG207, NLG919, and other product candidates could take significantly longer to gain regulatory approval than we expect or we may never gain approval for additional indications, which could reduce our revenue by delaying or terminating their commercialization.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Some of our product candidates have been studied, or in the future may be studied, in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have little control over the conduct of such trials.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have in the past and currently supply indoximod in support of Phase 2 investigator-initiated clinical trials, and we provided clinical supply of dorgenmeltucel-L in support of a Phase&#160;2 investigator-initiated clinical trial. Our Ebola vaccine product candidate was studied in clinical trials in West Africa. We may continue to supply and otherwise support similar trials in the future. However, because we are not the sponsors of these trials, we do not control the protocols, administration or conduct of these trials, including follow-up with patients and ongoing collection of data after treatment, and, as a result, are subject to risks associated with the way these types of trials are conducted, in particular should any problems arise. These risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues and difficulties or differences in interpreting data.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we cannot demonstrate the safety of our product candidates in preclinical and/or other non-clinical studies, we will not be able to initiate or continue clinical trials or obtain approval for our product candidates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In order to move a product candidate not yet being tested in humans into a clinical trial, we must first demonstrate in preclinical testing that the product candidate is safe. Furthermore, in order to obtain approval, we must also demonstrate safety in various preclinical and non-clinical tests. We may not have conducted or may not conduct in the future the types of preclinical and other non-clinical testing ultimately required by regulatory authorities, or future preclinical tests may indicate that our product candidates are not safe for use in humans. Preclinical testing is expensive, can take many years and can have an uncertain outcome. In addition, success in initial preclinical testing does not ensure that later preclinical testing will be successful. We may experience numerous unforeseen events during, or as a result of, the preclinical testing process, which could delay or prevent our ability to develop or commercialize our product candidates, including:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our preclinical testing may produce inconclusive or negative safety results, which may require us to conduct additional preclinical testing or to abandon product candidates that we believed to be promising;</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">our product candidates may have unfavorable pharmacology, toxicology or carcinogenicity;</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">our product candidates may cause undesirable side effects; and</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">the FDA or other regulatory authorities may determine that additional safety testing is required.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if ultimately approved, indoximod, NLG802, NLG207, NLG919, our Ebola vaccine product candidate or any other potential product we or our collaborators may commercialize and market may be later withdrawn from the market or subject to promotional limitations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We or our collaborators may not be able to obtain the labeling claims necessary or desirable for the promotion of any potential future products. We or our collaborators may also be required to undertake post-marketing clinical trials. If the results of such post-marketing studies are not satisfactory, the FDA or a comparable agency in a foreign country may withdraw marketing authorization or may condition continued marketing on commitments from us or our collaborators that may be expensive and/or time-consuming to fulfill. In addition, if we or others identify adverse side effects after any of our potential products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and reformulation of our potential products, additional clinical trials, changes in labeling of our potential products and/or additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of our potential products.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to develop or acquire additional capabilities in order to commercialize any product candidates that obtain FDA approval, and we may encounter unexpected costs or difficulties in doing so</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will need to acquire additional capabilities and effectively manage our operations and facilities to successfully pursue and complete future research, development and commercialization efforts. Currently, we have limited experience in preparing applications for marketing approval, commercial-scale manufacturing, managing large-scale information technology systems or managing a large-scale distribution system. We will need to add personnel and expand our capabilities, which may strain our existing managerial, operational, regulatory compliance, financial and other resources. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">To do this effectively, we must:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">train, manage and motivate a growing employee base; </span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">accurately forecast demand for our products; and</span></div><div style="text-indent:-28pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:24.5pt;">expand existing operational, financial and management information systems.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will need to increase our manufacturing capacity, which may include negotiating and entering into additional third-party agreements to meet our commercial manufacturing requirements. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate significant product revenue.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We do not have a sales organization and have no experience in the sales and distribution of pharmaceutical products. There are risks involved with establishing our own sales capabilities and increasing our marketing capabilities, as well as entering into arrangements with third parties to perform these services. Developing an internal sales force is expensive and time consuming and could delay any product launch. On the other hand, if we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us could potentially be lower than if we market and sell these products ourselves.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We entered into the Merck Agreement in November 2014 for the research, development, manufacture and distribution of our Ebola vaccine product candidate. Even if our Ebola vaccine product candidate is approved by regulators for marketing and sale, Merck may be unsuccessful in its efforts to commercialize our Ebola vaccine product candidate, respectively, or may devote fewer resources to such efforts than we would consider optimal.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may establish our own specialty sales force and/or engage other biopharmaceutical or other healthcare companies with established sales, marketing and distribution capabilities to sell, market and distribute any future products.  We may not be able to establish a specialty sales force or establish sales, marketing or distribution relationships on acceptable terms. Factors that may inhibit our efforts to commercialize any future products without strategic collaborators or licensees include:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the inability of sales personnel to obtain access to an adequate number of physicians to educate them about the attributes of any future products;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because the establishment of sales, marketing and distribution capabilities depends on the progress toward commercialization of our product candidates, and because of the numerous risks and uncertainties involved with establishing those capabilities, we are unable to predict when, if ever, we will establish our own sales, marketing and distribution capabilities. If we are not able to collaborate with third parties and are unsuccessful in recruiting sales, marketing and distribution personnel or in building the necessary infrastructure, we will have difficulty commercializing our product candidates, which would adversely affect our business and financial condition.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Failure to attract and retain key personnel could impede our ability to develop our products and to obtain new collaborations or other sources of funding.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Because of the specialized scientific nature of our business, our success is highly dependent upon our ability to attract and retain qualified scientific and technical personnel, consultants and advisors. We are highly dependent on the principal members of our scientific and management staff. Effective August 3, 2019 Charles J. Link, Jr., our founder and former Chief Executive Officer, Chief Scientific Officer and Chairman of the Board, retired from his posts as Chairman, Chief Executive Officer and Chief Scientific Officer and as a member of the Board of Directors of the Company. Effective September 27, 2019, Dr. Nicholas Vahanian retired from his posts as President and a member of the Board.  These changes, or the long-term loss of services of any other key executives, might significantly delay or prevent the achievement of our research, development, and business objectives. We do not maintain key-man life insurance with respect to any of our employees, nor do we intend to secure such insurance.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will need to recruit additional personnel in order to achieve our operating goals. In order to pursue product development and marketing and sales activities, if any, we will need to hire additional qualified scientific personnel to perform research and development, as well as personnel with expertise in clinical testing, government regulation, manufacturing, marketing and sales. We also rely on consultants and advisors to assist in formulating our research and development strategy and adhering to complex regulatory requirements. We face competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities and other research institutions. There can be no assurance that we will be able to attract and retain such individuals on acceptable terms, if at all. Additionally, our most significant facility is located in Iowa, which may make attracting and retaining qualified scientific and technical personnel from outside of Iowa difficult. The failure to attract and retain qualified personnel, consultants and advisors could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our workforce reduction may cause undesirable consequences and our results of operations may be harmed.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, we commenced a restructuring plan in the context of the anticipated merger. Under the restructuring plan, we reduced our workforce by 28 employees (approximately 60%), including several members of management. This workforce reduction may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. Additional attrition could impede our ability to meet our operational goals. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation. Furthermore, employees whose positions were eliminated or those who determine to seek alternate employment may seek employment with our competitors. We cannot assure you that we will be able to realize the cost savings and other anticipated benefits from our previous or any future reduction plans.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Manufacturing Activities </span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on third-party manufacturers to produce our preclinical and clinical product candidate supplies and we intend to rely on third parties to produce commercial supplies of any product candidates that may be approved in the future. Any failure by a third-party manufacturer to produce supplies for us may delay or impair our ability to complete our clinical trials or commercialize our product candidates.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We do not possess all of the capabilities to fully commercialize any of our product candidates on our own. If we are unable to arrange for third-party manufacturing sources or to do so on commercially reasonable terms, we may not be able to complete development of such product candidates or market them. In addition, we currently rely on our partner Merck for the supply of our Ebola vaccine product candidate and other third party manufacturers for our supply of indoximod, NLG802, NLG207, and NLG919 for preclinical and clinical studies. Problems with any of our facilities or processes, or our contract manufacturers&#8217; facilities or processes, could prevent or delay the production of adequate supplies of indoximod, NLG802, NLG207, NLG919, our Ebola vaccine product candidate or other finished products. </span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any prolonged delay or interruption in the operations of our current or future contract manufacturers&#8217; facilities could result in cancellation of shipments, loss of components in the process of being manufactured or a shortfall in the availability of a product. A number of factors could cause interruptions, including the inability of a supplier to provide raw materials, equipment malfunctions or failures, damage to a facility due to natural disasters, changes in international or U.S. regulatory requirements or standards that require modifications to our manufacturing processes, action by regulatory authorities or by us that results in the halting or slowdown of production of components or finished product due to regulatory issues, a contract manufacturer going out of business or failing to produce product as contractually required or other similar factors. Because manufacturing processes are highly complex and are subject to a lengthy regulatory approval process, alternative qualified production capacity and sufficiently trained or qualified personnel may not be available on a timely or cost-effective basis or at all. Difficulties or delays in our contract manufacturers&#8217; production of product candidates could delay our clinical trials, increase our costs, damage our reputation and cause us to lose revenue and market share if we are unable to meet market demand for any products that are approved for sale on a timely basis.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, failure of the third party to accept orders for supply of drug substance or drug product and the possibility of termination or nonrenewal of the agreement by the third-party based on its own business priorities and at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMP and similar foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale-up manufacturing processes as needed, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for action by the FDA to withdraw approvals for product candidates that may have been granted to us and for other regulatory action, including recall or seizure, fines, imposition of operating restrictions, total or partial suspension of production or injunctions.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical studies. There are a small number of suppliers for certain capital equipment and raw materials that are used to&#160;manufacture&#160;our product candidates. Such suppliers may not sell this capital equipment or these raw materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of this capital equipment or these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Because of the complex nature of many of our early-stage compounds and product candidates, our manufacturers may not be able to&#160;manufacture&#160;such compounds and product candidates at a cost or in quantities or in a timely manner necessary to develop and commercialize related products. If we successfully commercialize any of our product candidates, we may be required to establish or access large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. To meet our projected needs for commercial manufacturing in the event that one or more of our product candidates gains marketing approval, third parties with whom we currently work will need to increase their scale of production or we will need to secure alternate suppliers.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we do not currently have experience with the management of relationships related to commercial-scale contract manufacturing, and we may incur substantial costs to develop the capability to negotiate and enter into relationships with third-party contract manufacturers.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing of our products.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">All entities involved in the preparation of a therapeutic drug for clinical trials or commercial sale, including our Company, our existing contract manufacturers and those we may engage in the future, and Merck in its capacity as our licensee, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Our facilities and quality systems and the facilities and quality </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">systems of some or all of our third party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of any of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. In addition, to the extent that we rely on foreign contract manufacturers, as we do currently for our Ebola vaccine product candidate, we are or will be subject to additional risks including the need to comply with export and import regulations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If our current or future contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our facility is located in areas where floods and tornados are known to occur, and the occurrence of a flood, tornado or other catastrophic disaster could damage our facilities and equipment, which could cause us to curtail or cease operations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our primary facility is located in Ames, Iowa, which is susceptible to floods and tornados, and our facility is therefore vulnerable to damage or disruption from floods and tornados. We are also vulnerable to damage from other types of disasters, such as power loss, fire and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. We currently carry business insurance (real, personal and business income) of approximately $14.4 million in the aggregate, but this policy does not cover disasters such as floods and earthquakes. We may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced elements of our information technology infrastructure, and as a result we manage a number of third-party vendors who may or could have access to our confidential information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent the adverse effect of such events. Significant disruptions of our information technology systems or breaches of data security could adversely affect our business.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Regulation of Our Industry</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The industry within which we operate and our business are subject to extensive regulation, which is costly and time-consuming and which may subject us to unanticipated delays.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research, development, testing, manufacturing, labeling, packaging, marketing, distribution, promotion and advertising of biologic and pharmaceutical products such as our product candidates are subject to extensive regulation by governmental regulatory authorities in the United States and other countries. The drug development and approval process is generally lengthy, expensive and subject to unanticipated delays. Data obtained from preclinical and clinical testing are subject to varying interpretations that could delay, limit or prevent regulatory approval. In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of development and regulatory review of each submitted application for approval. To obtain approval for a product candidate, we must demonstrate to the satisfaction of the regulatory authorities that the product candidate is safe and effective in the case of a small-molecule pharmaceutical product, or is safe, pure and potent in the case of a biologic, which typically takes several years or more depending upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. </span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There can be no assurance that we will not encounter problems in clinical trials that would cause us or the regulatory authorities to delay or suspend clinical trials. Any such delay or suspension could have a material adverse effect on our business, financial condition and results of operations. There can be no assurance that we will not encounter problems in clinical trials that would cause us or the regulatory authorities to delay or suspend clinical trials.  Any such delay or suspension could have a material adverse effect on our business, financial condition and results of operations.  There can be no assurance that clinical trials for any of our product candidates currently under development will be completed successfully or within any specified time period, if at all. Further, there can also be no assurance that such testing will show any product to be safe, pure, potent or effective. We cannot predict when, if ever, we might submit for regulatory review our product candidates currently under development. In addition, regardless of how much time and resources we devote to the development of a product candidate, there can be no assurance that regulatory approval will be obtained for that product candidate. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Even if such regulatory approval is obtained, we, our products and any contract manufacturers or commercial collaborators of ours will be subject to continual regulatory review in both the United States and other countries. Later discovery of previously unknown problems with regard to a product, distributor or manufacturer may result in restrictions, including withdrawal of the product from the market and/or disqualification or decertification of the distributor or manufacturer. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:</span></div><div style="text-indent:45pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">warning letters;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">civil or criminal penalties;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">injunctions;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">suspension of or withdrawal of regulatory approval;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">total or partial suspension of any ongoing clinical trials or of production;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">voluntary or mandatory product recalls and publicity requirements; </span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">seizure or detention of our products or import bans.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of new biologic and pharmaceutical products through lengthy and detailed preclinical and clinical testing procedures, sampling activities and other costly and time-consuming compliance procedures. Clinical trials are vigorously regulated and must meet requirements for FDA review and oversight and requirements under GCP guidelines. A new drug may not be marketed in the United States until the FDA has approved it. There can be no assurance that we will not encounter delays or rejections or that the FDA will not make policy changes during the period of product development and FDA regulatory review of each submitted BLA and new drug application (NDA). A delay in obtaining, or failure to obtain, such approvals would have a material adverse effect on our business, financial condition and results of operations. Even if regulatory approval were obtained, it would be limited as to the indicated uses for which the product may be promoted or marketed. A marketed product, its manufacturer and the facilities in which it is manufactured are subject to continual review and periodic inspections. If marketing approval is granted, we would be required to comply with FDA requirements for manufacturing, labeling, advertising, record-keeping and reporting of adverse experiences and other information. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. Companies may also share truthful and not misleading information that is otherwise consistent with the labeling. In addition, we would be required to continue to comply with federal and state anti-kickback and other healthcare fraud and abuse laws that pertain to the marketing of pharmaceuticals, among other things. Failure to comply with regulatory requirements and other factors could subject us to regulatory or judicial enforcement actions, including product recalls or seizures, injunctions, withdrawal of the product from the market, civil penalties, criminal prosecution, refusals to approve new products and withdrawals of existing approvals, as well as enhanced product liability exposure, any of which could have a material adverse effect on our business, financial condition and results of operations. Sales of our products outside the United States will be subject to foreign regulatory requirements governing clinical trials, marketing approval, manufacturing and pricing. Noncompliance with these requirements could result in enforcement actions or penalties or could delay the introduction of our products in certain countries.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement outside the United States vary greatly from country to country. The time required to obtain approvals outside the United States may differ from that required to obtain FDA approval. We may not obtain foreign regulatory approvals on a timely basis, or at all. Approval by </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could also require additional testing. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to develop foreign markets for our products and may have a material adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are also subject to laws generally applicable to businesses including, but not limited to, federal, state and local regulations relating to wage and hour matters, employee classification, mandatory healthcare benefits, unlawful workplace discrimination and whistleblowing. Any actual or alleged failure to comply with any regulation applicable to our business or any whistleblowing claim, even if without merit, could result in costly litigation or regulatory action or otherwise harm our business, results of operations, financial condition, cash flow and future prospects.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The availability of coverage and amount of reimbursement for our product candidates, if approved, and the manner in which government and private payers may reimburse for our potential products, are uncertain.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In both the United States and foreign markets, sales of our proposed products will depend in part on the availability of coverage and reimbursement from third-party payers such as government health administration authorities, private health insurers and other organizations. In addition, the process for determining whether a third party payor will provide coverage for a pharmaceutical typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payors are increasingly challenging the price and cost-effectiveness of medical products and services.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. There can be no assurance that our proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our future levels of revenues and profitability may be affected by the continuing efforts of governmental and third-party payers to contain or reduce the costs of healthcare. We cannot predict the effect that private sector or governmental health care reforms may have on our business, and there can be no assurance that any such reforms will not have a material adverse effect on our business, financial condition and results of operations. Legislation and regulations affecting the pricing of pharmaceuticals may change before any of our proposed products are approved for marketing. Adoption of such legislation could further limit reimbursement for medical products and services. As a result, we may elect not to market future products in certain markets.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Moreover, while we are in clinical trials, we will not be reimbursed for any of our materials used during the clinical trials, however, certain services rendered to clinical trial participants may be reimbursable by third-party payors for standard of care treatment if not otherwise reimbursed under the applicable clinical trial study budget.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The biopharmaceutical industry is subject to significant regulation and oversight in the United States, in addition to approval of products for sale and marketing; our failure to comply with these laws could harm our results of operations and financial condition.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to FDA restrictions on marketing of biopharmaceutical products, our operations may be directly, or indirectly through our relationships with healthcare providers, customers and third-party payers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute. These laws may impact, among other things, our proposed sales, and education programs, and these laws have been applied to restrict certain marketing practices in the biopharmaceutical industry. In addition, we may be subject to patient privacy regulation by both the U.S. federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others, the following:</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The federal civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, to the federal government a claim for payment or approval that is false or fraudulent or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Several pharmaceutical and other health-care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of off-label promotion. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit.</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The federal Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA), imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.&#160;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their implementing regulations imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization on covered entities, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information.</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The federal Food, Drug and Cosmetic Act (FDCA) prohibits, among other things, the adulteration or misbranding of drugs and medical devices.</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">The federal Physician Payments Sunshine Act, and its implementing regulations require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services (CMS), information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members.</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">Analogous state laws and regulations include: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. It is possible that some of our business activities could be subject to challenge under one or more of these laws, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January&#160;30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that required that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order included a budget neutrality provision that required the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations that can be repealed to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the United States Office of Management and Budget on February&#160;2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. Further, on February&#160;24, 2017, President Trump issued an Executive Order requiring each agency to designate a regulatory reform officer and create a regulatory reform task force to evaluate existing regulations and make recommendations regarding their repeal, replacement, or modification. It is difficult to predict how these requirements will continue to be enforced, the extent to which they will continue to impact the FDA&#8217;s ability to exercise its regulatory authority, and the negative impact they may have on our business.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The U.S. and some foreign jurisdictions are considering or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, in the United States, the pharmaceutical industry has been affected by the passage of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the ACA), which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs and expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. There have been judicial and congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Act includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share,&#160;and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018 (the BBA) among other things, amends the ACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act.  Although the Texas U.S. District Court Judge, as well as the presidential administration and CMS have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods.  There have been several recent U.S. Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. The </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Trump administration&#8217;s budget proposals for fiscal years 2019 and 2020 contain further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is implementing others under its existing authority.  For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.  While some of the existing measures and other proposed measures will require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.  This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. Any of these initiatives could harm our ability to generate revenues.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which pharmaceutical products and suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications have fluctuated over the last 10 years, and we cannot predict the review time for any of our submissions with any regulatory authorities. In addition, review times can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (the Right to Try Act) was signed into law. The law, among other things, provides a federal framework for certain patients to access certain IND products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislative or administrative action, either in the United States or abroad.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our research and development involves the controlled use of hazardous materials, chemicals, various active microorganisms and volatile organic compounds, and we may incur significant costs as a result of the need to comply with numerous laws and regulations. We are subject to laws and regulations enforced by the FDA, the Drug Enforcement Agency, foreign health authorities and other regulatory requirements, including the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Food, Drug and Cosmetic Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of our products, materials used to develop and manufacture our product candidates, and resulting waste products. Although we believe that our safety procedures for handling and disposing of such materials, and for killing any unused microorganisms before disposing of them, comply with the standards prescribed by state and federal regulations, the </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Failure to comply with existing or future data protection laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regulation of data processing is evolving, as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our partners may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our partners&#8217; ability to process or use data in order to support the provision of our products or services, or affect our or our partners&#8217; ability to offer our products and services in certain locations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to civil and/or criminal penalties including if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.&#160;</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">International data protection laws, including, without limitation, the European Union Directive 95/46/EC (the Directive), and the European Union&#8217;s General Data Protection Regulation (the GDPR) that took effect in May 2018, and member state data protection legislation, may also apply to health-related and other personal information obtained outside of the United States. These laws impose strict obligations on the ability to process health-related and other personal information of data subjects in the European Union, including in relation to use, collection, analysis and transfer of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Directive and the GDPR prohibits, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross-border data transfers, such as the European Union-U.S. and Swiss-U.S. Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the GDPR, regulators may impose substantial fines and penalties for non-compliance.  Companies that violate the GDPR can face fines of up to the greater of 20 million Euros or 4% of their worldwide annual turnover (revenue). The GDPR has increased our responsibility and liability in relation to personal data that we process, requiring us to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of our commitments to customers or partners.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Any of these matters could materially adversely affect our business, financial condition, or operational results.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Financial Risks</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have a history of net losses. We incurred a net loss for the years ended December 31, 2016, 2017 and 2018 and expect to continue to incur net losses for the foreseeable future, and we may never achieve or maintain profitability in the future.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We were profitable in the year ended December 31, 2014, primarily as a result of upfront payments under the Genentech Agreement and the Merck Agreement. We are not entitled to receive any additional upfront payments under these licensing or collaboration agreements. We do not expect any milestone or royalty payments under these or other agreements, if any, to be sufficient to make us profitable in future years. We incurred a loss of $34.7 million for the nine months ended September&#160;30, 2019 and we do not expect to be profitable for the foreseeable future. We anticipate that we will continue to incur operating losses over the next several years as we continue our clinical development programs.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations primarily through the sale of equity securities, government grants, economic development loans and capital lease and equipment financing. The size of our future net losses will depend, in part, on the rate of growth or contraction of our expenses and the level and rate of growth, if any, of our revenues. Our ability to achieve profitability in future years is dependent on our ability, alone or with others, to complete the development of our products successfully, obtain the required regulatory approvals, manufacture and market our proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when we will achieve profitability.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We may require substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Development of our product candidates will require substantial additional funds to conduct research, development and clinical trials necessary to bring such product candidates to market and to establish manufacturing, marketing and distribution capabilities, either internally or through collaborations with third parties. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the scope, rate of progress, results and costs of our preclinical studies, clinical trials and other research and development activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the scope, rate of progress and costs of our manufacturing development and commercial manufacturing activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the cost, timing and outcomes of regulatory proceedings (including FDA review of any BLA or NDA we file);</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">payments required with respect to development milestones we achieve under our in-licensing agreements;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the costs associated with commercializing our product candidates, if they receive regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the cost of manufacturing our product candidates and any products we commercialize;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the cost and timing of developing our ability to establish sales and marketing capabilities;</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the potential requirement to repay our outstanding government provided loans;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">competing technological efforts and market developments;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">changes in our existing research relationships;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the timing and receipt of revenues from existing or future products, if any; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">payments received under any future strategic collaborations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We anticipate that we will continue to generate significant losses in the future to the extent we incur expenses to complete our clinical trial programs for our product candidates, develop our pipeline and pursue regulatory approval of our product candidates. We believe that our existing cash and cash equivalents will allow us to fund our operating plan in the near and medium term. However, our operating plan may change as a result of factors currently unknown to us.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that our revenue and expense forecasts will prove to be accurate, and any change in the foregoing assumptions could require us to obtain additional financing earlier than anticipated. There is a risk of delay or failure at any stage of developing a product candidate, and the time required and costs involved in successfully accomplishing our objectives cannot be accurately predicted. Actual drug research and development costs could substantially exceed budgeted amounts, which could force us to delay, reduce the scope of or eliminate one or more of our research or development programs.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We are party to license agreements with various parties pursuant to which we have obtained licenses to certain patents, patent applications and other intellectual property related to our product candidates and product development efforts. We are obligated to make aggregate payments ranging from approximately $250,000 to $2.8 million under our license agreements (and in some cases, for each product candidate in such license) upon achievement of development and regulatory approval milestones specified in the applicable license. The timing of our achievement of these events and corresponding milestone payments to our licensors is subject to factors relating to the clinical and regulatory development and commercialization of our product candidates, many of which are beyond our control. We may become obligated to make a milestone payment when we do not have the cash on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization or marketing efforts or seek funds to meet these obligations on terms unfavorable to us.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We may never be able to generate a sufficient amount of product revenue to cover our expenses. Until we do, we expect to seek additional funding through public or private equity or debt financings, collaborative relationships, capital lease transactions or other available financing transactions. However, there can be no assurance that additional financing will be available on acceptable terms, if at all, and such financings could be dilutive to existing stockholders. Moreover, in the event that additional funds are obtained through arrangements with collaborators, such arrangements may require us to relinquish rights to certain of our technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs. Our failure to obtain adequate financing when needed and on acceptable terms would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Even though we have received governmental support in the past, we may not continue to receive support at the same level or at all.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We have received significant financial assistance, primarily in the form of forgivable loans, from state and local governments. We have also received significant financial assistance, primarily in the form of grants and contracts, from federal agencies to support our infectious disease research. There can be no assurance that we will continue to receive the same level of assistance from these or other government agencies, if at all.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Through our subsidiary, BPS, we have received funding from multiple government agencies for our Ebola vaccine product candidate development efforts. There is no guarantee that we will receive sufficient, or any, future grant funding to meet our obligations related to our Ebola vaccine development or that we or Merck will succeed in developing an Ebola vaccine. The termination of a United States government grant, contract or relationship as a result of our failure to satisfy any of our obligations under the grants or contracts would have a negative impact on our operations and harm our reputation and ability to </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">procure government contracts. Additionally, there can be no assurance that we will secure comparable contracts with, or grants from, the United States government in the future.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in our effective income tax rate could adversely affect our results of operations in the future.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">For the nine months ended September&#160;30, 2019 we have no income tax benefit or expense. Our effective income tax rate, as well as our relative domestic and international tax liabilities, will depend in part on the allocation of any future income among different jurisdictions. In addition, various factors may have favorable or unfavorable effects on our effective income tax rate in individual jurisdictions or in the aggregate. These factors include whether tax authorities agree with our interpretations of existing tax laws, any required accounting for stock options and other share-based compensation, changes in tax laws and rates (including the recently enacted U.S. federal income tax law changes), our future levels of research and development spending, changes in accounting standards, changes in the mix of any future earnings in the various tax jurisdictions in which we may operate, the outcome of any examinations by the U.S. Internal Revenue Service or other tax authorities, the accuracy of our estimates for unrecognized tax benefits and realization of deferred tax assets and changes in overall levels of pre-tax earnings. The effect on our income tax liabilities resulting from the above-mentioned factors or other factors could have a material adverse effect on our results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The comprehensive tax reform bill of 2017 could adversely affect our business and financial condition.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On December 22, 2017 the Tax Act was signed into law. The Tax Act significantly revised the Internal Revenue Code of 1986, as amended (the Code) and included, among other things, significant changes to corporate taxation, including a reduction of the corporate income tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income for net operating losses arising in taxable years beginning after December 31, 2017 and elimination of net operating loss carrybacks for net operating losses arising in taxable years beginning after December 31, 2017, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.  Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act did not have a material impact on our business.  In addition, it is uncertain if and to what extent various states will conform to the Tax Act.  The impact of the Tax Act on holders of our common stock is also uncertain and could be adverse.  We urge our stockholders to consult with their legal and tax advisors with respect to the Tax Act and the potential tax consequences of investing in or holding our common stock.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Competition</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We compete in an industry characterized by extensive research and development efforts and rapid technological progress. New discoveries or commercial developments by our competitors could render our potential products obsolete or non-competitive.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">New developments occur and are expected to continue to occur at a rapid pace, and there can be no assurance that discoveries or commercial developments by our competitors will not render some or all of our potential products obsolete or non-competitive, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We expect to compete with fully integrated and well-established pharmaceutical and biotechnology companies in the near and long term. Most of these companies have substantially greater financial, research and development, manufacturing and marketing experience and resources than we do and represent substantial long-term competition for us. Such companies may succeed in discovering and developing pharmaceutical products more rapidly than we do or pharmaceutical products that are safer, more effective or less costly than any that we may develop. Such companies also may be more successful than we are in production and marketing. Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies. Academic institutions, governmental agencies and other public and private research organizations also conduct clinical trials, seek patent protection and establish collaborative arrangements for the development of oncology products.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We may face competition based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, reimbursement coverage, price and patent position. There can be no assurance that our competitors will not develop safer and more effective products, commercialize products earlier than we do, or obtain patent protection or intellectual property rights that limit our ability to commercialize our products.</span></div><div style="text-align:justify;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide us with proprietary protection or a competitive advantage.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the products that we are attempting to develop and commercialize will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies both in the United States and abroad. Our competitors may utilize discovery technologies and techniques or collaborate with third parties in order to develop products more rapidly or successfully than we or our collaborators are able to do. Many of our competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources than we do. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies and may establish exclusive collaborative or licensing relationships with our competitors.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies, firms specialized in the development and production of vaccines, checkpoint inhibitors, and other immunotherapies, and major universities and research institutions. Many companies have entered into the field of immuno-oncology and are developing or commercializing products in areas that we have targeted for product development. Some of these products use therapeutic approaches that may compete directly with our product candidates. Most of our competitors possess substantially greater financial, technical and human resources than we possess. In addition, many of our competitors have significantly greater experience than we have in conducting preclinical and nonclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of drugs and manufacturing facilities. Accordingly, our competitors may succeed in obtaining regulatory approval for drugs more rapidly than we do. We expect to face growing competition for enrollment of patients in our clinical trials, which could delay or adversely affect our ability to complete such trials. We may also be adversely affected by the clinical trial results of our competitors. For example, if a competitor announces inconclusive or negative clinical trial results with respect to an IDO pathway inhibitor, expectations about IDO pathway inhibitors may be generally impacted and we may experience difficulty in enrolling patients in our indoximod trials. If we obtain regulatory approval and launch commercial sales of our product candidates, we also will compete with respect to manufacturing efficiency and sales and marketing capabilities, areas in which we currently have limited experience.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We also face competition from pharmaceutical and biotechnology companies, academic institutions, government agencies and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. Moreover, technology controlled by third parties that may be advantageous to our business may be acquired or licensed by our competitors, thereby preventing us from obtaining technology on commercially reasonable terms, if at all. We will also compete for the services of third parties that may have already developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies to target the diseases on which we have focused both inside and outside of the United States.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Our competitive position will also depend upon our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes and secure sufficient capital resources for the often lengthy period between technological conception and commercial sales. We will require substantial capital resources to complete development of some or all of our products, obtain the necessary regulatory approvals and successfully manufacture and market our products. In order to secure capital resources, we may elect to sell additional capital stock, which would dilute the holdings of existing stockholders. We may also attempt to obtain funds through research grants and agreements with commercial collaborators. However, these types of financings are uncertain because they are at the discretion of the organizations and companies that control the funds. Accordingly, we may not receive any additional funds from grants or collaborations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Research and discoveries by others may result in breakthroughs that render indoximod, NLG802, NLG207, and NLG919 product candidates, or our other potential products obsolete even before they begin to generate any revenue. If the FDA approves the commercial sale of any of our product candidates, we will also be competing with respect to marketing capabilities and manufacturing efficiency, areas in which we have limited or no experience. We expect that competition among products approved for sale will be based, among other things, on product efficacy, price, safety, reliability, availability, patent protection, and sales, marketing and distribution capabilities. Our profitability and financial position will suffer if our products receive regulatory approval but cannot compete effectively in the marketplace.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our future products, if any, may not be accepted in the marketplace and therefore, we may not be able to generate significant revenue, or any revenue.</span></div><div style="text-align:justify;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Even if our potential products are approved for sale, physicians and the medical community may not ultimately use them or may use them only in applications more restricted than we expect. Our future products, if successfully developed, will compete with a number of traditional immuno-oncology products manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products will also compete with new products currently under development by such companies and others. Physicians will prescribe a product only if they determine, based on experience, clinical data, side effect profiles and other factors, that it is beneficial as compared to other products currently in use. Many other factors influence the adoption of new products, including marketing and distribution restrictions, course of treatment, adverse publicity, product pricing, the views of thought leaders in the medical community and coverage and adequate reimbursement by government and private third-party payers.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Arrangements with Third Parties</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We rely on third parties to conduct our preclinical studies and our clinical trials. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for our product candidates, or we may be delayed in doing so.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We do not have the ability to conduct preclinical studies or clinical trials independently for our product candidates. We must rely on third parties, such as contract research organizations, medical institutions, academic institutions, clinical investigators and contract laboratories, as well as our strategic collaborators and the third parties that they may use, to conduct our preclinical studies and clinical trials. Other than to the extent that Merck is responsible for clinical trials of our Ebola vaccine product candidate, we are responsible for confirming that our studies are conducted in accordance with applicable regulations and that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. The FDA requires us to comply with GLP for conducting and recording the results of our preclinical studies and with GCP for conducting, monitoring, recording and reporting the results of clinical trials, to assure that data and reported results are accurate and that the clinical trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, do not meet expected deadlines, fail to comply with GCP, do not adhere to our clinical trial protocols or otherwise fail to generate reliable clinical data, we may need to enter into new arrangements with alternative third parties and our clinical trials may be more costly than expected or budgeted, be extended, delayed or terminated or may need to be repeated, and we may not be able to obtain regulatory approval for or to commercialize the product candidate being tested in such trials, or may be delayed in doing so.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Further, if our contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could materially harm our business.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">We are also dependent on Merck for the development of the product candidates that are the subject of the Merck Agreement. If the company does not succeed in advancing the product candidate to final approval, or decides to discontinue its collaboration with us, such failure or decision, could materially harm our business.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to enter into any needed collaboration agreements for our product candidates, or if we enter into collaborations that are ultimately unsuccessful, we may be unable to commercialize any potential product effectively or at all.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">To successfully commercialize any potential product, we will need substantial financial resources as well as expertise and physical resources and systems. We may elect to develop some or all of these physical resources and systems and expertise ourselves or we may seek to collaborate with another company that can provide some or all of such physical resources and systems as well as financial resources and expertise, as we did in the case of the Genentech Agreement and the Merck Agreement. Such collaborations are complex, and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of our clinical trials, the potential market for the subject product candidates, the costs and complexities of manufacturing and delivering the potential product to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. If we were to determine that a collaboration for a potential product is necessary or beneficial and were unable to enter into such a collaboration on acceptable terms, we might elect to delay or scale back the commercialization of the potential product in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves.</span></div><div style="text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we enter into a collaboration agreement we consider acceptable, including the Merck Agreement to develop and commercialize our Ebola vaccine product candidate, the collaboration may not proceed as quickly, smoothly or successfully as we plan. The risks in a collaboration agreement include the following:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the collaborator may not apply the expected financial resources, efforts or required expertise in developing the physical resources and systems necessary to successfully commercialize the subject potential product;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the collaborator may not invest in the development of a sales and marketing force and the related infrastructure at levels that ensure that sales of the potential product reach their full potential;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">disputes may arise between us and a collaborator that delay the commercialization or adversely affect its sales or profitability of the potential product; or</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the collaborator may independently develop, or develop with third parties, products that could compete with the potential product.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Merck Agreement and any other collaboration for our product candidates, we will be dependent on our collaborators&#8217; performance of their responsibilities and their cooperation with us. Our collaborators may not perform their obligations under our agreements with them or otherwise cooperate with us. We cannot control whether our collaborators will devote the necessary resources to the activities contemplated by our collaborative agreements, nor can we control the timing of their performance. Our collaborators may choose to pursue existing or alternative technologies in preference to those being developed in collaboration with us. Disputes may arise between us and our collaborators that delay the development and commercialization of our product candidates, and such disputes may be difficult and costly to resolve or may not be resolved. In addition, a collaborator for the potential product may have the right to terminate the collaboration at its discretion, or to discontinue development of a particular product candidate. For example, in June 2017, Genentech gave notice that it was terminating the Genentech Agreement with respect to NLG919 and gave notice in May 2018 that the remainder of the Agreement would terminate no later than November 6, 2018. Further, Merck has the right to terminate the Merck Agreement for any reason after a specified advance notice period. Any termination may require us to seek a new collaborator, which we may not be able to do on a timely basis, if at all, or may require us to delay or scale back the development or commercialization efforts. The occurrence of any of these events could adversely affect the development or commercialization of the potential product and materially harm our business and stock price by delaying the sale of any product that may be approved by the FDA in the future, by slowing the growth of such sales, by reducing the profitability of the product and/or by adversely affecting the reputation of the product.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may explore strategic collaborations that may never materialize or may fail.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may, in the future, periodically explore a variety of possible strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in the process of seeking appropriate strategic collaborators, and such collaborations can be complicated and time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are required under the Merck Agreement, and we may be required under other collaborations, to relinquish important rights to and control over the development of our product candidates to our collaborators or otherwise be subject to unfavorable terms.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our collaborations, including any future strategic collaborations we enter into, could subject us to a number of risks, including:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may be required to undertake the expenditure of substantial operational, financial and management resources;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">other than under the Merck Agreement, we may be required to issue equity securities that would dilute our existing stockholders&#8217; percentage ownership;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may be required to assume substantial actual or contingent liabilities;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates;</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators may experience financial difficulties;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Protecting Our Intellectual Property</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect our proprietary rights or to defend against infringement claims, we may not be able to compete effectively or operate profitably.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our success will depend, in part, on our ability to obtain patents, operate without infringing the proprietary rights of others and maintain trade secrets, both in the United States and other countries. Patent matters in the biotechnology and pharmaceutical industries can be highly uncertain and involve complex legal and factual questions. Accordingly, the validity, breadth, and enforceability of our patents and the existence of potentially blocking patent rights of others cannot be predicted, either in the United States or in other countries.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There can be no assurance that we will discover or develop patentable products or processes, or that patents will issue from any of the currently pending patent applications or that claims granted on issued patents will be sufficient to protect our technology or adequately cover the products we may actually sell. Potential competitors or other researchers in the field may have filed patent applications, been issued patents, published articles or otherwise created prior art that could restrict or block our efforts to obtain additional patents. There also can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated, rendered unenforceable or circumvented or that the rights granted thereunder will provide us with proprietary protection or competitive advantages. Our patent rights also depend on our compliance with technology and patent licenses upon which our patent rights are based and upon the validity of assignments of patent rights from consultants and other inventors that were, or are, not employed by us.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, competitors may manufacture and sell our potential products in those foreign countries where we have not filed for patent protection or where patent protection may be unavailable, not obtainable or ultimately not enforceable. In addition, even where patent protection is obtained, third-party competitors may challenge our patent claims in the various patent offices, for example via opposition in the European Patent Office or reexamination or interference proceedings in the United States Patent and Trademark Office (USPTO). The ability of such competitors to sell such products in the United States or in foreign countries where we have obtained patents is usually governed by the patent laws of the countries in which the product is sold.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Merck, which has sublicensed our Ebola vaccine product candidate, has received correspondence from Yale University asserting that it owns certain intellectual property rights with respect to the Ebola vaccine that they assert, among other things, may need to be licensed by Merck.  We also received correspondence from Yale University relating to the research and construction of the Ebola vaccine product by our licensor PHAC. If Merck were required to pay royalties to Yale University, </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">that could result in a reduction of Merck&#8217;s royalty obligations to us. If Merck otherwise suffered damages as a result of claims by Yale University, it is possible that Merck could seek indemnification from us. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will incur significant ongoing expenses in maintaining our patent portfolio. Should we lack the funds to maintain our patent portfolio or to enforce our rights against infringers, we could be adversely impacted. Even if claims of infringement are without merit, any such action could divert the time and attention of management and impair our ability to access additional capital and/or cost us significant funds to defend.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We intend to rely on patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#8217; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technologies and product candidates.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have sought to protect our proprietary position by filing patent applications related to our technologies and product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable, or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection or data exclusivity, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not have sufficient patent term protections for our product candidates to effectively protect our business.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Additional patent terms may be available through a patent term adjustment process, resulting from the USPTO delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from generic medications.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations, and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.</span></div><div style="text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September&#160;16, 2011, the Leahy-Smith America Invents Act (the Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The United States Patent and Trademark Office has developed regulations and procedures to govern administration of the Leahy-Smith Act, but many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first-inventor-to-file provisions, only became effective 18&#160;months after its enactment. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend or pursue and uncertain in its outcome.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned or controlled by others. Pharmaceutical companies, biotechnology companies, universities, research institutions, and others may have filed patent applications or have received, or may obtain, issued patents in the United States or elsewhere relating to aspects of our technology. It is uncertain whether the issuance of any third-party patents will require us to alter our products or processes, obtain licenses, or cease certain activities. Some third-party applications or patents may conflict with our issued patents or pending applications. Any such conflict could result in a significant reduction of the scope or value of our issued or licensed patents.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, if patents issued to other companies contain blocking, dominating or conflicting claims and such claims are ultimately determined to be valid, we may be required to obtain licenses to these patents or to develop or obtain alternative non-infringing technology and cease practicing those activities, including potentially manufacturing or selling any products deemed to infringe those patents. If any licenses are required, there can be no assurance that we will be able to obtain any such licenses on commercially favorable terms, if at all, and if these licenses are not obtained, we might be prevented from pursuing the development and commercialization of certain of our potential products. Our failure to obtain a license to any technology that we may require to commercialize our products on favorable terms may have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Litigation, which could result in substantial costs to us (even if determined in our favor), may also be necessary to enforce any patents issued or licensed to us or to determine the scope and validity of the proprietary rights of others. There can be no assurance that our issued or licensed patents would be held valid by a court of competent jurisdiction or that any third party would be found to infringe our patents.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, if our competitors filed patent applications in the United States that claim technology also claimed by us, and such applications were filed before the Leahy-Smith Act took effect, we may have to participate in interference proceedings to determine priority of invention. These proceedings, if initiated by the USPTO, could result in substantial cost to us, even if the eventual outcome is favorable to us. Such proceedings can be lengthy; are costly to defend and involve complex questions of law and fact, the outcomes of which are difficult to predict. An adverse outcome with respect to a third party claim or in an interference proceeding could subject us to significant liabilities, require us to license disputed rights from third parties, or require us to cease using such technology, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We also rely on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable or where patents have not issued. We attempt to protect our proprietary technology and processes, in part, with confidentiality agreements and assignment of invention agreements with our employees and confidentiality agreements with our consultants and certain contractors. There can be no assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors. We may fail in certain circumstances to obtain the necessary confidentiality agreements, or their scope or term may not be sufficiently broad to protect our interests.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If our trade secrets or other intellectual property becomes known to our competitors, it could result in a material adverse effect on our business, financial condition and results of operations. To the extent that we or our consultants or research collaborators </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">use intellectual property owned by others in work for us, disputes may also arise as to the rights to related or resulting know-how and inventions.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Exposure to Litigation </span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are exposed to potential product liability or similar claims, and insurance against these claims may not be available to us at a reasonable rate in the future.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our business exposes us to potential liability risks that are inherent in the testing, manufacturing, marketing and commercial sale of human therapeutic products. Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan and carry a risk of liability for personal injury or death to patients due to unforeseen adverse side effects, improper administration of the product candidate, or other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable to further illness or death. In addition, healthy volunteers in our indoximod clinical trial or our Ebola vaccine product candidate clinical trial may suffer, or perceive themselves to suffer, personal injury or death related to the Ebola vaccine product candidates and may initiate legal action against us.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We carried clinical trial liability insurance in the amount of $5.0 million through July 9, 2019 in the aggregate for claims related to our product candidates other than our Ebola vaccine product candidate. We currently carry clinical trial liability insurance in the amount of $10.0 million in the aggregate for claims related to our Ebola vaccine product candidate. We additionally currently carry clinical trial coverage in lower aggregate amounts in local markets where our clinical trials are conducted on a selective, trial by trial basis. There can be no assurance that we will be able to maintain such insurance or that the amount of such insurance will be adequate to cover claims. We could be materially and adversely affected if we were required to pay damages or incur defense costs in connection with a claim outside the scope of indemnity or insurance coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability exceeds the amount of applicable insurance. In addition, there can be no assurance that insurance will continue to be available on terms acceptable to us, if at all, or that if obtained, the insurance coverage will be sufficient to cover any potential claims or liabilities. Similar risks would exist upon the commercialization or marketing of any future products by us or our collaborators.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On December 9, 2014, the HHS declared our Ebola vaccine product candidate covered under the Public Readiness and Emergency Preparedness Act. This declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of our vaccine candidate. It does not generally provide immunity for a claim brought in a court outside the United States.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:36pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Regardless of their merit or eventual outcome, product liability claims may result in:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">decreased demand for our product;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">injury to our reputation and significant negative media attention;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">withdrawal of clinical trial volunteers;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">costs of litigation;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">distraction of management; and</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">substantial monetary awards to plaintiffs.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are involved in a securities class-action litigation and are at risk of additional similar litigation in the future that could divert management&#8217;s attention and adversely affect our business and could subject us to significant liabilities.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of securities. We are a party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading &#8220;Legal Proceedings.&#8221; The defense of this litigation may increase our expenses and divert our management&#8217;s attention and resources and any unfavorable outcome could have a material adverse effect on our business and results of operations. Any adverse determination in this litigation, or any amounts paid to settle this litigation could require that we make significant payments. In addition, we may in the future be the target of other securities class actions or similar litigation.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Ownership of Our Common Stock</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market price of our common stock may be highly volatile, and could decline significantly.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including those described elsewhere in this &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q and the following:</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">new products, product candidates or new uses for existing products introduced or announced by our strategic collaborators, or our competitors, and the timing of these introductions or announcements;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actual or anticipated results from and any delays in our clinical trials, as well as results of regulatory reviews relating to the approval of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">variations in the level of expenses related to any of our product candidates or clinical development programs, including those relating to the timing of invoices from, and other billing practices of, our clinical research organizations and clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">expenses related to, or our ability or perceived ability to secure, an adequate supply of any future products approved for commercial sale;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="text-indent:-18pt;padding-left:63pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures and capital commitments;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the commercial or clinical success or failure, or perceived success or failure, of our collaborators, including Merck;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">additions or departures of key scientific or management personnel;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">conditions or trends in the biotechnology and biopharmaceutical industries;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">media attention, or changes in media attention, given to cancer and cancer treatment, the recent Ebola epidemic and efforts to develop treatments and vaccines for Ebola, or any other condition or disease that our product candidates are being developed to treat;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">actual or anticipated changes in earnings estimates, development timelines or recommendations by securities analysts;</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">actual and anticipated fluctuations in our quarterly operating results;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the financial projections we may provide to the public, and any changes in these projections or our failure to meet these projections;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">deviations from securities analysts&#8217; estimates or the impact of other analyst rating downgrades by any securities analysts who follow our common stock;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">other events or factors, including those resulting from political uncertainty, war, incidents of terrorism, natural disasters or responses to these events;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">changes in accounting principles;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">discussion of us or our stock price by the financial and scientific press and in online investor communities;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">general economic and market conditions and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; and</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">sales of common stock by us or our stockholders in the future, as well as the overall trading volume of our common stock.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, the stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. We are currently party to the securities class action litigation described in Part II, Item 1 of this Quarterly Report on Form 10-Q under the heading &#8220;Legal Proceedings.&#8221; This litigation and others like it that could be brought against us in the future could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business and financial condition.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 33.8% of our common stock, including shares subject to outstanding options that are exercisable within 60&#160;days after September&#160;30, 2019. These stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our Board of Directors, future issuances of our common stock or other securities, declarations of dividends on our common stock and approval of other significant corporate transactions. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock. In addition, sales of shares beneficially owned by executive officers and directors and their affiliates could be viewed negatively by third parties and have a negative impact on our stock price. Moreover, we cannot assure you as to how these shares may be distributed and subsequently voted.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated bylaws designates the state courts in the State of Delaware of, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against us or our directors, officers, or employees.</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Our amended and restated bylaws (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Bylaws</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8221;) provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1) any derivative action or proceeding brought on behalf of the corporation; (2) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of the corporation to the corporation or to the corporation&#8217;s stockholders; (3) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or the Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or (4) any action asserting a claim governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. </span></div><div><span><br/></span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, if a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to meet compliance obligations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As a public company, we incur significant legal, accounting and other expenses to comply with reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), as well as rules subsequently implemented by the SEC and The Nasdaq Global Market. Meeting the requirements of these rules and regulations entails significant legal and financial compliance costs, makes some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel devote a substantial amount of time to these compliance requirements. In addition, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees or as executive officers.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Failure to achieve and maintain effective internal controls in accordance with Section&#160;404 of the Sarbanes-Oxley Act could have a material adverse effect on our ability to produce accurate financial statements and on our stock price.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, we are required to publish a report by our management on our internal control over financial reporting. To achieve compliance with Section&#160;404, we have engaged in a process to document and evaluate our internal control over financial reporting, which has been both costly and challenging. To maintain compliance on an ongoing basis, we will need to dedicate internal resources, engage outside consultants and adopt a detailed work plan. Despite our effort, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not expect to pay any cash dividends for the foreseeable future. Investors may never obtain a return on their investment.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking only cash dividends should not purchase our common stock.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provisions in our certificate of incorporation, our by-laws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Provisions of our certificate of incorporation, our by-laws or Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest. These provisions include:</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the division of our Board of Directors into three classes with staggered, three-year terms;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">advance notice requirements for stockholder proposals and nominations;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the inability of stockholders to call special meetings;</span></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">limitations on the ability of stockholders to remove directors or amend our by-laws; and</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:72pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, Section&#160;203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The holdings of our stockholders may be diluted, and the prices of our securities may decrease, by the exercise of outstanding stock options or by future issuances of securities by us.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may issue additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock. Furthermore, substantially all shares of common stock for which our outstanding stock options are exercisable are, once they have been purchased, eligible for immediate sale in the public market. The issuance of additional common stock, preferred stock, restricted stock units, or securities convertible into or exchangeable for our common stock or the exercise of stock options would dilute existing investors and could adversely affect the price of our securities. In addition, such securities may have rights senior to the rights of securities held by existing investors.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections&#160;382 and 383 of the Code.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Sections&#160;382 and 383 of the Code limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. A Section 382 ownership change can, therefore, result in significantly greater tax liabilities than a corporation would incur in the absence of such a change, and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on Section 382 ownership change analyses, we believe that, from our inception through June 30, 2019, we experienced Section&#160;382 ownership changes in September 2001 and March 2003, and BPS experienced Section 382 ownership changes in January 2006 and January 2011. These ownership changes limited our ability to utilize federal net operating loss carryforwards and certain other tax attributes that accrued prior to the respective ownership changes of us and our subsidiaries and may continue to limit our ability to utilize such attributes in the future.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Additional ownership changes may occur in the future as a result of events over which we will have little or no control, including purchases and sales of our equity by our 5% stockholders, the emergence of new 5% stockholders, additional equity offerings or redemptions of our stock or certain changes in the ownership of any of our 5% stockholders.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting pronouncements may impact our reported results of operations and financial position.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">U.S. GAAP and related implementation guidelines and interpretations can be highly complex and involve subjective judgments. Changes in these rules or their interpretation, the adoption of new pronouncements or the application of existing pronouncements to changes in our business could significantly alter our reported financial statements and results of operations.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.</span></div><div id="i_0_112"></div><div><span><br/></span></div><div></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div style="text-indent:22pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:22pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div><span><br/></span></div><div id="i_0_115"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span><br/></span></div><div id="i_0_118"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160;MINE SAFETY DISCLOSURES</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Not applicable. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div><span><br/></span></div><div id="i_0_121"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 5.&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div><span><br/></span></div><div id="i_0_124"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 6.&#160;EXHIBITS</span></div><div><span><br/></span></div><div style="text-indent:22pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following exhibits are filed with this Form 10-Q or incorporated herein by reference to the document set forth next to the exhibit listed below. Where so indicated, exhibits that were previously filed are incorporated by reference.</span></div><div id="i_0_127"></div><div style="text-indent:18pt;padding-left:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:7.705882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:51.088235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.058824%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.323529%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.352941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.823529%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Incorporated By Reference</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Exhibit Number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Description</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Form</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Filing Date</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Filed Herewith</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex21.htm">Agreement and Plan of Merger and Reorganization, dated September 30, 2019, by and among NewLink Genetics Corporation, Cyclone Merger Sub, Inc and Lumos Pharma, Inc.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex22.htm">Form of Support Agreement, by and between NewLink Genetics Corporation and it</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex22.htm">s directors and officers and by and between NewLink Genetics Corporation and Stine Seed Farm, Inc. </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000110465911065213/a11-30155_1ex3d1.htm">Amended and Restated Certificate of Incorporation filed on November&#160;16, 2011</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11/18/2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623413000085/nlnk20130514-8xkxex31.htm">Certificate of Amendment to Restated Certificate of Incorporation filed on May 10, 2013</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5/14/2013</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000110465911065213/a11-30155_1ex3d2.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000104746911008688/a2205792zex-4_1.htm">Form of the Registrant&#8217;s Common Stock Certificate</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">S-1/A</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10/26/2011</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623412000024/nlnk-20120331xex43.htm">Amended and Restated Investor Rights Agreement by and between the Registrant and certain holders of the Registrant's capital stock dated as of December 1, 2010</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5/10/2012</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="new-2019930x10qxex101.htm">Separation Agreement by and between the Registrant and Charles J. Link, Jr. dated August 3, 2019</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex102.htm">Transition Agreement, by and between NewLink Genetics Corporation and Nicholas Vahanian, dated September 27, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex103.htm">Employment Agreement, by and between NewLink Genetics Corporation and Carl Langren, dated September 30, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex104.htm">Employment Agreement, by and between NewLink Genetics Corporation and Eugene Kennedy, dated </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex105.htm">Employment Agreement, by and between NewLink Genetics Corporation and Brad Powers, dated September </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex106.htm">Employment Agreement, by and between NewLink Genetics Corporation and Lori Lawley, dated September 30, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1126234/000112623419000130/nlnk-20190930x8kxex101.htm">Form of Lock-Up Agreement</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">8-K</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9/30/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nlnk-2019930x10qxex311.htm">Certification of principal executive officer required by Rule 13a-14(a) / 15d-14(a)</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nlnk-2019930x10qxex312.htm">Certification of principal financial officer required by Rule 13a-14(a) / 15d-14(a)</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">#</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nlnk-2019930x10qxex321.htm">Section&#160;1350 Certification</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.INS</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.SCH</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#160;&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.CAL</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#160;&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Calculation Linkbase Document </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.DEF</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#160;&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.LAB</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#160;&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Label Linkbase Document </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">101.PRE</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#160;&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Presentation Linkbase Document </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">X</span></div></td></tr></table></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">____________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.397661%;"><tr><td style="width:0.1%;"></td><td style="width:1.481013%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:94.518987%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">#</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">"The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NewLink Genetics Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing."</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">&#8225;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:100%;">Filed herewith electronically.</span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div id="i_0_130"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i_0_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:53.070175%;"><tr><td style="width:1.0%;"></td><td style="width:8.468320%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:87.531680%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">NEWLINK GENETICS CORPORATION</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Brad J. Powers</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Brad J. Powers</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General Counsel</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: November 6, 2019</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By:</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">/s/ Carl W. Langren</span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Carl W. Langren</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Secretary</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: November 6, 2019</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>new-2019930x10qxex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Execution Copy</font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">7&#47;29&#47;2019</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">July 29, 2019</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Charles J. Link, Jr.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Apt. 2726</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Austin, TX 78701</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Re&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Separation and Release Agreement</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Dear Chuck&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">This letter sets forth the terms of the separation agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that NewLink Genetics Corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is offering to aid in your employment transition.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Separation Date.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You hereby resign as Chief Executive Officer, Chairman and Chief Scientific Officer of the Company, and from any other office or position you may hold with the Company and any affiliated entities, including your position on the Board of Directors of the Company and any affiliated entities, effective as of August 3, 2019 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Separation Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Within six (6) days after the Separation Date, the Company will pay you all accrued base salary and all remaining accrued but unused vacation earned for your services through the Separation Date, less applicable payroll deductions and withholdings.  You are entitled to these payments regardless of whether or not you sign this Agreement.  Reimbursement for rent payments for the apartment in Austin, TX will end on the Separation Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Expense Reimbursements.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You agree that, within thirty (30) days of the Separation Date, you will submit to the Company your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.  The Company will reimburse you for these expenses pursuant to its regular business practice.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Severance Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  Although under the circumstances of your separation from the Company you are not eligible for any severance benefits set forth in your Employment Agreement with the Company dated December 31, 2015 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Employment Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or otherwise, in consideration for the general release of claims and the ADEA Waiver you are providing in Section 14 (Release of Claims&#59; ADEA Waiver) of this Agreement, and for all other promises you are making and obligations you are undertaking by entering into this Agreement, allowing it to become fully effective and non-revocable, and for complying with its terms, the Company shall provide you with the severance payments and benefits (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Severance Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) described below.  Except as expressly provided otherwise, all cash benefits shall be paid subject to applicable payroll deductions and withholdings.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;padding-left:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:20.41pt;">Cash Severance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="padding-left:4.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:98.57pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">2019 Bonus.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">The Company also will pay you a bonus for your 2019 services (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Bonus Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) equal to $220,521, calculated as follows&#58; (i)&#160;$374,000 (representing the actual 2018 Bonus paid) multiplied by .589 (representing a prorated portion (215&#47;365 days) for the period of employment in 2019).  The Bonus Payment will be paid to you no later than the time 2019 bonuses are paid to other executives, and in any event not later than March 15, 2020.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:95.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Continuation Payments.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Consistent with the severance provisions set forth in Sections 9(g) and 11 of your Employment Agreement, the Company will pay you cash severance equal to $1,319,800, representing the base salary provided in your Employment Agreement, for a period of twenty-four (24) months (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Salary Continuation Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  As required by Section 409A of the Internal Revenue Code of 1986, as amended (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">&#8220;Code&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">) and the regulations and other guidance thereunder and any state law of similar effect (collectively </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">&#8220;Section</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">409A&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">), the Salary Continuation Payment shall be paid in a lump sum upon the first regularly scheduled payroll date that is six (6) months after the Separation Date, provided the Company has received the executed Agreement from you on or before that date.  No interest will be paid to you on any amounts for which payment is delayed pursuant to the foregoing provision</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:24.34pt;">Healthcare Continuation Coverage Payments.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:98.57pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">COBRA Election</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, you may be eligible to continue your group health insurance benefits at your own expense after the Separation Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:95.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">COBRA Premiums</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  As an additional severance benefit, if you timely elect continued coverage under COBRA, and execute, return and do not revoke this Agreement, the Company will pay that portion of your premiums that it was paying prior to the Separation Date for your basic medical coverage (including coverage for any eligible dependents, if applicable, but excluding dental and vision insurance coverage) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">COBRA Premiums</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) for the period (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">COBRA Premium Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) starting on the Separation Date and ending on the earliest to occur of&#58; (i) eighteen (18) months after the Separation Date&#59; (ii) the date you become eligible for group health insurance coverage through a new employer&#59; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination.  In the event you become covered under another employer&#8217;s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you shall immediately provide written notification of such event to the Company&#8217;s Human Resources Manager.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:93.03pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Alternative Cash Payments in Lieu of COBRA Premiums</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company instead shall pay you, on the first day of each calendar month following such determination, a fully taxable cash payment which, after taxes, is equal to the COBRA Premium amount the Company would have otherwise paid you for that month (assuming a 35% tax rate) (such amount, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Alternative Cash Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;), for the remainder of the COBRA Premium Period.  You may, but are not obligated to, use such Alternative Cash Payments toward the cost of COBRA premiums.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:24.91pt;">Equity.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You have been granted options to purchase shares of the Company&#8217;s common stock (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and certain restricted stock units (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">RSUs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">,&#8221; and together with the Options, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) pursuant to the Company&#8217;s 2009 Equity Incentive Plan (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Under the terms of the applicable governing agreements and Plan documents, vesting of any unvested Awards would cease on the Separation Date.  As an additional severance benefit, the Company will (i)&#160;accelerate the vesting of the outstanding and unvested Awards set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit&#160;B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Subject Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) so that you are credited with an additional twelve (12) months of vesting as of the Separation Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Accelerated Vesting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (ii) make an option grant on or about August 1, 2019, and prior to your Separation Date, for 331,258 shares of Common Stock, which option shall have an exercise price equal to the fair market value of the Common Stock on the date of grant, shall be fully vested, and shall become exercisable beginning upon November 3, 2019&#59; and (iii)&#160;extend the exercise period under the governing agreements and Plan documents so that you have two (2) years from the Separation Date to exercise the 83,333 shares vested under your March 2019 option grant and the option to be granted under clause (ii) above (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Extended Exercise Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  To the extent that any performance criteria under any Award have not been satisfied as of the Separation Date, such Awards shall terminate as of the Separation Date.  Except as expressly provided in this Section, the Options and RSUs will continue to be governed by the terms of the governing agreements and Plan documents.  You acknowledge and agree that the Extended Exercise Period may convert any portion of the Options that were incentive stock options into non-qualified stock options, thereby changing their tax treatment&#59; and you should seek advice from your own tax advisors about this extension.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;">Priority Review Voucher.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">If the Company receives the Current Product Voucher contemplated by section 5.3.1 of the License and Collaboration Agreement between Merck Sharpe &#38; Dohme Corp. (&#34;Mereck&#34;), Bioprotection Systems Corporation, and the Company, dated November 21, 2018, as amended and as the same may be amended from time to time, then the Company shall pay you (or a charity designated by you) an amount equal to one half of one percent (0.5%) of the net amount actually received by the Company (in the event of a sale of such voucher), or the portion of the Current Product Voucher Value retained by the Company (if such voucher is retained by the Company), in each case after deducting all amounts paid or payable by the Company to Merck, Public Health Canada (as defined therein), or any other third parties entitled to a share of such amounts, and after deducting any fees or costs incurred in obtaining or selling such voucher.  The foregoing right shall expire if such voucher has not been issued to the Company by December 31, 2023.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">409A Compliance.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">It is intended that the Severance Benefits provided to you hereunder comply with, or be exempt from, Section 409, and that any ambiguities herein will be interpreted to so comply and&#47;or be exempt from Section 409A.  It is intended that all of the benefits and payments under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A&#8209;1(b)(4), 1.409A&#8209;1(b)(5) and 1.409A&#8209;1(b)(9), and this Agreement will be interpreted accordingly.  To the extent not so exempt, this Agreement (and any definitions hereunder) will be interpreted in a manner that complies with the Section 409A requirements.  For purposes of Section 409A, your right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  If the period of time you could sign this Agreement crosses over two calendar years, the Agreement shall be deemed to have become effective on the last possible date it could become effective.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt;">280G Compliance.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Section 12 of the Employment Agreement is incorporated herein.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Benefits.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Your participation in Employer-Sponsored Group Life Insurance and Short and Long Term Disability Insurance will cease as of&#160; the Separation Date&#59; however, you may elect to convert your&#160;Life&#160;Insurance by contacting &#160;Mutual of Omaha at (800) 228-7104 or refer to the conversion notice attached hereto.  &#160; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Deductions for the 401(k) Plan will end with your last regular paycheck.&#160; You will receive information by mail concerning 401(k) plan rollover procedures should you be a participant in this program.&#160; </font></div><div style="text-align:justify;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">You have the right to continue your current Health Care Spending Account if you are participating in this program.&#160; Information on how to continue this benefit will be mailed to you by Discovery Benefits along with your COBRA details.&#160; Dependent Care Spending Accounts cannot be continued.&#160; Your last full Spending Account payroll deductions will be processed on your final paycheck.  Unless you elect to continue your Health Care Spending Account, you will only be eligible to claim expenses that you incurred through the end of the month of your separation date.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Other Compensation or Benefits.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive after the Separation Date any additional compensation, severance or benefits, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account).  By way of example, you acknowledge that you have not earned and are not owed any bonus, incentive compensation, commissions or equity (other than as provided or referenced herein) from the Company.</font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Return of Company Property.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  No later than the close of business on the Separation Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property or information in your possession or control (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Company Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;), including, but not limited to&#58; Company hardcopy and softcopy files, databases, notes, emails, correspondence, financial and operational information, current or potential customer lists and contact information, product and services information, research and development information, drawings, records, plans, forecasts, reports, payroll information, spreadsheets, studies, analyses, compilations of data, proposals, agreements, sales and marketing information, personnel information, specifications, code, software, electronically or computer-recorded information, tangible property and equipment (including, but not limited to, computing and communications devices, facsimile machines, mobile telephones, servers), credit cards, entry cards, identification badges and keys&#59; and any materials of any kind which contain or embody any proprietary or confidential information of the Company and all reproductions thereof in whole or in part and in any medium.  You shall make a diligent search to locate any such Company Property by the close of business on the Separation Date.  In addition, if you have used any personally owned computing or communication device, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you shall permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part)&#59; and you agree to make any such device or system available for inspection and analysis by the Company, upon its reasonable request, in order to permit the Company to determine whether you are in compliance with this provision.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Your timely compliance with the provisions of this Section is a precondition to your receipt of the Severance Benefits and other benefits provided hereunder.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Proprietary Information, Non-Solicitation and Non-Competition Obligations.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You acknowledge and agree to abide by your continuing obligations under your Employee Proprietary Information, Inventions, Non-Competition, and Non-Solicitation Agreement with the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Proprietary Information Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221; attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit&#160;A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">), effective as of the beginning of your employment with the Company and continuing after the Separation Date, including but not limited to your obligations not to use or disclose any confidential or proprietary information of the Company and to refrain from certain solicitation and competitive activities.  Confidential information that is also a &#8220;trade secret,&#8221; as defined by law, may be disclosed (A) if it is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, in the event that you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding, if you&#58; (A) file any document containing the trade secret under seal&#59; and (B) do not disclose the trade secret, except pursuant to court order.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Non-Disparagement.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Both you and the Company agree not to disparage the other party, and the other party&#8217;s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation&#59; provided that both you and the Company will respond accurately and fully to any question, inquiry or request for information when required by legal process.  The Company&#8217;s obligations under this Section are limited to Company representatives with knowledge of this provision. Notwithstanding the foregoing, nothing in this Agreement shall limit your right to voluntarily communicate with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, other federal government agency or similar state or local agency or to discuss the terms and conditions of your employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act.  </font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt;">Public Statements. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> Both the Company and you shall respond to third party inquiries, and the Company shall issue a press release, effectively stating that you have resigned from your position as Chief Executive Officer, and from your employment with the Company, effective as of the Separation Date.  The content of such press release will be mutually agreed.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">References.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">In response to any request for references from a prospective employer, the Company will verify only your last job title and dates of employment.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">Cooperation.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Transition Briefings.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  Prior to and after the Separation Date, you agree to cooperate fully with the Company in all matters relating to the transition of your work and responsibilities on behalf of the Company, including, but not limited to, transitioning any work relationships and providing oral and written briefings (as requested) with respect to any past or present work activities and institutional knowledge, to such other persons as may be designated by the Company.  You agree to make yourself available to respond to such inquiries with reasonable promptness, either telephonically or by email (as requested), unless the Company requests that you come to the Company for such discussion or to review certain documents or materials related to the inquiry.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;No Voluntary Adverse Assistance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You agree that you will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any third party (including both persons and entities) in connection with any claim or cause of action of any kind brought against, or being prepared against, the Company by any third party, nor shall you induce or encourage any person or entity to bring such claims&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">, that nothing herein shall limit or restrict your right to engage in any of the protected activities described in Section 15 (Protected Rights) below.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Other Voluntary Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during your employment with the Company.  Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony.  The Company will reimburse </font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding forgone wages, salary, or other compensation), and will make reasonable efforts to accommodate your scheduling needs.  In addition, you agree to execute all documents (if any) necessary to carry out the terms of this Agreement.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">No Admissions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Nothing contained in this Agreement shall be construed as an admission by you or the Company of any liability, obligation, wrongdoing or violation of law.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">Release of Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">In exchange for the Severance Benefits, including the Salary Continuation Payments, the reimbursement of your COBRA Premiums (or Alternative Cash Payments), the Accelerated Vesting,  and all other consideration provided to you by the Company under this Agreement that you would not otherwise be entitled to receive (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Release Consideration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;), you agree to the terms below.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;General Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  You hereby generally and completely release the Company and its parent or subsidiary entities, successors, predecessors and affiliates, and its and their directors, officers, employees, consultants, shareholders, agents, attorneys, insurers, affiliates and assigns (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of and from any and all claims, liabilities and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Released Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Scope of Release.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  The Released Claims include, but are not limited to&#58; (1) all claims arising from or in any way related to your employment with the Company, or the termination of that employment&#59; (2)&#160;all claims related to your compensation or benefits from the Company (except as expressly provided in this Agreement), including but not limited to salary, bonuses, commissions, vacation pay, PTO, expense reimbursement, severance pay, fringe benefits, profit sharing, stock, stock options, or any other ownership or equity interests in the Company&#59; (3)&#160;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including but not limited to any claims arising under or based on your initial employment offer letter or subsequent Employment Agreement (including claims for severance benefits thereunder)&#59; (4)&#160;all tort claims, including but not limited to claims for battery, negligence, fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (5) all federal, state, and local statutory claims in all jurisdictions, including but not limited to claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964, the federal Americans with Disabilities Act of 1990, the federal Family and Medical Leave Act, the Equal Pay Act of 1963, the Fair Labor Standards Act, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (together, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">ADEA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act (and all similar state and local laws), the Iowa Civil Rights Act of 1965, the Iowa Wage Payment Collection Law, the Texas Commission on Human Rights Act, the Texas Payday Law, the Texas Labor Code, and any statute or regulation administered by the Texas Workforce Commission.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Excluded Claims.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Excluded Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;  (1) rights to apply for unemployment insurance benefits&#59; (2) rights to workers&#8217; compensation disability benefits, claims and payments, if applicable&#59; (3)&#160;any rights or claims for indemnification pursuant to any written indemnification agreement with the Company to which you are a party, or under Company bylaws or articles, or under applicable law&#59; (4)&#160;any rights which are not waivable as a matter of law&#59; or (5) any claims for breach of this Agreement.  You represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or </font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">may have against any of the Released Parties that are not included in the Released Claims.  You and the Company agree that the sole reason for the termination of your employment is a business reorganization which is occurring on July 29, 2019.  All individuals who are being terminated in the business reorganization on July 29, 2019 will be eligible for benefits based upon their execution of a release substantially similar to this release.  You are acknowledging by signing this Agreement that you understand that you are eligible for the benefits which you will receive contingent upon your executing this release, because you were part of this business reorganization.  A description of the employees on the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Senior Executive Team </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">that this business reorganization will affect is more fully set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;ADEA Waiver.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You further specifically agree that, as part of the Released Claims, you are releasing any claims that you could assert under the ADEA, as amended (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">&#8220;ADEA Waiver&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">).  You acknowledge that&#58; you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA&#59; that the Release Consideration is being given in partial consideration for the ADEA Waiver&#59; and that the Release Consideration is in addition to anything of value to which you were already entitled.  You further acknowledge that you have been advised, as required by the ADEA, that&#58; (1) this ADEA Waiver does not apply to any rights or claims that arise after the date you sign this Agreement&#59; (2) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so)&#59; (3) you have forty-five (45) days to consider this Agreement (although you may choose voluntarily to sign it earlier)&#59; (4) you have seven (7) days following the date you sign this Agreement to revoke the Agreement (in a written revocation provided to and received by the Company&#8217;s CEO within the 7-day revocation period)&#59; and (5)&#160;the Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement, provided that you have not timely revoked it (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  You understand and agree that, if you revoke the ADEA Waiver, you will not be entitled to the Release Consideration.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">Protected Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">.  Nothing in this Agreement shall prevent you from challenging the validity of the release of claims provided herein in a legal or administrative proceeding.  You further understand that nothing in this Agreement (including, without limitation, Section 8 (Confidentiality), Section 9 (Non-Disparagement) and Section 14 (Releases of Claims) above)&#58; limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Government Agencies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; prevents any party from providing information or disclosing the fact or terms of this Agreement as part of any government investigation&#58; or prohibits any party from reporting possible violations of law or regulation to any Government Agencies or self-regulating entity under applicable law (including, but not limited to, the U.S. Securities and Exchange Commission&#8217;s Whistleblower Rule, of Section 21F of the U.S. Securities Exchange Act of 1934, as amended).  While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any of the Released Claims and any rights you have waived by signing this Agreement. </font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">Representations.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  You hereby represent that, except for amounts to be paid to you under this Agreement, you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.  You also represent and affirm that all of the decisions of the Released Parties regarding your pay and benefits through the date of your execution of this Agreement were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law.  You further affirm that you have not filed, caused to be filed, and are not presently a party to a claim or cause of action against any of the Released Parties.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">Breach.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">You agree that upon a material breach of this Agreement you will forfeit all amounts paid or owing to you under this Agreement.  The parties acknowledge that it may be impossible to assess the damages caused by a violation of the terms of Sections 6, 7, 8 and 9 of this Agreement and further agree that any threatened or actual violation or breach of those Sections of this Agreement will constitute immediate and irreparable injury to the non-breaching party.  Therefore, the parties agree that any such breach of this Agreement is a material breach of this Agreement, and, in addition to any and all other damages and remedies available, the non-breaching party shall be entitled to an injunction to prevent violation or breach of this Agreement.  The parties agree that if a party is successful in whole or part in any legal or equitable action under this Agreement, that party may recover all of the costs, including reasonable attorneys&#8217; fees, incurred in enforcing the terms of this Agreement.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;padding-left:23.5pt;">General.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">  This Agreement, including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to this subject matter.  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter (including but not limited to your Employment Agreement with the Company).  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties.  This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of Iowa as applied to contracts made and to be performed entirely within Iowa.  The parties hereby consent to the sole and exclusive jurisdiction of the state or federal court for Des Moines, Iowa for any actions, suits or proceedings arising out of or relating to this Agreement.  Any ambiguity in this Agreement shall not be construed against either party as the drafter.  Any waiver of a breach of this Agreement, or rights hereunder, must be in writing to be effective and shall not be deemed to be a waiver of any successive or other breach or rights hereunder.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile, .PDF and electronic signatures shall be equivalent to original signatures.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">To accept the terms set forth above, please sign and date this Agreement and return the fully&#8209;executed Agreement to the Company within 45 days after the Separation Date.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">We wish you the best in your future endeavors.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div style="text-align:justify;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">NewLink Genetics Corporation</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">By&#58;  _</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47;Thomas A. Raffin, M.D.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">___________________________</font></div><div style="text-indent:22.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Thomas A. Raffin, M.D.</font></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Lead Director</font></div><div style="text-align:justify;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Exhibit A -Proprietary Information Agreement</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Exhibit B - Options and RSUs Subject to Twelve-Month Acceleration and Extended Exercise Period</font></div><div style="text-align:justify;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Understood and Agreed&#58;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">_</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Charles J. Link, Jr.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">____________________________________</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Charles J. Link, Jr.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">__</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">July 29, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">__________________________________________</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Date</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Exhibit A</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Proprietary Information Agreement</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Incorporated by reference from Exhibit A to Employment Agreement dated January 4, 2016 as filed with the Securities and Exchange Commission as Exhibit 10.31 to the Company's Annual Report on Form 10-K for year ended December 31, 2018.</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Exhibit B</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">Options and RSUs Subject to Twelve-Month Acceleration</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">and Extended Exercise Period</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">Options granted March 1, 2019, to be vested as to an additional 62,500 shares for a total of 83,333 shares.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">RSU award granted January 4, 2016 to be vested as to an additional 11,660 shares for a total of 46,639 shares.  </font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>nlnk-2019930x10qxex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Brad J. Powers, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this Form 10-Q of NewLink Genetics Corporation&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November 6, 2019</font></div><div><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.345029%;"><tr><td style="width:1.0%;"></td><td style="width:7.148265%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.851735%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Brad J. Powers</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Brad J. Powers</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General Counsel</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>nlnk-2019930x10qxex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.2</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Carl W. Langren, certify that&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">I have reviewed this Form 10-Q of NewLink Genetics Corporation&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November 6, 2019</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.345029%;"><tr><td style="width:1.0%;"></td><td style="width:7.148265%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.851735%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Carl W. Langren</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Carl W. Langren</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Secretary</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>nlnk-2019930x10qxex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Brad J. Powers, General Counsel of NewLink Genetics Corporation (the &#8220;Company&#8221;), and Carl W. Langren, Chief Financial Officer and Secretary of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2019, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">In Witness Whereof</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">, the undersigned have set their hands hereto as of the 6th day of November, 2019.</font></div><div><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.345029%;"><tr><td style="width:1.0%;"></td><td style="width:7.148265%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.851735%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Brad J. Powers</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Brad J. Powers</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General Counsel</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:46.345029%;"><tr><td style="width:1.0%;"></td><td style="width:7.148265%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.851735%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Carl W. Langren</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Carl W. Langren</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer and Secretary</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#34;This certification &#8220;accompanies&#8221; the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#34;</font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nlnk-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nlnk="http://www.linkp.com/20190930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.linkp.com/20190930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="nlnk_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nlnk_A2010EmployeeStockPurchasePlanMember" abstract="true" name="A2010EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nlnk_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nlnk_A2009EquityIncentivePlanMember" abstract="true" name="A2009EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_LumosPharmaIncMember" abstract="true" name="LumosPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_MergerAgreementCovenantsTerminationFeePayable" abstract="false" name="MergerAgreementCovenantsTerminationFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" abstract="true" name="A2010NonEmployeeDirectorsStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_DeferredGovernmentGrantsObligationsNoncurrent" abstract="false" name="DeferredGovernmentGrantsObligationsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_GovernmentContractAccruedSubcontractorFees" abstract="false" name="GovernmentContractAccruedSubcontractorFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_MerckSharpeAndDohmeCorpMember" abstract="true" name="MerckSharpeAndDohmeCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nlnk_FinancingsTable" abstract="true" name="FinancingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nlnk_OperatingLeaseRightofUseAssetNoncurrent" abstract="false" name="OperatingLeaseRightofUseAssetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nlnk_FinancingsLineItems" abstract="true" name="FinancingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nlnk_ContractManufacturingOrganizationEquipmentMember" abstract="true" name="ContractManufacturingOrganizationEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" abstract="false" name="LesseeOperatingLeaseLiabilityUnamortizedIncentives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" abstract="false" name="FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeOptionsConverted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" abstract="false" name="ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nlnk-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.linkp.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofStockholdersEquity" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.linkp.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.linkp.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.linkp.com/role/BasisofPresentation">
        <link:definition>2103102 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.linkp.com/role/SignificantAccountingPolicies">
        <link:definition>2104103 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2205201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDetails" roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.linkp.com/role/Revenues">
        <link:definition>2107104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.linkp.com/role/RevenuesDetails">
        <link:definition>2408403 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandResearchCollaborationAgreements" roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements">
        <link:definition>2109105 - Disclosure - License and Research Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandResearchCollaborationAgreementDetails" roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails">
        <link:definition>2410404 - Disclosure - License and Research Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlan" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan">
        <link:definition>2111106 - Disclosure - Common Stock Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanTables" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables">
        <link:definition>2312301 - Disclosure - Common Stock Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanNarrativeDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails">
        <link:definition>2413405 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails">
        <link:definition>2414406 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanStockOptionActivityDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails">
        <link:definition>2415407 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails">
        <link:definition>2416408 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanRestrictedStockActivityDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails">
        <link:definition>2417409 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityIncentivePlanOptionExchangeProgramDetails" roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails">
        <link:definition>2418410 - Disclosure - Common Stock Equity Incentive Plan (Option Exchange Program) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.linkp.com/role/Leases">
        <link:definition>2119107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.linkp.com/role/LeasesTables">
        <link:definition>2320302 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetails" roleURI="http://www.linkp.com/role/LeasesDetails">
        <link:definition>2421411 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.linkp.com/role/IncomeTaxes">
        <link:definition>2122108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.linkp.com/role/IncomeTaxesDetails">
        <link:definition>2423412 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareofCommonStock" roleURI="http://www.linkp.com/role/NetLossperShareofCommonStock">
        <link:definition>2124109 - Disclosure - Net Loss per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareofCommonStockTables" roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockTables">
        <link:definition>2325303 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareofCommonStockNetLossPerShareComputationDetails" roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails">
        <link:definition>2426413 - Disclosure - Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails">
        <link:definition>2427414 - Disclosure - Net Loss per Share of Common Stock (Antidilutive Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandSeveranceCharges" roleURI="http://www.linkp.com/role/RestructuringandSeveranceCharges">
        <link:definition>2128110 - Disclosure - Restructuring and Severance Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandSeveranceChargesTables" roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesTables">
        <link:definition>2329304 - Disclosure - Restructuring and Severance Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandSeveranceChargesDetails" roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails">
        <link:definition>2430415 - Disclosure - Restructuring and Severance Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.linkp.com/role/CommitmentsandContingencies">
        <link:definition>2131111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nlnk-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.linkp.com/role/CoverPage" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a438e578-2974-4e5b-916a-3790768814d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bd935fd-1ad6-4747-9206-aa29d88f828c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a438e578-2974-4e5b-916a-3790768814d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bd935fd-1ad6-4747-9206-aa29d88f828c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_908ea533-fcc8-4556-88d3-a4b2c59b9307" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a438e578-2974-4e5b-916a-3790768814d6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_908ea533-fcc8-4556-88d3-a4b2c59b9307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_8023c054-cc8b-4e00-a94d-15da1ee0875c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a438e578-2974-4e5b-916a-3790768814d6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_8023c054-cc8b-4e00-a94d-15da1ee0875c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_9aa1ec07-2a84-4e77-b2e1-8f34cdda9bac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a438e578-2974-4e5b-916a-3790768814d6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_9aa1ec07-2a84-4e77-b2e1-8f34cdda9bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1460f622-7288-486b-b396-e113f4e4528b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:to="loc_us-gaap_AccountsPayableCurrent_1460f622-7288-486b-b396-e113f4e4528b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_88ccefe1-d2a6-4fe8-bc51-d5f4cb3f17bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_88ccefe1-d2a6-4fe8-bc51-d5f4cb3f17bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_6d4d1bee-cb26-4f00-a081-400006340a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_6d4d1bee-cb26-4f00-a081-400006340a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ad9c6f54-edc9-437f-9aa9-414767e59ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ad9c6f54-edc9-437f-9aa9-414767e59ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8e84856-f31e-4504-b466-512d74e43088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_25c89bea-b6da-4e2b-b87a-4406b7eff689" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f8e84856-f31e-4504-b466-512d74e43088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_07f286cb-707c-4a9b-9821-29963e57b0b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4888bdcf-75be-4423-95f8-17f6d4197b58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07f286cb-707c-4a9b-9821-29963e57b0b3" xlink:to="loc_us-gaap_AssetsCurrent_4888bdcf-75be-4423-95f8-17f6d4197b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_49626ca0-090d-42a9-aa6d-928e56f0b820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07f286cb-707c-4a9b-9821-29963e57b0b3" xlink:to="loc_us-gaap_AssetsNoncurrent_49626ca0-090d-42a9-aa6d-928e56f0b820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_b702d9d7-db09-46f1-87d1-c67188666a84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ce27de27-6f2c-4296-a41c-f2ff468efbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b702d9d7-db09-46f1-87d1-c67188666a84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ce27de27-6f2c-4296-a41c-f2ff468efbcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_73e68f90-95d9-4efd-81d6-8a44512eabfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b702d9d7-db09-46f1-87d1-c67188666a84" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_73e68f90-95d9-4efd-81d6-8a44512eabfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent_7ff822e5-9a98-4003-b5ba-d583c08314e7" xlink:href="nlnk-20190930.xsd#nlnk_OperatingLeaseRightofUseAssetNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b702d9d7-db09-46f1-87d1-c67188666a84" xlink:to="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent_7ff822e5-9a98-4003-b5ba-d583c08314e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_960632bf-7552-4518-af35-0b2782ddf38a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_960632bf-7552-4518-af35-0b2782ddf38a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_bbd8c728-4fd3-4f56-921b-e61c4c7dc72f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:to="loc_us-gaap_CommonStockValueOutstanding_bbd8c728-4fd3-4f56-921b-e61c4c7dc72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_071f3e63-ea3e-4fcc-a7b5-87f1c7b76f92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_071f3e63-ea3e-4fcc-a7b5-87f1c7b76f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_547d74b5-5b03-46b5-9113-eb9dee881202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:to="loc_us-gaap_TreasuryStockValue_547d74b5-5b03-46b5-9113-eb9dee881202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97245be8-f10e-4973-b6c3-a62b4b9f07b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcdd946e-ea1d-401b-ab7c-5f265c43a59d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97245be8-f10e-4973-b6c3-a62b4b9f07b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_89d4fb97-b8b7-406c-9640-278184fe08b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_862371db-5c80-41e8-826b-4b8c911771fe" xlink:href="nlnk-20190930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_89d4fb97-b8b7-406c-9640-278184fe08b7" xlink:to="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_862371db-5c80-41e8-826b-4b8c911771fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2f4e23dc-5ab2-424c-af3a-f82263896fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_89d4fb97-b8b7-406c-9640-278184fe08b7" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2f4e23dc-5ab2-424c-af3a-f82263896fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfe6e973-969c-4d1f-adc6-6e37a4225f92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_89d4fb97-b8b7-406c-9640-278184fe08b7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfe6e973-969c-4d1f-adc6-6e37a4225f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7f00df46-57c3-4283-b354-03c4b06b5554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_89d4fb97-b8b7-406c-9640-278184fe08b7" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_7f00df46-57c3-4283-b354-03c4b06b5554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2cebfeb1-91dc-4a59-9434-bc033aeb88dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7ba2255f-82ec-4f4e-9b51-2c8d7275d901" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cebfeb1-91dc-4a59-9434-bc033aeb88dc" xlink:to="loc_us-gaap_LiabilitiesCurrent_7ba2255f-82ec-4f4e-9b51-2c8d7275d901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d5517107-0e28-4395-9448-288c51be82f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2cebfeb1-91dc-4a59-9434-bc033aeb88dc" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_d5517107-0e28-4395-9448-288c51be82f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e621dd4-a318-438d-8d43-61105dd1025a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_617c0f86-9260-400a-b97a-32f06717a5f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e621dd4-a318-438d-8d43-61105dd1025a" xlink:to="loc_us-gaap_Liabilities_617c0f86-9260-400a-b97a-32f06717a5f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53533b66-8ac3-42dd-9959-c2d888c78ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e621dd4-a318-438d-8d43-61105dd1025a" xlink:to="loc_us-gaap_StockholdersEquity_53533b66-8ac3-42dd-9959-c2d888c78ab3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d97382ff-8937-4ec0-a28a-0fce136e71d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_52ebe84a-03aa-461b-9c21-6fd8b51edf91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d97382ff-8937-4ec0-a28a-0fce136e71d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_52ebe84a-03aa-461b-9c21-6fd8b51edf91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b9a828d1-7508-4fc0-bbdd-d35e008484ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d97382ff-8937-4ec0-a28a-0fce136e71d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b9a828d1-7508-4fc0-bbdd-d35e008484ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_865da2a0-5547-422c-bcb3-3d5512e64c92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d97382ff-8937-4ec0-a28a-0fce136e71d1" xlink:to="loc_us-gaap_InterestExpense_865da2a0-5547-422c-bcb3-3d5512e64c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f05dfc76-b973-443a-a06c-1231a031cec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_84ae2a51-72d1-4acd-a7e2-15f8e258071e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f05dfc76-b973-443a-a06c-1231a031cec7" xlink:to="loc_us-gaap_Revenues_84ae2a51-72d1-4acd-a7e2-15f8e258071e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9bea2543-251d-4276-8ad0-b6f203803a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f05dfc76-b973-443a-a06c-1231a031cec7" xlink:to="loc_us-gaap_OperatingExpenses_9bea2543-251d-4276-8ad0-b6f203803a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b98e00-f966-4ee7-93e8-8d65fa4f5d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f57fa998-4028-40b7-b57d-4472c078c495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b98e00-f966-4ee7-93e8-8d65fa4f5d4b" xlink:to="loc_us-gaap_OperatingIncomeLoss_f57fa998-4028-40b7-b57d-4472c078c495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_63eebe5b-7b40-4368-aab1-9c5f339f54dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b98e00-f966-4ee7-93e8-8d65fa4f5d4b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_63eebe5b-7b40-4368-aab1-9c5f339f54dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_318cb55e-b973-4376-a552-92f432930b62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d517e0f7-7958-4891-809d-0d7167a4b061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_318cb55e-b973-4376-a552-92f432930b62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d517e0f7-7958-4891-809d-0d7167a4b061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0963b8f2-323f-4433-b926-ea715ef8b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_318cb55e-b973-4376-a552-92f432930b62" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0963b8f2-323f-4433-b926-ea715ef8b8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50a1aefb-65ec-4813-81e4-d0dfda31006f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8959542-cd42-4a51-b89d-9e52458379f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_50a1aefb-65ec-4813-81e4-d0dfda31006f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8959542-cd42-4a51-b89d-9e52458379f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_771b8bcd-6ded-4c59-9d7c-b39a36f23bda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_50a1aefb-65ec-4813-81e4-d0dfda31006f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_771b8bcd-6ded-4c59-9d7c-b39a36f23bda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c6883c0-5aab-4436-815d-c3bd307c1783" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73f2e255-9963-4450-a781-e7e6581d8cec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c6883c0-5aab-4436-815d-c3bd307c1783" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_73f2e255-9963-4450-a781-e7e6581d8cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_594a7630-74b9-4bd3-96ba-ef41886775c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c6883c0-5aab-4436-815d-c3bd307c1783" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_594a7630-74b9-4bd3-96ba-ef41886775c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_ff78231a-27a9-4527-ac53-1c3fbbaa58ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c6883c0-5aab-4436-815d-c3bd307c1783" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_ff78231a-27a9-4527-ac53-1c3fbbaa58ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c018b35a-57dc-46b2-a768-bfa578871bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0740691f-38bb-4baa-ba13-78cda430a99d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c018b35a-57dc-46b2-a768-bfa578871bf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0740691f-38bb-4baa-ba13-78cda430a99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1719fa1a-c494-4c79-8172-cd84ef9ba52f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c018b35a-57dc-46b2-a768-bfa578871bf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1719fa1a-c494-4c79-8172-cd84ef9ba52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c51c06c4-a0ce-4b49-92a8-aced6cbcfad4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c018b35a-57dc-46b2-a768-bfa578871bf7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c51c06c4-a0ce-4b49-92a8-aced6cbcfad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ddac513c-a944-49ef-99ef-13ed4ad4333b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75951c04-23aa-4d5f-9cf2-9b71129cd5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ddac513c-a944-49ef-99ef-13ed4ad4333b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_75951c04-23aa-4d5f-9cf2-9b71129cd5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7f33503b-46e6-4fae-bc00-5c33ddfa7e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ddac513c-a944-49ef-99ef-13ed4ad4333b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7f33503b-46e6-4fae-bc00-5c33ddfa7e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5a69eb75-876a-4e3d-8076-c5b4d0390aba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_NetIncomeLoss_5a69eb75-876a-4e3d-8076-c5b4d0390aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_70eb3ec1-ebf0-4c27-b334-28e41548ca68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_ShareBasedCompensation_70eb3ec1-ebf0-4c27-b334-28e41548ca68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f23a025f-4bfa-4731-b529-e7cb6e628d49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f23a025f-4bfa-4731-b529-e7cb6e628d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6c1919a0-084f-4456-a7b2-ac3e6ef52d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6c1919a0-084f-4456-a7b2-ac3e6ef52d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6063eb84-be41-4e90-b2d9-b2e870e57879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6063eb84-be41-4e90-b2d9-b2e870e57879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_381e6907-4495-4fbd-b9f2-c4526ac9b79f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_381e6907-4495-4fbd-b9f2-c4526ac9b79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_958e79c9-e8f0-43f9-ae2f-7f251576cf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_958e79c9-e8f0-43f9-ae2f-7f251576cf2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7346d7c8-61a6-4c27-bdd1-1b49164e2aff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7346d7c8-61a6-4c27-bdd1-1b49164e2aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7d8fc656-0627-42c2-a673-98ba0fcfdee6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7d8fc656-0627-42c2-a673-98ba0fcfdee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_f6f0b6f0-9f7c-4e71-9616-17ddf75bb7e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_f6f0b6f0-9f7c-4e71-9616-17ddf75bb7e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_ebfad637-a4e6-49ed-bc7c-550b11de37b3" xlink:href="nlnk-20190930.xsd#nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_892c10ea-94c2-4701-a9a2-ee13c8f81e79" xlink:to="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_ebfad637-a4e6-49ed-bc7c-550b11de37b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/BasisofPresentation" xlink:type="simple" xlink:href="nlnk-20190930.xsd#BasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/BasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/Revenues" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RevenuesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlan"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanTables"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanOptionExchangeProgramDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/Leases" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2a17b501-4919-4dc3-b0d9-90200ce7ad75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2a17b501-4919-4dc3-b0d9-90200ce7ad75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ae573c6a-a7ee-4879-b57f-d5473153dfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ae573c6a-a7ee-4879-b57f-d5473153dfa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9e2de8ed-0370-4ffb-94b0-05efe32ecad9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9e2de8ed-0370-4ffb-94b0-05efe32ecad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dcd0abe-7824-418f-948e-bf510b46cdff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dcd0abe-7824-418f-948e-bf510b46cdff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bfbf3196-1d7b-41f5-8e60-d0059d92ef49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bfbf3196-1d7b-41f5-8e60-d0059d92ef49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_735730e6-932d-476d-9740-f47df727a1af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8feffab7-3bcf-4306-a438-95f4245da6d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_735730e6-932d-476d-9740-f47df727a1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1e36447c-3a65-4c7c-8413-d2a2128b93a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1e36447c-3a65-4c7c-8413-d2a2128b93a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6428dd73-83b3-49a8-803d-e364038789a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6428dd73-83b3-49a8-803d-e364038789a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92e2ae73-01e1-4b47-8f09-c4b524a3977e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92e2ae73-01e1-4b47-8f09-c4b524a3977e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3b95f012-cc01-495b-a1f5-f896df4be175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3b95f012-cc01-495b-a1f5-f896df4be175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7e81aff4-410f-4103-bc95-37cebc28ff68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7e81aff4-410f-4103-bc95-37cebc28ff68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_01223175-520b-4f0e-9aa8-7d83a807d30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ea7c6cec-5884-4d49-8f69-53c3403c1f73" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_01223175-520b-4f0e-9aa8-7d83a807d30f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStock"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockTables"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockNetLossPerShareComputationDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceCharges"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesTables"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesDetails"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nlnk-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CoverPage" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CoverPage" xlink:type="extended" id="i703c81b2c1d04caa99b7b7a50a5acdc3_3f6318e7-e475-4663-ab74-7e4e5b825e06"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ib779c562fcdc4de68c75cd635ca6bf6f_5a83b73a-bcd6-445b-b749-89b203472e73"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ib4b09b3222354d7a91f09d874ac356e5_90ab793b-3b83-43da-8e13-2f9a3376b46e"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="ie2e737dfd62a4a15aae2155654fca9d5_ea2a6bf4-dfb4-4823-86d6-a6b9d01251e5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f7a7a7b9-842c-4901-a047-765e6e9165d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f7a7a7b9-842c-4901-a047-765e6e9165d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6844ff27-248c-428e-bab8-bde59de36237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_Revenues_6844ff27-248c-428e-bab8-bde59de36237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a0877bf-3aa8-4e62-9f40-43310551462d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a0877bf-3aa8-4e62-9f40-43310551462d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6426d5c3-9c77-4036-83e2-ad7a61589df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6426d5c3-9c77-4036-83e2-ad7a61589df2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53a4339c-d8b8-4497-bdef-2b5af58f8a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_OperatingExpenses_53a4339c-d8b8-4497-bdef-2b5af58f8a53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_939651ff-f19e-4cb3-8fca-55b5ba95b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_OperatingIncomeLoss_939651ff-f19e-4cb3-8fca-55b5ba95b8bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0c3728a0-5e39-456c-90d0-3c8539fb3956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0c3728a0-5e39-456c-90d0-3c8539fb3956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_97c62679-5a7e-4aea-8fca-f07ecfe8911e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_97c62679-5a7e-4aea-8fca-f07ecfe8911e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4685f2f9-e762-465d-812f-14d315daec50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_InterestExpense_4685f2f9-e762-465d-812f-14d315daec50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cdd9c5ba-dcaf-487d-951f-30b7d0f53d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cdd9c5ba-dcaf-487d-951f-30b7d0f53d39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83b86c7e-6e4d-4f79-8024-95d09d0c5622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83b86c7e-6e4d-4f79-8024-95d09d0c5622" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea04467f-d8d8-4340-846c-b9cb705716d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea04467f-d8d8-4340-846c-b9cb705716d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd7acc4-180b-4636-9401-ea6b47b13297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NetIncomeLoss_ecd7acc4-180b-4636-9401-ea6b47b13297" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1678a0d1-b026-4262-a53c-b78055f8da21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1678a0d1-b026-4262-a53c-b78055f8da21" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b395fc01-fde3-44b5-8a4e-8cd2133c9a33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b395fc01-fde3-44b5-8a4e-8cd2133c9a33" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:to="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93640a76-faf8-4178-b782-7d5d077de4fa_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:to="loc_srt_ProductsAndServicesDomain_93640a76-faf8-4178-b782-7d5d077de4fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:to="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e491060a-8264-4a36-a167-d2188d61c736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:to="loc_us-gaap_GrantMember_e491060a-8264-4a36-a167-d2188d61c736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_03e75559-8d0f-4238-b4d9-a1e28eba66df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:to="loc_us-gaap_LicenseAndServiceMember_03e75559-8d0f-4238-b4d9-a1e28eba66df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="extended" id="i55e1f77de19d4f309e1d6610e90259f7_7663f8a4-6418-4973-a738-625ff8f2d818">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5b9ef0b-62e2-4f2c-963c-dffccd2ed13e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockholdersEquity_f5b9ef0b-62e2-4f2c-963c-dffccd2ed13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d687cea0-5bb3-4b61-9353-cc2c43520050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d687cea0-5bb3-4b61-9353-cc2c43520050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_276dd25a-9836-499d-a913-521c310aa02b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_276dd25a-9836-499d-a913-521c310aa02b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_905fbdf1-d11a-485c-aa4c-d430f9fc2c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_905fbdf1-d11a-485c-aa4c-d430f9fc2c3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_de64a160-218d-49ae-a381-c7a5a1f8b351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_de64a160-218d-49ae-a381-c7a5a1f8b351" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86b40611-f29f-4aad-9bf4-6debe2ddde70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86b40611-f29f-4aad-9bf4-6debe2ddde70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a91dc6b-a878-4817-af67-7a01d5979b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a91dc6b-a878-4817-af67-7a01d5979b6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_975a0f3d-3497-4d58-9285-028c0a7ed164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_975a0f3d-3497-4d58-9285-028c0a7ed164" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2afdc699-131c-41e1-8f96-f92890138799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2afdc699-131c-41e1-8f96-f92890138799" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_67511364-0325-44e8-bd09-1bb8b5c5bfba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_67511364-0325-44e8-bd09-1bb8b5c5bfba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73f9a53e-4eba-4b2f-9f1b-4373231d2bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_NetIncomeLoss_73f9a53e-4eba-4b2f-9f1b-4373231d2bef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0b1e780-9a38-48aa-8694-8e0bd2f0aff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6f0d851-0218-4344-8f54-df15c4e6ac27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:to="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ef06e6f-fabb-4706-853c-26d86b76e766_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:to="loc_us-gaap_EquityComponentDomain_7ef06e6f-fabb-4706-853c-26d86b76e766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:to="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5b4e7d1-78d9-4a8b-a0b6-d9194954ff17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_CommonStockMember_b5b4e7d1-78d9-4a8b-a0b6-d9194954ff17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_086d07f8-38b6-48c9-aa12-e274ded10f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_086d07f8-38b6-48c9-aa12-e274ded10f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2c8ddfba-af91-4768-8ba3-d62597a1cbb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_TreasuryStockMember_2c8ddfba-af91-4768-8ba3-d62597a1cbb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65417c74-37d6-436b-bed2-abd4b676084b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_RetainedEarningsMember_65417c74-37d6-436b-bed2-abd4b676084b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="if60e7091da174bb49d6909a83406f8e0_45daf3a0-9a34-4eeb-8bba-aa4f426f96d8"/>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="extended" id="ic5f54ae5ef9e41a086bef6394f8c4111_9280dd3b-2dcf-4f5c-a2bc-aa4e626c4546"/>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="id4aeb298f9454adc864e26e33b6d042c_eefe1009-0f22-4f22-8189-8b77cc8eedc6">
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_6d50b2fa-1dd6-4fc0-a1d8-e12d412090fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_6d50b2fa-1dd6-4fc0-a1d8-e12d412090fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable_546f93fd-786f-4137-b457-fdce18095a76" xlink:href="nlnk-20190930.xsd#nlnk_MergerAgreementCovenantsTerminationFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:to="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable_546f93fd-786f-4137-b457-fdce18095a76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:to="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:to="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LumosPharmaIncMember_1ca9cb81-050a-490c-b925-fe0016794c7c" xlink:href="nlnk-20190930.xsd#nlnk_LumosPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:to="loc_nlnk_LumosPharmaIncMember_1ca9cb81-050a-490c-b925-fe0016794c7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/BasisofPresentation" xlink:type="simple" xlink:href="nlnk-20190930.xsd#BasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/BasisofPresentation" xlink:type="extended" id="i2918695d4a8b450ab9a9a9db6235a71f_3dc66b1c-0386-4903-8ec9-08f14e208f57"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended" id="ibd4e2bcb14ef4768871281decae30f06_8fada977-60db-40dc-92da-482dc481476e"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i26430259553d435eacbe56bd043823f9_e99b1d2d-4df0-43e5-8bbd-53b58038858c"/>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended" id="iac768e0f03a8408cb61bdde5ee4d7329_a421fc01-1da0-4469-b0fb-4cd7bd8a4243">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92832d75-aa54-4e9e-b091-c912249a3730" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92832d75-aa54-4e9e-b091-c912249a3730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2840d30-f159-4729-8a9e-3803ef0f8de9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2840d30-f159-4729-8a9e-3803ef0f8de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c504b76c-d5cc-423e-a2dd-200109ebf76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c504b76c-d5cc-423e-a2dd-200109ebf76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_893f48b0-010e-4fd6-a9f6-3f0d22d7eede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_893f48b0-010e-4fd6-a9f6-3f0d22d7eede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eb02fc4b-8a74-4a40-9164-8c38bad8643a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_us-gaap_ComputerEquipmentMember_eb02fc4b-8a74-4a40-9164-8c38bad8643a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_89fedc1f-9fcf-4d98-9016-fad8e0b23d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_us-gaap_EquipmentMember_89fedc1f-9fcf-4d98-9016-fad8e0b23d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_e60578d7-668c-4182-aa7b-83f94a25fc1d" xlink:href="nlnk-20190930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_e60578d7-668c-4182-aa7b-83f94a25fc1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:to="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77d661b8-203e-409f-a29f-6504a59f02f5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:to="loc_srt_RangeMember_77d661b8-203e-409f-a29f-6504a59f02f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:to="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_202e9cfb-59a8-4b93-9d08-b9917880d68f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:to="loc_srt_MinimumMember_202e9cfb-59a8-4b93-9d08-b9917880d68f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_636ef8d1-f4b3-4844-94af-1708cdd74635" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:to="loc_srt_MaximumMember_636ef8d1-f4b3-4844-94af-1708cdd74635" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/Revenues" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/Revenues" xlink:type="extended" id="i0cab17eb8e2546df860c5d674be7d75e_113b7224-1e59-43cf-be5c-1561d508f05a"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RevenuesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/RevenuesDetails" xlink:type="extended" id="i021f1205b6bf4e5a8370541d36d018e0_c6b96a34-e9d7-487f-b77a-be9e10d53d90"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="extended" id="i1cfe0c5fdb2945f2b4d8a09734d712ed_93871e31-2da1-4266-bfd6-9b0c02fb13d1"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="extended" id="ie0442e7ff3a64b1c8608de45ae03390d_5e3744e2-f8d5-4efd-8fbd-22d58750a727">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_f8738f2d-32ac-4182-b097-05536f39ade7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_f8738f2d-32ac-4182-b097-05536f39ade7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c14f91cd-a144-40f7-b726-e4133abd5eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c14f91cd-a144-40f7-b726-e4133abd5eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d49f911-f8c2-4128-8dc9-03e6040922b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d49f911-f8c2-4128-8dc9-03e6040922b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ee0279b6-032f-4a3d-a550-5aa4b6510847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ee0279b6-032f-4a3d-a550-5aa4b6510847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MerckSharpeAndDohmeCorpMember_7732c361-7460-4fe0-9fba-65214ee10cc2" xlink:href="nlnk-20190930.xsd#nlnk_MerckSharpeAndDohmeCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:to="loc_nlnk_MerckSharpeAndDohmeCorpMember_7732c361-7460-4fe0-9fba-65214ee10cc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f30dba36-166c-45e5-97eb-ddcd1e1479e9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:to="loc_srt_ProductsAndServicesDomain_f30dba36-166c-45e5-97eb-ddcd1e1479e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:to="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_090b7c70-a215-42c8-9c08-6ff304a1ad41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:to="loc_us-gaap_LicenseAndServiceMember_090b7c70-a215-42c8-9c08-6ff304a1ad41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlan"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended" id="i3bbd7f060da4409987874fcaa06f887d_6c847c24-888b-43d6-a5dc-ec5fe93c0659"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanTables"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended" id="i9055b1cc50fa4790b84b3a547ddbc83b_fa85f75f-f75e-4b8b-9681-bde9ddfb8213"/>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="extended" id="ic31e2b1f4d014875914ee499464c851a_290dd179-fcd4-484c-b68e-bad30433e01a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_145f956b-e9bc-40a4-863d-e36f9b8c9e35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_145f956b-e9bc-40a4-863d-e36f9b8c9e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7031d065-9923-4619-aaba-9143bef4fd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7031d065-9923-4619-aaba-9143bef4fd7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6a7203c9-9cbd-41e9-99cf-e88e49957a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6a7203c9-9cbd-41e9-99cf-e88e49957a60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_b7422f0e-f32b-4c1f-8d3d-e428c229d3b3" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_b7422f0e-f32b-4c1f-8d3d-e428c229d3b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38218994-8bc5-4f77-8669-366080a45d34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38218994-8bc5-4f77-8669-366080a45d34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3dff1e30-b7bf-4c87-a610-dfd856c9d591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3dff1e30-b7bf-4c87-a610-dfd856c9d591" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4da50aea-c193-4d73-aad8-c2dd3a794a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4da50aea-c193-4d73-aad8-c2dd3a794a3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95388dde-ec56-4172-866e-a31c03686c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95388dde-ec56-4172-866e-a31c03686c4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_f6f2c9b4-4bb0-4e43-882a-864f80881ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_f6f2c9b4-4bb0-4e43-882a-864f80881ddd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_058f5946-7b64-459d-b2ac-d6105c90276b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_058f5946-7b64-459d-b2ac-d6105c90276b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d2b0987-6fc4-4ca5-87ec-bdad8e2ac7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d2b0987-6fc4-4ca5-87ec-bdad8e2ac7b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc0f5d13-1387-4d2a-8548-f7694f2a2fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc0f5d13-1387-4d2a-8548-f7694f2a2fef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_00ab79af-c2fb-4156-823c-7208031a8180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_00ab79af-c2fb-4156-823c-7208031a8180" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65d53309-282a-4ff6-8e90-615deaf7cf11_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:to="loc_srt_RangeMember_65d53309-282a-4ff6-8e90-615deaf7cf11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:to="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0f2520fd-5c66-4f5a-8deb-68753f71d88b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:to="loc_srt_MinimumMember_0f2520fd-5c66-4f5a-8deb-68753f71d88b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_239f5e4e-039b-45e7-adff-c111d0262428" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:to="loc_srt_MaximumMember_239f5e4e-039b-45e7-adff-c111d0262428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_292d2e71-c944-4aa4-9510-60b65c97c79b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_292d2e71-c944-4aa4-9510-60b65c97c79b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b49fd4b-4e6f-4edf-a251-b67b0b8ebb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b49fd4b-4e6f-4edf-a251-b67b0b8ebb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_eb24ceae-7b03-4bc0-bc04-f198fa26f5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_PerformanceSharesMember_eb24ceae-7b03-4bc0-bc04-f198fa26f5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_024c346d-379b-4fa1-88af-d1db9313a47e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_RestrictedStockMember_024c346d-379b-4fa1-88af-d1db9313a47e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:to="loc_us-gaap_PlanNameDomain_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:to="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_fcdcf308-ae24-40be-9696-ef7ba221e908" xlink:href="nlnk-20190930.xsd#nlnk_A2009EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_fcdcf308-ae24-40be-9696-ef7ba221e908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_de85a59f-f4a5-4557-a94a-699a6f80369a" xlink:href="nlnk-20190930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_de85a59f-f4a5-4557-a94a-699a6f80369a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember_fa8cc666-836d-476d-aac2-2a28d81207e8" xlink:href="nlnk-20190930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2010EmployeeStockPurchasePlanMember_fa8cc666-836d-476d-aac2-2a28d81207e8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="extended" id="i8bb58ac29a4446e3a15e0b35f2945ff0_64eba570-8b87-47ff-9562-cf84e71d8b18">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b8cd0b61-0207-4864-8dcf-5d50e5c50203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b8cd0b61-0207-4864-8dcf-5d50e5c50203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:to="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_de1cf7d8-43c0-4c82-996e-9756933834cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:to="loc_us-gaap_PlanNameDomain_de1cf7d8-43c0-4c82-996e-9756933834cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:to="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_a79d36a7-f9c8-4be6-afb1-fe3ad0e71ea7" xlink:href="nlnk-20190930.xsd#nlnk_A2009EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_a79d36a7-f9c8-4be6-afb1-fe3ad0e71ea7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended" id="iaa85fc1c98f64509ad9f12adaeb97997_5b9c4de0-b20f-4864-93c1-75590801f772">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fc72f-bc0c-4bf8-b359-96d64b7078aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fc72f-bc0c-4bf8-b359-96d64b7078aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0ff42280-2643-41fa-85ec-dfccf77fc70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0ff42280-2643-41fa-85ec-dfccf77fc70a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ba4cb4c-cf79-4e59-bfb7-cc57ad2bea1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ba4cb4c-cf79-4e59-bfb7-cc57ad2bea1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6c5f2d37-edcc-489f-962a-ecaa95f76ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6c5f2d37-edcc-489f-962a-ecaa95f76ef8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b286cd1b-878c-48f9-b1bc-4977ad874c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b286cd1b-878c-48f9-b1bc-4977ad874c16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7e69bddf-03a1-4524-b37c-3468ca64d0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543332d2-3708-41b3-b10a-0316ad06a920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543332d2-3708-41b3-b10a-0316ad06a920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c96f40e3-3052-471a-9513-21f904ecfadd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c96f40e3-3052-471a-9513-21f904ecfadd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e1a2d5c2-a34a-4dd5-abb5-9fd6181e5ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e1a2d5c2-a34a-4dd5-abb5-9fd6181e5ec3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_61b054da-9fa4-4124-af7b-2f1892d57a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_61b054da-9fa4-4124-af7b-2f1892d57a48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef19263d-484a-4897-b3fd-dd672590867f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef19263d-484a-4897-b3fd-dd672590867f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01673914-3dd8-442f-8aec-46449bb94fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54234e5a-30e7-4d67-b500-efa0cb92ecb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54234e5a-30e7-4d67-b500-efa0cb92ecb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee863984-792b-453e-b73c-c2d3d658845a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee863984-792b-453e-b73c-c2d3d658845a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac15feb-5713-4989-b1c9-25851aa41190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac15feb-5713-4989-b1c9-25851aa41190" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eb07c1a1-0ada-4546-94e2-e17435e5bd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eb07c1a1-0ada-4546-94e2-e17435e5bd8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:to="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67d8457b-c2ef-4b20-b638-76ca874d0bae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67d8457b-c2ef-4b20-b638-76ca874d0bae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_08a5b719-db1b-413f-9585-ee3071566b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_08a5b719-db1b-413f-9585-ee3071566b0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="extended" id="i3024be901e924b06856081b3f663d6b8_e204d955-4695-45ab-9108-39597436205c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_161f210b-843b-4e02-9583-61a133595dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_161f210b-843b-4e02-9583-61a133595dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8378c7e3-db82-4433-a175-741483422b91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8378c7e3-db82-4433-a175-741483422b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0506c4a1-097a-4ace-8b6a-a2ff94b6fa5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0506c4a1-097a-4ace-8b6a-a2ff94b6fa5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6ee0710b-add2-4591-8c7d-429d6ca67802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6ee0710b-add2-4591-8c7d-429d6ca67802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_86d4ae65-40aa-472f-89fc-2db8a88e2900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_86d4ae65-40aa-472f-89fc-2db8a88e2900" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89168915-41df-4990-a3fa-1522db7446af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89168915-41df-4990-a3fa-1522db7446af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4bf963d0-acd1-4572-9b8e-1dd0f0385d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4bf963d0-acd1-4572-9b8e-1dd0f0385d70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:to="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bf35cef-8410-4b83-af27-ef261b2f1860_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3bf35cef-8410-4b83-af27-ef261b2f1860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c7e03685-b720-42b5-8cf8-df0900e360b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c7e03685-b720-42b5-8cf8-df0900e360b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:to="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0bf5081a-992c-44c6-87c1-d83028c3f2f2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:to="loc_srt_RangeMember_0bf5081a-992c-44c6-87c1-d83028c3f2f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:to="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_abe6f0dd-57ff-4e8a-aa91-0c638a9f4e7f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:to="loc_srt_MinimumMember_abe6f0dd-57ff-4e8a-aa91-0c638a9f4e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb591ecc-1b07-4131-8f98-3156bc4f72b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:to="loc_srt_MaximumMember_fb591ecc-1b07-4131-8f98-3156bc4f72b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended" id="ibc740441fd7345c8872970bdcc78a082_ae4bc93e-a4cb-4f48-9f22-af8f6e6f4142">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6fa41caf-05b3-4dd5-8012-5d23e8bc3850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6fa41caf-05b3-4dd5-8012-5d23e8bc3850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff7e054b-dc9a-4378-8452-c0efd97e0f55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff7e054b-dc9a-4378-8452-c0efd97e0f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c23e540d-dcf0-4adb-a92d-e116b950151f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c23e540d-dcf0-4adb-a92d-e116b950151f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6a003b70-ec43-4e14-b1a9-fd9b765d0e59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6a003b70-ec43-4e14-b1a9-fd9b765d0e59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc7a2111-7cc7-4b5b-9896-cd2779c10acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca7435bd-2055-4462-a0ac-4417f0746004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca7435bd-2055-4462-a0ac-4417f0746004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6fac94a-02bb-4ba9-87b1-aa44b477cb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6fac94a-02bb-4ba9-87b1-aa44b477cb5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50628685-e52c-41db-9aa7-ebf26ccf24e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50628685-e52c-41db-9aa7-ebf26ccf24e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23999cb7-8f00-42ba-b816-cf09e621c660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23999cb7-8f00-42ba-b816-cf09e621c660" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94799493-d2e4-4ef3-b416-83b382ffa433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:to="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2a54111a-cc3c-41db-8a59-8167774ae023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:to="loc_us-gaap_RestrictedStockMember_2a54111a-cc3c-41db-8a59-8167774ae023" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanOptionExchangeProgramDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="extended" id="ia2bc92c55f7e443e8ba0e2ce8d77e9c8_470997b9-4780-4e55-9bdb-6f6a00228b7d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_65e4cb70-9445-454e-87b9-dde997f3b2df" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_65e4cb70-9445-454e-87b9-dde997f3b2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_c282893a-a381-474a-b10b-380f9fd5d328" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_c282893a-a381-474a-b10b-380f9fd5d328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_edc3b2af-fbc7-4849-ae08-adf1b6c34641" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_edc3b2af-fbc7-4849-ae08-adf1b6c34641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_550d50f2-67b8-4949-99a7-476fd8659346" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_550d50f2-67b8-4949-99a7-476fd8659346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_4917cf86-e39b-48d9-8167-3bc263767b50" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_4917cf86-e39b-48d9-8167-3bc263767b50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_254c4745-775a-4e0a-a6c9-88ffa6f9dc68" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_254c4745-775a-4e0a-a6c9-88ffa6f9dc68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_d3d28f3a-1fe2-455d-a428-81b52a9ab9a4" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_d3d28f3a-1fe2-455d-a428-81b52a9ab9a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_21c013de-7173-438d-a817-3910310a37bc" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_21c013de-7173-438d-a817-3910310a37bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44735d55-86d5-4639-aa21-a7dc2f36d506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44735d55-86d5-4639-aa21-a7dc2f36d506" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a607076b-cb8f-4617-ad35-73bbe8ec3b85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a607076b-cb8f-4617-ad35-73bbe8ec3b85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4b42e830-b5a2-4a9e-bf58-183da9816369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4b42e830-b5a2-4a9e-bf58-183da9816369" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2854a46b-28d8-440a-bfec-830df50da908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2854a46b-28d8-440a-bfec-830df50da908" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75d2964b-2dc4-4437-b59c-b104e75af9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75d2964b-2dc4-4437-b59c-b104e75af9c1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:to="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcff3b59-0428-4725-ae96-4f1982bfb98a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:to="loc_srt_RangeMember_fcff3b59-0428-4725-ae96-4f1982bfb98a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:to="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_833b4f19-4094-4ce0-87c2-00f253e1ffe8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:to="loc_srt_MinimumMember_833b4f19-4094-4ce0-87c2-00f253e1ffe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99b672a5-26da-4f2d-81ca-68c5460d1d4c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:to="loc_srt_MaximumMember_99b672a5-26da-4f2d-81ca-68c5460d1d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a1c822a5-82b5-4e51-b183-de3c63126ca9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a1c822a5-82b5-4e51-b183-de3c63126ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeOneMember_85296265-b3c1-4dbf-b773-55da3461df82" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeOneMember_85296265-b3c1-4dbf-b773-55da3461df82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeTwoMember_5c6d6dbf-3756-4e1d-9894-672b9ec3aa9c" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeTwoMember_5c6d6dbf-3756-4e1d-9894-672b9ec3aa9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeThreeMember_86d5a3b3-93ac-4b3f-b191-081651c56cac" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeThreeMember_86d5a3b3-93ac-4b3f-b191-081651c56cac" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/Leases" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/Leases" xlink:type="extended" id="ie631bb21f7a640208d41dea573fe6a90_a1de35ab-b551-48e5-9b43-962f6c0c4846"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/LeasesTables" xlink:type="extended" id="i315b43da326f4cab9c7df87140864274_1486b907-bd83-4955-9186-224fc26d3094"/>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/LeasesDetails" xlink:type="extended" id="ic94d82897a914b669bb00cd15b2beddc_ee687c5f-bf4e-4407-be2c-dff416b9ba28">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_869bd90e-6491-47db-acf0-ae77b862ee1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_869bd90e-6491-47db-acf0-ae77b862ee1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_667acd0d-a0ea-4d4f-9012-805f211a8f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_667acd0d-a0ea-4d4f-9012-805f211a8f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b853011b-c16d-4db9-9bcd-030b0276381d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b853011b-c16d-4db9-9bcd-030b0276381d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5a175e-b15d-4405-8c36-85afb85567b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5a175e-b15d-4405-8c36-85afb85567b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f135b680-5981-4f92-bc0a-ec574e8caff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f135b680-5981-4f92-bc0a-ec574e8caff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c1cf3a-26cb-43a4-952c-7101fedd5f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c1cf3a-26cb-43a4-952c-7101fedd5f2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cd5c7f6-2da1-442c-8032-695b27cf73f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cd5c7f6-2da1-442c-8032-695b27cf73f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98528921-994c-4bcf-9d40-321ffba79460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98528921-994c-4bcf-9d40-321ffba79460" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_51633cc8-6eb5-42f2-a067-8ec9e97b5239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_51633cc8-6eb5-42f2-a067-8ec9e97b5239" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b98edb-afb5-4206-821e-3e7ea468ae71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b98edb-afb5-4206-821e-3e7ea468ae71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20771bb9-4cfd-420f-954a-a6ab28e80f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20771bb9-4cfd-420f-954a-a6ab28e80f17" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_120f9e52-6ece-4b84-a9cd-6f4911c57ce3" xlink:href="nlnk-20190930.xsd#nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_120f9e52-6ece-4b84-a9cd-6f4911c57ce3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_12903dc6-5bb5-4996-90af-a8aecd37862b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_OperatingLeaseLiability_12903dc6-5bb5-4996-90af-a8aecd37862b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_13c4608b-381a-4b4e-aeef-607380b4673d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_13c4608b-381a-4b4e-aeef-607380b4673d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ab63ff1a-a3c3-488c-a7d7-3d533025444d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ab63ff1a-a3c3-488c-a7d7-3d533025444d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_efd7b86a-0ce5-4fc3-9b52-b573c1134a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_efd7b86a-0ce5-4fc3-9b52-b573c1134a62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_657b60fd-7416-4a90-8bee-e50f3aca875d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_657b60fd-7416-4a90-8bee-e50f3aca875d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_81848eb4-1a99-45ec-800e-d7f1ba3a2fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_81848eb4-1a99-45ec-800e-d7f1ba3a2fe7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_89eb7beb-e355-43a4-9aaf-77c655136067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_89eb7beb-e355-43a4-9aaf-77c655136067" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5a5855e6-8a0a-4d3f-a971-36e3d6424d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5a5855e6-8a0a-4d3f-a971-36e3d6424d80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:to="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ef62327-9434-4c7d-9ab1-df2900b023a8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:to="loc_srt_RangeMember_2ef62327-9434-4c7d-9ab1-df2900b023a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:to="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d511f691-da54-4085-bc93-0d653e4e45ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:to="loc_srt_MinimumMember_d511f691-da54-4085-bc93-0d653e4e45ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_412b763d-83b0-47e1-9cc1-f5990bcc2682" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:to="loc_srt_MaximumMember_412b763d-83b0-47e1-9cc1-f5990bcc2682" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended" id="i2ddce78a7d4249789cb0a562907cbd8d_beaf8e2f-c37f-493a-9f73-e69c5604941a"/>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended" id="i9b894e86ffe7498baf220e02d99af501_45c67674-d2d0-4fdd-b23a-b7c420874cb2"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStock"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="extended" id="id3bdcec2fe6445e8a09e98988fd20f3d_333f99db-3d33-4b80-b159-28c269acd12a"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockTables"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="extended" id="i3ffa9a171e98477fbc13895217e1303b_5bf9cd8a-c3e5-4dc0-83f8-277f4fead3a8"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockNetLossPerShareComputationDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="extended" id="i8909fef7aa57496cab8d34176f4566b4_dee0ffab-694a-4568-acc1-b45b8df53119"/>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended" id="if7d7553bae60459498a54a5343439ab6_5096a094-a894-469e-af35-937ce804b753">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57592714-7e84-4d7a-9d89-ee5b955b2ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57592714-7e84-4d7a-9d89-ee5b955b2ddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c52a1dff-ee41-402b-944c-a3fd73306a7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c52a1dff-ee41-402b-944c-a3fd73306a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb8ac50f-b680-45e6-8c0d-714ecbdff453" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb8ac50f-b680-45e6-8c0d-714ecbdff453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1221c654-c0c5-42c4-9b59-6d1710c73348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:to="loc_us-gaap_RestrictedStockMember_1221c654-c0c5-42c4-9b59-6d1710c73348" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceCharges"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="extended" id="i925d2711e9484d48a8dcf4fb8708f060_e4ea64c7-3d90-4539-8c09-77812e6e182f"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesTables"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="extended" id="id96bef32b1ce4bff909d942428e503eb_199b9041-411e-4e29-8c6a-78986c39d766"/>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesDetails"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="extended" id="i14fc87de8ca14985a3fae2512a04967f_af19a359-1e5e-48c9-a8a8-61acdad268d3">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fbb153b0-6993-4031-b874-bb20a82ac853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fbb153b0-6993-4031-b874-bb20a82ac853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f568ec50-eb00-428b-a873-0d8c39d393ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f568ec50-eb00-428b-a873-0d8c39d393ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_8b9ea973-c7f1-49ca-a43d-7ff095068374" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_RestructuringReserve_8b9ea973-c7f1-49ca-a43d-7ff095068374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1db897dd-7951-4f2a-86da-f530cf6a62de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_RestructuringCharges_1db897dd-7951-4f2a-86da-f530cf6a62de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_23b06ee9-e065-4ae1-862c-fbf8901caeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_PaymentsForRestructuring_23b06ee9-e065-4ae1-862c-fbf8901caeb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3c51b677-8163-458d-955a-8f81252663ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51c4a950-e1df-4fad-87ce-c010371223a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51c4a950-e1df-4fad-87ce-c010371223a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9febaa87-79e2-48ee-9af4-2adfacb58257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9febaa87-79e2-48ee-9af4-2adfacb58257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3a27a49e-bad4-4dab-94a0-b176df9adc32_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3a27a49e-bad4-4dab-94a0-b176df9adc32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8ead1339-9fc6-4a2c-afbe-75bdf1b9499f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8ead1339-9fc6-4a2c-afbe-75bdf1b9499f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="extended" id="i048144565589493ba730c701e8d0037e_d624b8f6-cd56-46c1-a359-64d17e8ceb3e"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nlnk-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommonStockMember_34fb6948-1a9b-46dc-bb47-fd2c068cb594_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b19a3aa7-139a-46a4-bee3-5e2c3db740c0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_af361a51-2b1b-4775-8e73-e7427af900cc_verboseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c15761d9-e076-47b8-8cdd-ded34dbef26f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_0422509a-b2cb-4fa6-8b35-6db3e88419ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_3dbe7a41-2773-405f-8dac-dc020dfa5b89_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c80dafbe-fc88-440b-9eec-c072338ef122_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_43af2646-0d2a-4709-810f-52dc72daa6e3_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent_0a6e4677-f634-46ab-8d68-215a72f1d64d_terseLabel_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax receivable</link:label>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent_label_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Current</link:label>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent_documentation_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:href="nlnk-20190930.xsd#nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:to="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_505fb62b-44a7-45ca-bc68-1e12c3a43f66_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8994005a-9950-4007-a653-5acdcb8b7ba9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2c114129-676b-4db7-b25b-a4c30d7af6a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_56cc89b3-57e2-4e37-a428-627dbf5a2358_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_f125c97f-5286-4f70-98e7-25eb9c868daf_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exchange shares authorized (in shares)</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_70dd1518-9d1b-42b7-a2d7-81e28d1a9b5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0d0bf40-b129-46f1-9054-c683d6db9519_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_394911a5-fd84-4a09-bd47-d498f7674d31_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_02633338-f5b5-4d93-ad5b-11af10a0667d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_489bb33b-eb79-49b7-a239-fcbc6c0a8f21_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_71fcf555-7937-4ab0-8ab9-e73a9db4401d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of notes payable and capital lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_db0c1364-34e0-42cd-8bc7-f5b3ccdeb2af_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_de609c5c-e786-4e94-89a4-bb036c61f845_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_276b8732-c41a-4767-9c61-0bef55bf1c28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_d38ed239-6554-4db6-af24-527cecb26474_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_e4632d52-afdb-4d8e-bbd0-174e780f56a2_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Outstanding Eligible Options (in shares)</link:label>
    <link:label id="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_label_en-US" xlink:label="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Option Exchange, Outstanding</link:label>
    <link:label id="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_documentation_en-US" xlink:label="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Option Exchange, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:to="lab_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_f2a10b47-320f-4a16-8885-c280a5b69c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_b71f6f92-4771-4bdb-8233-f64b3a04209d_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of eligible options converted</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized, Converted, Percent</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized, Converted, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d41f9ce4-ab94-470d-8150-19eef6f10def_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fdee2fcd-b1a1-4fc5-90ba-4872ec8828c8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7bdb64c0-d5bf-4d2e-b82b-3187d8fc9668_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_01e74e36-5936-4054-8b29-c641fd7e5dd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_955f7169-d005-4106-b627-d3b2ceec01a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dfb283e2-0484-45c4-94ba-d9efdcd32026_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc744b9d-5d92-4cd2-812d-29246c77dcd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e23e1294-c4af-4243-a372-c7b8a976a2cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48abc239-2388-420f-92e8-7661cf1a5c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_5601e3c8-264d-4860-b7f7-48f1bca79f7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fa0ca23b-7b01-4588-beff-12020485078d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_23343490-f085-4be0-95f3-b72658cc1d5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b992df82-f6bb-4a14-96f7-de305eb0dd16_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06953342-8a86-4222-8f21-7f5f1d8e7018_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equity Incentive Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_de9d7aea-278a-4f86-8d29-a98541f21b46_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e09fe03b-aa3b-4e2b-bd1c-ea72f0243024_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9c765877-4216-44f2-9d79-4eecba1e8668_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df18d970-3c3b-4b6c-b7c0-3e87fdf2491b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_847be712-3fc3-4617-ae6c-e3b6c2882733_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payments</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_370a6e58-1df6-4eb0-9eba-4a78a7418c30_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of accounting change</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_46b85193-3e76-41b3-b625-85a8d6268396_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_45b2c587-be66-45e1-9ce2-9948a242456d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7abb4b2c-aae5-4231-8743-7930ee1a44b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5b537959-3f87-4377-acdb-b5b6b79d59c7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited / cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b71be34d-87cc-44d6-ad0d-096667779ec2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_42f6f81f-8138-4cd1-b7aa-eb96ef8efc1a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_786e2fff-8185-4c6a-bc19-d062a3a51a41_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blank check preferred stock, outstanding shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4054a1b-0bd1-427b-9267-317d0661f0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c32706b5-f6f5-4ddb-ac8f-76495f4d8740_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a2343d8-5231-4863-89e3-e1837e88287d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4cef0f40-c007-4d08-af58-fcf4c09d8e8c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Severance Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fb4dcc15-9181-4649-a707-e40bac97ffa1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_64f18199-fb2c-4635-91bd-5550a212f54a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0ed70429-3c78-4508-8dd4-8d1be5058896_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2fb731d5-e80d-4ac8-a6cd-4308cfc43ee6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c8dc6e34-4cc6-47cf-a30a-bce4512b7875_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_404401c7-66a4-4225-a2de-9598921523b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4b022ec9-4125-4624-90c7-f54132e44b95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eab6c0af-101a-49ff-8c45-bee7f58de1ee_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70a2e865-d7c6-477b-ad5c-4a3fdc1ae67b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3446b8b0-9591-4d07-82d9-d7d571a252fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent_cc069662-b8c7-401f-a6b7-b37b85630a78_terseLabel_en-US" xlink:label="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent_label_en-US" xlink:label="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Noncurrent</link:label>
    <link:label id="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent_documentation_en-US" xlink:label="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:href="nlnk-20190930.xsd#nlnk_OperatingLeaseRightofUseAssetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:to="lab_nlnk_OperatingLeaseRightofUseAssetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9450e0c9-e81a-4762-8f1a-46544a9d056b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_FinancingsTable_f6cee1fb-e625-4444-9a19-6ab3b1b65e4c_terseLabel_en-US" xlink:label="lab_nlnk_FinancingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financing Rounds</link:label>
    <link:label id="lab_nlnk_FinancingsTable_label_en-US" xlink:label="lab_nlnk_FinancingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financings [Table]</link:label>
    <link:label id="lab_nlnk_FinancingsTable_documentation_en-US" xlink:label="lab_nlnk_FinancingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsTable" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FinancingsTable" xlink:to="lab_nlnk_FinancingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e1db846a-a941-4dd4-9f38-bd21362d8be3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average vesting period for non-vested option awards, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_053106d2-7d34-4b2f-acd9-f77a7de98373_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_d1133d10-022c-4419-9c5b-dc32f4418fda_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4a1ad92-d961-4846-bb48-43f4470c4884_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_df7690f4-afe8-442a-b348-9a38385ea31e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0dc6f007-97a4-4de5-8d73-09d78cdff0ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares remained available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_f1b05c58-f0e9-4c34-9840-2afaaf525e50_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_cba0a201-04ed-4382-999f-7bd08844dacf_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69373a47-1690-440d-a5b9-d45a03df81f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9f32209f-1f59-48e1-8c46-923a348a4976_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f71209ab-9e9b-40c4-aedf-c21f196f745b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bd0342b1-1f4f-4822-b093-8bb60e6e069c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_547131c8-fd4b-4bc0-9696-070022df213d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_20a496fd-55f4-4d8e-a515-b4fa366da887_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2db798e3-002a-4b5e-b87f-6a17a5c4fdfd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_bc201bcb-3586-4860-81d7-7ba992407e94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_f59f84dc-3ecf-4ae1-a475-994c9e335907_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_86573ab4-a011-460f-9955-4728e653d0ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4378617c-c9e8-41b8-980b-c0e65cf14cb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_dcf8c403-e348-44b0-88d1-6003e4defcf8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b19c34b4-ed21-4843-8d25-2c54aa3e5ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_767390c7-71ce-4a11-8588-04d4bb8eabd1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fb2c984d-33e4-44fa-ab45-3a3544eaed45_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_39453c5c-0579-4350-90f1-993ab054e46a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b2472ad3-8d17-47af-bd83-af6872cd2446_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_94d265c8-c9f1-45c7-b462-d4f439eedb1f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e269a948-4db5-41e5-9765-6f81d44da04a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7308c28c-95e8-4dd8-ab1a-bc53173eac68_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3921b50e-523d-414c-96d1-9608168b295a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock_da28a2f1-7a48-45b5-8256-eb9e79bab377_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exchange Eligible For Exchange</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ea9923f8-b4d2-498e-8ab9-b88e6390c436_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flows information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0cf0d408-07bb-49f8-9818-5bd9b9282560_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of shares under stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8494a019-d2b3-4d95-a1c8-79e07d30a878_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_63257333-9a25-4d4d-bc75-7ca2cfff3fd1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f962dbdc-913b-4361-bf88-a91e0dd9b373_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_1abfaebb-fc80-4f9f-b676-f8a036754230_terseLabel_en-US" xlink:label="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Non-Employee Directors' Stock Option Plan</link:label>
    <link:label id="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_label_en-US" xlink:label="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A 2010 Non Employee Directors Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:href="nlnk-20190930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:to="lab_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_db9372b9-6e94-4187-8d58-2c03b97eea27_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_07438c3b-36e8-4cca-9362-c974aa1f42db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_653f8f07-7009-4f25-a454-4360437c47a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_dc9c5bce-2100-4f02-8358-a1215d58aa08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bbe24821-3bcf-488c-be86-9beb389bdef1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_467e1c23-15d7-48f6-8702-da4dcfcc8215_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value: Authorized shares &#8212; 75,000,000 at September&#160;30, 2019 and December&#160;31, 2018; issued 37,426,844 and 37,343,547 at September&#160;30, 2019 and December&#160;31, 2018, respectively; and outstanding 37,314,076 and 37,251,220 at September&#160;30, 2019 and December&#160;31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_937ee7c4-3068-495b-90fb-a58a87023fd0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6411bf18-2188-410d-91fb-3023a5620b4a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_37b74d01-78fd-4098-8151-3d051aef57c9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_MerckSharpeAndDohmeCorpMember_219d6d3d-2265-4356-a0b1-11d0d7b684e0_terseLabel_en-US" xlink:label="lab_nlnk_MerckSharpeAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_nlnk_MerckSharpeAndDohmeCorpMember_label_en-US" xlink:label="lab_nlnk_MerckSharpeAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharpe And Dohme Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MerckSharpeAndDohmeCorpMember" xlink:href="nlnk-20190930.xsd#nlnk_MerckSharpeAndDohmeCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_MerckSharpeAndDohmeCorpMember" xlink:to="lab_nlnk_MerckSharpeAndDohmeCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_ee08c978-ee28-46e6-ae7b-225070c3cf3e_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of participants</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Participants</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Number of Participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_da8fa52e-50b4-45b0-8e35-c43530674bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ExercisePriceRangeOneMember_6f901b1f-5bff-4226-b788-d06df488c5cb_terseLabel_en-US" xlink:label="lab_nlnk_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$2.97-$10.99</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_nlnk_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_nlnk_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeOneMember" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ExercisePriceRangeOneMember" xlink:to="lab_nlnk_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_083b9612-4867-402a-9eb5-0ef286808108_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_47c95860-98cd-4478-99a0-4d8452fc6b28_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d404be7e-2ae2-4465-b18d-9c61c91bbeab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blank check preferred stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1176e694-2503-472d-a0e5-3ca794f29f03_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_11b2ba1e-ea76-4130-b580-1c9bcedcfbff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance Cost</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1e4d5c10-9e88-41fd-97af-e733939de105_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage reduction in force</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_FinancingsLineItems_82bdacbb-3933-4b33-9584-04b0fa3e27aa_terseLabel_en-US" xlink:label="lab_nlnk_FinancingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financings</link:label>
    <link:label id="lab_nlnk_FinancingsLineItems_label_en-US" xlink:label="lab_nlnk_FinancingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financings [Line Items]</link:label>
    <link:label id="lab_nlnk_FinancingsLineItems_documentation_en-US" xlink:label="lab_nlnk_FinancingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Financings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsLineItems" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FinancingsLineItems" xlink:to="lab_nlnk_FinancingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_eeb91c21-ea88-4714-ba32-94ed04e4eab2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6905655-deb5-45c9-a202-a842ae190fcc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_98ed106d-a5e1-4a48-bd36-113a581ceeab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost: 112,768 and 92,327 shares at September&#160;30, 2019 and December&#160;31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e44dd378-0512-454a-a830-95c66a03883a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e29c1d4c-ddc7-45a4-8211-bfe787757d35_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f7a01e02-36a4-47bb-a542-97cf20b16a82_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average remaining contractual term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d87c7e26-cdad-4efc-a4e7-5297c3c0701e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of awards vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3649b8e2-9dfa-4a9c-8e5d-2f4a1be63e5e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_20e30e44-4665-4af7-9c16-d792b4cba9c5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_A2009EquityIncentivePlanMember_314a0772-6094-4aec-bd25-8f08796a6290_terseLabel_en-US" xlink:label="lab_nlnk_A2009EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Equity Incentive Plan</link:label>
    <link:label id="lab_nlnk_A2009EquityIncentivePlanMember_label_en-US" xlink:label="lab_nlnk_A2009EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A 2009 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember" xlink:href="nlnk-20190930.xsd#nlnk_A2009EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2009EquityIncentivePlanMember" xlink:to="lab_nlnk_A2009EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_64822f4a-5eaa-42ce-a421-043e8c24a395_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1ed211a1-b85d-4dad-b887-f7bacc8fb60b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractReceivable_f654c859-735b-4a89-b9cd-5f37e09b1a41_verboseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government contract receivable</link:label>
    <link:label id="lab_us-gaap_GovernmentContractReceivable_label_en-US" xlink:label="lab_us-gaap_GovernmentContractReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentContractReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractReceivable" xlink:to="lab_us-gaap_GovernmentContractReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_04d798ff-3da6-413e-8520-eef0adbe21c4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f9573d98-d5a4-445e-9ef5-13e0b0fc060b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_313512c7-57fd-4dbb-8330-c918718d0319_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4f842108-3c19-4246-bcdb-b47215fa014c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_75161c94-9141-406a-8d8d-4dfbbe55e6d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:to="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e128f1e0-d0fc-4bc1-a919-8a609494f989_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3071a1da-2d78-4239-a7be-a26d6634ee0f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blank check preferred stock, issued shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_9d64d559-8741-4f99-a019-f6b1abb7dfda_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_007b1429-90b7-4875-ab49-dffc91dea3b7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_68e220c9-6392-4ef0-af14-567b5e305486_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ac6ed83d-39f7-4d81-a823-802e4c481188_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d7690f61-f62d-4908-ad1e-f0b00f62414a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_04e6580e-53b6-480b-be80-d01e784800db_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exchange, number of options converted (in shares)</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Options Converted</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Options Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_899e76c4-8b7b-43c2-8f7a-4c6dfe5a1218_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_98392841-fedf-4255-8084-41ebefdc44b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a5aef8f6-c8bb-4527-bd82-969ba0c71f37_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2c21f411-e88d-4f92-91a2-cf5f6b8cf603_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f5ba6a5a-a037-4943-8ede-1f3bf739b745_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income and expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f7fd0470-9ef5-4798-bc0d-2ec0b303c466_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_c3e48dc0-68a7-4d12-84d0-1fa9f247b703_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5d1d4bc3-b4ba-4b84-9ef6-05e9daa9c6d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_012ce8ab-a566-4604-afb9-cab4bbf86771_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_3ae34212-a0be-4542-8b37-8e9e503893c1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2259fcde-474d-4bb0-87e3-ddceb7f8b0d9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a748b714-3a77-4368-bdab-a8c3edd62892_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c824739-65ab-4428-a693-3be0d884fb3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8a098486-6b29-4c5a-9016-71bb89698d07_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7847cc0f-848c-4ba1-84da-5f6ccf47ae58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6c4c3a7-b0c7-4d7d-91fd-57a45544fa3c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2345564-0525-418a-8a60-65ad1dc2bd75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost related to non-vested option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_992dce41-f2e6-41e1-9c62-2f16e1e07eae_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2604b0f1-9ddd-469a-9f04-6c2b0a45eb56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ae82a34b-bc4d-4db3-ba4e-e10001545e75_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_92efaacf-e496-4ba5-9477-551bdd1dfe0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cec68f7-95dc-4e55-9917-dc810975003f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4c8c0fb3-6b3f-41d2-8e67-071a0e4e9ce2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5ce1dd3-e11b-432b-8a70-88c5a8a9c8a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79075f7d-3962-40ca-8787-d3aa7997fd73_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e3db74ce-131b-4b9a-ad6c-503640b6ec76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8df25104-7cd7-41ad-b110-c14eaaa6e117_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_dd086bbb-a51e-45ce-9fef-882f832c6e95_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e8372a87-f458-4af1-ba7b-66ecf781d313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8815679b-4fd1-41e6-960f-07177c47ae4c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Increases of Common Stock under the 2009 Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_891034e6-277e-4666-9dde-09dd2695df65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3b31497d-d557-45f9-913a-8173a2d3cf65_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_c129ed5d-0f16-444d-8f12-43925707b63d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expensed</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_125fc200-a7c3-4bff-a1b4-69f2126e38bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f36fac73-f08c-49ac-a341-6f0982c51774_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e1b0be2c-f531-4e43-a5d6-ad1d8462a72d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_a115c2c5-5ad3-4e59-820f-06b1f1d8efff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e8ad2291-3f65-477e-9032-90b105e72620_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bf7299cf-0b01-498b-a9b2-a6b1b522f71b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_4737e8aa-9ae8-470a-b593-dcab8b41c6f9_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df3c0be8-c0ac-427f-84fe-1d25a7a6662e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_81b25b9a-cba2-4447-b59b-f03492b30834_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a6333bdc-d813-46c8-8d9c-4549dae9ad3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c0ba9878-5e50-46a5-b5eb-cace1ad2d651_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/cancelled, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f9769692-2b04-469d-8d3a-c756a8d5359d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used in Black-Scholes Pricing Model for New Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_77f7771c-d735-4a6e-89e4-0a28ae03a12a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_58833ce8-4197-4226-a76b-ddb7475623fb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_49e4ef69-7a7d-404c-a32e-375bd585198b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_2fd0e387-9d5c-4755-bdee-1eceda20fcb6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_343051c9-c711-47dc-ae48-51402de11ee4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d6d5e8cb-cf99-44c9-a161-8ad67afd8fd6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_938a5deb-7068-4d7c-bf25-ea7a77215ea4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8fb2016-003b-405c-9f0b-f5649c58bedd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_161bf9e0-7c82-42b2-b3a2-204f8f88dd72_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d65de6a8-da28-4844-8383-f6262fb3630b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a208415d-d437-4f5d-9ad5-4cef98d1a770_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_02553b90-bd8b-4f04-a1aa-ae321ecbaf6a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_44fe3790-1197-4b18-bd94-67eaf04db00b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blank check preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_d25dc90f-194d-4274-9fae-248316c1f12a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_82c19b37-f017-411e-82b1-d6166b385182_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f23b26e6-9145-4103-bfc4-5887146909ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_584b51b3-de02-4e79-8fce-47a4be72e90a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dca69614-f1b3-42e5-a9d5-78e402a0cecc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78ef94d0-ff67-4f52-94c4-29d528a74a03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_bbfd7042-29fe-4175-986a-25307bf93d06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fc03671-bb34-4fbe-9fa8-6eb4c3f752bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average exercise price at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_02c25af1-50ce-42d3-b50d-2a9de860d741_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average exercise price at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_531e8ecb-4f15-49af-970b-a356ff8a3589_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_968ab664-420c-4ff9-978c-09d9141b44d9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5e8f02db-4fbf-4ae3-969a-bae83b6942e3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average remaining contractual term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_65ecd443-45bc-4e86-bf51-017835baa172_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_GovernmentContractAccruedSubcontractorFees_946d806d-85ee-40dc-8951-c6d9cef0b4a0_terseLabel_en-US" xlink:label="lab_nlnk_GovernmentContractAccruedSubcontractorFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses for subcontractor fees</link:label>
    <link:label id="lab_nlnk_GovernmentContractAccruedSubcontractorFees_label_en-US" xlink:label="lab_nlnk_GovernmentContractAccruedSubcontractorFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract Accrued Subcontractor Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_GovernmentContractAccruedSubcontractorFees" xlink:href="nlnk-20190930.xsd#nlnk_GovernmentContractAccruedSubcontractorFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_GovernmentContractAccruedSubcontractorFees" xlink:to="lab_nlnk_GovernmentContractAccruedSubcontractorFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ffffea8f-a153-40ce-8c59-68ce6ed5cdd5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ExercisePriceRangeThreeMember_6f4f786b-f6e1-4682-9459-aa458259a3fb_terseLabel_en-US" xlink:label="lab_nlnk_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$25.00-And Up</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_nlnk_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_nlnk_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeThreeMember" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ExercisePriceRangeThreeMember" xlink:to="lab_nlnk_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75820c2a-15d2-4b4d-bf11-1b45aae67677_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_86ec8adc-6d12-42bd-a85b-2053985ea7c2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4e8346f0-d676-4bbc-ac01-dced4873afae_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_009ffa8c-8080-4229-9b26-338e2ecdd1de_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4363991b-e702-41ac-a422-87fb3081f121_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8e2acbe8-44e2-4bb0-891c-92641d87140d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3340903b-0d20-4d70-bd7f-15ed2e6b6239_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_0d64f238-0483-4121-9c10-a23396a806cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d9faed0b-0fa4-4874-8cb3-cdf3365383a5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_47e44e08-6ad7-4202-aa77-9668d56fd650_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_59f17eee-2898-4b53-a6c8-5be33143752e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Shares Added</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_46e1cdd6-9df8-4d7c-9922-f0344f8ca07a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4fb9df22-c2cf-4ebf-a159-0b69b442def7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_de59b12c-12f9-46a7-bef0-ec2da57e9d74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fe661872-2097-42ba-82c7-36ca6d085bc0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_4dab7ef8-e1e7-44ab-a276-3ccac87791af_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1b0c92a-4229-4bb7-b119-83a023d034cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_86700ece-7fe7-4dfa-a958-17fd76be8167_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_235afd9e-8e76-4464-8140-b69875f30b37_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_b32bd68b-f794-4163-8d4e-03ae944f5949_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Future Minimum Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_LumosPharmaIncMember_c428618e-b603-48b0-ac47-8c4e1d46bf58_terseLabel_en-US" xlink:label="lab_nlnk_LumosPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumos Pharma, Inc.</link:label>
    <link:label id="lab_nlnk_LumosPharmaIncMember_label_en-US" xlink:label="lab_nlnk_LumosPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumos Pharma, Inc. [Member]</link:label>
    <link:label id="lab_nlnk_LumosPharmaIncMember_documentation_en-US" xlink:label="lab_nlnk_LumosPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumos Pharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LumosPharmaIncMember" xlink:href="nlnk-20190930.xsd#nlnk_LumosPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_LumosPharmaIncMember" xlink:to="lab_nlnk_LumosPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_4f4ed56e-0043-4db6-a5e3-8a31fa2b0c39_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e39debc1-a63d-4346-aee6-1c91930deb00_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_b94d236b-6515-4530-b641-aa3d072180f4_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exchange, lower exercise price range (in usd per share)</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Lower Range Limit</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_3ea912de-71f4-4295-bde3-e2bb180be9e4_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evergreen increase (percent)</link:label>
    <link:label id="lab_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_label_en-US" xlink:label="lab_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Percentage of Authorized Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" xlink:to="lab_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_db64a0ae-879e-4f4b-8888-88f337246b6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a06b35f7-40d4-45c9-8a78-0b44cfd51296_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds on sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c265678a-5620-482b-8ef8-ed82a8ae8d89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0c8c2288-7da6-4f82-b8ec-e858a377d274_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24e4e414-2422-4dd3-b833-07bd24eaedf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_3f5ca97a-59a8-4042-9220-f3352d9c963b_terseLabel_en-US" xlink:label="lab_nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Organization Equipment</link:label>
    <link:label id="lab_nlnk_ContractManufacturingOrganizationEquipmentMember_label_en-US" xlink:label="lab_nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractManufacturingOrganizationEquipmentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:href="nlnk-20190930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:to="lab_nlnk_ContractManufacturingOrganizationEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_eb9c9f74-f30e-4b1a-9fde-092d40410f95_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d259e9b7-7ea5-47b1-8b2e-29a360f34087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_44fbf82a-ab8c-4060-bf0a-bf1ee09bb8c6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_afe54631-a341-4a27-a26c-9b74a8419518_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1573bf61-45c7-4ee8-b0ae-7795c7db5963_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3b32a286-802e-44a4-8778-bc571e2f3a00_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0b0c0bc0-8d20-4a22-b681-1ad7270f40cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aa282252-b519-4169-ba7f-3b5c7b1fc7d8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_e348996d-9ce5-40ee-9802-16128f4411f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_90f082fe-7ab7-42fd-8936-9c30fe32a2eb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage after transaction</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b7850507-a754-4b8e-82bf-96da9402de76_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_ec7b9557-f7a0-4e98-9eef-55cf69368add_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash refunds received for taxes, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b1442b6a-e825-4485-b413-0bef1357a056_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_15d59822-1581-4183-a6c0-a2a9c35f8b06_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_adb63c16-7ba1-4b19-8b0c-97832528078e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1a7c0f6f-9357-4666-a2aa-044956091e85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of shares under stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b0a26fef-766c-4150-bc3f-a18da6ba78db_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_35759810-a91d-4b8b-975c-552741830e9b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_830ddc88-8bc7-4bcf-951c-4ed497fce360_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4eede9b3-70d5-4ac9-8766-1fc998ea6431_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3e806422-23b3-418f-90ee-3c4a16fa467a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21942dcc-c9e0-45f6-ac6b-838abc5b9c37_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_63c38a7a-7dfd-4638-9938-3765038483a0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_80236192-0361-4e9f-8f2a-e7cd33fe85b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable_559ea100-5432-4d44-af04-769e6ad9b4ab_terseLabel_en-US" xlink:label="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants termination fee</link:label>
    <link:label id="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable_label_en-US" xlink:label="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Covenants Termination Fee Payable</link:label>
    <link:label id="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable_documentation_en-US" xlink:label="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Covenants Termination Fee Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:href="nlnk-20190930.xsd#nlnk_MergerAgreementCovenantsTerminationFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:to="lab_nlnk_MergerAgreementCovenantsTerminationFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_ce09c343-46f5-4300-9187-e05d837805b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e0ef6274-e879-4f85-89f9-8287cfaaede0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_19e39320-3aef-48c6-ab89-8d4d729baa66_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of operating lease contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8c509809-cf25-498d-923f-10714a19cd17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a38858a6-84ca-4667-b7e8-2868024d77df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_fc4b428e-8282-486f-a5ec-69410dbe56b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent_32d23181-3ba6-47cd-b4c1-db2d09c63dd4_terseLabel_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent income tax receivable</link:label>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent_label_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Noncurrent</link:label>
    <link:label id="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent_documentation_en-US" xlink:label="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:href="nlnk-20190930.xsd#nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:to="lab_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_49e1b1fe-f114-4eea-9693-fe73a844bdcf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_60023b72-27b2-40e9-9555-8ebf92bf6a60_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted-average shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7c1317ad-e4e6-4694-b2b0-2609d049b380_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dba65045-ed4f-4b5e-9157-8abae74519ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f08d199d-fd44-4c68-befd-3a424ecb3217_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_5a81d27e-02c2-47ed-adbd-b2ad2e817bfe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8dbcbe96-9295-4e50-8996-d05aac8f272a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_1019fb0a-b045-478a-82a4-74ac667a235b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6283c4e7-bc43-40d3-99a4-5d99e4025cb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d3c7ac51-7ac3-4767-a666-d913a0df7f6c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6493592d-db67-4cf1-9a52-984d650ff67c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0b0d1b44-c43d-40f8-95a7-a3e684ff0fe9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b7fc8613-a80c-45eb-913f-e07a6940b20c_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_25a5033a-fdc8-4308-a89e-7aea9f29885e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14283d5e-0f8d-4b34-9827-91ac1cbf4090_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ad8fd407-bce9-42a3-99f1-9e410c371538_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_27b8dc38-3ec2-49ac-b758-6741d80370bc_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range per share, upper limit (in usd per share)</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Upper Range Limit</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ExercisePriceRangeTwoMember_3c5b3958-b6b2-4a70-8260-93b0255905ef_terseLabel_en-US" xlink:label="lab_nlnk_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$11.00-$24.99</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_nlnk_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_nlnk_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_nlnk_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeTwoMember" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ExercisePriceRangeTwoMember" xlink:to="lab_nlnk_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_599aeb79-cf74-4064-a8f9-8ff846c00f26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_c07fad30-75a9-4ad9-9b38-f9b95021f832_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e13d32ea-e612-40d0-a3c2-8ef8b189770c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_3b11758c-f453-4b0d-84ff-d0561ca943ad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_03b3e1ca-dd12-4c01-a3dc-a9d28d325950_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ce12f362-c864-4be2-8ee7-de7c109c8093_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_1b2328af-4038-466d-b23e-300b6d6a9df6_terseLabel_en-US" xlink:label="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation payable to Iowa Economic Development Authority</link:label>
    <link:label id="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_label_en-US" xlink:label="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DeferredGovernmentGrantsObligationsNoncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:href="nlnk-20190930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:to="lab_nlnk_DeferredGovernmentGrantsObligationsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c6ff3491-e1d6-425e-ba2d-ac97a0cc256b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5a1970ca-3628-4ed7-bff6-71e5f1fdb343_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_A2010EmployeeStockPurchasePlanMember_15bfcab1-45e0-44a3-a2c2-02b3f3448245_terseLabel_en-US" xlink:label="lab_nlnk_A2010EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nlnk_A2010EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nlnk_A2010EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A 2010 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember" xlink:href="nlnk-20190930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_A2010EmployeeStockPurchasePlanMember" xlink:to="lab_nlnk_A2010EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_1811069e-c1c9-41b4-bb52-0483ac399409_terseLabel_en-US" xlink:label="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized lease incentive</link:label>
    <link:label id="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_label_en-US" xlink:label="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Unamortized Incentives</link:label>
    <link:label id="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_documentation_en-US" xlink:label="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Unamortized Incentives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:href="nlnk-20190930.xsd#nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:to="lab_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_dacbad69-5f6b-4eae-ae9b-a6bba44a5d07_terseLabel_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_label_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exchange Ratio</link:label>
    <link:label id="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_documentation_en-US" xlink:label="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option Exchange, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:to="lab_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4e969fcb-d1e1-4fc1-9cd3-2ec5f93edd87_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_642496c3-bbb6-41b5-b4e6-f8b1566c49cd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5f4e35e2-3ab0-44c2-9d05-34ae1da1c9c5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_eb8f20ad-8750-43bb-922c-9621267df061_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_082edcf0-dddc-4dc9-9114-dc4a7598333a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_a8f337a8-c02d-4767-8100-c7d844f31005_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blank check preferred stock, $0.01 par value: Authorized shares &#8212; 5,000,000 at September&#160;30, 2019 and December&#160;31, 2018; issued and outstanding shares &#8212; 0 at September&#160;30, 2019 and December&#160;31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9c6641df-5555-4df2-8037-d4ef1f6e6c9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c40e1295-dabd-4e5d-afb9-f14db7a7dc7e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Research Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dae48959-6f43-4449-95e1-27074af88926_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_e86dab20-5ea7-445d-9521-aa48221c1fff_negatedLabel_en-US" xlink:label="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset and change in operating lease liability</link:label>
    <link:label id="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_label_en-US" xlink:label="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right Of Use Asset, Amortization And Change in Operating Lease Liability</link:label>
    <link:label id="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right Of Use Asset, Amortization And Change in Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:href="nlnk-20190930.xsd#nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:to="lab_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_63fc4897-7f11-4422-8526-b5f1572e94af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_13f2627b-fe46-41d4-b3e4-bb2c8b51a799_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e550ecb7-6770-49ed-ab99-599c833fce42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2176dcc9-6dfb-41aa-af5d-e9557fb59245_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_db12b567-9db4-4c3e-b981-6f67c611b5b5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_38020c01-3867-4adc-9061-650767b0dae3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_00a5b70a-25cc-45d4-a0cf-29f7078827cc_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_4ced170c-e705-4462-8e48-deed72508d52_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_440fb324-adc0-48cb-9434-93e578cdf114_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7f9580c9-8d25-439c-a530-57b85ea79744_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nlnk-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:6a1815a0-8603-437f-906e-2d21454308f9,g:b61312a0-bf4b-43c9-b26a-7febbeed5f08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.linkp.com/role/CoverPage" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3a8411b0-3d91-4eec-8483-483527aeedfe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentTransitionReport_3a8411b0-3d91-4eec-8483-483527aeedfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1173c6cc-72c2-4769-89df-3d3bdb6113b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityRegistrantName_1173c6cc-72c2-4769-89df-3d3bdb6113b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0338c5a8-7de2-44b4-aff0-86f300704d10" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityCentralIndexKey_0338c5a8-7de2-44b4-aff0-86f300704d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06b1ed05-feab-429b-b674-3d73ec5d4a4e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_CurrentFiscalYearEndDate_06b1ed05-feab-429b-b674-3d73ec5d4a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_42f93bd3-0028-41c7-a8ef-d918621d2b02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityFilerCategory_42f93bd3-0028-41c7-a8ef-d918621d2b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_44ec3ae9-d89c-4a73-a29e-6fde93f46509" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentType_44ec3ae9-d89c-4a73-a29e-6fde93f46509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5f7b671a-eaf3-49e4-966c-01de2f6b7e6a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5f7b671a-eaf3-49e4-966c-01de2f6b7e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e9d9c1a1-44c7-4469-b2a0-d06479adc2f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentPeriodEndDate_e9d9c1a1-44c7-4469-b2a0-d06479adc2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bb676d68-31d7-43ea-ba81-f5969d16dd5f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityAddressAddressLine1_bb676d68-31d7-43ea-ba81-f5969d16dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c2603a84-0ade-4d08-b95b-be069336648e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityAddressCityOrTown_c2603a84-0ade-4d08-b95b-be069336648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ce8e944-4bdc-450d-9b2c-78298d3b62a9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityAddressStateOrProvince_6ce8e944-4bdc-450d-9b2c-78298d3b62a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0eaa462e-2526-4464-9f04-ed56d8c7c712" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityAddressPostalZipCode_0eaa462e-2526-4464-9f04-ed56d8c7c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6546f645-2efc-48c3-afdd-4e2084261cb0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_CityAreaCode_6546f645-2efc-48c3-afdd-4e2084261cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4209bb92-6c23-4b1d-90e4-390b95438ee9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_LocalPhoneNumber_4209bb92-6c23-4b1d-90e4-390b95438ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6c0d3210-778c-4a0e-8c32-8acb325d4a98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityTaxIdentificationNumber_6c0d3210-778c-4a0e-8c32-8acb325d4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33704c9b-f62e-45fd-82e7-8aab851a906b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentFiscalYearFocus_33704c9b-f62e-45fd-82e7-8aab851a906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ccbeaa89-06bd-45a5-8356-4ad8392691ac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ccbeaa89-06bd-45a5-8356-4ad8392691ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cb058138-f963-4ed6-9254-20616709b593" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_AmendmentFlag_cb058138-f963-4ed6-9254-20616709b593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_870647d9-453c-459c-9bb1-5fa13eadac45" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntitySmallBusiness_870647d9-453c-459c-9bb1-5fa13eadac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_48e7fb42-784f-4a29-842d-0d4530fb5eed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityEmergingGrowthCompany_48e7fb42-784f-4a29-842d-0d4530fb5eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_117910ff-f953-4a74-ad86-b723afebd5a4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_Security12bTitle_117910ff-f953-4a74-ad86-b723afebd5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_88b61f89-9e55-4f8a-a63d-ef7ec456b939" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_TradingSymbol_88b61f89-9e55-4f8a-a63d-ef7ec456b939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_11b0b4e1-ea37-47fa-85d6-74ffefe117d2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_SecurityExchangeName_11b0b4e1-ea37-47fa-85d6-74ffefe117d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c46925cd-9e3f-4715-aa61-0d1c6a7929be" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c46925cd-9e3f-4715-aa61-0d1c6a7929be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7e319f41-4c85-4485-be60-1c7575265ba1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e2f2a53e-78e6-4488-9e97-ed5576920077" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityFileNumber_e2f2a53e-78e6-4488-9e97-ed5576920077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5d7ba5bd-76b8-48f1-91b6-f2c53122a108" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_DocumentQuarterlyReport_5d7ba5bd-76b8-48f1-91b6-f2c53122a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bb7c7ee8-c4de-48de-a8ef-4f3742b9b92d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityShellCompany_bb7c7ee8-c4de-48de-a8ef-4f3742b9b92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_178d3291-dea5-4d10-bedd-57edede486f5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityInteractiveDataCurrent_178d3291-dea5-4d10-bedd-57edede486f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4d640028-9661-4a61-b621-87651123a8bf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2d9ca27-7438-457a-a620-0e479ea40a59" xlink:to="loc_dei_EntityCurrentReportingStatus_4d640028-9661-4a61-b621-87651123a8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6765f7c5-2ffd-4f17-8782-20e3838b2b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6765f7c5-2ffd-4f17-8782-20e3838b2b9c" xlink:to="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4c8191d-79c8-4fd9-bd8c-9a57aec493cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a4c8191d-79c8-4fd9-bd8c-9a57aec493cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a5217a3a-58a7-4e95-9b6c-c2ceb9086b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a5217a3a-58a7-4e95-9b6c-c2ceb9086b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_c619de5d-2910-45d9-bb53-5e7efa0b4a93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:to="loc_us-gaap_IncomeTaxesReceivable_c619de5d-2910-45d9-bb53-5e7efa0b4a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_78bae509-3bfb-4cb2-a3b7-cad79b83fbce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_78bae509-3bfb-4cb2-a3b7-cad79b83fbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_00697529-7bfd-45aa-b7e4-93318ceb68e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fb36031-d366-4cb3-87d5-d13d45c696f5" xlink:to="loc_us-gaap_AssetsCurrent_00697529-7bfd-45aa-b7e4-93318ceb68e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_39cd926e-0b15-420c-a6e9-a7dee0674bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_39cd926e-0b15-420c-a6e9-a7dee0674bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent_7392ab8b-22ba-4ccf-b915-cbf770494da2" xlink:href="nlnk-20190930.xsd#nlnk_OperatingLeaseRightofUseAssetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_nlnk_OperatingLeaseRightofUseAssetNoncurrent_7392ab8b-22ba-4ccf-b915-cbf770494da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_ee5f4995-e228-4359-9d45-91abf14b946f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_ee5f4995-e228-4359-9d45-91abf14b946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_673a5044-edba-4eb5-8970-a451c9cf4076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_us-gaap_AssetsNoncurrent_673a5044-edba-4eb5-8970-a451c9cf4076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e31337bb-f522-47e6-b9a7-b04c9abf9d42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d65c396e-cdb6-485b-8cca-fdfc302b72db" xlink:to="loc_us-gaap_Assets_e31337bb-f522-47e6-b9a7-b04c9abf9d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6765f7c5-2ffd-4f17-8782-20e3838b2b9c" xlink:to="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eb01d4fc-a8be-4eac-826a-8487d8e5246d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_AccountsPayableCurrent_eb01d4fc-a8be-4eac-826a-8487d8e5246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_130f6376-767b-4dd4-8e34-d4c8176f681a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_130f6376-767b-4dd4-8e34-d4c8176f681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_9368bc4f-4468-4ca5-9385-9b5ceccc86d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_9368bc4f-4468-4ca5-9385-9b5ceccc86d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_67b53e9f-ae38-47f8-b539-1d44160e708b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_67b53e9f-ae38-47f8-b539-1d44160e708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a1c0fc60-f570-4657-a428-9bee0f636aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_a1c0fc60-f570-4657-a428-9bee0f636aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72723889-24fb-4d07-a65d-2348c52fa089" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bbf59c0b-91af-49e7-b197-e47f3d8c1bda" xlink:to="loc_us-gaap_LiabilitiesCurrent_72723889-24fb-4d07-a65d-2348c52fa089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_7b61a10b-2051-427c-a2cd-0ac2ae89ceac" xlink:href="nlnk-20190930.xsd#nlnk_DeferredGovernmentGrantsObligationsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:to="loc_nlnk_DeferredGovernmentGrantsObligationsNoncurrent_7b61a10b-2051-427c-a2cd-0ac2ae89ceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d51c6027-a1c9-4361-949b-27006a7b929d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d51c6027-a1c9-4361-949b-27006a7b929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_370ea74b-9235-485c-a77a-1f7ef4c4d5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_370ea74b-9235-485c-a77a-1f7ef4c4d5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_8a1196c0-c6e1-4fff-a02f-a285e9fd8f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_8a1196c0-c6e1-4fff-a02f-a285e9fd8f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_7d0e0345-eceb-49d8-8bc6-13fa09fe92d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_cf44c60a-c717-448c-be94-b6fe57da1aa0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_7d0e0345-eceb-49d8-8bc6-13fa09fe92d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c0e42d3-41b2-4d0a-a79d-3202250148b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:to="loc_us-gaap_Liabilities_9c0e42d3-41b2-4d0a-a79d-3202250148b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:to="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_da96d4d5-53ab-44bb-bb82-81d0d3acf3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_da96d4d5-53ab-44bb-bb82-81d0d3acf3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_203fffd4-5698-44a2-a9a4-06928bbbc65f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_CommonStockValueOutstanding_203fffd4-5698-44a2-a9a4-06928bbbc65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_21c6fe0a-3431-4d03-9d99-e99203c75a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_AdditionalPaidInCapital_21c6fe0a-3431-4d03-9d99-e99203c75a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0a36f535-0b81-40a4-a7e6-a901ed81ce15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_TreasuryStockValue_0a36f535-0b81-40a4-a7e6-a901ed81ce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99ebd531-76b4-4add-bdc1-10841c7cac13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99ebd531-76b4-4add-bdc1-10841c7cac13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76fb4893-1232-451c-8964-b67f70d60070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31a20a11-c011-46bd-956e-50e38cc41288" xlink:to="loc_us-gaap_StockholdersEquity_76fb4893-1232-451c-8964-b67f70d60070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_47037e07-3270-4ca0-943e-342d8985ffbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_bf234f39-4593-4a96-8239-4455a4f6e994" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_47037e07-3270-4ca0-943e-342d8985ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d4ea6e52-12b9-4c1f-aa94-415d9b30d96c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d4ea6e52-12b9-4c1f-aa94-415d9b30d96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8ec2c179-3abb-4ec0-abba-f5013a9691d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8ec2c179-3abb-4ec0-abba-f5013a9691d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e5bd158b-9ea0-4af2-bcdb-6afa6f3dbda5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e5bd158b-9ea0-4af2-bcdb-6afa6f3dbda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d482ed88-4749-4a34-b126-c930cc0cfd94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d482ed88-4749-4a34-b126-c930cc0cfd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_57d06491-2677-4dc5-bb5d-502bbca5dd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_57d06491-2677-4dc5-bb5d-502bbca5dd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9cd8fbf8-ccad-4cf9-bd18-678b3a79586b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9cd8fbf8-ccad-4cf9-bd18-678b3a79586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_632a4338-ad9f-4b6e-92c6-dcf01828319b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_CommonStockSharesIssued_632a4338-ad9f-4b6e-92c6-dcf01828319b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70ab0505-0819-435a-b9b9-8c174101441b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70ab0505-0819-435a-b9b9-8c174101441b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f89d2da3-3729-4676-975a-52ec7319d802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79df5aa3-0cbe-4b53-bb67-880f1ea840dd" xlink:to="loc_us-gaap_TreasuryStockShares_f89d2da3-3729-4676-975a-52ec7319d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_368bc700-dea8-45fd-83f6-669269693629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_368bc700-dea8-45fd-83f6-669269693629" xlink:to="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:to="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_93640a76-faf8-4178-b782-7d5d077de4fa" xlink:to="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e491060a-8264-4a36-a167-d2188d61c736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:to="loc_us-gaap_GrantMember_e491060a-8264-4a36-a167-d2188d61c736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_03e75559-8d0f-4238-b4d9-a1e28eba66df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99dc9004-34fb-4875-a3d7-f6c01c18af6c" xlink:to="loc_us-gaap_LicenseAndServiceMember_03e75559-8d0f-4238-b4d9-a1e28eba66df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bf2be2-0c28-44b0-9ca2-2fe98f054e91" xlink:to="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f7a7a7b9-842c-4901-a047-765e6e9165d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f7a7a7b9-842c-4901-a047-765e6e9165d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6844ff27-248c-428e-bab8-bde59de36237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_Revenues_6844ff27-248c-428e-bab8-bde59de36237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3a0877bf-3aa8-4e62-9f40-43310551462d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3a0877bf-3aa8-4e62-9f40-43310551462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6426d5c3-9c77-4036-83e2-ad7a61589df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6426d5c3-9c77-4036-83e2-ad7a61589df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53a4339c-d8b8-4497-bdef-2b5af58f8a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_886b4728-851d-423a-83d0-03196c2a8417" xlink:to="loc_us-gaap_OperatingExpenses_53a4339c-d8b8-4497-bdef-2b5af58f8a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_939651ff-f19e-4cb3-8fca-55b5ba95b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_OperatingIncomeLoss_939651ff-f19e-4cb3-8fca-55b5ba95b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0c3728a0-5e39-456c-90d0-3c8539fb3956" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0c3728a0-5e39-456c-90d0-3c8539fb3956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_97c62679-5a7e-4aea-8fca-f07ecfe8911e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_97c62679-5a7e-4aea-8fca-f07ecfe8911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4685f2f9-e762-465d-812f-14d315daec50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0a390707-7bbd-42b7-93e0-9a28d0792d95" xlink:to="loc_us-gaap_InterestExpense_4685f2f9-e762-465d-812f-14d315daec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cdd9c5ba-dcaf-487d-951f-30b7d0f53d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cdd9c5ba-dcaf-487d-951f-30b7d0f53d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83b86c7e-6e4d-4f79-8024-95d09d0c5622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83b86c7e-6e4d-4f79-8024-95d09d0c5622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea04467f-d8d8-4340-846c-b9cb705716d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea04467f-d8d8-4340-846c-b9cb705716d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd7acc4-180b-4636-9401-ea6b47b13297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_NetIncomeLoss_ecd7acc4-180b-4636-9401-ea6b47b13297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1678a0d1-b026-4262-a53c-b78055f8da21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1678a0d1-b026-4262-a53c-b78055f8da21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b395fc01-fde3-44b5-8a4e-8cd2133c9a33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f7f4837e-c892-49a3-af6d-60fa7381e040" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b395fc01-fde3-44b5-8a4e-8cd2133c9a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9fc3e24c-d2de-40ef-8b53-c9cfef94f262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9fc3e24c-d2de-40ef-8b53-c9cfef94f262" xlink:to="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ef06e6f-fabb-4706-853c-26d86b76e766" xlink:to="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5b4e7d1-78d9-4a8b-a0b6-d9194954ff17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_CommonStockMember_b5b4e7d1-78d9-4a8b-a0b6-d9194954ff17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_086d07f8-38b6-48c9-aa12-e274ded10f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_086d07f8-38b6-48c9-aa12-e274ded10f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2c8ddfba-af91-4768-8ba3-d62597a1cbb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_TreasuryStockMember_2c8ddfba-af91-4768-8ba3-d62597a1cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65417c74-37d6-436b-bed2-abd4b676084b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e3a8d689-bc4f-4cd1-be94-ca10f461cca8" xlink:to="loc_us-gaap_RetainedEarningsMember_65417c74-37d6-436b-bed2-abd4b676084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc0624b8-bfb8-4343-a14d-92b31b1d2ca7" xlink:to="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdc3c1c0-9eec-41d3-bfd3-5dd48d3ecf1c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5b9ef0b-62e2-4f2c-963c-dffccd2ed13e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockholdersEquity_f5b9ef0b-62e2-4f2c-963c-dffccd2ed13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d687cea0-5bb3-4b61-9353-cc2c43520050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d687cea0-5bb3-4b61-9353-cc2c43520050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_276dd25a-9836-499d-a913-521c310aa02b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_276dd25a-9836-499d-a913-521c310aa02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_905fbdf1-d11a-485c-aa4c-d430f9fc2c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_905fbdf1-d11a-485c-aa4c-d430f9fc2c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_de64a160-218d-49ae-a381-c7a5a1f8b351" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_de64a160-218d-49ae-a381-c7a5a1f8b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86b40611-f29f-4aad-9bf4-6debe2ddde70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86b40611-f29f-4aad-9bf4-6debe2ddde70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a91dc6b-a878-4817-af67-7a01d5979b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8a91dc6b-a878-4817-af67-7a01d5979b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_975a0f3d-3497-4d58-9285-028c0a7ed164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_975a0f3d-3497-4d58-9285-028c0a7ed164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2afdc699-131c-41e1-8f96-f92890138799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2afdc699-131c-41e1-8f96-f92890138799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_67511364-0325-44e8-bd09-1bb8b5c5bfba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_67511364-0325-44e8-bd09-1bb8b5c5bfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73f9a53e-4eba-4b2f-9f1b-4373231d2bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_NetIncomeLoss_73f9a53e-4eba-4b2f-9f1b-4373231d2bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0b1e780-9a38-48aa-8694-8e0bd2f0aff5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_StockholdersEquity_b0b1e780-9a38-48aa-8694-8e0bd2f0aff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6f0d851-0218-4344-8f54-df15c4e6ac27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40f9ada5-6cbc-40b1-bcdc-06349d1eaa5d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a6f0d851-0218-4344-8f54-df15c4e6ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7aeb4388-3e01-4e9a-a700-75af773d6c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:to="loc_us-gaap_NetIncomeLoss_7aeb4388-3e01-4e9a-a700-75af773d6c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d70d884e-0138-4c3a-8a42-61e495087d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:to="loc_us-gaap_ShareBasedCompensation_d70d884e-0138-4c3a-8a42-61e495087d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_033cf067-8196-4f83-8951-7603a6e6243f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_033cf067-8196-4f83-8951-7603a6e6243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d29dbb1c-f2d2-40d9-8efd-e99c4e7e1400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d29dbb1c-f2d2-40d9-8efd-e99c4e7e1400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae606a55-9847-45c5-9dbc-297867908b32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae606a55-9847-45c5-9dbc-297867908b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_f4934bdf-6dd9-4ce5-8b81-5a5c77da610e" xlink:href="nlnk-20190930.xsd#nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1380c82f-7cab-452f-87f3-9c58e748f25e" xlink:to="loc_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability_f4934bdf-6dd9-4ce5-8b81-5a5c77da610e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a073a2-5588-43eb-9f42-c5195b767ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a073a2-5588-43eb-9f42-c5195b767ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6008cd6b-70da-4469-834c-c946eb56bee7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6008cd6b-70da-4469-834c-c946eb56bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb255022-b18f-46aa-8347-2d3186d1965e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb255022-b18f-46aa-8347-2d3186d1965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a7b79d6f-0905-4540-a0ff-54e0d5b4bc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a7b79d6f-0905-4540-a0ff-54e0d5b4bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ee92d9d3-0a1d-424f-8e73-3d634a68e7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ee92d9d3-0a1d-424f-8e73-3d634a68e7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_b80a67a0-e718-4b9a-ad5a-b2becb5e2a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23c54486-747b-489f-80e8-869848974485" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_b80a67a0-e718-4b9a-ad5a-b2becb5e2a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03605644-7bde-4f89-989b-ff66e1e370c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b6f553a-599f-474e-9651-944f88c0520e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_03605644-7bde-4f89-989b-ff66e1e370c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38cf2115-41ca-43e9-8230-bc904de21ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38cf2115-41ca-43e9-8230-bc904de21ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10ef5aaa-4990-468d-81c3-2a08f60767df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38cf2115-41ca-43e9-8230-bc904de21ef1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10ef5aaa-4990-468d-81c3-2a08f60767df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ea93748c-621e-469d-9be4-b0749a420e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38cf2115-41ca-43e9-8230-bc904de21ef1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ea93748c-621e-469d-9be4-b0749a420e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c45f5681-4082-4743-83a5-519513224dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38cf2115-41ca-43e9-8230-bc904de21ef1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c45f5681-4082-4743-83a5-519513224dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_182a8f80-8272-4ee4-b554-963569b35953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_182a8f80-8272-4ee4-b554-963569b35953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8c054b91-10f7-43a5-ab13-50722a7adbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8c054b91-10f7-43a5-ab13-50722a7adbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_c7c833ea-aa17-4995-af7b-3f76df3989fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_c7c833ea-aa17-4995-af7b-3f76df3989fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e692bc32-6641-4570-a345-95aced35a4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0a48de83-e771-4eaf-8e34-4b4e4afa1a7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e692bc32-6641-4570-a345-95aced35a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71121ba7-36e9-442a-abda-971cb326751f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71121ba7-36e9-442a-abda-971cb326751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_979a300e-b760-46ea-a532-bb8974807155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_979a300e-b760-46ea-a532-bb8974807155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baf5f6b6-5652-4caf-8370-7452cff437ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baf5f6b6-5652-4caf-8370-7452cff437ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4783a1f-f74d-472e-af91-0a65f16b5e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e4935023-01ce-400b-a549-14766be09f85" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4783a1f-f74d-472e-af91-0a65f16b5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_83417e07-2801-4400-a5e7-7c81d573c6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4783a1f-f74d-472e-af91-0a65f16b5e37" xlink:to="loc_us-gaap_InterestPaidNet_83417e07-2801-4400-a5e7-7c81d573c6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_97662c29-d955-4c34-a70b-da914793b37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4783a1f-f74d-472e-af91-0a65f16b5e37" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_97662c29-d955-4c34-a70b-da914793b37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_df050e03-2996-4607-b4f2-6784973cff0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c4783a1f-f74d-472e-af91-0a65f16b5e37" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_df050e03-2996-4607-b4f2-6784973cff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3c9f3cd-019c-4c7a-93a0-3617c165611b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_6ac6ee45-bfec-4424-ba23-0824d1984813" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d3c9f3cd-019c-4c7a-93a0-3617c165611b" xlink:to="loc_us-gaap_NatureOfOperations_6ac6ee45-bfec-4424-ba23-0824d1984813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46346aac-e1cc-45f7-86b8-bbd62e27661a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46346aac-e1cc-45f7-86b8-bbd62e27661a" xlink:to="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:to="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9c1a8a78-b42f-4a9c-8cc7-c65d67404bc9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LumosPharmaIncMember_1ca9cb81-050a-490c-b925-fe0016794c7c" xlink:href="nlnk-20190930.xsd#nlnk_LumosPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b8c891-2dd3-423d-9590-cc1b3f35eae9" xlink:to="loc_nlnk_LumosPharmaIncMember_1ca9cb81-050a-490c-b925-fe0016794c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:href="nlnk-20190930.xsd#nlnk_FinancingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsTable_56ee93c6-ea6a-461a-9c99-80f3a77b860f" xlink:to="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_6d50b2fa-1dd6-4fc0-a1d8-e12d412090fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_6d50b2fa-1dd6-4fc0-a1d8-e12d412090fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable_546f93fd-786f-4137-b457-fdce18095a76" xlink:href="nlnk-20190930.xsd#nlnk_MergerAgreementCovenantsTerminationFeePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nlnk_FinancingsLineItems_1b65b61c-e88a-4c47-b0ef-a01aa58b8377" xlink:to="loc_nlnk_MergerAgreementCovenantsTerminationFeePayable_546f93fd-786f-4137-b457-fdce18095a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/BasisofPresentation" xlink:type="simple" xlink:href="nlnk-20190930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16287b82-859d-44ba-a61a-6c0221514cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_374927c2-cca2-4e97-968f-b8896d02ef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16287b82-859d-44ba-a61a-6c0221514cee" xlink:to="loc_us-gaap_BasisOfAccounting_374927c2-cca2-4e97-968f-b8896d02ef3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be9d75fd-fef1-4a4b-97b1-1d9acf15f028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fee09838-5fd0-4ac3-a7f5-0a82840a021d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be9d75fd-fef1-4a4b-97b1-1d9acf15f028" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fee09838-5fd0-4ac3-a7f5-0a82840a021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_47581f1a-dd4f-426a-b43c-f5549637214d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_UseOfEstimates_47581f1a-dd4f-426a-b43c-f5549637214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a2c71d2e-7317-467f-af7c-d958f312a54e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a2c71d2e-7317-467f-af7c-d958f312a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fc46fcab-fcf7-4397-b631-d917ce416dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fc46fcab-fcf7-4397-b631-d917ce416dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e35111ec-1097-47ca-b5d7-54ee17b14561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e35111ec-1097-47ca-b5d7-54ee17b14561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_adf5b1ff-682a-46b4-99a2-166f7c0fd59c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_adf5b1ff-682a-46b4-99a2-166f7c0fd59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e988d8a-dff8-41bc-813d-07f43f225362" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e988d8a-dff8-41bc-813d-07f43f225362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a20d4d0b-7d22-4c13-99ad-e84e45521627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1beb564f-538c-4e52-b749-073f2d333400" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a20d4d0b-7d22-4c13-99ad-e84e45521627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#SignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8be0973a-56be-44e3-a147-e3f5ecae8e92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_0da8203f-17ae-4475-8d8c-b853ea08166f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be0973a-56be-44e3-a147-e3f5ecae8e92" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_0da8203f-17ae-4475-8d8c-b853ea08166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fc0c5cea-ecdf-4273-98ac-15216bde4689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be0973a-56be-44e3-a147-e3f5ecae8e92" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fc0c5cea-ecdf-4273-98ac-15216bde4689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be0973a-56be-44e3-a147-e3f5ecae8e92" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f3b1594e-68d7-4fbb-951b-84e7a6bfbf5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eb02fc4b-8a74-4a40-9164-8c38bad8643a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_us-gaap_ComputerEquipmentMember_eb02fc4b-8a74-4a40-9164-8c38bad8643a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_89fedc1f-9fcf-4d98-9016-fad8e0b23d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_us-gaap_EquipmentMember_89fedc1f-9fcf-4d98-9016-fad8e0b23d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_e60578d7-668c-4182-aa7b-83f94a25fc1d" xlink:href="nlnk-20190930.xsd#nlnk_ContractManufacturingOrganizationEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07d3563e-f8ea-4f3e-aac8-bf5ca58f088c" xlink:to="loc_nlnk_ContractManufacturingOrganizationEquipmentMember_e60578d7-668c-4182-aa7b-83f94a25fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:to="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77d661b8-203e-409f-a29f-6504a59f02f5" xlink:to="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_202e9cfb-59a8-4b93-9d08-b9917880d68f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:to="loc_srt_MinimumMember_202e9cfb-59a8-4b93-9d08-b9917880d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_636ef8d1-f4b3-4844-94af-1708cdd74635" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_63674294-f440-41f5-9ece-56b501ae2b19" xlink:to="loc_srt_MaximumMember_636ef8d1-f4b3-4844-94af-1708cdd74635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c72e9ed4-6288-4648-a05f-4c7314fda23e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92832d75-aa54-4e9e-b091-c912249a3730" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_92832d75-aa54-4e9e-b091-c912249a3730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f2840d30-f159-4729-8a9e-3803ef0f8de9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_OperatingLeaseLiability_f2840d30-f159-4729-8a9e-3803ef0f8de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c504b76c-d5cc-423e-a2dd-200109ebf76f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c504b76c-d5cc-423e-a2dd-200109ebf76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_893f48b0-010e-4fd6-a9f6-3f0d22d7eede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a2153d5-fcd3-40b5-831a-d6aff9b1c616" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_893f48b0-010e-4fd6-a9f6-3f0d22d7eede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/Revenues" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3cd0f49-1f8d-48d2-adae-48dcd4066d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d870a0ef-d2d7-40ba-9a09-d7be6e7382c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f3cd0f49-1f8d-48d2-adae-48dcd4066d2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d870a0ef-d2d7-40ba-9a09-d7be6e7382c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/RevenuesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97e2c90b-ca41-4ee6-9a92-7fb89c47b5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractReceivable_09a21535-a62e-4024-868e-1413619ef657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentContractReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97e2c90b-ca41-4ee6-9a92-7fb89c47b5ff" xlink:to="loc_us-gaap_GovernmentContractReceivable_09a21535-a62e-4024-868e-1413619ef657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_GovernmentContractAccruedSubcontractorFees_f3fade3c-7a71-4731-8bc8-ef46adc1823d" xlink:href="nlnk-20190930.xsd#nlnk_GovernmentContractAccruedSubcontractorFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97e2c90b-ca41-4ee6-9a92-7fb89c47b5ff" xlink:to="loc_nlnk_GovernmentContractAccruedSubcontractorFees_f3fade3c-7a71-4731-8bc8-ef46adc1823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01eed1f7-d7e9-4a9d-8e71-e936d6038c08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0597788f-81c7-4584-ad21-bcf2a79b84d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01eed1f7-d7e9-4a9d-8e71-e936d6038c08" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0597788f-81c7-4584-ad21-bcf2a79b84d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LicenseandResearchCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a13894d-359e-4a21-9359-9cb65c4b9e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a13894d-359e-4a21-9359-9cb65c4b9e4f" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d49f911-f8c2-4128-8dc9-03e6040922b4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ee0279b6-032f-4a3d-a550-5aa4b6510847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9016f051-f30b-4ed2-96b9-cacc881e5ede" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ee0279b6-032f-4a3d-a550-5aa4b6510847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1eeca639-4b44-4e17-8c5c-dfa74ae8fa72" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_MerckSharpeAndDohmeCorpMember_7732c361-7460-4fe0-9fba-65214ee10cc2" xlink:href="nlnk-20190930.xsd#nlnk_MerckSharpeAndDohmeCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_534771c8-2bcd-4fc8-8ee5-973ccc41a357" xlink:to="loc_nlnk_MerckSharpeAndDohmeCorpMember_7732c361-7460-4fe0-9fba-65214ee10cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f30dba36-166c-45e5-97eb-ddcd1e1479e9" xlink:to="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_090b7c70-a215-42c8-9c08-6ff304a1ad41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4709cfd0-f906-4df7-9cd8-217d8817a5a8" xlink:to="loc_us-gaap_LicenseAndServiceMember_090b7c70-a215-42c8-9c08-6ff304a1ad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_88646eb6-e745-43ae-aa23-e3dff33ca85e" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_f8738f2d-32ac-4182-b097-05536f39ade7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_f8738f2d-32ac-4182-b097-05536f39ade7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c14f91cd-a144-40f7-b726-e4133abd5eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_e39dbe37-9fce-4ee5-89af-16562aa8ead6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_c14f91cd-a144-40f7-b726-e4133abd5eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlan"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d178a23-d730-4a28-92ff-99c2dd064be9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_992deb6f-a6ec-41bf-8b9a-e4122658bd86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d178a23-d730-4a28-92ff-99c2dd064be9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_992deb6f-a6ec-41bf-8b9a-e4122658bd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanTables"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_a405dd7a-aae8-4aed-afd1-c01ea07c6856" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_a405dd7a-aae8-4aed-afd1-c01ea07c6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_a2b0cfd5-b0ec-4a40-bb4e-8c908c1d38d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_a2b0cfd5-b0ec-4a40-bb4e-8c908c1d38d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_61f6c826-d83b-462b-b94f-88969d84dfea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_61f6c826-d83b-462b-b94f-88969d84dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6984253a-30ec-4134-acb8-7208fd8acd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6984253a-30ec-4134-acb8-7208fd8acd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock_295257f4-0c2e-4b40-82d0-f61def02ad7a" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef68d56d-8aea-4a34-9bb4-be921f2c3211" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock_295257f4-0c2e-4b40-82d0-f61def02ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f5adf0a-d0aa-49ba-9ad8-5a084a3ed61d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f5adf0a-d0aa-49ba-9ad8-5a084a3ed61d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_65d53309-282a-4ff6-8e90-615deaf7cf11" xlink:to="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0f2520fd-5c66-4f5a-8deb-68753f71d88b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:to="loc_srt_MinimumMember_0f2520fd-5c66-4f5a-8deb-68753f71d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_239f5e4e-039b-45e7-adff-c111d0262428" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90b0d096-bd4b-48a5-b973-fc86f026af68" xlink:to="loc_srt_MaximumMember_239f5e4e-039b-45e7-adff-c111d0262428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_292d2e71-c944-4aa4-9510-60b65c97c79b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b49fd4b-4e6f-4edf-a251-b67b0b8ebb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b49fd4b-4e6f-4edf-a251-b67b0b8ebb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_eb24ceae-7b03-4bc0-bc04-f198fa26f5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_PerformanceSharesMember_eb24ceae-7b03-4bc0-bc04-f198fa26f5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_024c346d-379b-4fa1-88af-d1db9313a47e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bc5166c-73cc-4cae-9a32-003ea513fa74" xlink:to="loc_us-gaap_RestrictedStockMember_024c346d-379b-4fa1-88af-d1db9313a47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e5abe709-92c5-4d63-87a6-ea7f9e8a8cb6" xlink:to="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_fcdcf308-ae24-40be-9696-ef7ba221e908" xlink:href="nlnk-20190930.xsd#nlnk_A2009EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_fcdcf308-ae24-40be-9696-ef7ba221e908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_de85a59f-f4a5-4557-a94a-699a6f80369a" xlink:href="nlnk-20190930.xsd#nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember_de85a59f-f4a5-4557-a94a-699a6f80369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2010EmployeeStockPurchasePlanMember_fa8cc666-836d-476d-aac2-2a28d81207e8" xlink:href="nlnk-20190930.xsd#nlnk_A2010EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9daaf797-9064-45b8-963f-b58295c9df6d" xlink:to="loc_nlnk_A2010EmployeeStockPurchasePlanMember_fa8cc666-836d-476d-aac2-2a28d81207e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72e20216-e283-454e-bf3a-43757834e4e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_145f956b-e9bc-40a4-863d-e36f9b8c9e35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_145f956b-e9bc-40a4-863d-e36f9b8c9e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7031d065-9923-4619-aaba-9143bef4fd7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7031d065-9923-4619-aaba-9143bef4fd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6a7203c9-9cbd-41e9-99cf-e88e49957a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_6a7203c9-9cbd-41e9-99cf-e88e49957a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_b7422f0e-f32b-4c1f-8d3d-e428c229d3b3" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum_b7422f0e-f32b-4c1f-8d3d-e428c229d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_38218994-8bc5-4f77-8669-366080a45d34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_38218994-8bc5-4f77-8669-366080a45d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3dff1e30-b7bf-4c87-a610-dfd856c9d591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3dff1e30-b7bf-4c87-a610-dfd856c9d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4da50aea-c193-4d73-aad8-c2dd3a794a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4da50aea-c193-4d73-aad8-c2dd3a794a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95388dde-ec56-4172-866e-a31c03686c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_95388dde-ec56-4172-866e-a31c03686c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_f6f2c9b4-4bb0-4e43-882a-864f80881ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_f6f2c9b4-4bb0-4e43-882a-864f80881ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_058f5946-7b64-459d-b2ac-d6105c90276b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_058f5946-7b64-459d-b2ac-d6105c90276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d2b0987-6fc4-4ca5-87ec-bdad8e2ac7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2d2b0987-6fc4-4ca5-87ec-bdad8e2ac7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc0f5d13-1387-4d2a-8548-f7694f2a2fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc0f5d13-1387-4d2a-8548-f7694f2a2fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_00ab79af-c2fb-4156-823c-7208031a8180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8bd4ea18-0545-4098-8500-321bff5fcec7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_00ab79af-c2fb-4156-823c-7208031a8180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1d19f8f-25ff-43be-8eaf-a2cb56ce7376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1d19f8f-25ff-43be-8eaf-a2cb56ce7376" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:to="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_de1cf7d8-43c0-4c82-996e-9756933834cc" xlink:to="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_A2009EquityIncentivePlanMember_a79d36a7-f9c8-4be6-afb1-fe3ad0e71ea7" xlink:href="nlnk-20190930.xsd#nlnk_A2009EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74ceff9e-7c5a-4dff-8b15-bf539663da89" xlink:to="loc_nlnk_A2009EquityIncentivePlanMember_a79d36a7-f9c8-4be6-afb1-fe3ad0e71ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e7466e3-5d0d-4daa-aeb1-01d1b939cede" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b8cd0b61-0207-4864-8dcf-5d50e5c50203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050fdc23-7882-4d65-9a3f-ddfce9c52253" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b8cd0b61-0207-4864-8dcf-5d50e5c50203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5d8af01-bc3f-494f-822c-49af9a0f7e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5d8af01-bc3f-494f-822c-49af9a0f7e0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:to="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_67d8457b-c2ef-4b20-b638-76ca874d0bae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_08a5b719-db1b-413f-9585-ee3071566b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a49df5b-4b16-407f-bbea-d96288f8bb2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_08a5b719-db1b-413f-9585-ee3071566b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_308554ef-acf6-486f-ac09-06b68a12701a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fc72f-bc0c-4bf8-b359-96d64b7078aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fc72f-bc0c-4bf8-b359-96d64b7078aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0ff42280-2643-41fa-85ec-dfccf77fc70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0ff42280-2643-41fa-85ec-dfccf77fc70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ba4cb4c-cf79-4e59-bfb7-cc57ad2bea1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ba4cb4c-cf79-4e59-bfb7-cc57ad2bea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6c5f2d37-edcc-489f-962a-ecaa95f76ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6c5f2d37-edcc-489f-962a-ecaa95f76ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b286cd1b-878c-48f9-b1bc-4977ad874c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b286cd1b-878c-48f9-b1bc-4977ad874c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7e69bddf-03a1-4524-b37c-3468ca64d0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7305871c-5cf2-4f55-89d0-7eb21ccb7696" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7e69bddf-03a1-4524-b37c-3468ca64d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543332d2-3708-41b3-b10a-0316ad06a920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_543332d2-3708-41b3-b10a-0316ad06a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c96f40e3-3052-471a-9513-21f904ecfadd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c96f40e3-3052-471a-9513-21f904ecfadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e1a2d5c2-a34a-4dd5-abb5-9fd6181e5ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e1a2d5c2-a34a-4dd5-abb5-9fd6181e5ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_61b054da-9fa4-4124-af7b-2f1892d57a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_61b054da-9fa4-4124-af7b-2f1892d57a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef19263d-484a-4897-b3fd-dd672590867f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ef19263d-484a-4897-b3fd-dd672590867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01673914-3dd8-442f-8aec-46449bb94fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0f7b01a-6c7b-412d-85f8-8cb4d79078c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01673914-3dd8-442f-8aec-46449bb94fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54234e5a-30e7-4d67-b500-efa0cb92ecb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54234e5a-30e7-4d67-b500-efa0cb92ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee863984-792b-453e-b73c-c2d3d658845a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee863984-792b-453e-b73c-c2d3d658845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac15feb-5713-4989-b1c9-25851aa41190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7ac15feb-5713-4989-b1c9-25851aa41190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eb07c1a1-0ada-4546-94e2-e17435e5bd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4545799a-0181-4fb1-8cd1-83fd5cc0f38a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eb07c1a1-0ada-4546-94e2-e17435e5bd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a80a037-2c67-492b-bc49-7171f4f91612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a80a037-2c67-492b-bc49-7171f4f91612" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:to="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3bf35cef-8410-4b83-af27-ef261b2f1860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c7e03685-b720-42b5-8cf8-df0900e360b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d60bfc68-2827-4dfe-a74a-4bccb1c48cff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c7e03685-b720-42b5-8cf8-df0900e360b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:to="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0bf5081a-992c-44c6-87c1-d83028c3f2f2" xlink:to="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_abe6f0dd-57ff-4e8a-aa91-0c638a9f4e7f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:to="loc_srt_MinimumMember_abe6f0dd-57ff-4e8a-aa91-0c638a9f4e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb591ecc-1b07-4131-8f98-3156bc4f72b4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8bd2afa-01b5-428f-b18e-2928aa083817" xlink:to="loc_srt_MaximumMember_fb591ecc-1b07-4131-8f98-3156bc4f72b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f9f535-1530-4c09-82ae-02be69ba70c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_161f210b-843b-4e02-9583-61a133595dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_161f210b-843b-4e02-9583-61a133595dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8378c7e3-db82-4433-a175-741483422b91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8378c7e3-db82-4433-a175-741483422b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0506c4a1-097a-4ace-8b6a-a2ff94b6fa5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0506c4a1-097a-4ace-8b6a-a2ff94b6fa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6ee0710b-add2-4591-8c7d-429d6ca67802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6ee0710b-add2-4591-8c7d-429d6ca67802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_86d4ae65-40aa-472f-89fc-2db8a88e2900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_86d4ae65-40aa-472f-89fc-2db8a88e2900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89168915-41df-4990-a3fa-1522db7446af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89168915-41df-4990-a3fa-1522db7446af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4bf963d0-acd1-4572-9b8e-1dd0f0385d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcf93786-ccfd-4b61-8c54-d1c5003cceef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4bf963d0-acd1-4572-9b8e-1dd0f0385d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acdd56c8-5093-437c-b909-19011a3840e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acdd56c8-5093-437c-b909-19011a3840e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:to="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0b6de79f-fc7f-4978-ad49-e6c2ac3ce536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2a54111a-cc3c-41db-8a59-8167774ae023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83262645-ca9f-4ec9-8613-c9419fd880ec" xlink:to="loc_us-gaap_RestrictedStockMember_2a54111a-cc3c-41db-8a59-8167774ae023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5120428e-7c07-4875-b71a-eb22f1d82db2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6fa41caf-05b3-4dd5-8012-5d23e8bc3850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6fa41caf-05b3-4dd5-8012-5d23e8bc3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff7e054b-dc9a-4378-8452-c0efd97e0f55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff7e054b-dc9a-4378-8452-c0efd97e0f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c23e540d-dcf0-4adb-a92d-e116b950151f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c23e540d-dcf0-4adb-a92d-e116b950151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6a003b70-ec43-4e14-b1a9-fd9b765d0e59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6a003b70-ec43-4e14-b1a9-fd9b765d0e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc7a2111-7cc7-4b5b-9896-cd2779c10acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_33e6c16b-6807-4ba3-bae5-65e75b820cfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc7a2111-7cc7-4b5b-9896-cd2779c10acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d866a11f-5ba9-4d72-9223-03c33b03342f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca7435bd-2055-4462-a0ac-4417f0746004" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca7435bd-2055-4462-a0ac-4417f0746004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6fac94a-02bb-4ba9-87b1-aa44b477cb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6fac94a-02bb-4ba9-87b1-aa44b477cb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50628685-e52c-41db-9aa7-ebf26ccf24e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_50628685-e52c-41db-9aa7-ebf26ccf24e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23999cb7-8f00-42ba-b816-cf09e621c660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23999cb7-8f00-42ba-b816-cf09e621c660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94799493-d2e4-4ef3-b416-83b382ffa433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_98f953e3-fb47-414b-a6aa-bf6917ed1d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_94799493-d2e4-4ef3-b416-83b382ffa433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommonStockEquityIncentivePlanOptionExchangeProgramDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39b8e960-5e31-48c7-8788-a423efc6dda0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39b8e960-5e31-48c7-8788-a423efc6dda0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:to="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fcff3b59-0428-4725-ae96-4f1982bfb98a" xlink:to="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_833b4f19-4094-4ce0-87c2-00f253e1ffe8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:to="loc_srt_MinimumMember_833b4f19-4094-4ce0-87c2-00f253e1ffe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99b672a5-26da-4f2d-81ca-68c5460d1d4c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36300149-d218-4fcf-b13a-57d77849187e" xlink:to="loc_srt_MaximumMember_99b672a5-26da-4f2d-81ca-68c5460d1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a1c822a5-82b5-4e51-b183-de3c63126ca9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeOneMember_85296265-b3c1-4dbf-b773-55da3461df82" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeOneMember_85296265-b3c1-4dbf-b773-55da3461df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeTwoMember_5c6d6dbf-3756-4e1d-9894-672b9ec3aa9c" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeTwoMember_5c6d6dbf-3756-4e1d-9894-672b9ec3aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ExercisePriceRangeThreeMember_86d5a3b3-93ac-4b3f-b191-081651c56cac" xlink:href="nlnk-20190930.xsd#nlnk_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_04061ce8-4be9-46db-9745-6f811f7ab44c" xlink:to="loc_nlnk_ExercisePriceRangeThreeMember_86d5a3b3-93ac-4b3f-b191-081651c56cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_77b9effb-4fed-46e7-a1e7-76f833707980" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_65e4cb70-9445-454e-87b9-dde997f3b2df" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized_65e4cb70-9445-454e-87b9-dde997f3b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_c282893a-a381-474a-b10b-380f9fd5d328" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit_c282893a-a381-474a-b10b-380f9fd5d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_edc3b2af-fbc7-4849-ae08-adf1b6c34641" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit_edc3b2af-fbc7-4849-ae08-adf1b6c34641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_550d50f2-67b8-4949-99a7-476fd8659346" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding_550d50f2-67b8-4949-99a7-476fd8659346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_4917cf86-e39b-48d9-8167-3bc263767b50" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio_4917cf86-e39b-48d9-8167-3bc263767b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_254c4745-775a-4e0a-a6c9-88ffa6f9dc68" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants_254c4745-775a-4e0a-a6c9-88ffa6f9dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_d3d28f3a-1fe2-455d-a428-81b52a9ab9a4" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted_d3d28f3a-1fe2-455d-a428-81b52a9ab9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_21c013de-7173-438d-a817-3910310a37bc" xlink:href="nlnk-20190930.xsd#nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent_21c013de-7173-438d-a817-3910310a37bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44735d55-86d5-4639-aa21-a7dc2f36d506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44735d55-86d5-4639-aa21-a7dc2f36d506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a607076b-cb8f-4617-ad35-73bbe8ec3b85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a607076b-cb8f-4617-ad35-73bbe8ec3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4b42e830-b5a2-4a9e-bf58-183da9816369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4b42e830-b5a2-4a9e-bf58-183da9816369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2854a46b-28d8-440a-bfec-830df50da908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2854a46b-28d8-440a-bfec-830df50da908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75d2964b-2dc4-4437-b59c-b104e75af9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_5b6511b3-fd2a-40d0-ad80-2a66500ab844" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75d2964b-2dc4-4437-b59c-b104e75af9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/Leases" xlink:type="simple" xlink:href="nlnk-20190930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ab1ccea7-aca6-43e4-959c-cddf725eae89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7e28c644-d8dc-46a6-9484-e8bfcb2a68f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab1ccea7-aca6-43e4-959c-cddf725eae89" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7e28c644-d8dc-46a6-9484-e8bfcb2a68f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7cb40b1e-cc66-4a6c-ae77-1bf3fdd1a434" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63726785-fdce-4ad6-966f-0a5495b605f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7cb40b1e-cc66-4a6c-ae77-1bf3fdd1a434" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63726785-fdce-4ad6-966f-0a5495b605f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_bf48b25a-c12d-4ea7-8214-e5d9657c85cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7cb40b1e-cc66-4a6c-ae77-1bf3fdd1a434" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_bf48b25a-c12d-4ea7-8214-e5d9657c85cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/LeasesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#LeasesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/LeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e5bc7fac-411f-4d39-908a-84a6a0375cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e5bc7fac-411f-4d39-908a-84a6a0375cfc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:to="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2ef62327-9434-4c7d-9ab1-df2900b023a8" xlink:to="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d511f691-da54-4085-bc93-0d653e4e45ba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:to="loc_srt_MinimumMember_d511f691-da54-4085-bc93-0d653e4e45ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_412b763d-83b0-47e1-9cc1-f5990bcc2682" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c43b228-34fa-4d35-afae-9e372acf6326" xlink:to="loc_srt_MaximumMember_412b763d-83b0-47e1-9cc1-f5990bcc2682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44f22a68-a7f6-44b0-804c-abd9e320a356" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_869bd90e-6491-47db-acf0-ae77b862ee1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_869bd90e-6491-47db-acf0-ae77b862ee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_667acd0d-a0ea-4d4f-9012-805f211a8f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_667acd0d-a0ea-4d4f-9012-805f211a8f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b853011b-c16d-4db9-9bcd-030b0276381d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b853011b-c16d-4db9-9bcd-030b0276381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5a175e-b15d-4405-8c36-85afb85567b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df5a175e-b15d-4405-8c36-85afb85567b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f135b680-5981-4f92-bc0a-ec574e8caff7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f135b680-5981-4f92-bc0a-ec574e8caff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c1cf3a-26cb-43a4-952c-7101fedd5f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84c1cf3a-26cb-43a4-952c-7101fedd5f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cd5c7f6-2da1-442c-8032-695b27cf73f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cd5c7f6-2da1-442c-8032-695b27cf73f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98528921-994c-4bcf-9d40-321ffba79460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98528921-994c-4bcf-9d40-321ffba79460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_51633cc8-6eb5-42f2-a067-8ec9e97b5239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_51633cc8-6eb5-42f2-a067-8ec9e97b5239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b98edb-afb5-4206-821e-3e7ea468ae71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81b98edb-afb5-4206-821e-3e7ea468ae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20771bb9-4cfd-420f-954a-a6ab28e80f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20771bb9-4cfd-420f-954a-a6ab28e80f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_120f9e52-6ece-4b84-a9cd-6f4911c57ce3" xlink:href="nlnk-20190930.xsd#nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives_120f9e52-6ece-4b84-a9cd-6f4911c57ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_12903dc6-5bb5-4996-90af-a8aecd37862b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_49be5b44-d961-4d48-8655-764a03d86852" xlink:to="loc_us-gaap_OperatingLeaseLiability_12903dc6-5bb5-4996-90af-a8aecd37862b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f180f635-9f92-478c-83c1-be68aaebb2a3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_13c4608b-381a-4b4e-aeef-607380b4673d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_13c4608b-381a-4b4e-aeef-607380b4673d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ab63ff1a-a3c3-488c-a7d7-3d533025444d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ab63ff1a-a3c3-488c-a7d7-3d533025444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_efd7b86a-0ce5-4fc3-9b52-b573c1134a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_efd7b86a-0ce5-4fc3-9b52-b573c1134a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_657b60fd-7416-4a90-8bee-e50f3aca875d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_657b60fd-7416-4a90-8bee-e50f3aca875d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_81848eb4-1a99-45ec-800e-d7f1ba3a2fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_81848eb4-1a99-45ec-800e-d7f1ba3a2fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_89eb7beb-e355-43a4-9aaf-77c655136067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_89eb7beb-e355-43a4-9aaf-77c655136067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5a5855e6-8a0a-4d3f-a971-36e3d6424d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_487fca9d-3a66-4ac3-8147-f27842cf6754" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5a5855e6-8a0a-4d3f-a971-36e3d6424d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_81fd5a04-5992-44f3-9f9f-57d13f32363c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d1256e63-bc5c-4002-be8c-a01ed16d4c64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_81fd5a04-5992-44f3-9f9f-57d13f32363c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d1256e63-bc5c-4002-be8c-a01ed16d4c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17680e99-5a2e-4b4e-8574-b9c3585b05a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17680e99-5a2e-4b4e-8574-b9c3585b05a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_d438f811-dcbf-4712-89a7-7574912e21ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_d438f811-dcbf-4712-89a7-7574912e21ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent_d1f074ee-c396-4171-a85a-044e84d00890" xlink:href="nlnk-20190930.xsd#nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:to="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent_d1f074ee-c396-4171-a85a-044e84d00890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent_29f100a5-c675-4d45-aaf3-cfa1044ffd1c" xlink:href="nlnk-20190930.xsd#nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:to="loc_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent_29f100a5-c675-4d45-aaf3-cfa1044ffd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_f6beca8c-1d8f-4be2-9597-574acbeb2b16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24f27dbc-2c02-4c20-898c-ba93916c2a8c" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_f6beca8c-1d8f-4be2-9597-574acbeb2b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStock"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9bcfa444-385f-4e7c-95d8-8c09fecc89b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_fb666c5a-1661-42b3-b4da-59a9ba61b858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9bcfa444-385f-4e7c-95d8-8c09fecc89b5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_fb666c5a-1661-42b3-b4da-59a9ba61b858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a1cdcfc3-8eb6-4f3e-9014-bdfecac40743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a4e3ce5-dc79-4ad7-8999-e2b023a88dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1cdcfc3-8eb6-4f3e-9014-bdfecac40743" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a4e3ce5-dc79-4ad7-8999-e2b023a88dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockNetLossPerShareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4930df0f-acea-4dd5-8d51-918b0a7ff393" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eda0f7fa-775b-4e05-afe0-1c5d8243c04f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4930df0f-acea-4dd5-8d51-918b0a7ff393" xlink:to="loc_us-gaap_NetIncomeLoss_eda0f7fa-775b-4e05-afe0-1c5d8243c04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_01307d14-0e4f-4b0c-991b-636322e0c92f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4930df0f-acea-4dd5-8d51-918b0a7ff393" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_01307d14-0e4f-4b0c-991b-636322e0c92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_31921c01-53e5-47f0-ac5b-39cb11625fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4930df0f-acea-4dd5-8d51-918b0a7ff393" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_31921c01-53e5-47f0-ac5b-39cb11625fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f86438d5-26d1-4bf3-b863-308187a4d8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f86438d5-26d1-4bf3-b863-308187a4d8e6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c52a1dff-ee41-402b-944c-a3fd73306a7e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb8ac50f-b680-45e6-8c0d-714ecbdff453" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb8ac50f-b680-45e6-8c0d-714ecbdff453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1221c654-c0c5-42c4-9b59-6d1710c73348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b598964c-8695-450e-9635-0b1809cb9a91" xlink:to="loc_us-gaap_RestrictedStockMember_1221c654-c0c5-42c4-9b59-6d1710c73348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a5421e8f-9e24-421e-a93d-d03c2c2a7e4a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57592714-7e84-4d7a-9d89-ee5b955b2ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f19d557e-54f0-4dc0-8d49-e35a7fce635d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57592714-7e84-4d7a-9d89-ee5b955b2ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceCharges"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a85eec76-5cfd-4689-a187-0ed486806b40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3244efd4-b7fb-4ebe-a7f1-ecd9032cba0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a85eec76-5cfd-4689-a187-0ed486806b40" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3244efd4-b7fb-4ebe-a7f1-ecd9032cba0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesTables"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1286a9e-b546-4f38-85b4-0fe12cd2565b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ead8cabb-9f55-4c1e-b76d-cdb9c1961fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b1286a9e-b546-4f38-85b4-0fe12cd2565b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ead8cabb-9f55-4c1e-b76d-cdb9c1961fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="simple" xlink:href="nlnk-20190930.xsd#RestructuringandSeveranceChargesDetails"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/RestructuringandSeveranceChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0db1b4f7-f07d-4621-a767-dcc6125b48e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0db1b4f7-f07d-4621-a767-dcc6125b48e9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f514e5bc-dc23-4acf-a39f-63a2e8cdcccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51c4a950-e1df-4fad-87ce-c010371223a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51c4a950-e1df-4fad-87ce-c010371223a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9febaa87-79e2-48ee-9af4-2adfacb58257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a37b737-8f72-4ef2-8df6-e8a34e8d9f4a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9febaa87-79e2-48ee-9af4-2adfacb58257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3a27a49e-bad4-4dab-94a0-b176df9adc32" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8ead1339-9fc6-4a2c-afbe-75bdf1b9499f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2a853205-8f5e-42c8-b272-8be9f572dcfd" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8ead1339-9fc6-4a2c-afbe-75bdf1b9499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1248e452-b3c2-43db-b0e3-59cde2f90478" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fbb153b0-6993-4031-b874-bb20a82ac853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_fbb153b0-6993-4031-b874-bb20a82ac853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f568ec50-eb00-428b-a873-0d8c39d393ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f568ec50-eb00-428b-a873-0d8c39d393ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d33219e3-f6b9-40dd-8e85-18da029f6e4a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_8b9ea973-c7f1-49ca-a43d-7ff095068374" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_RestructuringReserve_8b9ea973-c7f1-49ca-a43d-7ff095068374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1db897dd-7951-4f2a-86da-f530cf6a62de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_RestructuringCharges_1db897dd-7951-4f2a-86da-f530cf6a62de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_23b06ee9-e065-4ae1-862c-fbf8901caeb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_PaymentsForRestructuring_23b06ee9-e065-4ae1-862c-fbf8901caeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3c51b677-8163-458d-955a-8f81252663ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_7f7146e3-10bd-44fb-ae1c-eb5c65fdb6d1" xlink:to="loc_us-gaap_RestructuringReserve_3c51b677-8163-458d-955a-8f81252663ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nlnk-20190930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.linkp.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_065c5991-5b67-4e48-afb9-45c043d260dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1bbdbee3-fdf6-457a-890b-9e34fea2bf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_065c5991-5b67-4e48-afb9-45c043d260dc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1bbdbee3-fdf6-457a-890b-9e34fea2bf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>nlnk-20190930_g1.jpg
<TEXT>
begin 644 nlnk-20190930_g1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_^X
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ML6$%T_I/20L<6N95-,]W"TJ
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MG*C4DY24L:5269TY5+$@R#Q\
M
M
M
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MU,^%:5=E%8G5UE72F)L"?"E-I>C2X4R,MV/*BR&5DI#B%*0M)D9&9&+"X^Z
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M/&$FN'C46U"HN&/P:B2C4B2:"0^)
M
M
M
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M:U=;>URC.WU>SK2I5:<N<9P>#]#B^<9+&,XM2BW%IG8(J:@
M
M
M
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MT
M
M
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MMY=KK(I<=3Q5=S&22$S:V7Y3BJ^SCDJ'/;;7X%)>:D,,P-.+P+T\3V.*%0
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M/);E5MM5S67(TR'(0W)B2FG&74)<0I)1M8/!EYV6*
M
M
M
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M-I_H_&V\OH2E*-4=1<F7Q+3XB+@
M
M
M
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MYG=HH  /YO/,QV79$AUMAAAM;S[[RTM,LLM)-;CKKBS2AMMM"3-2C,B(BZF
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M>0W(8=04,Y8OAR+XK!$V0L+@
M
M
M
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MY1]/,GUF09C-NI5#-=+T&JN]3(D&:$D2#-)G)OF,$CW2+2H
M
M
M
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MSY/<-R48_P &C452@L>/XKF^;DZ$I\0
M
M
M
M                            J5^T2\#FHCE/SLUM2^!$V13X1R"B5\=7
MA3)6TS58%LF4339MMH?\EJAL75K3U=.L)*34MY8EIR_!99)=I5"$A: !+EV3
M^4SO&?G5KNOMK-<+7N]UMZ6S5IQQ)0D3,IF,)P"Y?2Z:8["ZK.VX+;DI1I]6
MKY<L_%X5+)5LUBBL>9H/B D  SYN\_PJL^)/+W++^BJ'F--[YL;;9FN;!EDR
MK:VTM9GKF=8,2TI2S'D8QD,U;L9A/H14S(?0S5XR3/!XKTD<E@R(<7%
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M_GC<:?/Y7:IOC\GK2RUX)=D:5=QJ=[E<R[%PJ4#$.@( %J[V6/E0>$<B=O\
M$N_L3;I-Y8BC8."17E)-M&QM8L2'+N!";(B64C(=?SI4I]1F9>"@;+H1GU/*
MM9X2<'VG@WSV;$_.FS].Z@6D,;K2[CY/7:_W>Y:4)2]%.XC&,5WUV7L!G'+(
M
M
M
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M6WK3MZ\7"O3DXRB^#4HO!I^E-8,^Z!$
M
M
M
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MX2
M
M
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M"<5J6('KTE#9-?"%U/Z.6=_;.(+HY,G/2)3O_C<4(VV^9?R.V10
M    !2 ]J]T.BEW#Q>Y)UL'HUG^!97J'*9;"#2TU::XNH^4XNY./T(7-MZS8
M$]II9>):F:OPJ,DH;(\*ZCQ4CIWY"-U.YV[KFRZTOA6EW2NZ2?-QN(.E5R_P
M82H4VURQJXKBV5(!B'00 "\+[)[N9=OI/E9Q_ER>IX%LS#=LTS#ID;BXVS\9
MDXI=IBJ-1N>K0)6K(BW$="0AR;XBZJ=6,VUE\%Q])S!\_.VU;[FT'=M./^UV
M5:UFUWVU1588^F2NII/FU##E%%MD99S^
M
M
M
M                             A@[^]?&F]M;9\E\EF[49WJ2PAFE9I),
MEW/*FJ4;A%_YB/5+-TNG_P",9'_L%\/6+9<B@:)BP "Q)[-/826^:^X:I)H]
M4F\6\JL'R-!&X<FLVSIR-%-*_JI035L]XB_VF9?]@LJ<BZ/,NVB$O
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MI+#%K#04&><CP
M
M
M
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MHI3;]PD22]TF5%A4   *@/M96VLIJL$X>Z1KI%E$Q#-,DVOLC*&TDIJMN+C
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M!>:'3%JW0;<5OAC*G:TJRX8M?)[FC6;7!X<*;3?<WBTL6:?HV9P]
M
M
M
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MGW%B;+3$B]R6YD*>M<DR":VP@GILUYZ0M*$H\1(0A*86VWBR3# [H%
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M9<TYZ!?Y5CA\-6M5PXXKE-)\>'?PQ-90;4X$
M
M
M
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M/P /3/"S^^/Q,_F8T/\ Q3Q47T_7C[J/Q/4O[.=P?4E]]%JFN*-J?S[
M
M
M
M     'X.495B^#X_;9;FF24.(8K0Q%S[S)LHN*_'\?I8#9I2Y-MKFVD1*ZNB
M(4LB-QYQ"",RZF#:7%\C+L;"^U2[IZ?IM&K<7]666%.E"52I.7[V$()RD_0D
MV0WYQ[07VQ,-V+\FL#<.1[$L_A"OJ?Q@UM@5]DN%.VEA)3%;AP<H<175]PAI
M;B#7)@G)A&2R)#RU)6E,+N*2>&.)Z,TORC];]1T?\]5=.HV=#)*?AW->G3K*
M,5BW*E\*4,>.$9Y9\.,4FFYKA,>:
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MC(B^J?H%]/UX^ZC\)U2K4[;IEN.XJO"E3T*_E)\\%&TJM\/<1K;C:G\_8
M   %#7VD;D7R#U9W"J;&=8[VW)KC&W..NMK1>/X'L_-L0HUV<K)]B,RK%=3C
M]Y70%3I+45I+CQM^8M+:2,S))=,&YE)5,$VE@=5O)EL[:.N](:M[KFE:;>7J
MUBYCXE>VHUIY52MVHYZD)2RIMM+'!8OO(!/GI\Q_\6?)C]_&T_\ JH0>)/\
M?/\ ;/6?]FG3G^C^B?R&U_T0^>GS'_Q9\F/W\;3_ .J@\2?[Y_MC^S3IS_1_
M1/Y#:_Z(?/3YC_XL^3'[^-I_]5!XD_WS_;']FG3G^C^B?R&U_P!$/GI\Q_\
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MI!NYH)N,X4U*+:;3P:X-KDS2"&P.-
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MU;6UEU5W-9V=.%*TI;AU&$(0BHPA"-Y6C&$(Q2C&,8I*,4DDDDE@>N1>?/@
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MXHZ7JS5SHMRI2M+N,7&%>,<,T7'&7AUJ>9*I3<GAC&492A*,G)$)#XR
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MJLUBL<)3<4_52.A=<_I"P3XY8O\ ?N"+5S1^KUG]#W?S:K\21L5C;G\Z0
M                                    !XYY_P#(YCBCP^WKNU,Q$3(,
M=PJ=58)U4CS'MAY6:,8P?RFE$HY"(>16K$I]"2,RBQW5>@DF95BL7@4?!&9N
MXXXZXMUU:W'7%J<<<<4:W''%F:EK6M1FI:UJ/J9GZ3,9!&?  =Y<9=,V?(?D
M+I?1]4E[UC:&R,3Q"5)92:E5E-:6\9O(;MPD]5^KT-"4F:Z:2-1-,*,B,^A&
M;P6(7,U$:RL@4M;7T]5%9@U=3!B5E;"CI\#$.! CMQ8<5A/4_"S'CM)0DO\
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M  FV )J'M5^SL/@/FC^P3<?S:C]*MS3Z&R.'P
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M3VRQJX]R/*/G/UI:5T,N[/-A+4;^TMEWO+4^5-+_ +-L\?1CV8HT<AL3C<
M    !GH^U!?234?\L^K_ ,Z]EC NO:>\=>?([]B]7Z[N?R5L5SQC'L8
M #0W]FUYH)Y$<*7-!93;+F;*XF6$#"T)E...2K#4&1E83]7SDNO.J\Y%!\'V
M-"33221$A54/Q>EY/786T\T,KYHY!><_IL]G]2UNRPIJ.B[@A*MPY1NZ>6-S
M'!<O$S4Z^+XSG5J8>JRQ.,@\>@           5G/:JOH]=.?SF:]_@CR'&-=
M>S7N_>9[8\AWVO:C_5NX^FZ>4!!@'6< "63L8_2N\.?CGF?\)M@":A[5?L[#
MX#YH_L$W'\VH_2K<T^ALCA\
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M;C^;4?I5N:?0V1P^
M                               ,Y[VEKZ4'*OV,ZA^]$\:ZY]K[QV+\
ME7V'4/K*[^/$@"$!ZT   #62[<GT>O _^3/B_P#P1P<;6G[./N+[AP(ZR?:]
MNK^LFI_3:Y[,%Y\W                      Z#Y2<=L&Y9\>MM\<MCH7^*
M.V</GXS-FLLMR)=%9>-FQQK*JUAY26';;$<F@0[2&3A^6<J(WXNJ>I"V45.+
MB^3/UFQ=X:IL#=^G[RT9K\X:?<1J*+;2G'C&I2DUQ4*M.4Z4\..6;PXF5_S"
MX@;JX0;RRK1&\,;E5%_0RGGJ'(&H<]O%M@XJN0\S4YOA%I-C1DW6.6R65$2T
M%XXTE#L5]+<EAYI&LG"4)99'=KIWU#VUU.VO;[JVQ6C4M*L4JE-N/BV]7!.=
M&M%-Y*D,>3X2BXS@Y0E&3\NBP_<@ 6VO9P.UKF&2;,I>X'N_%YU#KO!8\Y7'
M2FO(2XK^P,SLX<FK?V6U"EH);N&XA62WTUD@V_!-N'D2([A%7J\W+MZ3;\27
M+L.?OG+ZZ:=9:)5Z2;8KQJZQ=./YPG!XJA1BU)6SDN5:M)1\2..,*2<)K\<L
MMX09IS"                              *YWM0?T;5%_,SJ_\T]F#'N?
M9^^>Q?([]M%7ZDN?RML9Z0UYUZ  YGKG](6"?'+%_OW!%5S1K=9_0]W\VJ_$
MD;%8VY_.D                                      %33VC/FX2SQ3@
MW@%UU2GX*V+OHX3J#0:R6S8:WP.:I)FHEM*05_,941%U.L<2KJ2TE+37:62?
M85.1(6@ 2J=G;AV[R]YG8/"O:SUS56G7H>V]HKD1TOUT^OQRQC.8QATE+R%1
MI/XYY24>,_&49+<JFYKB.ILF+9O!>DK%8LT/1 2$-W?>WD]IGMY;#IZV:N#?
M[PR3%],UCK#W@D%77;TO)<Q1Y:>JG(EAA6*6$![KT0132(SZJ21WP6,BDN1G
M_B8C  E#[/'&%KE)SOU-C]U6HLL#UB\_NG83+[#<F&_1X#)@R*2KG1GS)B9!
MR#.IM3 DLJZ^.))>/PJ))I.V;PCZ2L5BS1.$!(          >..7O 3BASFQ
M)>+<C=2T.73(\1<7'\\@-)HMF8?U6;S:\6SNM0U>U\=$HR=7"<<>K92DD4F,
M\CJD[)TX36$D?1NGO5C?W2[4%?;-U"K;TW+&I0D\]M6[/QM"6,)/#@II*I%>
MI.+XE-;GG[-#R2T6JUSKA_<R^3NLF$R)CF$2V:ZEWIC<-LU*)A%6RN+C^S$M
M,I(_-J2A6+[JO U5&1>,\.=M*/&'%?NG1WI3YUME[I5/2NHE..AZV\%XR<IV
M-1]^9XU+;%]E7/3BN,J_8JU.08]?XG=VN,Y51W&,Y)13I%7>8_D%9-IKNFLX
M;BF9==:U-BQ&GUTZ*ZDTN,O-H<0HC)1$8QVFN#YGM.TO+34+6G>V%6G7LJL%
M*%2G*,X3B^*E&<6XRBUQ33:?8?CBAD@  !V'JW;>T-(9K4[&T]L',-99W1K-
M57EF#Y!9XW>1D+4A3\4YU7(C//U\PFR3(C.&N/(;ZH=0M!FDZIN+Q7!FGUW;
M^A[GTRIHVXK2WOM*JKX5*O3C4@^YY9)I27.,EA*+XQ:?$M><#O:A\JHUT6O>
M?."(RVH3ZM7GOW5U:Q7Y3$01):*QSO6S7DTN0=5J\<B51KK7&FD?T==)</TY
M4+E\JG[9X(ZJ^1NPNE5U?I/=.WN.,OD%U)RI/MRT+EXSI]T8UU43;XUH1+=G
M'_DSH'E1@T?9''C;.&;9P][R42+'%+5$B932I#9O-5N3T,E,7(<2N393XS@V
MD6),2GTFT1&1C+C*,UC%XHY\;MV3NS8FJ/1MX:?<Z?J*QPC5C@II<'*E46-.
MK#'AGI2G!OE([S%Q^6     ,M3O!<HFN7/<,Y#[.J+$K'"*/*"U7KAYESS(*
M\)U@R6)P[*M6:W#.#E-O!FW2>I^E5DHR))=$EK*TL]1OL.Z?EWV-+I]TAT?1
M+B&34ZM#Y5<)^MXUR_%<9?PJ4)0HO_PUSYN,P1'VP #3#[!/'ESCWVQ]'%95
MRZW)MW/WW(+)&G&E,KD?**[$9PF:9*/Q*]:U70T"B49%U+ZA=.AGLJ$<M)=[
MXG%'S8[OCN[K=JG@S4[+3%3L*;QQP^3INM'WKJI71,V)CS<      !GH^U!?
M234?\L^K_P Z]EC NO:>\=>?([]B]7Z[N?R5L5SQC'L8 "\/V1N.6/<L>QIR
MEX\3&ZQJ1MO:^[<=BSWFV_+K<YCX#JNSU_?V?DEYKR\:RBNJYR4K]T;<=!%[
MDR&;1BIT''O;.8'F;WE>;!\T6A;PIN;AI]A95'%?A4'7NHW%../!>)2E5APX
M8R?:4B[JFM<<N;;'KV!*JKRALY]-<U<UI3,RMM:N4[!L8$ME7NFI4.6PMMQ)
M^E*TF0PN7 Z<6US0O+:G>6LXU+6K",X2B\5*,DI1DGVIIII]Q^8!. !IJ]C+
MF@GF5P$UO,R"T5/VMHQ+.C=HE)>)RPG3L/K()8?E;YN+.5+3EF#2(#S\M:22
M];-3D)-1LJ,;*A//37>N!Q+\T?39]..K%[3M*>30=4QO;7!?!C&M*7C4EV+P
MJZJ*,%RI.DWAF1,2)CSH          5G/:JOH]=.?SF:]_@CR'&-=>S7N_>9
M[8\AWVO:C_5NX^FZ>4!!@'6< "63L8_2N\.?CGF?\)M@":A[5?L[#X#YH_L$
MW'\VH_2K<T^ALCA\
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MCL,H)"$((DI21$1$1"<\IU*E2K4E5JR<JLFVVVVVV\6VWQ;;XMOBV?8 L
M                           *YWM0?T;5%_,SJ_\ -/9@Q[GV?OGL7R._
M;15^I+G\K;&>D->=>@ .9ZY_2%@GQRQ?[]P15<T:W6?T/=_-JOQ)&Q6-N?SI
M                                     >6^9W*?"^&?'/8F_,T\F6G%
MZQ47$\<5)3&D9GGEJER-B6)Q%GU=3\)V?14IUM#BXD!J1)\"DLJ(52Q>!1O
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M9_PFV )J'M5^SL/@/FC^P3<?S:C]*MS3Z&R.'P
M                                                    !G/>TM?2
M@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@/6@   :R7;D^CUX'_R9\7_X
M(X.-K3]G'W%]PX$=9/M>W5_634_IM<]F"\^;@
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M_'/,_P"$VP!-0]JOV=A\!\T?V";C^;4?I5N:?0V1P^
M                                                         ,Y[
MVEKZ4'*OV,ZA^]$\:ZY]K[QV+\E7V'4/K*[^/$@"$!ZT   #62[<GT>O _\
MDSXO_P $<'&UI^SC[B^X<".LGVO;J_K)J?TVN>S!>?-P
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MGXSB>S!>?-P
M    SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2 (0'K0   -9+MR?
M1Z\#_P"3/B__  1P<;6G[./N+[AP(ZR?:]NK^LFI_3:Y[,%Y\W
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M+%_OW!%5S1K=9_0]W\VJ_$D;%8VY_.D
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M;$ZE;(ZE:8M4V9J%"\I))S@GEK4F_P &M1EA4IO'@G**C+G!RC@SRV+#]T
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M)G 3?VS]0V!O/4MFZIC\KT^ZE3S-8>)#UJ55+CA&M2E"K%?O9H]""X_(
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MIU&3:RPFUWH\4>>C;;U3I;9[AI1QK:7JD,S_ 'M&YA*E/]NLK=%_T9YR7
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M#!0V0 %Y7V3G^[URS_;-A/YD/#-M?5?NG+OS]?\ -^W_ *MK?ET6R1EG@0
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MQK1VEHNKVU6UMHX9X6MO<TJTWABHNXKJGGJ/-AFRTU)PIQ9-2)CS2
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M2W7DW(?7$@9[@BI\B5+L,'O74DE3:W7951-4<62I:5194O8TJJJ+^%VG&/S
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MVEA4P[T>3O.?MK\^]$KC481QKZ3?6]TN_*Y.VG[RC<9Y+E\!/\%&C2-B<<0
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MZ+9(RSP(   &<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:
M7R/91_[G'(O^9A[^%FOQGVOJ/W3E5Y]OM&T;ZD7TJX+2PR3PJ5N.^7WHF^%M
M-.XO<;;6%.Y3Y;1(=RC+6E1IT306,W45+D&>N,LGF).S;ZO?)^KB/)-NOBK1
M/D(43D5J1C5ZV3X,?6^X>SO*[Y:WU*N8;YWI3E'8EO5PI4GC%W]2#PE''@U;
M4Y++5FN-22=*#6%24,_JXN+?(;:ROK^TL;R\N9TJTN+FXG2;.VM;.<^N3.L;
M*QFNOS)TZ9)<4XZ\ZM;CBU&I1F9F8P#K7;V]O9V\+2TIPI6M."C"$(J,(1BL
M(QC&*2C%)8))))<$?F@3        !I)]@#G+<<R>#];C^PKMZ\W)QMMHNI<U
ML["3ZS<9+BJ*Y$[6&9V3BC6^]*LL=;=JI$A]:Y,VPHY4EPS4]U/8V\\\,'S1
MQB\VG2ZWZ<=3YW>D4E2VYK5-W=&,5A"G5S9;FC%<DHU&JL8Q2C"G6A"/").6
M)SRZ !7.]J#^C:HOYF=7_FGLP8]S[/WSV+Y'?MHJ_4ES^5MC/2&O.O0 ',]<
M_I"P3XY8O]^X(JN:-;K/Z'N_FU7XDC8K&W/YT@        J3^T>=U,]<XO8]
MOW0V2*;SO.J=EWDCE--,23N*8!<1E.1=2L2(RO.8OL]A.HD7)>)'DT2T1E)=
M39.>1B7%7!>''GVG0'R:]!_SS?0ZM[KHXZ5:U&M.I37"K7@^-VT^#IT))QH\
M'C73FG%T8YJ/(PCI\   %]3V=_M1_-YP"!S<WUC7J^\]J8^HM/XS<1.D[5.J
M[Z&77(9$>0@EUV<[*KW^JR\/GP*):&#4AR;.CHSK>EE6>7K,Y2^<#KW^M^K3
MZ8[4K8[6L*W^MU8/X-U=4W[-->M0MI+A^#4KISP:I4INT4,H\-
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MK:^XJ9D>QJK:#$LZRPANI?B3Z^?';E0ID5Y!FAZ/*C.I6A1&9*2HC(8Y*?>
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MC&/8P %OSV2O](?-OXF:.^_FS!F6G.7O??.>/G__ $/MCYS>_$MB[$,PYG
M9J'?OX7GQ$Y\YU;8Y5*@:IY&)E;MP V6$M5T"UO[!Y.R<5C&V?D-G1YL;\EJ
M.A+:8M;90T$GIT4>MKPR5.')\3M/Y4>I/]H72>UM[VIGU[1L+*OB\92C3BOD
MU5X\?AT<L7)MYJE.H\>PA0$)Z8  ]%<2>1N6\1^2>FN1V%&ZY=ZHSBIR1VM;
MD.149#C_ (UP,MQ24^TI"T0<LQ6;,K7S(R,F92C+TBZ$G"2DNP_'=0-FZ?U!
MV7J6S=3P5K?VLZ:EACX=3UJ55)_A4JL85(^F*-9[6FP\3VYKO!-JX%:(NL(V
M3A^-YUB-NVDVTV6-Y740[REF&TKW;*WZ^<VI3:O=-J,TJZ&1C:IIK%<F<!-:
MT?4-O:Q=:#JL'2U.RN*E"K#][4I3<)K'MPE%X/D^:.;"IK     "LY[55]'K
MIS^<S7O\$>0XQKKV:]W[S/;'D.^U[4?ZMW'TW3R@(, ZS@ 2R=C'Z5WAS\<\
MS_A-L 34/:K]G8? ?-']@FX_FU'Z5;FGT-D</@    "O-W]^Z=)X3:8C: TK
MD"H')O?%#/2Q=5DHV;34.KI"Y%3:YW'>944B#E>12&WZ['W$&AR,ZS*G)6AV
M&PE['KU<D<L?69Z]\IW0F'4W<DMV[EHY]D:55CC"2QC=W2PG&@T^$J5-.-2N
MGBI)PI-.-23CG>*4I:E+6HU+49J4I1FI2E*/JI2E'U,S,S])C7G8%))8+D?$
M"I\DI4M24(2:EJ,DI2DC4I2E'T2E*2ZF9F9^@@*-I+%\BT-VV/9N-J<AJ6AW
M'S/N\DT%JRYCQ[/'M6TL:-&W?EE<\2'F)M\F\@3:S5]5+961M-S(LVW=(E$Y
M$AD;3R\JG;.7&?!?NGAOK1YSM!VA<U=N=-J5'5M=IMQJ74VW94I+@U3R2C*Y
MDGS<)0I+AA4J?"BK96A.U%V\.-U=!B:VXH:CD6D%#/AS#8&,P]HYPY(:\2ES
M$97L)&26]<](<6:EHA.16.O0DMI2E"4Y4:5./)(\![KZ]]7]YUIU-:U_4%0F
MW^)MZKM:&#[/"M_#A)+L<U*7:VVVW[&?T[J.55IHY6K-<R:5+,:,FG?PC&7J
MM,>&;2H;":]RL5$)F*IA!MI\'A0:$^$BZ$+\%RPX'SJ&XMP4Z_RJ%]>1N<6\
MZK5%+%XXO-FQQ>+Q>/'%XD>?)'LK]MODU538V2\:\,UKD4E!^JYWH>!!U!E-
M=),B0<[R,4A1\1OI7E]4]+BJLVO3XO!XB2HHY4:<NS!^@^O;,\RO6?9-Q&=E
MK5S>V<7QH7TI7=*2_>XU9.K37_@U:;[,<,44M.Z+V/M_=O3U_:&*SI6\>,*Y
MK32=F550N'DFOCG/H8@5NUL<BKEM5#+LIY,6/=17%UDMXVTN%"??9B'AU:$J
M?%<8G2KH9YGMI]7LFAW\8Z7OA1;^33GC3N,JQE*UJ/!S:2<I49)58+%KQ(0E
M4(/A >G@ /1/%/D_M7ASOG7_ "$TY<KJLQP2V;E+ANN/%3Y5C\A26<APS)HK
M*T'/QS)JPUQI+?4EH\27F5-OM-.(NA)PDI+F?CM^['T'J-M2[VCN.FJFG75-
MK'!9Z51<:=:FWZM2G+"47R?&,DX2E%ZH_$GD_K?F3QYUER-U7*4[BNQJ%NP7
M62'4.6>+9##=<KLHPZ[)"6R3<8O?Q9$-Y1))M_RB>:-3+C:U;2$E.*DN3.$?
M4#8^L].-WWVS=>CA?V=7+F2PC5IM9J5:'\"K3<9KMCCEEA*+2]'"X_&@ 1_=
MU#01\F>WMRNU)&A*L+RPU1=9=B,1M*3DR<UUD[%V3B$&*XHC-EVTR'%(\12B
M,NK;ZDG[E2B..K'-3:]!];Z$;L_4GJ]H&X)RR6L+^%*JWR5&Y3MJTGWJ-.K*
M?NQ3YI&5$-6=Y  /ZL/O1GF9,9YV/(CNMOL/L.+:>8>:63C3S+K9I6VZVM)*
M2I)D9&74@+91C.+A-)P:P:?%-/FFNU,UW>*NXFN0G&;C_O)MUEUS;6G-<Y_/
M)A+2$1K?)\3JK6[KU-,FIEAZLN)+\=QM)F3;C2DE]0;:+S14N]'\]V_-NRVC
MO;5MKR32T_4;BA'''C"E5E&$L7Q:E!1DGVIIG?@N/R8      &9;W[=SJW/W
M1^1[L>8J52:OF8MIBA0:S<*$G7V-5T+*8:3\*22E.PI=RYX2+W)N&74SZF>M
MKRS57Z.!VS\J.VUMOH9HT9QRW5]&K>5/X7RBI)TG_)U17O$.8A/1@   >A^(
M^YGN._*/CUO1IU33.J-R:[SBS21+,I5#0Y363<BKG2;2ITX]I0MR8SO@+S/+
M=5X3)70Q="662EW,_']0=MQWAL76-K26,K_3;BA'T5*E*2IR79C&IEDL>&*6
M/ UU&W&WFVWF7$.M.H0XTZVM*VW&UI)2'&UI,TK0M)D9&1F1D8VQ_/C*+BW&
M2:DG@T^P^8%     ")+OG[@/3/:XY4VD:4J/:YYBE1I^J;2:4KF%M7):C#LA
MBD:C+W/XEV5FZHBZF:&S(A%7>6DST#Y7-N_K)UST&A..-O:W$[N7H^2TYUJ;
M_P ]&DEZ69APUAV^  EL[&NAD\@.YWQEIIT14K'M;9+.WAD:R03B(K.I:V1E
M>,N/MJ2I"X\O8$6GBK)70O#(/ZOU#EH1S55Z.)Y^\T.ZWM+HAK=S2EEO+VA&
MRI^EW<E2J8>E4'6DO\4T\ALSB"   &<][2U]*#E7[&=0_>B>-=<^U]X[%^2K
M[#J'UE=_'B0!" ]:   !K)=N3Z/7@?\ R9\7_P"".#C:T_9Q]Q?<.!'63[7M
MU?UDU/Z;7/9@O/FX                       8ZFQOTA9W\<LH^_<X:A\V
M?T6Z-^A[3YM2^)$X8*&R  O*^R<_W>N6?[9L)_,AX9MKZK]TY=^?K_F_;_U;
M6_+HMDC+/ @   9SWM+7TH.5?L9U#]Z)XUUS[7WCL7Y*OL.H?65W\>) $(#U
MH !?(]E'_N<<B_YF'OX6:_&?:^H_=.57GV^T;1OJ1?2K@E6[L7<<Q'MP\9;;
M/R757.[<\388EH3!)SGF%=Y@<5*I64W,)E:9;F%8#'DMS;)23;3(=5&@D\R[
M-:<3)5J*G''\+L/@W0+HWJ'67>U/2<*E/;-IEJWU>/X%''A2A)\/&KM.%/GE
M2G5RRC2DGF'9YG>8;0S7*]C;!R*SRW.<YR"URK+<GN7SDVE[D%W,>L+2SFO=
M$I-Z7+?4HR224)(_"E*4D1%K6VWB^9V^TK2M.T/3+?1M(HPM]+M:,:5*E!81
MA3@E&,8KN227'B^;;9W[Q(X5<DN<.R&=8\<=;VN:VS)Q7<DOW.E7A&"U<I;B
M4W6<9=+2FIQ^ :([JF6UK5,FJ:4U$8D/^%H[H0E-X11^3Z@]2]F=,-&>N;RO
M:=M;O%4Z?K5J\E^!0I+X=27%8M)0ABI5)0CC(N.<3/9;^,6 UE;><NMBY=OS
M,U-,NV.&X/8S]:ZIA.J)2I, IU<;6R,C2TKPI;FHL:3QI\1JB),R\&7&UBO7
M>+.<V_\ SS[WU:O.UZ>V=OI.FXM1K5XQN;J2[)99?ZO3Q[8.G6PX85'@\94&
M^REVL6J@J1/#+6!PDLG')YR;FCUOX#6:S4>0.Y4N^4]U/_S#DFX1>CQ=/0)?
M!I=R/A,O,OUUE<?*GN2^\3''!*BH?YM4O#P]&7#T$)?<A]F=UJ6 9)M?M[JR
M:@S;&X4JW?X[9-D4W+,?S&NB)<DOUNNLJR-^7E=3EB6"44:+:S[*/8K2AHGH
MBS-QR&I;+#&GS[CTUT9\Z^M?G:CH'5WP*NF5I*"U"G3C2J49/!*5Q2II4ITL
M?6E2A3E36,LM1<(TI),:1#D/Q);#T67%>=C2HLEI;$B-(86IIYA]EU*7&7F7
M$FE25$2DJ(R,NHPCI="<*D%4IM2IR2::>*:?%--<&FN3/X 7@ 6??97=ORL4
MYI[FT\_*?:I-OZ&EW2(B%EY,K+]79723*-;[*E))7JV,99?^%9>)2#7X23X5
MJ4G*M7A-KO1X>\]VWJ=_TUTW<48IW6G:JH8]JI7-*:G@_35I4,5R>&..*2=^
M$9QRA  KG>U!_1M47\S.K_S3V8,>Y]G[Y[%\COVT5?J2Y_*VQGI#7G7H #F>
MN?TA8)\<L7^_<$57-&MUG]#W?S:K\21L5C;G\Z0      $77=E[CV)=N+C-:
MYVE=?<;NV BTQ+0F$2U)=3:Y>4-*I>6W41*B>7AF LRVIMAT\!27EQH).-.3
M$.HBJU%3CC^%V'W/H#T:U#K+O:GI;4Z>V+1QJW]9<,M''A2@^7C5VG"GSRI3
MJX25-Q>8AG&;Y;LO,LJV'GV06>69OF^06V59;DUS(5+M;[(;V<]96UK82%=/
M,E39LA;BNA$DC5T(B(B(:UMMXOF=O=+TS3]%TVAH^DT86^F6M&%*E3@L(4Z<
M(J,(178HQ22.*BAG@ 61O9_NT^CE[M!/*??.,^M<:--Y RG&L>N8IJKMT[3K
M5-RX].Y%=3X++ L'6;4JX\?6-/F*CU_A?:.Q;9R;>EG>>7JK]T\8^;7KX^GF
MA_J)M2OEWKJ5%^)4@_A6=K+%.::]6O7XQI8?"IPSUL82\%RT&!GG(X
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M\*>=[I='7=I6_4O3*:_.FD-4KG!<9V=6:49/M;H5I)I=D*U63>$47PQG'*L
M#XJ2E:5(6E*T+2:5)41*2I*BZ*2I)]2-)D?0R,"J;3Q7,R6.>6A#XO\ ,SDO
MH9J)ZE4ZYV_F-7BC!DM)G@<^S<O=?2%)<+Q(7,P>UKWE)ZJ))K,B4LB)1ZJI
M'+-Q])W^Z5;K_7CIOHFZY2S7%YIU&55_^OC%0N%[U>-1=G+DN1Y*%A]   T?
M?9P]T'MCMA:]QJ5*]:M=$;#V3I^>ZXXM<E45-PULG'TNI7T(F8..;&B0F#07
M@\J(2>IK2L;&WEC2P[CC5YRMM?F#KA>7L(Y:&JV=M=Q2Y8Y';5,/3*I;SG+'
MCC/'DT3PB<\J@    'X.59+487B^29CD,E,*@Q.AN,EO)BC228E115\BTLI*
MC6I""2Q"BK6?51%Z/29 W@L3+L+*XU*^HZ=:1S7=Q5A3@N^<Y*,5[[:1C_[8
MV'<;=VGLO:^1'XL@V?G^9;#O5=?%XKC-<BL<DLS\1^E76;9+]/\ M&H;Q;;Y
ML_H=T#1[;;VA66@6?^R6-I1MX?XE&G&G'_\ +%'7XH;<EWR3LX<AL;[:M!W(
MW\BQE_%;5$+*+35"8EBUF%)J:\OHV,8SL0[1:E5MDNVLI;,MRN:;(XU-(9F'
M(6KSX[$SHR5/Q.P\]67F-VA>]::W1B-&NK^GFI1NL8NC.ZA3=6I;Y?6CDBG!
M5&_A5HRIY$LLYQ$"$]"@ :N';#W07(+M]<1-J.2U3[&YTCA]#D4U2E*5+S#7
M\16N\TD*4M2U^)W+,4FJ/JHS+KT,S/TC:TI9J:?H."G6_;7ZH]7-PZ"HY*-/
M4ZU2G'NHUW\HHKWJ56![N%Y\K     *G7M7VX4TG'KB]HB-.2B5L7;>4;,L8
M3*B-Y=7JO%$X]&]<)/534219;3);:5]$O.Q3-/B-E7AQ;I_!4>]GOKR$;==U
MN_7-U3AC"ST^E;1D^6:ZJ^(\.]J-K@\.2E@\,RQHS#!.HH %Q+V3K0Z).2\L
M.3=E!Z*J*7#-%X?8&@U$X=]-=SW8D4E'T2VN*G'\8473Q&HGSZ^$B+QYEK'G
M+WCG3Y^MU.%EH&R*,N%2I6OJT?\ PTJ%N_3CXES_ .BN?9=,&8<U@   SGO:
M6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2 (0'K0   -9+MR?1Z\#_P"3
M/B__  1P<;6G[./N+[AP(ZR?:]NK^LFI_3:Y[,%Y\W
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MFXM8W;KUWN7<%:5QK-[6E5JU)=LI=B7*,(K",(1PC"$8PBE&*2[-%32
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M5MN(4I"T*(R,R,;0X.5:52A4E1K1E"M"3C*,DTXM/!II\4T^#3XIGV@+
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MH9]K+&#7<SDMYZ-M?FOJG9[AI1PH:II<,S[ZUM.5*?[5%V_I][ LOC)/%(
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M71;)&6>!    SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2 (0'K0
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M<_'/,_X3; $U#VJ_9V'P'S1_8)N/YM1^E6YI]#9'#X "N=[4']&U1?S,ZO\
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MYXT[5\&H-*I57&JHQ;I*S ,D\4                 9Z/M07TDU'_+/J_\
M.O98P+KVGO'7GR._8O5^N[G\E;%<\8Q[&  M^>R5_I#YM_$S1WW\V8,RTYR]
M[[YSQ\__ .A]L?.;WXEL78AF',X   *P?M.W"\MO<7\0Y;8C5)?SCC3:IJ<V
M<BL*7,L]-YS8Q8,EYY31J<DIPK-'(4IM!H-#$.QL'E*2E*NN-<PQCG7-'N#R
M0]2?U>WQ<=/]0J8:7K5//1Q?"-Y0BY)+'EXU'/%O'&4Z=&*3;6%!T8!U?
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M1]2Z'-;RPJKT\#S7YMMMO<?0S5I4XYKK3Y4;R'H\&I%57[UO.LS2\&R.*@
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MLL)N/>CPSY\-M?G#IWI>YZ<<:^FZFZ;?[VE=TVIO'_Q:%".';CZ"^D,XY3
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M=.A>@;9+!8+DC^>76M5N]=UB[UR_>:^O;FK7J/GC4K3E4F^/?*39S45-8
M&<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:   !K)=N3Z/7@
M?_)GQ?\ X(X.-K3]G'W%]PX$=9/M>W5_634_IM<]F"\^;@
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MV-8EB=-78]C>/U,=$2LIJ6IBM0JZN@QT>Y:CQ(K*4)+TGT+J9F?4Q 2'(@
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MCGEAV#TFC3U2I!:KO&*3=Y7@L*4N'^RT<91HX-<)MSK\6O%47E4+PA/28
M>AN,7%;?',3:M/IKCWK^VS[-+7I(E)AH*-1XS3(>:9F9-F%_)\NKQG'("GDD
MY*E.(2IQ2&6B<?<::7=&,IO"*XGY#>^_-J].M!J;CW?=T[33:?!8\9U)X-JG
M1IKX52I+!X1BG@DY2PC&4EH;]JOLR:1[<V/QLWO7*S;7*2\J4QLHVO+KS^",
M0;EM];#%M2UT]HI5'3>[\F19NI1:6R4FIPHS"RA-;"E1C3X\Y'(+KQYD=S]8
M[R6F6JGI^Q:53&E:J7PZK7JU;J47A.?;&FL:5+DL\EXLIH1,>;
M         ST?:@OI)J/^6?5_YU[+&!=>T]XZ\^1W[%ZOUW<_DK8KGC&/8P %
MOSV2O](?-OXF:.^_FS!F6G.7O??.>/G_ /T/MCYS>_$MB[$,PYG   !P[8F
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M/(<8UU[->[]YGMCR'?:]J/\ 5NX^FZ>4!!@'6< "63L8_2N\.?CGF?\ ";8
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MW77O]1=$ET\VK6PW?J-'\?4@_A6EK--/!KU:]=8J'X4*>:I\%RI2=_L9YR8
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M*$;KB(T5I2W7GY,J0MV7865A+=<D2Y3ZW'Y4EU;KBE+6I1P-XO$D.QP
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MZ_X\.&?_ -]!I'_K@/$I_OE^VA_8WU>_HKN3_P"F7O\ H!_F-]O7_'APS_\
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MPRSG2     9SWM+7TH.5?L9U#]Z)XUUS[7WCL7Y*OL.H?65W\>) $(#UH
M&LEVY/H]>!_\F?%_^".#C:T_9Q]Q?<.!'63[7MU?UDU/Z;7/9@O/FX
M                 8ZFQOTA9W\<LH^_<X:A\V?T6Z-^A[3YM2^)$X8*&R
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M*4FW*4F\7*3>+;;>+;XM\6?; C                      ST?:@OI)J/\
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MG%X/FCOWH6M:?N31;3<&DS533+VWIUZ4N'&G5BIQQP;P>#XK'@\5V' A0VP
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M0W\)Y-DUGY;;UUDET\V3DF2X1=>B6VTMLMM-(@;;>+)#NT4
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MED^O_P"*1E_M&/<^S]\]@>2&A3J]:W4GCFI:/=2C[KG0AQ_[,V9X0UYU_
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MG]%NC?H>T^;4OB1.&"AL@ +ROLG/]WKEG^V;"?S(>&;:^J_=.7?GZ_YOV_\
M5M;\NBV2,L\"   !G/>TM?2@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@
M/6@ $Y7LYOTKNCOB;NW^$N6B>W]JO?/+OG&^P35/G-E]*I&DH-B<8@
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M\J;4TZOIKQZ>TZ_^N1IIYU<MX6\Z[QP=O@W&GP457:\3&4J&6]$,XY;@
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M;^$\FR:S\MMZZR2Z>;)R3)<(NO1+;:6V6VFD0-MO%DAW:*
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M? ]O[#Z(]+^FRC4VII%M2U"*_P!IJ)U[EOM:K57*<,W;&FX0[HI<#P8(SZL
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M?/4KKUU-ZJRE1W-J$H:,Y8JSMTZ-JN.*S4XMRK./X,J\ZLX]DD2."0^-@
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MAP?Z_P!M*UZU;GI2P3>L7$^'+"I-U%[^$N/IQY\R0T2'R
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MCQ( A >M  )RO9S?I7='?$W=O\)<M$]O[5>^>7?.-]@FJ?.;+Z52-)0;$XQ
M       !2=]K4_2'PD^)F\?OYK,8=WSC[_WCICY /T/N?YS9?$N2H&,,Z'
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M]U;7UK9>XKO:VXJ+H:S95G3J0?+%<5*+_"ISBU.G-<)PE&2X-';8J?GP
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MA@H;( "\K[)S_=ZY9_MFPG\R'AFVOJOW3EWY^O\ F_;_ -6UORZ+9(RSP(
M &<][2U]*#E7[&=0_>B>-=<^U]X[%^2K[#J'UE=_'B0!" ]:  3E>SF_2NZ.
M^)N[?X2Y:)[?VJ]\\N^<;[!-4^<V7TJD:2@V)QB        "D[[6I^D/A)\3
M-X_?S68P[OG'W_O'3'R ?H?<_P YLOB7)4#&&=#@ )9.QC]*[PY^.>9_PFV
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ML5AF-%C,MQXT:.VAEB.PRA+;+##+:4MM,M-I)*4I(DI21$1=!0J?V
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M^(9%':4HHEY06!*9=+_RWF_ ^RIR.\TXN!IIX,EYGH 4
M              !GH^U!?234?\L^K_SKV6,"Z]I[QUY\COV+U?KNY_)6Q7/&
M,>Q@ +?GLE?Z0^;?Q,T=]_-F#,M.<O>^^<\?/_\ H?;'SF]^);%V(9AS.
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M+KZ/3T$U1Y8-^@\P](MOK=/5';^@SCFH7&K6RJ+GC2C5C.M_[J,S)E&J._0
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M7F9#+4B.ZV^P^VAYA]E:767F74DMMUIQ!J0XVXA1&E1&9&1]2$!(?T
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M!RU/1JD;^FDN+A24H7$>_!6\ZE7#ME2BO2M)P;$XO@
M    !^9=TU7D=-;X]>0F;*EOJR?37%=)(U1["KM(KL&PA/DE25&S*B/K;41&
M1^%1^D">VN:]G<T[RUDX7-*<9PDN<91:E&2]*:31D1<E=-V?'CD+N[1-P;JY
MVHMJ9WKU4ETC(["-BN26-1 M6S-#?CCV]?%:E-+\*26T\E1$1&-3)99./<S^
MA'96XZ&\-H:9NJWP\+4+"A<8+\%U:<9RC[L)-Q:[&FCI$6GZ<M;>R@[3*DY,
M\H-,NR$,M;'TGC6P66W'$-E+L-2YLU1LL,DM1&]*3 VY*=)">JO*;<5T\*%&
M65:OX3CZ#P5Y]]"^5;)T/<D4W*SU.I;OT1NZ+FV^Y9K2*Q?:TN;)K/:5=M)U
MSVQLJQ!N:J--WCMO5FLV6FC+UB1$J[67MBP+W*5.M1#8UF3;RR-*3)U+2E&3
MO@7/<O"EAWL\T>2W;[UGK=0U!QS4]+T^ZN6WR3E%6L?0WC<XI<7P<DO@XK.=
M&N.Q@ &K/VN-)JX\]O/B+JF1#576E3IC&<ER*O61DN#EVR"D;+S*(X1DD_-C
MY5E\Q"O1Z5$8VE*.6FEZ#@OUTW,MW]7MPZ]"6>A4U*I3IR_?4K?"VHM>ATJ,
M&CWN)#Y0   $ WM*&FT[.[9.5YBS&2]8Z&VKK+:4=;:".64"RM).J;=EM24*
M=5$3$V44I]OJE'2(EQ77RD](+E8TL>YGK+R7;C>A];;?3I2PHZK87-J^[-&*
MNH/NQQMLL7S^&XKUF9S0UQV-  O"^R<;319:/Y;:3<D,I<PS:V#;3B15.&F0
M\C9N(RL2L)#32E$3K,96I8J7%((S;4Z@EF7C;ZYMJ_@N/I.8/G[T)T=T;?W,
MD\+FPKVK?8ODU558IOL;^5RPQYX/#DR/?VJ7:7XS<U]+:KBR?/@:MX^0+>8T
M3O4H>3[&S3)Y5C'-CP=&UKQO&:9TU^(S63I%X2\)&JRZ>,TNY'UWR(:%\BZ9
MZEKTUA5O]7E!/#G3MZ-)1>/_ (E2LL.S#GQX5@ABGN$L'^S2Z&5MCN/UFQYL
M1+U%QTU=G.QUOOH-<1639%%9UCC4 T^%:3G>5FLVQC^(B2DZQ2R42TH(\BVC
MC4Q[D>1?.INM:!T:GHU*6%UK-]0M\%S\.FW<U)?XN-&%.6'/Q$L,&\-$\; X
M]        !G/>TM?2@Y5^QG4/WHGC77/M?>.Q?DJ^PZA]97?QXD 0@/6@
M:R7;D^CUX'_R9\7_ .".#C:T_9Q]Q?<.!'63[7MU?UDU/Z;7/9@O/FX
M                  8ZFQOTA9W\<LH^_<X:A\V?T6Z-^A[3YM2^)$X8*&R
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MK]27/Y6V,](:\Z]  <SUS^D+!/CEB_W[@BJYHUNL_H>[^;5?B2-BL;<_G2
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M<ZY0PO,8L;(S,V9M1I%*R;=KH"4DIIS)G4^L/&I1UK;*4,V#V'5N/P:?[?\
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M-V3+U[+=9IY2B(DIA.UIF:W7'5"&<<'BN1?%XHL#"PN
M           #/1]J"^DFH_Y9]7_G7LL8%U[3WCKSY'?L7J_7=S^2MBN>,8]C
M  6_/9*_TA\V_B9H[[^;,&9:<Y>]]\YX^?\ _0^V/G-[\2V+L0S#F<
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M\0'JH "63L8_2N\.?CGF?\)M@":A[5?L[#X#YH_L$W'\VH_2K<T^ALCA\
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MET6R1EG@0   ,Y[VEKZ4'*OV,ZA^]$\:ZY]K[QV+\E7V'4/K*[^/$@"$!ZT
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MK6=5PES<9QYPJTVTLU.K!J<)8+&,EBD\4N]!<?E@
M .'[ V!A&J<*R;8^R<JHL(P3#:F5>Y3EF2V,>JHZ.IAI\3\R?.E+0TT@C,DH
M3U-;CBDH02EJ2DZ-I+%\C8Z3I&IZ]J=#1M%H5;K5;FHH4J5.+E.<WR48KB^]
M]B6+>"39GN=X+OA["YU6]SH[0DR^UMQ)JYST63'2X[5Y;O-^%)D-Q[_-S:)F
M75X6ZUX'8..*4:35TD6'FR"89A8%:NY_!CPA]TZZ^7?RP:1TLMZ>Z-UQI7O4
M"<4T^$J5BI)8TZ..*E63Q4[CG^!2RPS2JU]!CGKD   /?? [MK\H^X=G:L8T
M9A_JV'T\IEO.MP9:4NIUE@K"_ LVK*[;BR';?('FG"./45S4JQ>(_,-IN,AU
M]J2G3E4>$>1\FZJ]:-B](-*^7;IN,VHU(MT+2EA.YKOOC#%*%-/UJM1QIKEF
M<W&$KY? ;M!\*>V=4T.;6<C']A;ZFS:ZA5O_ &VFFJ93&1WCQ5]=0ZGQVTGR
MZ; '[9]]4:.F&]*O9OG+8<FOM*2RC.IT84^/X7><J>K'F&ZE]:[BKIE!5K/:
MD8RG\@M,\TZ<%FE4NJD8J==02S2<U&A#!2C2A).3F8$QYO             "
ML1[0;V^6\ZPUOG%JRD->:8# @TF]JZO8ZN9%KV*E,.BSY3+*?&]:X*M2(D]P
MTK4NE<;<6M#-:1*DA+L9;)=I3E$I8 !Z=X;\F\KX?\D-7[]Q14IX\,R"/^,]
M'&>)HLKP6R44#,L5>\Q11S.YH7GD,+<)28\PF7R+Q-),J-8K )X,TRL&S7&-
MDX7B6P\*MH][A^<XW29=B]U$,SC6N/Y%6QK:HGL^(B6E$J#+0OPJ(E)Z]#(C
M(R&.2G*@                           &>C[4%])-1_RSZO\ SKV6,"Z]
MI[QUY\COV+U?KNY_)6Q7/&,>Q@ +?GLE?Z0^;?Q,T=]_-F#,M.<O>^^<\?/_
M /H?;'SF]^);%V(9AS.            J+^U,<+T9)KG57.3#ZI)W.N)<33^X
MWXK#9+D8-DUB])UUD<]TE-^%K&\SF2*M2C)QQY5_&3[E# Q+J&*4UV'0;R*]
M279:S?\ 2[4:G^K7L7=V:;?"O3BE<4XKCQJ45&KV)>!-\7(I$C".G(
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M@G&GF76S4AQIQ"B4E23,C(^I#-.9,HRA)PFFIIX-/@TUS378T?U M
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M\K;&>D->=>@ .9ZY_2%@GQRQ?[]P15<T:W6?T/=_-JOQ)&Q6-N?SI
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MD+0HC(S(QL3C;5I5*%25&M&4*T).,HR33BT\&FGQ33X-/BF?: L
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M8L&'5=5(C19L%DO"GP$(JBXXE\7P+$PC+@
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MPJ8]Z.NOD>W(]6Z0U="J2QK:3J=:G&/=2KJ-S%^A.K4K\.]-]I7$&.>R@
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M]27/Y6V,](:\Z]  <SUS^D+!/CEB_P!^X(JN:-;K/Z'N_FU7XDC8K&W/YT@
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M<BE<=.X!IF?/L#@XCMB:_I#,B5(.-%=A;#<C0L8>F.J/U=N+6;!C4\IUQPO
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MQT&1GG(T          SGO:6OI0<J_8SJ'[T3QKKGVOO'8OR5?8=0^LKOX\2
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MA5*=2MTUU_7+2E1GC+&-.M=4H5[.<UQC4IPFU3GCC4I.,U)S52,+$(R#Q^
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M T77K_O*AGZQ)'D3#BPJ
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MQ9J,DI+J9F?U3%Q^*JUJM>HZM>4IU9<Y2;;?NM\6?; C
M
M
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M=Q99DVDB-"_$I7^^0BJ<R^/(L>B,N
M
M
M
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MS9]->H_AZ;JM1:'N>;4? N9Q\&I)]E"ZPC3GB\$H551J2D\(0ES(*Q >I0
M  #3Y['F[<NWWVP^,>7YU-E6N48_1Y/K&;;S'E295M7:OS3(,(QB;*D.&I^3
M-/$Z:"W(>=4IU^0VXXM2C69GLZ#<J2;YG#[S/[9T_:G7#7-/TJ,:=C6JTKF,
M$L%"5S1IUZJ2Y*/BSFXI8*,6DDL"642GP$J[>TZ18*]6<3IKDKP64?/]FQ8D
M+QH+UB#+QW%G;"5X#+S%>IOPHR.I&22\_P!/4S3TDI\V6R*>XE+  +D7LR7Z
M"^3O[6<0_,]T15.:+HEF\1EX
M
M
M
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MI]4Q%4YE\>19.$9<
M
M
M
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M^L7QY$U0L+@
M
M
M
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MXDBY'I<4*@
M
M
M
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MJMC96VI7EM7I:=>1G*A5G3E&G6C3FZ<W2FTHU%"I&4)96\LDT\&<P%37
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M+47(/@ANJ)1ET\Z>V7U3(4D\%B57%FDP,<D
M
M
M
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MQ1S\W#MO7]IZI4T3<UG<6.JT_6I5H2ISP>.$DI)9H2P>6<<8R7&+:.S14T@
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MCL;J1LCJ1IOYTV9J-O>T$EGC%Y:M)ODJU&:C5I-\<,\4I8-Q;7$\PBP_<
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MLI2Z>,T,N/<["N(RUMJ-V#<9,S70&UH4@TOTTI*B41I,HJC["^*[2TN(RX
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MO8-0RGJF0Y/PO(&*Z^5$BND:%RX[+\%2NAH?6E25'8XM<RJ:9Z[%"H
M          $..^>^1POXZ;AV!I#/ZK=KV9ZVOWL<R%W'L&Q^QI5V###$A:JZ
M=*S:ND28_ER$]%+8;/KU] N4&UB6YD=1_P"HR[?_ /4O(;]W.,?VABOAR&9#
M_49=O_\ J7D-^[G&/[0P\.0S(?ZC+M__ -2\AOW<XQ_:&'AR&9#_ %&7;_\
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M52K'ZC(<6QF4B/+K\JO'G+$['+XAH;-I*3:)Q1K(TDE5'%KBRJ:9)D+2H
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MP[;3F&SD7N136T&:"M,GOY$JQEF7H5*E.&70CZ#';Q>)*N!W.*
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M)Q:6(&)[):;2Q5UV435*)J#;-)8C6"_"S);1+43\N*4.U%ZEV,M"",N
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M>J9F03-HZ;M(M-'FV$9EEVQD5U-+?0T1^)34=Q1%T28LFTUP+HIXEO 1%X
M       !!YW]]'[@W[P[UMAVE-:YEM/*JWDMAV2V&/X/0S\AMH>/P]7;DJY5
MS(A5[3SS5='L;F(PMTR\*79#:3/JHA?!I/B6RY%0_P#RU.X!_@ZY#?NPR?\
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M2Y<IUN/&BQH[:G7Y$A]U2&F6&6D&I:U&24I(S,R(@!2 [M'>5S3DGD>4\?\
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M.7,]9^S)?IUY._LFQ#\\'1;4Y%8\RY"(B\
M"LA[3;^@OC%^UG+_ ,SVA)3YLLD0*]FOZ3'BE\;<M_ACG DEZK*1YFBR,<D
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M-CU3BV+T<%)IC5E)20F8%?%0:C4XZM$=DO&XLU..K,UK4I2C,\?GQ)#EX
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MAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR&(RX
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M1C](#3_R]:Y_.;80FI^J62YGH;V9+].O)W]DV(?G@Z*5.0CS+D(B+P
M       S]>^)RB?Y&<Z\\QRKGJDX%QZ)S3&*LH61QW+RAE..;(M3;2GP>M2,
MX7*@^82ED[$K8RNI?[I3P6$2.3Q9^EV0>%4'EIRWB95G%0S:Z?X\QZS8N90I
MK*'ZW(LJ=F/-:WPZ:PZEUJ3$L;F _8RF76UL28%2_'<Z$^GJF\%Z1%8LO\"
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ME"38=O:G3.Q+*A4;BGV?(?B6T5F0P9>,U2&6T>$_'U*L_5*1YFAX("0
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MJ)D6T$VVAM)K-+:$H2;CCCKAD@B21K==4MUQ9D7I4HS49^DS,Q85/F
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M3P]4CES/6?LR7Z=>3O[)L0_/!T6U.16/,N0B(O
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M/]7(F<Y=6R/ RRM+;U56N*0X12)3K4:*<L>"Y%\5AQ+)HC+@
M                   *2GM*67+M.9>I,/;<-<3$N.M%/<09+235ME&P=@N3
M$I)222LE5E/!5XDF9&9FD_2DQ-3Y%DN9XO[)V$1LY[E_&V-.90] QN=GF;R$
MJZ]42<3UIE]K1/-EX%I-;&2M0E^GP]$D9D?4B(ZS]4I'F:'8@)
M                 ,WGNP?2,\N?VLV/WKJAD1]5$3YDW_L_W++C/Q_XV;GQ
MK=V]=8:KO[K>#EY4T^<Y=4X]86-.>!8A *RB1;"0RZ_#.;#=:\Q)&GQMJ+ZI
M&+)IM\"Z+6!/1_F6=O[_ !B\>OWG8S_QPLRR[B[%#_,L[?W^,7CU^\[&?^.#
M++N&*'^99V_O\8O'K]YV,_\ '!EEW#%'ZM%W$."V3W=-C6/<L]#75_D-K7T=
M'3UVQL=E6%M<6TMF!65L",U-4[(F3ILA#33:2-2UK(B])AEEW#%'LH6E0
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M5>0Z^SYDRX??=5X%K1XEGT49=#&.^+9(N1Z@%"H
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MQNESMEHT>/QS, R-%/FD)!%U+Q.P$)ZI,NO4CZ6--<RN*9ZG%"H
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M.GAE<_X7J>&ZTDK=]")2^L!#:)T<Y8<$7*/:RX>(B\
M               *&'M"+SKO<7OT..N.(CZBU<S'0M:EI8:5 LI"FF4J,R:;
M-]]:S2GH7C6H_JF8FAZI'+F?R]GQ^D9QK]DVT_O7!%9^J(\R^H("0
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M_H+XQ?M9R_\ ,]H24^;+)$"O9K^DQXI?&W+?X8YP))>JRD>9HLC')
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M2&VFFT$E#;;:$D24D1$1%T(0EY_0
M  %#WVARL=@=P^9*<<;6BZTIK&SCI1XO$TTTO(Z93;WB21>8;]2M1>'J7@4G
MT]>I%-#U2.7,X?V";^-3=RK5]<^2#=RO!=MT$,U.FV:9,; [?*5&VCRG//7Z
MIC3I>#JCHDS5XO<^%59^J(\R_D("0   (>N^[8V%5VV-OS:N?,K9C>6:C2W+
M@2GX<EM+FR\:0XE#\=;;J26A1D9$?I(^AB^'K%)<B@_^/N<_EIEG_,5Q_P 8
M)L$1C\?<Y_+3+/\ F*X_XP,$!^/N<_EIEG_,5Q_Q@8(#\?<Y_+3+/^8KC_C
MP0-3G U*7@V&*4HU*5B>.J4I1F:E*.GAF:E&?4S,S/TF,=\R4Y8*
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M\HZ3CBL5S*Q?87B1"7E9#VFW]!?&+]K.7_F>T)*?-EDB!7LU_28\4OC;EO\
M#'.!)+U64CS-%D8Y(             %"OV@[Z1G)?V3:L^]<X3P]4CES/1?L
MW.$X9FV[>2<7,\1QC+HT'5>)R(4?)Z"JOV(;[F6N-N/16;6)+;CO.-EX34@B
M,R]!GT%*G(K'F6\/D#T5^I;4W[N</_ PBQ9=@A\@>BOU+:F_=SA_X&#%C!#Y
M ]%?J6U-^[G#_P #!BQ@A\@>BOU+:F_=SA_X&#%C!':<>.Q$88BQ6&8T6,RW
M'C1H[:&6([#*$MLL,,MI2VTRTVDDI2DB2E)$1%T%"I_8
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MDQGFB)7B4GT=2NC*3>#*-+ I3B4L-63 ?_M$PKXI8Y]YX8QWS)3EHH
M      ,WGNP?2,\N?VLV/WKJAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR
M&(RX                     "MY[3#_ '4="_S"M?PWS@24^9;+D5O.T_\
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MJ1RYGK/V9+].O)W]DV(?G@Z+:G(K'F7(1$7@
M  5D/:;?T%\8OVLY?^9[0DI\V62(%>S7])CQ2^-N6_PQS@22]5E(\S19&.2
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M(CZJ(GS+(?LSW]U'?7\PKO\ #?!Q'4YE\>19#$9<
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MB3-*VUD9>@Q'3YLK(@O[-?TF/%+XVY;_  QS@22]5E(\S19&.2
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M0R4\5B1<BTY[-1R3B6N![LXGW5@7PSB=TWN? XC[OB>DXOD+=7C&<1(39_\
ME0L?R&'62%%_XGKM:O\ M$51=I?'N+20C+@      .A^4.[*GCAQWW-O2Y6R
M4;6.O,ERB)'?4A";.]B5[K>,T:#<-+?K%_D;T2"T2C(C=D)(S(A5+%X!\#.\
MU_W'>=^KY:I6&\K]VQ$'(<E%5W&;6>78ZV\\ZIYU3&+Y>N]QR.AQQ1F:$14H
M,O1TZ$1"?+'N(\67C>TGN'D=R"X681NGDWD\7+,UV#D>76.-V;&,8]B3YX)3
MV*,4J#GU.,5=-5'*L+C'["<AY$9LG8\MHTEY?@$,DD\$7K'#B27"TJ
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M2,\N?VLV/WKJAD1]5$3YED/V9[^ZCOK^85W^&^#B.IS+X\BR&(RX
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M L_,_P#33E,=6VXS*388/$8\#O#LU_28\4OC;EO\,<X"7JLK'F:+(QR0
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M%&W702-Y\R4Y%9DW-I/ MP[3RV*@U9,!_P#M$PKXI8Y]YX8QWS)3EHH
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MEEHGTU]5P+FIG-H=;;FUEI$:G0):&WVVGD(D17T+(EI2HB/H9$?H%I4_4
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MSE_YGM"2GS99(@5[-?TF/%+XVY;_  QS@22]5E(\S19&.2
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ML?KHE118_0UT2HI::J@LICPJVKK(#3$*!!B,()#;32$H0DB(B(A$7G[(
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MLL%\*<XQ_&6_N7%-98K%+QHT92>6+3O(]X*_Y6XKPJS/8G$;/9V'V^&J;O\
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M-=;\"9<B6MM+A0N3D7I)$BXM*@
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M<*%0
M
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MP:ZNBL0H,*,TDDM1XD2,AJ/'8:271*$))*2^H0M*GW0
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M,QX4"%&:226VFD(0A)="(B$9<?J@
M
M
M
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MW,Z(TN9DN53HC)LMVF69/.7(N\AGD2E&@Y#RFV"6I#*&V^B"B;;YEZ6!Z'%
M
M
M
M
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MXVVNH6VZ.;=>DT7X\(KX5S91QE))?A5;9N52"7&5-U8?#DJ45H #/.2P
M
M
M
M
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M0X+"-*?&I;K@E%3I))4DY6$AD'D0
M
M
M
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M=2-)D?4C(9YR3::>#YGR H
M
M
M
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M&XP,PYT
M
M
M
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M1
M
M
M
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M6C5>+BVJ55N62=6Q.,@\>
M
M
M
M
M ''<NQ'%\^Q?(,)S;'Z?+,/RRGL,?R;&<@KXUK1WU':QG(=E56M;,;=BS8,V
M*ZIMQMQ)I4DS(R!I-8/D9FGZA?:3?4=3TRM4M]1MZD:E.I3DXSISB\8RC)8.
M,HM)IIF<?WF^T%EG;RV2O8^KX5]E?$C8=JO\4<GD-G.EZNR.<])?/5V:3FE+
M<433+?CIK-]#16,7JRHURH[ZEZZM1=-XKU#LCY;O,-8=7]%6C:Y*E;]0;.G^
M-I)Y5=4XI+Y31B^]\*U.+?AR^$L*<XI09B ]1  =X\9MIY5I#D1H_;V$RY$/
M*=<[4P7+*=<8G5JD/U&1U\EVM?89/QS(-O%2N))CF1IDQWEM*)25F1W1;C)-
M<TS\OO;0K#<^S]4V]J<8RL;RPKTIXX<%.G)*2;Y2@\)1ESC)*2::->T;8_GH
M     /$'<LRS*L$[?W,7,\'R7(,-S#&./6SKK&LKQ2YL<=R7'KF!C,Z1 MJ.
M]J),.TJ;.$^@ELOQW6W6UD1I41D+*C:IMKG@SZ?T5T^PU7JWMS3=4H4;G3J^
ML6T*E*K"-2G4A*I%2A.$TXSC)<'&2::X-%0GV?#F%RWW1W&<:P?<7*7D9MC"
MW]3;3LG\0V7N[9F=XN]8U]7!<@3W<?RG)[6I<FP7%FIETV36T9F:3(S&);SG
M*I@VVL.\Z%^;KIWT_P!M='*VJ;<T+1M/U):A:Q5:VLK:A5492EFBJE*E&>67
M:L<'VE]49QRE/$'<LRS*L$[?W,7,\'R7(,-S#&./6SKK&LKQ2YL<=R7'KF!C
M,Z1 MJ.]J),.TJ;.$^@ELOQW6W6UD1I41D+*C:IMKG@SZ?T5T^PU7JWMS3=4
MH4;G3J^L6T*E*K"-2G4A*I%2A.$TXSC)<'&2::X-%6/V:KECRFWMSIVOB.[^
M2V_]R8I7<3<ZR.OQC:NY-B[#QZ!D,3<&B*R)?0Z7+LCN*V+<Q:VWEQVY2&DO
MH8E/-DHDN+)6+;3E*;4FVL/\![K\Z6P=B;5Z6V&H;8T72=-OYZ_0IRJVMG;V
M]25-VE])TW.E3A)P<H0DXMY7*,6UC%87>QFG,4 #*;SSN(=P2+G.;187.;F/
M&APLKR)AB-%Y-;L9C1(K-U*889:9:S9+3$=I/A0A)$24ET(O]@U;J5,?6?[;
M.\^D]'^D=32[6I5VMMR525O3;;TVR;;<$VVW1Q;?%OM[2^-V)N<5GS7X+XJ]
MGN13<DW9HNP/46T[:YLIMKD.2_!D1J9A&=W4^R<D6-E895B;S*)LU]YYV;;P
M9KJE=5&DLZA//3X^LCE5YI^E]#IGU2N(Z31C1VSJD/E=K"$8QIT\S:K4(1CA
M&,:55-PA%)0I3I12X8N9X3'FTH5=Z[F%RWU5W:\OUOJ_E+R,UOKN-\WWU; L
M"W=LS#\+C_#6$89+N/(Q;'LGKJ-KX6E2G79/A8+SW'%*7XC49G@UIS57!-I<
M.TZL^6?IWT_U[R_V^LZYH6C7NL2^7XUZ]E;5JSR5JRAC5J4I3>1)*/PO@I)+
M# OJC..4P %0GVGKDMR-T#G?#^'HG?\ NS2L3)L2W')R2+J3:N=ZXCY!(J[C
M7K5;(NV,.OJ9JV>KFIKR6%ODXIE+RR09$I77$N92CERMKF="_)!LK9N[-*W%
M4W5I.F:G4H7%FJ;N[6A<.FI0N')0=:G-P4G%9E'#'!8\D2<>SX;8VGNCMS8U
MG&XME[ VSFC^V=IUK^7[+S+(L[RAZNK[2"W @.Y!E-E:VSD*"VLTLM&\:&B,
MR21$8DMVY4\6\7B?$?-UH&A;:ZQU]+VY96FGZ8M/M9*C;4:="DI2C+-)4Z48
MPQEVO#%]I-\)SS$     9I?<KYW\X<$[@/,7#,'YE<K,-P_&.0VSZ3&L4Q3D
M/MW'<:QZFK\GG1X%11T51E\.KJ:R$P@D,QX[3;3:"(DI(BZ#759S51I-X8]Y
MVHZ*]*^F&J])-N:EJFV]!N=1KZ/;3J5:NGVE2I4G*G%RG.<Z+E.4GQ<I-MOF
MS\:-)]H,F1X\R'([R,J)*9:DQ949WFR_'DQWT)=8D1WVE*:>9>:42D+29I4D
MR,CZ"G^L?P_W3)G#RC4YNG473B-2+:::T5--<&FGQ33YH_O_ /K"G_Z9?_\
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M,DO0S6N'+1KO'+/EWGGSS'^4W0'H5UOOI=;*TU.UA*M<6-/V-:E%8U)VT/\
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MIMUM?5=N:/;[GO\ 1[B=I*AI%J\LYQJTJ4_%C23IRC5CBI+C'!23- X9YR1
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MVC:_UW:_E8E)WV:7Z4'%?V,[>^]$ 8-M[7WCICYU?L.K_65I\>1HPC8G'0\
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MQOI3,\_G^RC_ -Q4X:N7M7_C??.\NC?83:_U2I?\/B:L VAP:
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MZ_TI<![&/,'?'-[A9:[EY%9/79;G\7=V=84S:5>-4&*1DX]1X_A$^NB'5XY
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ME/@)0$]JJ^D*TY_)GKW^-W(<8%U[1>Y]]G6?R'?9#J/]9+CZ%IY<O[<GT>O
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MN??1[7\^/V0Z=_62W^A:@7^QGG)@   *@7M:GZ/>$?QRWE]Y-9#$N^43H;Y
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M_LH_]Q4X:N7M7_C??.\NC?83:_U2I?\ #XFK -H<&@
M                            /('<&P:=LO@GS'P2JC/3+G)N,>\*ZAAQ
MU&EV7D)ZXR)Z@BD:6GE&B3<LL(6E*34I"C(O29&+*BQ@UZ&?0^D>J4M%ZI[<
MU6X:C;4-;LI5&^2I_**:J/FN4')KCS,^SL(;:HM1=TWC9.R>S344F=R,WU4[
M,<E>KL'<[ P;(*;"X#Z#0:92;?.U5D-#9J01//H<ZF:"2K H-*JL3KAYK]OW
M6X>A6M4K&'B75JJ-TEAB\E"O3G6DN[)0\6;?'A%KMQ6FD-D<3")WOA;<H]/]
MK[E9/MY\:+-SW"8^H\:A/K23]S>;+MX&-.P(#:DJ\Z3$Q^5/GK(O2F/"=7U+
MP=1%7>6DS[[Y8-OW6XNN.@TK>$I4K2Y=W4:Y0A;0E44I=R=10IKOE.*[2M/[
M*'@LZPY:\EMF-LNJK<1XZ1<%ER"-?DM3MB[+Q+(*]EQ),*;-U]C5TE2#-Q"B
M)M71*R,S1C6J^&WZ#VGY]]5I4>G^B:(VO&N-8==+M<;>VJTY/GR3NHX\'S7%
M<,;W0SCE> !G.]A/Z9_"?_NE/S SL:^A[;]L[%^:W_ILN?\ Y=^7H&C$-@<=
M#-;[P/'#+.VUW.[#8.HO/Q7'LGS"@Y3Z N8;+R8E!:NY,=[;4,8^B8Z?Q+V/
M5RVVHB7%FBI<A&YT)XDC75HNG5Q7NH[1^7?>6G]9^B$-(W!A7O*%M4TN_@VL
M:D53R0F^W\=;R@W-I8U54PQRXGY'=FV[CO(CN'ZOY&XF^RJAWYJ+B3L^+7,N
M>>K'95IAF,U-SBTJ3[DI-ACEY2R8DA1)1T?:4GI[GJ=*LLU127:D3] =O7FS
M^C]]LV_3^5Z3J&JVSD^'B*-:I.%5+LC4A.,X\7\%I]II=C9'%4 "D[[6I^D/
MA)\3-X_?S68P[OG'W_O'3'R ?H?<_P YLOB7)+)[-+]%]BO[9MO??>O$EM[+
MWSX#YU/MQN/JVT^)(G^&0>3     #*?[JWTDO.+^9G;7YV6(U=7VDO=.\O0;
M[%]K_4EK^2B:?7''^[UH?]C.K_S(HQLH^JO<.'V\O^;]5^LKG\M,[F%Q^;
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M@V\4L6RPQ[*/_<XY%_S,/?PLU^,BU]1^Z>0_/M]HVC?4B^E7!:6&2>%0
M  ,I_8WTIF>?S_91_P"XJ<-7+VK_ ,;[YWET;[";7^J5+_A\35@&T.#0
M! Y[1SHB9N;MFYQD=37JL+G0.P<%W2PTPG_U?P-"=L\"RQQM1*1UB5N,Y[)L
M)*%&:#:@^/H:T(Z07$<:?N<3U5Y-MU4]M];+6RN)Y+;5K.O9MOEGDHUZ2]V5
M2A&G%\\9X8X-D#GLK_(ZKU_REW=QPO;%J"UR#UU3Y)B"),AM*+#.=-2;N?\
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MXMKVMLT)0BRK,&K'7O&\GQ-NVDZ<XRM<=;)EG4:?AQP?K,Y:^9#K+'K)OO\
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MD48V$?57N'&+>7_-^J_65S^6F=S"X_-F4_S5^E,Y:?S_ &^/_<5E0U<_:O\
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M<DNT=RFJ\NP^9EL+7M?G+69\:.0U&VZ;1'6V*[?'J6[MF8J:VLV3C#48F["
M^A")J6E2&6G(;Q$-=4IRI2Q7+L9VPZ1]6=E^8+8L]/U&-O+5YVKHZEI\VL?A
M1R5)P@WFE;56\:=2+;@VH2DJD20^D]JHYHUVO&,?M-(<?,AV)&K&H*=B3(F;
MP8$Z6TAIKX:ML(JLGA0W;"0E"W'40YL&(;Z^K;+31>2<GRJ>')8GQ^Z\A_36
MMK#NZ&J:O1T>4W+Y.G1E**>+R0KSIMJ*X).<)SRKC*4GF(O]"<?N9W>EYDW=
MQ/L[C,,NS2[@7FZ]W7M:IO"M8XFVEF P_+3 9B5,!JNIH286/X_#\E<GR$,L
MI;8;>?9BC&=:?I[6?<=U[MZ;>6KIQ2MZ4*=OI]M2E"RLH2QK7-7C)I9FYR<I
MRSW%Q/%1S.4FY2C&6F'HG2^"<=--ZTT7K*N55X'JK#J3"\:C.FTN8[!I8;<9
M=E:/LM,(FW=S*)R9.D^!*I,Q]UU1>)9C912BE%<D<4=T[EU7>.X[W=.MS\35
M;^YG6J-8X*4WCEBFWA""PA"./P81C%<$=L"IH  *YWM0?T;5%_,SJ_\ -/9@
MQ[GV?OGL7R._;15^I+G\K;$9WLE?Z0^;?Q,T=]_-F".TYR][[Y]L\_\ ^A]L
M?.;WXEL78AF',X   ,CKFG_?'Y9_S,;X_BGE0U53UY>ZS^@GII]G.W_J2Q^B
MTCW_ /Z@KN\?XM__ )"\8_[%Q?\ **W?^XO\!\E_NC^7K^C_ /\ ':E_/!_J
M"N[Q_BW_ /D+QC_L7#Y16[_W%_@']T?R]?T?_P#CM2_GAV9I7OU=V'+=R:EQ
M3(>5GPA09-LS \>O('R&<;8GKM1=9355ME$]:A:=C38WK,*2M'F,N-NH\75"
MDJ(C*JKU6TL?W$:3<WE2Z!Z?MS4+^ST')=T+&O4A+Y;J+RSA2E*+PE=N+PDD
M\&FGVIHT>AL3C6 !G/=H+Z?W7_[9N97\&N0@UU'VZ]U_<9V+\PW_ $EW?U;H
M_P!,T\T81L3CH0A]_OA>GEMP&S7),<JSG;7XSJF[NP4XS).3[+'Z6O6C:>*-
M&E#LAUJVPAMZP9C,H4]+M*>"TG_>,05X9Z>*YKB>G?*9U*?3_JQ;65[4RZ!K
M>6RKXOX,:DY?ZK5?))PK84W)O"%*M5D^1FVS+:SL8U3#GV$V;$H:]RII(TJ2
M\^Q45CUK9WCM?6M.K4B%"=N;F7+4TV24'(E.N&7C<49ZX[.4[>A1G4J4H1C4
MJS4YM))SDHQ@I2:YM0A".+XY8Q7)(V&]<?H\P/XF8O\ >."-PN1_.QK/Z8N_
MG-7X\CF8&M  AH]H*^B'Y;__  %_]SFEQ#<>Q?O?=1Z0\H__ %"[?_\ /?\
M#;PK-^RJ_2%;C_DSV%_&[CP,:U]H_<^^CVOY\?LAT[^LEO\ 0M0+_8SSDP
M &:CW>>[5D/<C<UQ@MWI&EU.UH/,ME>IV55G,[+7,E_&%5%3K]9C2\9H$UGJ
MJ<72X7A6]XS>,O1X2,]=6J^)PPPP.TWEZ\O]GT95YJMMJ=6_EJUM;8QE0C2\
M/P\\^#52IFQ\7#BHX8>GAW/V2.[5D/"B;0\3JO25+L&OY'<F,"]=S6?G,['9
MN*?CP[A>MG?5:./C-NQ;?!S$7UM/CDL>8M7EGX2+QBM"KD^!AS9^;\S?E_L^
MIE.KOZOJ=6TK:-HE?+1C0C457P%6N5C-U(.&9O)PC+!<>/(T1QL#CZ5:?:G>
M2?XB\5]/<9J:T]7NM][&=RW*H+)^-<C7>I&8L\HD]"3_ /3L6&?W]-)CJ5T\
MU=4Z2.O@7TQ;J6$%'O9[J\B>R_SKOO4=[7-/&VTFS5*E)]EQ=MQQCWN-"G6C
M+#DJL<>:QZ$]E!XZ%$QSE!RPM8:O.N;3'M X/+4VILVX5,Q$S_9!)6LC*3'L
M)EIC*4*1T2VY!=2?B,^B+;6/.?O'ZOS\;Q\2\T/8-O+X-.G4OZZQQ^%-NA;^
MXXJ-SCCS4XM8=MQ$9ASJ  S .\WQ[F\2^YER!I,=CR\?HLLS&)OO6LV&:X9,
M5>S%%F+SE$MI+*HL3&<[<M*R-Y?_ )1UW1)GX>HUE:.2J_VSN'Y;MW4NH'1/
M2+F\<:UU;VSL;F+XXRMOQ*4\<<74H*E4ECS\3CS-%/@UR,A\M>(?'KD5%=9<
ME[/UG06^2HC):1'AYW7-+Q_8E7'2QT:)FGSNHL8J.A(]RR75*#]R6PA+/!2[
MT<>>J.SJG3_J%J^SYIJG8WM2%/''%T)/Q+>3QXXSH3IR?/GS?,]6"\_!&2GR
MPR&WQ+G1R5RO'I?P??XSRRW)D-'/]7BR_4K>EW!D=E6R_59K,F%)]6FQD+\M
MYMQI?AZ+2I)F1ZJ?"HWZ7]T_H V#9V^H=+=%L+R.>TKZ!9TYQQ:S0G:4XR6,
M6I+&+:Q3378TSW-_J"N[Q_BW_P#D+QC_ +%Q?\HK=_[B_P !\N_NC^7K^C__
M ,=J7\\'^H*[O'^+?_Y"\8_[%P^45N_]Q?X!_='\O7]'_P#X[4OYX2%]O+O,
M=R;>=KS)C;3Y'_C0SJGMZ<M-Y8"CY']"TGP#M+66&P;7!\H\6.ZNJ%VGP)/>
M4YZE-.372>OAD1W4]"$E.M4EFQ?*+?8?(>K_ );^B^UJ&W)Z%HW@2O\ =^E6
M5?\ UN^GXEK<UI0KTOQEU/+GBDL\,M2/.$XOB7NQG'*X
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M)I)=R2>"1]?Y.->?D'AG_*]'_P "&"+_ ,\ZQ_O=S_G9_P"4/DXUY^0>&?\
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M2W)BQ6GD)<;4:5$2O21]#] &76U+4;FFZ5Q<5JE)\XRG*2>'+@VT<E P@
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M>@R,".IJFI5</%N*\LLE)8U)O"2Y26+X-=C7%'* ,$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813854992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Option Exchange Program) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>employee</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>director</div>
</th>
<th class="th">
<div>Jun. 20, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized', window );">Option exchange shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,849,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants', window );">Number of participants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted', window );">Option Exchange, number of options converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,914,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent', window );">Percent of eligible options converted</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">1,720,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeOneMember', window );">$2.97-$10.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding', window );">Number of Outstanding Eligible Options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725,812<span></span>
</td>
<td class="nump">2,725,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,725,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeTwoMember', window );">$11.00-$24.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding', window );">Number of Outstanding Eligible Options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,373<span></span>
</td>
<td class="nump">720,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeThreeMember', window );">$25.00-And Up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding', window );">Number of Outstanding Eligible Options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,671<span></span>
</td>
<td class="nump">468,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit', window );">Option Exchange, lower exercise price range (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | $2.97-$10.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit', window );">Option Exchange, lower exercise price range (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.97<span></span>
</td>
<td class="nump">2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | $11.00-$24.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit', window );">Option Exchange, lower exercise price range (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | $25.00-And Up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit', window );">Option Exchange, lower exercise price range (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00<span></span>
</td>
<td class="nump">25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | $2.97-$10.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range per share, upper limit (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.99<span></span>
</td>
<td class="nump">10.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | $11.00-$24.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range per share, upper limit (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.99<span></span>
</td>
<td class="nump">24.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Option Exchange, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Lower Range Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Upper Range Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Number of Participants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized, Converted, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Options Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nlnk_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637949376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Antidilutive Securities) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">5,716,086<span></span>
</td>
<td class="nump">8,371,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">89,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6616105536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Authorized Increases of Common Stock under the 2009 Plan</a></td>
<td class="text"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"><tr><td style="width:1.0%;"/><td style="width:40.199488%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.078772%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:54.521739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Date Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Authorized Shares Added</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2010</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,238,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 7, 2011</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">714,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2012</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">823,649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2013</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">839,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2014</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,062,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,119,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,152,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,484,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,490,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity, including options with market and performance conditions and options granted and forfeited in conjunction with the option exchange program, for the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"><tr><td style="width:1.0%;"/><td style="width:39.090909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.818182%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.636364%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.727273%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">of options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">remaining contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">term (years)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,978,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,753,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,696,520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options expired</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,318,698)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.93&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at end of period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,716,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercisable at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,165,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.9</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used in Black-Scholes Pricing Model for New Grants</a></td>
<td class="text"><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"><tr><td style="width:1.0%;"/><td style="width:66.139535%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.962791%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.697674%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">1.8% to 2.7%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">77.0% to 86.3%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">4 to 7.7</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Weighted-average grant-date fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$1.89</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Activity</a></td>
<td class="text"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September&#160;30, 2019 and changes during the nine months ended September&#160;30, 2019 are as follows:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"><tr><td style="width:1.0%;"/><td style="width:54.235828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.954649%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.140590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number of restricted stock shares</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average grant date fair value</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">68,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(59,330)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Forfeited/cancelled</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34.73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock', window );">Option Exchange Eligible For Exchange</a></td>
<td class="text"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The eligible shares were exercisable for a reduced number of shares based on the following exchange ratios:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"><tr><td style="width:1.0%;"/><td style="width:23.559105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598722%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.559105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598722%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:45.284345%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price Range per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Outstanding Eligible Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exchange Ratio (Surrendered Stock Options to New Stock Options)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$2.97-$10.99</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,725,812</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">2 to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$11.00-$24.99</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">720,373</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">3 to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$25.00-And Up</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">468,671</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">4 to 1</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Option Exchange, Exercise Price Range</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797856496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text">Net Loss per Share of Common Stock<div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Basic loss per share is based upon the weighted-average number of shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.</span></div><div style="text-indent:22pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data):</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"/><td style="width:42.709389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545156%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545156%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.141282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.588376%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Loss attributable to common stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(14,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,718)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,308,523&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,214,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,286,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,178,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Basic and diluted loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.93)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div>All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September&#160;30, 2019, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 5,716,086 and 9,255, respectively.  As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 8,371,005 and 89,053, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632661568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Research Collaboration Agreement</a></td>
<td class="text">License and Research Collaboration Agreement<div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merck Sharp &amp; Dohme Corp. </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2014, the Company entered into a licensing and collaboration agreement (the Merck Agreement) with Merck to develop, manufacture and commercialize rVSV-ZEBOV-GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada (PHAC). Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV-GP and related technology. Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV-GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV-GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&#8217;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck is expected to lead the development of rVSV-ZEBOV-GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.</span></div><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation (BPS), from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC&#8217;s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck&#8217;s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018, the Company entered into an agreement with Merck, the U.S. BioMedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA) to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants.</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September&#160;30, 2019, the Company recognized revenues under the amended Merck Agreement of $246,000 and $503,000, respectively, for work the Company performed as a subcontractor of Merck under the government contracts that were transferred to Merck.  For the three and nine months ended September&#160;30, 2018, the Company </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">recognized license and collaboration revenue under the amended Merck Agreement of $120,000 and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> $949,000, respectively, </span>for the reimbursement of costs not covered under government contracts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6816256416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 09, 2019</div></th>
<th class="th"><div>May 08, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
<th class="th"><div>Jan. 01, 2014</div></th>
<th class="th"><div>May 09, 2013</div></th>
<th class="th"><div>Jan. 01, 2013</div></th>
<th class="th"><div>Jan. 01, 2012</div></th>
<th class="th"><div>Jan. 07, 2011</div></th>
<th class="th"><div>May 15, 2010</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 10, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Options exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember', window );">2009 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,653<span></span>
</td>
<td class="nump">12,400,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,271,904<span></span>
</td>
<td class="nump">5,271,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,271,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490,048<span></span>
</td>
<td class="nump">1,484,382<span></span>
</td>
<td class="nump">1,166,546<span></span>
</td>
<td class="nump">1,152,565<span></span>
</td>
<td class="nump">1,119,233<span></span>
</td>
<td class="nump">1,062,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,407<span></span>
</td>
<td class="nump">823,649<span></span>
</td>
<td class="nump">714,285<span></span>
</td>
<td class="nump">1,238,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum', window );">Evergreen increase (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember', window );">2010 Non-Employee Directors' Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,902<span></span>
</td>
<td class="nump">268,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember', window );">2010 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remained available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,542<span></span>
</td>
<td class="nump">29,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total compensation cost related to non-vested option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period for non-vested option awards, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Options exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average vesting period for non-vested option awards, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,963<span></span>
</td>
<td class="nump">$ 124,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2010EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803650544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership percentage after transaction</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_MergerAgreementCovenantsTerminationFeePayable', window );">Covenants termination fee</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nlnk_LumosPharmaIncMember', window );">Lumos Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinancingsLineItems', window );"><strong>Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership percentage after transaction</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_FinancingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Financings [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_FinancingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_MergerAgreementCovenantsTerminationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Covenants Termination Fee Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_MergerAgreementCovenantsTerminationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nlnk_LumosPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nlnk_LumosPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813307904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total operating revenues</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 12,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,024<span></span>
</td>
<td class="nump">7,570<span></span>
</td>
<td class="nump">17,464<span></span>
</td>
<td class="nump">39,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,279<span></span>
</td>
<td class="nump">7,588<span></span>
</td>
<td class="nump">19,484<span></span>
</td>
<td class="nump">23,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,303<span></span>
</td>
<td class="nump">15,158<span></span>
</td>
<td class="nump">36,948<span></span>
</td>
<td class="nump">63,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,057)<span></span>
</td>
<td class="num">(15,038)<span></span>
</td>
<td class="num">(36,445)<span></span>
</td>
<td class="num">(51,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous (expense) income, net</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">567<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">(14,548)<span></span>
</td>
<td class="num">(14,394)<span></span>
</td>
<td class="num">(34,718)<span></span>
</td>
<td class="num">(50,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,991<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,548)<span></span>
</td>
<td class="num">$ (7,403)<span></span>
</td>
<td class="num">$ (34,718)<span></span>
</td>
<td class="num">$ (43,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted average shares outstanding (in shares)</a></td>
<td class="nump">37,308,523<span></span>
</td>
<td class="nump">37,214,363<span></span>
</td>
<td class="nump">37,286,930<span></span>
</td>
<td class="nump">37,178,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795861168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&#160;GAAP) and the rules&#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&#8217;s opinion, reflect all adjustments necessary to present fairly the Company&#8217;s interim condensed financial information.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2018, included in the Company&#8217;s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nlnk-20190930.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "nlnk-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nlnk-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nlnk-20190930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nlnk-20190930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nlnk-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nlnk-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 334,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 10
   },
   "keyCustom": 18,
   "keyStandard": 280,
   "memberCustom": 9,
   "memberStandard": 17,
   "nsprefix": "nlnk",
   "nsuri": "http://www.linkp.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentTransitionReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.linkp.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentTransitionReport",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Revenues",
     "role": "http://www.linkp.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109105 - Disclosure - License and Research Collaboration Agreements",
     "role": "http://www.linkp.com/role/LicenseandResearchCollaborationAgreements",
     "shortName": "License and Research Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111106 - Disclosure - Common Stock Equity Incentive Plan",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlan",
     "shortName": "Common Stock Equity Incentive Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Leases",
     "role": "http://www.linkp.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - Income Taxes",
     "role": "http://www.linkp.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - Net Loss per Share of Common Stock",
     "role": "http://www.linkp.com/role/NetLossperShareofCommonStock",
     "shortName": "Net Loss per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Restructuring and Severance Charges",
     "role": "http://www.linkp.com/role/RestructuringandSeveranceCharges",
     "shortName": "Restructuring and Severance Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.linkp.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Common Stock Equity Incentive Plan (Tables)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables",
     "shortName": "Common Stock Equity Incentive Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320302 - Disclosure - Leases (Tables)",
     "role": "http://www.linkp.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325303 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "role": "http://www.linkp.com/role/NetLossperShareofCommonStockTables",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Restructuring and Severance Charges (Tables)",
     "role": "http://www.linkp.com/role/RestructuringandSeveranceChargesTables",
     "shortName": "Restructuring and Severance Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "ib799a2a817e04b59aab49144acc02919_D20190930-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.linkp.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "ib799a2a817e04b59aab49144acc02919_D20190930-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.linkp.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GovernmentContractReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues (Details)",
     "role": "http://www.linkp.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GovernmentContractReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9151d1bccda84d16ba78784a7225722a_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - License and Research Collaboration Agreement (Details)",
     "role": "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails",
     "shortName": "License and Research Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i09d3bfeeceed429b9919afe16c36b882_D20150201-20150228",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i0db96647bdad4850a6a856796387bea0_D20190731-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
     "shortName": "Common Stock Equity Incentive Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i107fa001f84543fa888d506c91a7babb_D20190509-20190509",
      "decimals": "INF",
      "lang": null,
      "name": "nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i4f210ec5feb14d6589ee87904ff50298_D20190101-20190101",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
     "shortName": "Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "id606702fb4024e63b1d691ef77f26589_D20190731-20190731",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails",
     "shortName": "Common Stock Equity Incentive Plan (Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
     "shortName": "Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
     "shortName": "Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i257055a317c4463eb42d9ef38312b06f_I20190620",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Common Stock Equity Incentive Plan (Option Exchange Program) (Details)",
     "role": "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
     "shortName": "Common Stock Equity Incentive Plan (Option Exchange Program) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i257055a317c4463eb42d9ef38312b06f_I20190620",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Leases (Details)",
     "role": "http://www.linkp.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i9ace74c0019743fe88745f618d835f4e_I20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Income Taxes (Details)",
     "role": "http://www.linkp.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details)",
     "role": "http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails",
     "shortName": "Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Net Loss per Share of Common Stock (Antidilutive Securities) (Details)",
     "role": "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss per Share of Common Stock (Antidilutive Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "ib799a2a817e04b59aab49144acc02919_D20190930-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Restructuring and Severance Charges (Details)",
     "role": "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails",
     "shortName": "Restructuring and Severance Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "ib799a2a817e04b59aab49144acc02919_D20190930-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i72e1400b763c49568b5cacb45201ccaa_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity",
     "role": "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity",
     "shortName": "Condensed Consolidated Statement of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "if05c8243e3884438adf343cadc3e292d_D20180101-20180331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.linkp.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation",
     "role": "http://www.linkp.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Significant Accounting Policies",
     "role": "http://www.linkp.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nlnk-20190930.htm",
      "contextRef": "i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nlnk_A2009EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 2009 Equity Incentive Plan [Member]",
        "terseLabel": "2009 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2009EquityIncentivePlanMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_A2010EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 2010 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2010 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2010EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_A2010NonEmployeeDirectorsStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 2010 Non Employee Directors Stock Option Plan [Member]",
        "terseLabel": "2010 Non-Employee Directors' Stock Option Plan"
       }
      }
     },
     "localname": "A2010NonEmployeeDirectorsStockOptionPlanMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_ContractManufacturingOrganizationEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractManufacturingOrganizationEquipmentMember",
        "terseLabel": "Contract Manufacturing Organization Equipment"
       }
      }
     },
     "localname": "ContractManufacturingOrganizationEquipmentMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_DeferredGovernmentGrantsObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "DeferredGovernmentGrantsObligationsNoncurrent",
        "terseLabel": "Royalty obligation payable to Iowa Economic Development Authority"
       }
      }
     },
     "localname": "DeferredGovernmentGrantsObligationsNoncurrent",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Current",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Current",
        "terseLabel": "Current income tax receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Noncurrent",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Noncurrent",
        "terseLabel": "Noncurrent income tax receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range One",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$2.97-$10.99"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Three",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$25.00-And Up"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise Price Range Two",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$11.00-$24.99"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Right Of Use Asset, Amortization And Change in Operating Lease, Liability",
        "label": "Finance Lease, Right Of Use Asset, Amortization And Change in Operating Lease Liability",
        "negatedLabel": "Amortization of right-of-use asset and change in operating lease liability"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_FinancingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Financings [Table]",
        "label": "Financings [Line Items]",
        "terseLabel": "Financings"
       }
      }
     },
     "localname": "FinancingsLineItems",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nlnk_FinancingsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financings [Table]",
        "label": "Financings [Table]",
        "terseLabel": "Schedule of Financing Rounds"
       }
      }
     },
     "localname": "FinancingsTable",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nlnk_GovernmentContractAccruedSubcontractorFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Government Contract Accrued Subcontractor Fees",
        "terseLabel": "Accrued expenses for subcontractor fees"
       }
      }
     },
     "localname": "GovernmentContractAccruedSubcontractorFees",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Unamortized Incentives",
        "label": "Lessee, Operating Lease, Liability, Unamortized Incentives",
        "terseLabel": "Unamortized lease incentive"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUnamortizedIncentives",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_LumosPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lumos Pharma, Inc.",
        "label": "Lumos Pharma, Inc. [Member]",
        "terseLabel": "Lumos Pharma, Inc."
       }
      }
     },
     "localname": "LumosPharmaIncMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_MerckSharpeAndDohmeCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Merck Sharpe And Dohme Corp [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckSharpeAndDohmeCorpMember",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nlnk_MergerAgreementCovenantsTerminationFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merger Agreement, Covenants Termination Fee Payable",
        "label": "Merger Agreement, Covenants Termination Fee Payable",
        "terseLabel": "Covenants termination fee"
       }
      }
     },
     "localname": "MergerAgreementCovenantsTerminationFeePayable",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_OperatingLeaseRightofUseAssetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-of-Use Asset, Noncurrent",
        "label": "Operating Lease, Right-of-Use Asset, Noncurrent",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightofUseAssetNoncurrent",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nlnk_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share based Compensation Arrangement by Share based Payment Award Percentage of Authorized Stock Maximum",
        "terseLabel": "Evergreen increase (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nlnk_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Option Exchange, Outstanding",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Option Exchange, Outstanding",
        "terseLabel": "Number of Outstanding Eligible Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Exchange Ratio",
        "label": "Share-based Payment Arrangement, Option Exchange, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeExchangeRatio",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Lower Range Limit",
        "label": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Option Exchange, lower exercise price range (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range",
        "label": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range [Table Text Block]",
        "terseLabel": "Option Exchange Eligible For Exchange"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Upper Range Limit",
        "label": "Share-based Payment Arrangement, Option Exchange, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise Price Range per share, upper limit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Number of Participants",
        "label": "Share-based Payment Arrangement, Option Exchange, Number of Participants",
        "terseLabel": "Number of participants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized",
        "label": "Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized",
        "terseLabel": "Option exchange shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized, Converted, Percent",
        "label": "Share-based Payment Arrangement, Option Exchange, Number of Shares Authorized, Converted, Percent",
        "terseLabel": "Percent of eligible options converted"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nlnk_ShareBasedPaymentArrangementOptionExchangeOptionsConverted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Option Exchange, Options Converted",
        "label": "Share-based Payment Arrangement, Option Exchange, Options Converted",
        "terseLabel": "Option Exchange, number of options converted (in shares)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionExchangeOptionsConverted",
     "nsuri": "http://www.linkp.com/20190930",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r70"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/LeasesDetails",
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/LeasesDetails",
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r95",
      "r121",
      "r122",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/LeasesDetails",
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/LeasesDetails",
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r124",
      "r126",
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r126",
      "r151",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r195",
      "r203"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r38"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r127",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r26",
      "r63"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r63",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r174"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Research Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "License and Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)",
        "verboseLabel": "Common stock, outstanding shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.01 par value: Authorized shares \u2014 75,000,000 at September\u00a030, 2019 and December\u00a031, 2018; issued 37,426,844 and 37,343,547 at September\u00a030, 2019 and December\u00a031, 2018, respectively; and outstanding 37,314,076 and 37,251,220 at September\u00a030, 2019 and December\u00a031, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r80",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r31",
      "r179"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Current portion of deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r33",
      "r179"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "auth_ref": [
      "r37",
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property, by the lessor or lessee, respectively. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee.",
        "label": "Deferred Rent Receivables, Net",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r61",
      "r91"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Common Stock Equity Incentive Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r127",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Authorized Increases of Common Stock under the 2009 Plan"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average vesting period for non-vested option awards, in years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to non-vested option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance Cost"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails",
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r66",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "Government Contract Receivable",
        "verboseLabel": "Government contract receivable"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r61",
      "r98",
      "r102",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of fixed assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r61",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of fixed assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r44",
      "r72",
      "r194",
      "r198",
      "r209"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r92",
      "r163"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r36",
      "r197",
      "r207"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivableNoncurrent": {
     "auth_ref": [
      "r14",
      "r202"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Noncurrent",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "negatedLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r42",
      "r90",
      "r175",
      "r176",
      "r200"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r55",
      "r58",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r48",
      "r89"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of operating lease contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r196",
      "r205"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r15",
      "r16"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities",
        "terseLabel": "Fair Value Disclosure of notes payable and capital lease obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r77",
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r40",
      "r41",
      "r45",
      "r62",
      "r75",
      "r199",
      "r208"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity",
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.",
        "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification",
        "terseLabel": "Cumulative effect of accounting change"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income and expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Liabilities Payments Due"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails",
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r189",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r188",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases Future Minimum Payments Due"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "calculation": {
      "http://www.linkp.com/role/LeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r56",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Cash Payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "verboseLabel": "Performance Stock"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r127",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Blank check preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Blank check preferred stock, authorized shares"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Blank check preferred stock, issued shares"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Blank check preferred stock, outstanding shares"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Blank check preferred stock, $0.01 par value: Authorized shares \u2014 5,000,000 at September\u00a030, 2019 and December\u00a031, 2018; issued and outstanding shares \u2014 0 at September\u00a030, 2019 and December\u00a031, 2018"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r1",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash refunds received for taxes, net"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds on sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r101",
      "r206"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r66",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Lease Obligation",
        "negatedTerseLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r159",
      "r213"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Severance Charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage reduction in force"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r61",
      "r104",
      "r108",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Expensed"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r105",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r117",
      "r204"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Grant revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "Upfront cash payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r43",
      "r87",
      "r88",
      "r94"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total operating revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/NetLossperShareofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring Charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r105",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Restructuring and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r127",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used in Black-Scholes Pricing Model for New Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited / cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/cancelled, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value at end of period (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "terseLabel": "Options exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility rate, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility rate, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares authorized",
        "verboseLabel": "Authorized Shares Added"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares remained available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r134",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, weighted average exercise price at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r125",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails",
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r148",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted average remaining contractual term, in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average remaining contractual term, in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of awards vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Repurchase of common stock (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity",
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity",
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Sales of shares under stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r17",
      "r18",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r116",
      "r117",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r116",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Sales of shares under stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r96"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.",
        "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions",
        "terseLabel": "Ownership percentage after transaction"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r34",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r34",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r34",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost: 112,768 and 92,327 shares at September\u00a030, 2019 and December\u00a031, 2018, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/RestructuringandSeveranceChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted average shares outstanding (in shares)",
        "verboseLabel": "Basic and diluted weighted-average shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77913719&loc=d3e40879-112712"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=118261985&loc=d3e55295-109406"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5)(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(a)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r214": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r215": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r216": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r217": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r218": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r219": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804301472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Collaboration Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Upfront cash payments</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">License and Collaborative Arrangement | Merck | License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nlnk_MerckSharpeAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nlnk_MerckSharpeAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797848896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Severance Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table shows the amount accrued for restructuring and severance activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"><tr><td style="width:1.0%;"/><td style="width:44.838407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.205152%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.824356%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.205152%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.526932%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Employee Severance Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expensed</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash Payments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6635240224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly-owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Instruments and Concentrations of Credit Risk</span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable was $58,000 and $104,000 as of September&#160;30, 2019 and December&#160;31, 2018, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  </span></div><div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.6 million and $7.0 million as of September&#160;30, 2019 and December&#160;31, 2018, respectively.  Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e">three</span> to five years, lab equipment has a useful life of five years, and contract manufacturing organization equipment has a useful life of five years. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases, to improve financial reporting for leasing transactions. The Company adopted the standard on January 1, 2019 using the modified retrospective method, as required, applying the new standard to all leases existing as of the date of initial application. The Company has elected that the date of the initial application, January 1, 2019, will be the effective date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to apply the use-of-hindsight or the practical expedient pertaining to land easements; as the latter is not applicable to the Company.</span></div>Upon adoption of the standard, the Company recorded a lease liability of $8.5&#160;million and a right of use asset of $7.5&#160;million associated with these leases. Included in the right-of-use asset are lease incentives that were previously recorded as deferred rent liability of $1.0&#160;million as of December 31, 2018 on the consolidated balance sheet.  There was no material impact to the consolidated statement of operations. Refer to Note 7 within for additional discussion around the lease liability and right of use asset as of September&#160;30, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6814819104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 151,557<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 389,786<span></span>
</td>
<td class="num">$ (1,142)<span></span>
</td>
<td class="num">$ (237,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,109,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Cumulative effect of accounting change</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2018</a></td>
<td class="nump">137,954<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">394,711<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
<td class="num">(255,727)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,165,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2017</a></td>
<td class="nump">151,557<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">389,786<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
<td class="num">(237,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,109,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2018</a></td>
<td class="nump">122,195<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">403,674<span></span>
</td>
<td class="num">(1,409)<span></span>
</td>
<td class="num">(280,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,216,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2018</a></td>
<td class="nump">137,954<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">394,711<span></span>
</td>
<td class="num">(1,403)<span></span>
</td>
<td class="num">(255,727)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,165,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of shares under stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of shares under stock purchase plan</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2018</a></td>
<td class="nump">124,946<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">399,018<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
<td class="num">(273,040)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,198,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,403)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2018</a></td>
<td class="nump">122,195<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">403,674<span></span>
</td>
<td class="num">(1,409)<span></span>
</td>
<td class="num">(280,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,216,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 115,143<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">407,199<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
<td class="num">(291,012)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2018</a></td>
<td class="nump">37,251,220<span></span>
</td>
<td class="nump">37,251,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2019</a></td>
<td class="nump">107,019<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">409,143<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(301,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,276,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 115,143<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">407,199<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
<td class="num">(291,012)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2018</a></td>
<td class="nump">37,251,220<span></span>
</td>
<td class="nump">37,251,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2019</a></td>
<td class="nump">$ 86,397<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">413,205<span></span>
</td>
<td class="num">(1,451)<span></span>
</td>
<td class="num">(325,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2019</a></td>
<td class="nump">37,314,076<span></span>
</td>
<td class="nump">37,314,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2019</a></td>
<td class="nump">$ 107,019<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">409,143<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(301,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,276,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Sales of shares under stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Sales of shares under stock purchase plan</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,134)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2019</a></td>
<td class="nump">98,687<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">410,946<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(311,182)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,300,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,548)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2019</a></td>
<td class="nump">$ 86,397<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 413,205<span></span>
</td>
<td class="num">$ (1,451)<span></span>
</td>
<td class="num">$ (325,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Sep. 30, 2019</a></td>
<td class="nump">37,314,076<span></span>
</td>
<td class="nump">37,314,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812209200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEWLINK GENETICS CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001126234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2503 South Loop Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ames<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">50010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">296-5555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">42-1491350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NLNK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109105 - Disclosure - License and Research Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LicenseandResearchCollaborationAgreements</Role>
      <ShortName>License and Research Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111106 - Disclosure - Common Stock Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlan</Role>
      <ShortName>Common Stock Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossperShareofCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Restructuring and Severance Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringandSeveranceCharges</Role>
      <ShortName>Restructuring and Severance Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.linkp.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Common Stock Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</Role>
      <ShortName>Common Stock Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlan</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2320302 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2325303 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossperShareofCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossperShareofCommonStock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Restructuring and Severance Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringandSeveranceChargesTables</Role>
      <ShortName>Restructuring and Severance Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.linkp.com/role/RestructuringandSeveranceCharges</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/DescriptionofBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/Revenues</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - License and Research Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LicenseandResearchCollaborationAgreementDetails</Role>
      <ShortName>License and Research Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/LicenseandResearchCollaborationAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Common Stock Equity Incentive Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanNarrativeDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanAuthorizedIncreasesofCommonStockDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanStockOptionActivityDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanRangeofAssumptionsUsedDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanRestrictedStockActivityDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Common Stock Equity Incentive Plan (Option Exchange Program) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/CommonStockEquityIncentivePlanOptionExchangeProgramDetails</Role>
      <ShortName>Common Stock Equity Incentive Plan (Option Exchange Program) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/CommonStockEquityIncentivePlanTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossperShareofCommonStockNetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossperShareofCommonStockTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Net Loss per Share of Common Stock (Antidilutive Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/NetLossperShareofCommonStockAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share of Common Stock (Antidilutive Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/NetLossperShareofCommonStockTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nlnk-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Restructuring and Severance Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.linkp.com/role/RestructuringandSeveranceChargesDetails</Role>
      <ShortName>Restructuring and Severance Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.linkp.com/role/RestructuringandSeveranceChargesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nlnk-20190930.htm">nlnk-20190930.htm</File>
    <File>new-2019930x10qxex101.htm</File>
    <File>nlnk-20190930.xsd</File>
    <File>nlnk-20190930_cal.xml</File>
    <File>nlnk-20190930_def.xml</File>
    <File>nlnk-20190930_lab.xml</File>
    <File>nlnk-20190930_pre.xml</File>
    <File>nlnk-2019930x10qxex311.htm</File>
    <File>nlnk-2019930x10qxex312.htm</File>
    <File>nlnk-2019930x10qxex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nlnk-20190930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6816327936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted average discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives', window );">Unamortized lease incentive</a></td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,929<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases Future Minimum Payments Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease contract</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease contract</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Unamortized Incentives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_LesseeOperatingLeaseLiabilityUnamortizedIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812681328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Severance Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage reduction in force</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">$ 4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="nump">$ 4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632047264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September&#160;30, 2019 and 2018, the Company has recorded</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> no and $7.0 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> income tax benefit (expense). The income tax amount for the three and nine months ended  September&#160;30, 2019 and 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to a full valuation allowance recorded against anticipated net operating loss carryforwards.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has an income tax receivable as of September&#160;30, 2019 for $140,000 of which $71,000 is recorded within short term receivables and $69,000 is recorded in long-term. The full amount was recorded as an income tax benefit in 2017 and is for the receipt of alternative minimum tax (AMT) credit carryovers. The Tax Cuts and Jobs Act of 2017 (the Tax Act), provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability.  The Company expects the amount to be fully refunded by 2021.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September&#160;30, 2019 and December&#160;31, 2018, respectively, due to the uncertainty of future recoverability.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has a reserve for uncertain tax positions related to state tax matters of $653,000 as of September&#160;30, 2019 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795708400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues <div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Prior to transferring the government contracts over to Merck Sharp &amp; Dohme Corp. (Merck) in June 2018, the Company received payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services (HHS). These agreements provided the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues were recognized over time and measured using the input method. The Company used labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. Under this method, the Company recognized revenue generally in the period during which the related costs were incurred, in an amount that reflected the consideration the Company expected to be entitled to in exchange for those goods or services transferred to the government entities due to the government entities' control over the research and development activities. </span></div>The grants and contracts with government entities were fully transferred to Merck as of June 2018. Accordingly, during the nine months ended September&#160;30, 2019, the Company recognized no grant revenue. The Company had $520,000&#160;and $309,000 of receivables relating to the government contracts on the balance sheet as of September&#160;30, 2019 and December&#160;31, 2018, respectively. The Company had $24,000 and $54,000 of accrued expenses for subcontractor fees incurred under the government contracts as of September&#160;30, 2019 and December&#160;31, 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804074352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the financial statements of NewLink and its wholly-owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments and Concentrations of Credit RiskCash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable was $58,000 and $104,000 as of September&#160;30, 2019 and December&#160;31, 2018, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.6 million and $7.0 million as of September&#160;30, 2019 and December&#160;31, 2018, respectively.  Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e">three</span> to five years, lab equipment has a useful life of five years, and contract manufacturing organization equipment has a useful life of five years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases, to improve financial reporting for leasing transactions. The Company adopted the standard on January 1, 2019 using the modified retrospective method, as required, applying the new standard to all leases existing as of the date of initial application. The Company has elected that the date of the initial application, January 1, 2019, will be the effective date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to apply the use-of-hindsight or the practical expedient pertaining to land easements; as the latter is not applicable to the Company.</span></div>Upon adoption of the standard, the Company recorded a lease liability of $8.5&#160;million and a right of use asset of $7.5&#160;million associated with these leases. Included in the right-of-use asset are lease incentives that were previously recorded as deferred rent liability of $1.0&#160;million as of December 31, 2018 on the consolidated balance sheet.  There was no material impact to the consolidated statement of operations. Refer to Note 7 within for additional discussion around the lease liability and right of use asset as of September&#160;30, 2019.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Prior to transferring the government contracts over to Merck Sharp &amp; Dohme Corp. (Merck) in June 2018, the Company received payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services (HHS). These agreements provided the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues were recognized over time and measured using the input method. The Company used labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. Under this method, the Company recognized revenue generally in the period during which the related costs were incurred, in an amount that reflected the consideration the Company expected to be entitled to in exchange for those goods or services transferred to the government entities due to the government entities' control over the research and development activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>35
<FILENAME>0001126234-19-000142-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001126234-19-000142-xbrl.zip
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MJ9:L%;9'A0TD@HJC]\TH,XF/T.8J51B(A/>.:0[$S$W.R_8 E8@MAA4')6)
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MH,BSU9I[!+OVG0%<&'MMEP)J\\&*'Y=OK(%J3S=7V^^ZRG:^7RK;.[+-T8*
M,Y3;4^Y%*X!N<)=;>>B'!*2#:GB7=4'- +@I#X-3 \US%;VX&?IJ8]DEYW.A
MDF OX\#K09XWWM;8.V=XON+@PC=)X@:S3M?#"F?H4TMD:3XLKEP5Z,L/KVZN
M@E"S97FD&1SHP6006V5!\1W';(/GRV@A16&?%*C"TN.DN[V]N^6J>!::/5@$
M.!H',?'VKF""OZD8KA#V17-:[H$-E2CJ&N8!R$5#U? V:Q >KK1UZ.<;+<HG
MQO''"D'L+"]\O /\XS-XX0>&T.!,-@ILO2^+.=A=.UUT\W8%]S?)"FY&X5KR
MK$^/#BO+!3ZD$]C#;US]K<M8.["MSI)B;CBP7^IB?!@ $-H?S64#\0Z')HP%
M )V3Q[,2L8.*">@ZW3X0NYYGUJ66[4]T8\VF*V6.U]0R,TJ$1[0K4SAH;G!7
M%>.:_AB#YEQ1_H-"A%?X)[R#NANB4ETABP<-L)H7R*(23!D%S31/C "UX$8I
M$9@!7<3.-J!.CA@SP5\DP*.+&9!59BH)/8FCH_WCN:02T$PMU'KK"<2FI3Q(
M<MN#;,Z*N<!M!T^EI<(:: I08.0 _H'RLZ+$5YV KDY?84(#?B4*>NL5%4AH
ME593K?&1JH;-9HAME2UINU @&ANH@KN*.TDK@"NA< -]<EM,B16\;LZ,93LH
M7+DNJR+/]<HL=.) (6C0%)/]X! 7(+)C-@G*(D=XGFP928\7L*G+(UXY*4W!
M"VO,4*.>'O9B$_ (R&_>QH-["2N6U]N""50#FMQ.#\\#3PQV624$3(H66C+E
MDO]9,<(/:ICR?%K01WC$L&X@9\Y-!RN+S@HF A:<_&%2:2<JOA,%R@QOY:U>
M5CZM#DE]IBBA,JNL,G9K4!6D1&8B.$-L2L]&1;J,+'\K#1B#I>Q>/N8!VW2]
MMC\H<5TA6<DE)#Z*S'$Q16@#8IID_H;8[ @!TLPDO9&Y-^=X1ZD!E89"0TSD
MP,VS(K$Z*F5U='F5S71YJ,Q@L!2K[CK<*E90*]'^F!J9I!8YX5?98V<2\Z<N
MAVX/DR+A^HC<6Q5E8 6A/KQ'14E85Y@+A[<%)T?[1*V)L1<?CM\ZAJ)LG1+?
ML^"DRWL.2E*QI#_@&!59C!&[/=K41-3+5]@28-HPI0S#NYFVD#V?YDT^D6+W
M^Z8=SE$T7SRP2K+4+*0%IT+93*$V>1VLH:O#=EZI),<6MFA@:6$@[J2[KIR)
MNH,#4A;&QN3(9QS2!?,X=+<LVWM)"?;<,A Q>>CW&(\&BX=2M9#?D!L:-\NT
M@2'@4P< XOJ36@<1]?FR,3!K6YG* YQN-R!!HSTU-1@<R4/T"?(("1+<ZKI:
M6.^VJY@-KIF*>D\@2@C?4%?#07=H7OM4[I54%:^]C5:R5UQL_ NJPDZ@*NRL
MR?=D!TRESS#YW@<L]E6HZ+PM\J,;PARME>-L^"&YRFJ^6^]\2[X=6/:#/65!
M&401J1&"B(VD:ZVXADE2!_T&@S(BB93JJ'?K7N68$<P*9V?'8K>-K;V]IX?F
M7A0:]6S%_C3.[(9XT?VV_3G_RH+EJ^VOH!_:/FBX6?G<2EN*:$,C03^HE9MA
MK6"YKO=HH??BEG')4'#7\7OX' O^0+=#=#4R#3;IU1NL'=+BQR5:4*2^6@R2
MJLMC$\LM[JC_EKFC/%=0X*[[;"N+W$]-V)1E%F 0I-@@!['A/!Z'S],'CI>I
M16RK,>PZT^C@ZA"M&D/OG.%+$"^36\G2!!+FFQ8'6["NR7)!:RN3 K49ET6
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M>%X>,=K^&9B?A++/?>OH%'_1H#)GQ/74"F1I&(?Q0V/@)H\.GLB@WHNT,;V
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MHV(";\]T]S"<);0.$MBUZ\TI?I2N8"2':O=#X7J7]^M'\J:9^F1FS<S"Z;9
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M5AENE/#+-RB>U#B;/:!!F."R>6U%X-H)BZ&?E:=41&FI4,L'Z!/;"K.'-)G
M<Y:,YT!Q6!%CG9*8AHC!DS+ZAYCCXD/Z]!;&[%$5,3(1:/*<12X8=<I;+4Q>
MY8$)C6&8S[/X8$[+&[X&S2,L1<T2YD+)Y(!)/:-@7# 6O:8^1NQM6AIH9N$-
M3PXF$:11GI@41>3)"AT3(U3!,XA/@I*E@6EZWO#DP)&,X22IBC1ICG/*#\ZI
M" R;*,!)9DL#SE2]X<GA0Q/5 ?I?2>]XB. &*$,QDXQ@' V7T\-G9O3!@E94
M">'!OC(N6K"7!0&=C%D@S(S2*_C(K)+S-P$XKW1_W;KB=[>NY(1F=YE1EDIA
MI)6%7TL2-R$D*G@,1.@9@+L0_18=HWD.',C:<TICSA<S!OI/,^&H,\LW**8:
M#Y@^H#I$'9(W,!82S[%H@BU0OP 7D@6!\?(!.N5XP/0AM3XQYP*.EG,NA-64
M6":DHX"=47P)Q^CTXP$S8%Z&59!!. ^X.DQ<2DPH&\!8!A.%C[R9Q0=SBO$
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M'Y E+"*MK14B,"-C&FHW7FJW1VFW[])6JK>?J[?^]YX:ZK?4[;0J@ZZ8[=^
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ME?+@J[E 1ZGGX3Q*%B1D!EY$AM ,;L/L<@PE&HQ;VQ),YSH);1@)$M!U'>@
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MJ2<#FMF$A4$"SH*5AN4J7[EBG54B;&T+VP=#"AX!WB,'O-7&_ CPE@9XYX%
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MJXUBD/[Y (ZC@]TFN;'JH#MO8M9<I&29XZ%I+.@=0PZZ^6O(VO!L@),"VJT
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M4U"K^;4[C*/C_$NUP<B1LI C97?:9G">.E*,3M(U.9O!-$/_>/+,1X7,:A_
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MO,CQW7/Y1D!N*N1+XS !!MIFA@XBTXEKKUP613>-T57?ZLMM5I?..4NY$V\
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M"<X*]XF!59ZY"(%!E(Y':Y/ST/2(Y<[3+$@J8Z R!BK,[*"G:_V%B,"#P(/
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MFT5"'[, QDM(#&SVS"4'S(OL0D!G>*,W:YJEW0DU^=&ZL[_<\;VFM)(\-YM
M+NND33\]Q/%;BITN2#1O+Q13 F!T)K*<)#(P@"Q$)YA6 31/",'+%6K3C\%/
M0]"XIM#XH"U "067C8)SZK9S@#D$P5 +SR"6TO@4D%E=A+7*:E?,UK9UY*/N
MGO)]!Q^$ZFK[S_T\[<6J"O5.)E6YOMAEJ K>QS9EC!PVS1K#:)SRN/V&NI[>
M9'0T2+UFPS>.4AZDO4F5Q*=5$'\=CSX.4DX_?OY]TL1(SYK=[9R)(_'/0OSS
M_D+73R=\E#&PJ'E@H+QF :Q@7&3I.82,F+:VI>R+*[*Z']#E\_V;KTNHNBH_
M]ZTAB0!UW71T M0. >J\_UQ4H4\>F,8 #)SC#+FM6KW14%5ZYT(N6]O*](V\
MW\23QP:H&^Q=M_?63;31]'\Z&GV:]'X:CXY[N\./>=(J^SMW4O8?9:=,6LWU
MJZ%1V)0!=WTP[]>3<3QLIH:,2B]_F2E$3H9U\4YW+W#W*WYN1&AR,-J)59[&
M^<+8JIUAHLE5MU)UW^W.^PYXR$$F69@'YQF$[%DHP3*ELA1))\.]IGRX+OH)
M"/G6TN8GD%L1R,V7>*.WV1M@P>G$ &-F08!BF)/^_^R]>5,;R;('^E44W'O?
MF8F@F*KJJNKJF?N(8(SMX_,&X07/A/F'J*U!("2N%F/\Z5]F=;?46E@-6$#/
MG..1I5YJR<H]?ZDRSI,@W=IFNDJF_!/A;,_88']\#7K0!Q+QPWI?[!_2I)L<
MD%63-3^SQKLB+W02+>D#V\B:.\N:F?X"*F5>IPDG,I,Q)2X0S4&AYBIW0L.N
M)C2L;;)':"[P$C)"&D[X_#GA_2O=#2=\,$Y8[[]G VB\H'6K+&%$9$(2:QTG
M*LT-5TF6QB@:8XMY<0TK7 U5_%DGQYV5,?26O6AU)C&S)D'N6<N2>]>J+TG(
MF 1AFX2,.XJ2F?8"(@>JDX(23:E"41)(IEU.8..82;@QVKO'4:J?IQNG86_/
M@[W=NZK<L+<'8V\U3=D*:;W.,<LL""*"TD1[IHF!+<R,$CQE"C7EQ>XI#7][
MZ6[J1\LK*WK:-WEES6B>=W?J%;5;+\4$'@['<"YCM,CU3T\Q>#3JNY/U5@\L
M7?BRG^=A@,?6]8>KT[IZ^6HR>MUR;@TZIGMW5>HGO;9:]$O6OE%Y5\BBKWN'
MJ\.UF[^*1^L3GJQ&T[V5ICN#@.RT#%2GGC#8) (6B063/K4$MLMPDX@\\5A9
M01M%MS'D7S)7>]"85\/5[H.KU>QWF@E.E4J)S@)P-7146NDR M(H<;![E!J[
MMLG58O^0AJV]=/O]T0V&C^&L5JI1-QF>B#7?9%:L$BC$\GSF-_W!E,X:.7-W
M.3,#7NRI#0E3BF14.B)\+HEQ/"&Y31)+C?,JP>Y]B^U#&J"A)JVL87Z/5<S1
M,+][8WXU)5O!3@B6)X0SBLPOX\1RX>$32T(FO14!46[4PY9QO 3NUSCD?ZR,
MH]-SG3/3Q=[9D1]@04>O/PJ3;MJ-R^8YRI-[5Z9!B)04M)MO!XN)R:_,66=D
MNG\AAN>NA=4T.*HF^>)V<F4&PUASEE"7@T@QJ2(B9YYH[2T)*0B5X#-O3+JV
M*58*.6UU^6'#VIXC:[MW5;EA;0_&VNK Q"I+T]PPPAB31*3.$]@U3;*0*T]S
MY1*?K6VRY&&1B9\G;UMEE_3J%U]4R,3Y)*GLQPHO7I8GYN6 ;-XG:O&-,ILG
M68Y-9O,=)= ,-+'P,LFS/"6.9@KAA7)BI$P(]Y;;8(0%I6%M4R[F>ZR,S^;)
M8VHV'/1%<]"':^'7<- 'XZ#U*FKO$A!^*4E]%HA0B2=6YSF1J4V\S00'!1]U
M^(?U3[QL%KI:#O&5UNY]V6 (E?NHZ9N>+SX@E-%7X *]U4E";YQ$JZJKWQ@0
M'R40_O_UE+H^AN%HT'&CX/&'K9Z?_:)VY?LPZ/3]8F\LUQWC1KS^YHY,[S!\
M-*/P.L^#:^! ;B7(OF_-F (\B,QEE-"0"0*& ::QY)[XA*>)#!G8"2)V*>%+
MZAP;?U3C:W\A;/2G]!5IV.A*L]&:/>"9LR85"6$JYT1DN2;6Y98$Q64J6)(9
MD12]240#:+H2JOZSSS1_=9F>WS*CE@V'G5X//?S]O'46.47CGGH.,NT6(HT#
MOS*YRKAS7*@L-P;^R)T..3692I.#=RC)&$_858T"'DZ -?+H5O+H]4SSP20!
M*R_D)!680T,33BRH]$11SC@H,HIA12?C=#U=$F=ND/X:CW[#,I<Y4WA@, Z;
MJL2)3"IMI3/."@F<TCEC(LM,&Y;Y9%AF786WW@L5%%%",R*X8L0:S-)17N4^
M]4EB!:+9Z?64-BQS5=7Z9YC2?J4B'^#['U+A']+U]&C[>(O \<_?S_]>_5:D
M3TTN9\:%5#A*609&31ZT3H7,%=->)S(7(<KE:WN>-7)Y1>3R3"^TA#OKM/&$
M:YF 7*:4Z$)"FUPJXQ659FTST^N2+[K6?C:2PY,/LC=2I)$B+T6*>*,3D!Q!
M:0[BPRJ=NC3HS-C$4Q CJG"(-5+DR4B1>M$%\UF2)8&$5(+LR)T@)LTU271.
M19JD.C71(<;7J5H]0-\G+T:: ,[ME_'3^.RL&[ <RW1;OC-TW?YP/"CP@= 2
MS",*<*=7,!\@T]^?B#_R@493.R0)'!+?']MNN%'Z\.JB\#Z995LM5\[*)F-&
M7\Z9 >X-IQ;.[B@,0-J_6(V[T:LO]]H^->WYWH$6WI6GXST<EW9HTI-NI_W.
M=NIA6AC+-='<*2*8Y 0=)X1;1:7UPN2,K6TF*Z?WKB(+?^%.DH9E/Q^6?>\
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M/X:7][*X;A^!UX9O9P%!%I"I6EAD#[<#&>!?A\ .A_E%?4LFK^QVX"V@2%_
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MX6JAJAWK^U $X;2Z6&!VV(GY7KX_MM7?)QZBV:E6HF(J3&? -@MDE!^;0/E
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M/(6L:*+ UF\);@_<7#'O4YE1);A/K-+!2!LR+E*;^"2"V^,_*P!N_VP<QC_
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MC^WNN-^$HQ79L:?JX+B<-U[FX'BB_:L?FSM.'1Q*&N6R1!&;Y(:(+(_Y192
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MB_6IEJ=P!N_F)2+^>'34'Z#8>KF:T/<M;$.N$^&5UXRH8$%69=01DRD-IJA
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MS2-P%./>>$K\2>KAEC'<C3%HZ[#341_F#1BIMWMBP)A7L!^GAS\_C@YP[I\
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M1%[9*,3GY%Z9D<L&UIZ,PXP0-6Q[D&:9J%:>H>,& 'F4Y"%:U*FUR](T6FB
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ME8JN7"3300(\<9!F("MX-JHQG?S.8'N3R:B7CL,M)34IZ>(X8*X9^(&M1D:
M>=,^\)G(!70&>K8;6 Y:/]Z\=_R;*0FH:)BBWQV(2$ =@@42AES4[$+*DJ K
ML!*, 03B$MTE>8F,B"0G4V1MK#K:LF@:CO"VT^V_4T*B!0$CTG. 0V(B</K*
MSFPJZ/FO-,B53DBCT<O>3N4C\.&[%N";]#R)J(@;F]+K8>CED1668:&V;)H
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M*8ZTO4*%6'$W#.,%W8V#\;(ER&_1J91;'Z43W$#6W#UE,F1C<>31#$X-Z6G
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M]?B-@;>'^WB'RP,CB$ A51U-#U7+X@X<KL=5S?;A. SFQ@X<KM5>=A4M^XZ
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M(+T0CFQ&"2)E$!A&;EWGVZR%H0F$+P.LLIIEHB/'VBOLE3)@+2PCA<-ZI'#
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MO^!C3"=F%'PD5H0+:2L_)L(7+!<2R/6E6>TZ%OPI3 >I" J=\"AA&!2XP*8
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MDR1\S3QJ:<X$X&6^Y@K_O-0^5L_Z0@:5*4. 9>B_Y34T<0.KWUS@ORXM:O=
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M<3MFW.ZJ&LZ>!,^FIQ]0 CKZX9'EZMCNXFQ+O!WGQ^T.@SP[PB#_T##(?57
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MP@_[]',][-E37N@PH.%//$A<SS;U@K5P1&4\A?_^YZ3W_.,<AJ&4?T=M?_?
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MM)\79:=QA<)Q1806N?ND[/=Q7W\/?("!77*9K!IJ"YAP9$Z4BDAM01'\#&D
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M,"+'M7#/GSF$^:%,^[!P'#?Z8#;:S/ZQXYPX21/C*XZG^5 W60.\RBU<55'
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MC?&].*6<T8XP A%A:LCWPL5>15.AWO)4J!]X*I0HV)6;TZM8,C"9##HT?U&
M:KQ@G71MCV>SM\ Z>JY//X2_0L^0$9@R>9$6^Y>H(AI6?/;3+YTE]]Z3QA"6
MHX4UNL-AT.),GB8]B>"#+(<W! *[KCGMN4Q+'9^B-8Z[.$*\>A"OLR/$ZPCQ
MNG,+RH'!P X)LQ"88)AHBFR.^,2&?WG AMA4@2G3ZY>&&2MV=(&BP:=^Y.FQ
MH^U@Q G<$.I4*HMAZ4G*M70DT%[;3J=@K.U0IY'^$_2140!%8K.56D[N:/ W
M74(,=A2?@Q&?8184/X?.Y.$U&6(GAQTW^J VF@I5-NJ>.PZR'08P=/Z'Y2&K
M SZV4V:*1A0>Y>%@Y&&18L9&F^<D[N[D.ZN,*OG:#=V#4_%D00V(?:'.]T@)
M<&T42A!2\T=-<DB2XUW0N&XH[%J<SVQKEIEYU5X>-_=@-A?UOQ^'A?D"TRX_
M[BLL4BHVY.6U'4.E-%SU]W"IHP@<B@C8P6,H"PA<RMP6SCQ+8!R2Y'=)A\MN
M[FU&/,[>WC@JRX_(HC <#THYF[658L/LR.\4FWC')A-(G7W!K=H\FH%O?II<
MX!=7?A1PC ;!L&U*#6_C,U?I@]ORWHQ3PDJ^%#MM;1#BP%1S$(BGF>A8"50>
M$5K8M.1W/8G3Y 6[$OQNIJG/DUC/D<>CG$^27W_^Z>F#<_KO^8,G]-]G9\\F
M%D,WUI% =59#PX^P0'%BR^1R;"A:##<T4_4*[F@@]%74'!':2 P&7!=M)AWG
MF+ZG;9%*)$;CA$.2Q=/JEP#SLZJ/N/Z,/=0'5#]\1]-11IM/*&PE=#]#Y.<3
MX6E $15(LI8M] -]5 PL]@F-'REU:'$TV@-W6<M&I<1-L'!MK3<+--UE!<8-
MY($\X%YB3PZ20Z2-PE;!W#8TQ+$SK\4D"0D'=G_5K-*F9,I"4C-^,J"#9':G
MUPL=MHTW2P3XG>^\#:*09>Z*^8#."%TD<Y  5ZQ<WL#!S4]^[O)[\#W_ZS_/
M'C_X?L<;[X; O$YKE=0A085?_89%NHM%!;_V<PY0>K)"1K_S2W@-27PB^NR>
M>])?+AR486RU%K^I(83/B)D9Y"7;P9)I99X$69P'-CJPYG/0;QD%#V06JDX6
MW%S+I+^)_.*D77?GDN.[Z?! F3_.MH8'P77'EJ<(-4AK8B3!S.:D6T8>!VDB
M9Z,\WF8M;M% J7>BW#"*DE4JCDT(E#' =DK-PW?D5W7Q)!/JQ=%9>&@&VH+,
M"KPL/9:5-NEX]&M+@YFI+1;">.J!H@L%<RGV.M"X].]-5">.<$:DVZ3!2^?L
M'2#PX6Z#9F;(!]M$42\= L9UCMLDE 33^"94.;S\15F<=%OB FRI,ZY$-8F<
M%C[A \,RE<O'NB7WIC?K1A>]K.;LTZW&NO9P6;&KB4&F#7?EP8(MVU5*8Y'1
M(^\-:D&_#Q$:BZRJ8RGH;+!BK3TH;S"CBF+30?=EYN$[>QANSP15YNZ**RX\
MAJ(C;;&0X=/% W'(V ;0B;0G&E15QW^B($^57_=> V*MZX$J9<4,BSX+/=V,
MU)RX*YEOV%U<CG7$NQ9Z[Y&SI]:*>!X6!#=Q8:N1.*N_;YCN!F^?\/,38@^A
MT(%H0:C[F+V1M."50\_/-V*4;0,:VG60/@J2)/69";ZS?^-YZ9@L"N[=*F\Y
M0YN'/JX8SQ!H^6TU8U2+%L(&E I3S)$,+V=V::6-,21@M6"M>_?L$&AQ.,.=
MY$2<*"T7&.4&KDT!92=E',6,40G>@7/E"'38NSP2[VU?@K@UA_!K/8REQU]J
MKPQC,^,VUZ%^%Q-T#]U36EZF(&)E,:0FZ*1=8^288SL]Y62FI+A75 0YLL+L
MO=P]BN1ND$E!:]KI5<F-[>ME6JW2F?2E-A!,\K])4Z6@IHH2HKYL!GKL* 'W
M00*DX;@(W 81GN%(_W-(^[PK>HG82SS4@<DN@KWH-$AF8<KNO0N.D/6'<H?B
M_S'EI^^(+5O+&;&;:[>;/V>=1=,>Q\4#_-(4Z\7D5X:QN&C;,]\G9>9J!$C;
MI^[0$5%^,Z+\_(@H/R+*]U'7W3:)ITVE)@UA.FMO+C'NTIVHY&A<B>S1?#,3
M!^O9/$^G)6=H)65O-2FWYB#=DP?<41X $[[S*KTN O6T?(PJKCZ!C9%+*1:.
MFAX_C\+<.Y/VVY85[61/):,V1(!U ^^57TPEYP@[ZS-4M,&<5QM]($K==3H?
MZ;!2?JE#\=7C1)/A\L80DBT?9@8SB:\FJ[F0OIE8P'=*5?F4WY3*F3*@6ENV
M:*IZQ33Q*G:6,I<]K'_[^HW4G<1F:WYZ;KY2%M&4 0&*#:^71Q$*(SFS64CN
M')&L)\CBVJYD_/>BS1=9GG?R;I[\A@YD;4:3#Z"9E3;.D!MV#W MA#[FW"F!
M0H^(E&L\A/B8#"(+Y.7"B68W!UG?A)]R_#DFUH/MU3,--,5+^I97XC4U%QQA
M\>_T[9XF%\23'#UP9<Z6/ 7Q,Q#O<E@U RL;?JH#5%1WZ(3F(H]3-+;/DJ:S
M'B7I+%WSHDG?D"\4=.W&9C2_)0J0B+/#;(@ 1@(5@$<>+ML6?@B )^2*RH+(
M&T75UKK\^B'CR/H>H C=:.LB@;E)2F3P#N/V<U3D!?*/$'E!Z K"3QFJ9 (,
M:#T!OK1NJ[I5?BM!^8G1Z]&G>::K/CND3,P[39XKB&-B$"],RF"*%EQ1 ^O4
M4T*+[I01D>-PRY-ZAN-3(H4\X9?'KU"3LWPF*XACDYXP,-0E]:9N2'E7X6MI
M]$5/"X??Y(^3Z8_W9SY'MH^Z+ K'Q3%X0^5)M3ME\]M8U,N8>=A]S#1ECAO'
M54B_<_B#,2NT.1DB#6T,'2IRL%EPS9F[D2U&,EP/'^]60-G'@_*^1/ )D>H8
M^?<EU&-1Z>!2?AZ?7A$;M6@RYKB#W>4&!'CB:SPN#DY"N<$1-VGMOM]-W(\)
MW3U(Z*;H+'-DCD'(+&6<!5FH&,)R3-4?ULZ*X?,6+;)BL;GBLRWC<X-Y%IM\
M[YVZ*!L?!Y7H,F I,@+@"V"P<)<E8L.4QI72R-RPS9Z(>HA@%:OY"2(3D5A2
MR*YJ;N1STBD0V+WB![#-#7\$KBJ&_3'3JF:1'/9$Y5F]%&;KD*C3+?+^-Q(@
M4CC%>Q 66\"DL!$,$66W6_)XS+8)$C%:3#',HOI4,E@AZF_P7Y86@UL=G7M%
MR_F;!R,S8$M)R0VHGY:=_EJ4G4"$,9ZZUY'G3UR9!"%P\(N9S5\8_EN%]EZ5
M^95"B;T8*<<R,\3F-*ZJ$\.)2M!/#DL;X9F)D S^VSG]5869F&VR)],&!-E<
MNPJG0,)+O+#DT S]+919$6WRS$5H.:8YQC;SD)SKUA)MAB)/VV*V/$U>\RIS
MI+(D=#:G[NSYV?TMZ/$F-DSL;IR^X20Z9780B>1]S0@2CTOO?1S3N'[NB::R
M<FF3O];V$'ZC[BF/+EDG-.H4Q.1VANZ^G5;:=L+D"N%DAYP1C^6OY94C1M#S
M!V>/?*I^,">QA=;=9%EO9'76 M*.9+:>F])B7'L)#)2#%"ER^16]9H])VI'X
M55(HPU7W&VG^86'6(1*6=#VL48GY')I@XC,$D@-:ACM*#QSC!71Z6H*LQ:OT
MTV9Y[JD 4CK46WJOGV$%,Z+LMPI0\N>NN*3L&NFP:59V#(,'J2P=7&$YXVZ1
M%;P[T8%&-L'-=U!AD9G '0-M,K'JQ8PN,/,X@H&R$'!3)@NOG8Z\,+YL[ 79
M!Z54L7E.1E* S"RS-4V6-BWBB,E!JFCI\_0UGZQ89E/I6QT5^X&7HG4LVR9A
M:/QE-NM4E; ^P:,@G&^V.::##BZLM!AC"!X#'*ERLZK-&BFER41KB%JHZR/P
M6@8VFR$GWN=LC\05!R,)1$I6&%>--S:DWTU+#?=BH$O9DXX^^SUV:DNGUPIT
M)"H7&B#9B&ZM%1/0445'V3DHV<F%))YK7,136VV"7>%V@)(:(<FAZXB73<FL
M6YIZB"A3NIQ# HTKJAFE\RL(S--+(47"WPI[AG$#:&I+&.#A8R4$2&Y/>Q[1
MBSWTXL,C>O&(7CPJV_U1MJ8+,6#-.8'D^AWWF/AJ?/9I[HAG'"=6#+AM-IUW
M[V+2'X2  6V5#[YTJLTM@T5>QEIQ;#3S@SVBZ[0: F^,MK8S?$C)(80ARC><
M"HD"S?.2_E@!#XUF0B%Z0W:C&!O13<&O*Z0<;)"TDC%^S%&A3?,#<?NMUH>0
MEH;H0F\;(DDWE'_4803=U(V$) 26NO$Y@K_*1#+3-LO]<-Z 4LV*197"UUK*
M:(57IP2V!VK%F&)-'X_W9UQW^C-DC(WMSV"T4+]%XZ[G[5DO/'YV,-6A'P,1
M(D8#V,IBPLX/;F-VDW/#&3B#<S?:'6W*VYQ(]R$+CBT/XJ<<1)Q/TJ0=C:\K
M4%A^W\WXSP7]WQ?3?V??6?TG.D824W"%>5(351T6O9(BI1A,]%5H*L*?? ]^
MG2SARODF">:$!JQUMF5@3XD9<9'%]Z2=0NP8UW]"1$ ED+Q)E:!&IVD34 PU
M1>\QO$+."AS8EB<KYU,6] KQ74VE'%3>8G&:O/1YC8OV$LDB'DXP/?XL>;Y,
M*[28?SM-?LZ*#Y/D;]4I+\NBY!DB K( =0$?SMPB>?G1S5JZUFO4)ZAA^0_O
MPE/(7^C+<(L,YU7K%A%]'.:=&X*Z$]B;QIRQU:_]%R9C-Y3+;KDGL1;P(D6W
MQ1]>P&TYK2A_>4YAUL:NTCNW;J2(\(17:I*\J$Z37T$=ECE<_7_2)?@4-+U[
M[#7>@.TD7+E,6AYXG--$2'X$$JTCUHE_[@23H#3NEDRY%*8TJ\!G')6)T^5!
M"X)'H\-EU^O4HS0%CX>W X%'*B1DR%7+E]1'@O<B897BZ0H-N.BV$]QI. R8
M=9$I9#IH@.H,G%[Q &^%9-4X)[#""UX[*B>RFJOAU7@P[3)<[U/4V#ZZ<%VD
MA\]5&NX";S LPELVT0)WP99?EMP58CXH6-VQ^;/]JA,(,&ZS.%HZ-_BZ\Z#+
M#LAX4 U&F38MQ*JLR9A5*VZA6!V^R?X@%M^;K.Y,J^3VW&CXM!35J-.CA_;M
MO2JK7>S J="YX1:5005-:U[7X)?A(_CV!O&?QMY):PX;N=:2*_">'?7C&$TH
M/1@\NPO9HI)N:Q8:N6ZNLGF+!$^D@KR3W2DST3'.2@-F]MFE";BF&8W'\OZJ
MAP;S&]F95@I@0)J;:3QNT+-E^"&#XB$/F$PYTN'I!PI +'G(;)2?)A=>SJA.
MB7@''*ML<2V"5J<!@'DY2X6]Z16$+S8/M\*F*GDDE01^*OSI-K:<E[QL&VH7
M I6&MPI^-BV5'<VRU778P4,0=U' *G[XHN=G%[^\^#*MTWNA2G=WQMD_1"K%
MZ[+ZP!5*XE?U@SG[I ^X\' "F=-.$?F#RZ0%>3QE=V<$V%>3]+HP+M##!^H"
M7<N$SP)'S!$ME(2:5!W+*1>CG*3XXNKL(%<T3QH&8^.J2P>NU#_\@,W^928\
M!I-'V971#DXWR?G3X#8DWQ":XJ,V[CY^\+^^M<20-)XZ=IB#=XSG,ZM'Q6.3
MN1Q3%.R.N'DD'1,_=)LJ/O2EJ=N4(C/^.^&2L#3A3GS\^ 4]+'T%01PB/H*J
MDMC&.DKP5W22- >QD''%,K1GY';D2KD/H$D)J(7C4NEZO I!M9J7V1:9>D2H
M@>L:OR/T6<;L8?$3<K>:W5P/822C1]+$F-=YHG/'PV,C'Z[,6>VPY45+55/_
M;";C&''9'+85%:DPVG%B"=?4,(%L62WNQ<&_FM^1?R((63+4&LT),R192)=L
MRG;41,)[$GA!&;/!-[D" ;;FV)XBF:E0JP5B[YY(_J35W/=BJ4#@P=IW[;Y=
ME[^EO.';,#8D'FEYX5W63X(@[PT9\AWZ1M6#M6!N W&K9&Y[Z5G&NRR-=N9;
M![E&=,'J($916G37"'<I=XK&0LM5M&-^I"=5S*O'RG4(B+'#6!TK4'WIZ!O;
MQ_#W9KY'0;I)=(RD,UDU0&/#K8U#LX9WI"V\IU3<$OR#=JTI 8S(=)DTUT&@
M<<-H'Z0USHPK+FQY7=BD>\CT"^97T)U#.\\]R)(!)2F YX483Z@&=!*XC)6U
M,<?U(/K-"X*-[#S5PL ;*)B3 "(=LXA^E.<LU]-#2P%O48#0,N93L:N!;7P7
MA*FA</;GL:L%M&LJ7'D+SPE>D+E.Z'NC*D,8)I [54@.R"Z:G3;MQ'0AH@R5
MM!>;SX(#I.AI96;T^+<%8*U$5,**;1EVE:)#03U6"WT^AA<93H$4VPC5#(C*
M6R*OC_B-F_$;CX[XC2-^8_][%B[8Q:%Y,H8TCQIFJG:MD1HUN9B!K*PN=7Q[
M(+S>64'J.!F*O#!?BOFY/+#'(.B:DHP37V% "U<6U$63>0  5<;@C\R(;NXZ
M9ZJ@>EE6#8WYDN^D5^"5&;BEIUD'G\U@*76"#S\GA[EV4:+I#CT,9ZH*7-T[
M',^1, T1Y\3@^YA)74O(EB_:8N;KH^(XPF?FZ0I!=T3K[K.',K^0:H8X&2&K
MTQJN&O/G2,N3Q+YPT7^<OCO=-DW93SUC_U;IBL'N4/J2'PXKN[WV3F/I4C9E
MH^3H>"/X8^MOPIDKV9MEFBL2O\[+ZSE"((BIW=I((P9EWYCIXIC;\X2("8$:
M!Z0SX>D;B(]%.?*5)-X&R82KAZYW26M_L5;<-&'&"N5M&5 BDG2::"5X9/%L
M9543[PK-,/QH:9*[XK)9QBNLU$R>Y5Q3 U@L-"G<L)+:D\MU!C\X#6Y.5 7\
M)@/)W\CWY+.4$[-42OUS.5,0([57P*I/TSKCN%]RY2]&IX3<[&7%TC Z-$M4
M63\JF@SPAOJ#QNG4==N$WDI)PI+LYYB+T<%7ANFN7N(N90.! &6BY%.&$<!$
MEG(4\&L^F,2/8.TG6E=:Q3]N=]U;QRPQV],'B'_.<H5PP08(0DA[P$1R]4!I
M:Z,Q&T.QDO8V6J5?1<_CHF"&1\\-4-R0T.B<2E^7DJD%8.>R8$/0+80GEY U
M5AJ^)5O3JO;F!M6F5LPD?F6JT<1G)^0&]@I4NL52%U=H.1PS(Z6J]A)7$"T&
M=U71;[QNQ*1+_WW\8#AF6RO* GP'=YWZJ'SXI627IY1E+;FA$.V"5]3K*E/C
M0NJRD1/#QRJKZ82S6J)#+AJ][::"E6'0EA='9LJS9=PVO6/:$2I83EA*+:O^
M],L;5KMJ(H2XT)O@7OX(;[,U9T8BMA'L*5X_N!&4+D;R)QP_-6I\:JJ:,Z.H
MBGAJ'H+P7CF689/1,9O#(X2\ H-[%XC&806=NY3)ID15(SU._-",(1OF(%24
MR5B&IC_'9.DOS?>?<BZ;;1/I9.^[J"B@^E#^2+US+3F&\:Q@F.1W":=;,L%M
MK4"E >&:">FCT2TS2E?!6KOLWX247*"T3S +*)&R*??1-Q",.1/7M"D;=OHH
MUTE9S9HZW<N>0X6^_C_5^?SC6A>3FXX=7,U)M]6,AO,)>VTXBNKIUZ*GQ;\W
MH-=>2KLG.YKNZJ>J AD#Q!0K%(H0HX0[X_=UD \X=IB2-^$%U?)L[!$\CK8F
M\>3Q?^:E^1=C1^L=GJ9P=_4(A18@JP>>@3.%M>L^2#>>P.O)\*F&=O7:"9P'
MV]APF6[(CUK<ETPYVO1G4OK(T<^14R.$U(3A@-WN;4111V]SFOP"VKU4H'=(
MJW:?T="L:%[5E"5BKW?@YFPR+-I$U6HG13LT5TPY",P%;9R%"LNA.T&>:QA8
M& _FG?M9N 8IMLZI5#I>_IA%K?FPCUKRB$?O#IV.B7\3G8& DAXH64?LQJC!
M6 S((H_-[<#X51<,R0!S\0[=&K["9H'MFNMQ@T7(]L[^,^'(EHK$M1HU6CVM
M':/R\'^1; C&.3($--_$$/KA&I/GZ/&\(9["FX.4T37]PYJ3#NI;X_D \UY9
MC&E:Y9N3FC:&3EV+32XDRP."T9?1?C5H1)^3%W33';3_LVZDE</Z>-6 0Q=;
M.FT*Z+*I2N=H5';@REG$VGJ+(IPEE++$Y*:-IM*>:4N!.LH2UNFEZ>!$\"$H
MSK$%MG6V1LYHYW,*VMO5</XNZF]!HD='9/BD'\EHQRHT7K01%C5P"@S"!=;E
MGXRPP8N**S!V"3$&"K/&^*4@[4^MN^/*!8>%UX/LM7%)G<*/ZR4HA\C4(8!F
MA"R.1X3SQO0\TRZ>5]#6 ?;B?9![US87 8;,3&*_IB11AN_+S_DUS16PH#&)
M216@*3W:X8&L&R&2#<\V[!K59"GR;]A)J+G)7(]]5%XGA: $?R[0^S$]4OQH
MH3%-O(3A+. !;O0=8#*I3=;TUJ";$K9.7X"6][H:8E40'_9#7-<;"EO84*EV
MRS=N^L(14G3[8E-*GE*Z)BPZ*_F^<N[ :83\*L3LN)K2J3.)6;#'=I'R9"4/
M)V<:^TOQS0*2B,\?PRV$3BMD[MDH*2]0;Q9XH&((4G%*SZCU$WQU7T&Q:^!S
M>38CW7GYA(?2SGE:0^/4@^FL&LW^[>;#F,VDK.:A_X:R5N%!:S]?//Q*>BC&
MDUCLT-#(<(3>1@D5N%GRP3FD!/S6YR@S3YKA\_V^S(G+HZE:)5;GR9T42W(;
M5ZUSA?63!-C0L>8ZV-/T1H8?NLG^T^1U#$&QN6)] 'WPD8\=&39V1VA\=T1H
M'!$:AV?8_(R'15*7*Y[<E?O$ABWCJ-VA*4ZHA=<IXB#1^IWXK 0X]D2O*)U;
MIE3E/4H98X$K;)4Q8>=#PPXYFY^<J&<$_M@TS D%IW Y#$#A!U#N$J6REY-V
M3$-HN(J8&X9<@.UP3\Z/&9*/KEX>6[MHP<(Z2IXL-#$*@,4/LZ?@.-6QEV:3
M<+OIM64D%%D 6S6QE:"1G>/!3VERE96=>4WRZM2E'E ?>,^1*R'Q?1TQG"CF
ME-HC>H\]D;E6O#:YNS).J]UPGMZEI3:$J<PIG(6@D6R[Q6!+@2\='+$E4&H"
M W5JG-[XBU7U'([,3$XY: ?.4B7SU< Q /&BCLFHG))VP_B^K^1%:.2"L[RL
M)3,4@#Z2TL7%["\ %8) $(D!H)7KC\?BZH)RNE73E11'5JNH':][(%E2R9=L
M?'>(UDK"R+4A%U>Z93%X#8&K)CUO)'Z5O"OF :07Q<)@0DN0LE1;-)9F#.QA
M@&"YK'BO<?&J)O(V[UO\\^IV$#U/&I,5/3TV!AH374QNOXV$.H/]0K(HY.NP
MFCF?,"VK5 I6):7(5!"Z4R*5K#9D/*3I2'I+X]ZW\# ,+8HG^6X5_\,3A-LF
M&$R8T6U%3C$KA_Q$( V+O"SG2NA2%>F\9"GY4"#^ BMW/")00Q+ZL>*M(36&
MWY_H=P,P#FZ&%$#E>HG!MH 7%;458%B=",<7W^*MM.@LN#V"?TC],K[KL\U;
MWKOC_9JL=;9"2S*REQ<K/ FVN1S^#I8+@3V9."$#>SSQV2=[72HEH;9/KMJ\
M<)5Z,;IAQ)VL@&$ZNP.7]@0RQ&8P>"%N%^3ND,V:824&X*H]K6MBIT=D,"(C
MA!M=X30\)-Q[4%[$J+LRR&VGRL7"XF+6* \5J4%AE&TMP[]YBN1O-L<]2RO8
M"O_%0"[R#79.3@1 J40'X6.@;-VW=&"B/N$_G3TZ?93 ^^0&@9U>7H(N)N,X
M)3I7HG.!4X_59%@KRA!3C=LOF5\QLQT./(0E.+ ?A%M"ZT=<I- 6E/ &9$?Q
MJI1MHG8J0>Z2@X4[%N[7P[_:[*1Y[PA*+3EF[=C"1FU;9S7&?N"IZ WEL4P-
MFBM8"ZFV4KL5E[^PX?K2]>OE<@F/C<!'P;S1E0@ITPUQ\[0^!*U^P+-WI>2+
M4I =D,5Y9V$)7D](=]--DPP9""FJ &P'EX$R"G!OY'W[I,4]G%Y'@A_[:2M=
M;JX;UI@\X@XQ7W"@5B7H2!>^1\"+$7U)L0/Y @AV3 GZBMC9/K$9Q21Y#ML%
M2KTI18.#8UK4.'"7ZK5)NL*QKM+\42PXXB4EX-_'/BDJ%;IDRTE7I./9$$@$
M+*4C7F2C@,*24%I6U;/Y [P- T@Q 4'1G40_W*E)E7 I24HEG*HLPC4E-!/^
MJ15KCT]Y62G9-ZNDX7<CY<Q*&>TETKA0PRAH\%S[-A:BD 8WN+NIGGE,^FZN
MM5H(OPJP,EN$ TLZQ_01\@^L4L'V!XH73T@NQ:J1UT"6F5J'PPL6P@Q1WBZ>
MZF"6"J<8>+JA4'?"/#JTPBKI=L9-['Y0BA<;3O!KJ-.1J0"VJFIK!I"JSO':
M*."$9QM8N9.T:4 9#.6SL/$SS8FNC]]!CM3<,6,:6QQ>R[%%-  #2IT(W42L
M#_798A=9@;;,VU;?<)Q@[>;H[L#=&F/-!\\6".@27T3GX?J$"I(3Z4.%E W!
M(!O5T/&CBP[:*@>TE?YRZK5$K'$=HB$Y8.H0;C%#-\OAT13M8.A[#!AO0ST:
MU@RCEE?%'-ZQVMR+U;BM(_2>.@5Y 4AM(0N.=JBH1=7X*SB.-]=U38@7TJ'=
M7"BYV6%@LUR1@^>VL/0MG#6YC\00[\=G;7FJO@X")D^G"/*"?ZWA#:B#Q!#U
M32(B9'(W<+2O^!6D$9JL%LC%-",7B@G;1B;P^9!MI!BQ@S0@$CGP#7:@L*:D
M(F[*/PH:8_ZNX>L'PX;N5Z4X]#[ZC5ZPTWJ($LB 432RTJLXZ4S:,X\_*'?)
M"U2N 2>+(>8HK8,'_\;K<@7^GGJ%U1K9[*2%%:VMZ1&<\!AW2T Z4,?JF'5I
M6*0VKW^Z6<2XY@I:-QZXD?H<O>G--=>7\-WVE/@5G7,1BUP(#"R)';:[_E%R
M]BJ#HX$L5"D!]*?P7KBJ9@X]8[C]2[T/PV7TKO2!D7P\51'G;@5O2YR1ZE;4
M<.UZD5I\^IC(T?(;YHMX]%R=+@0GYIM'U95.:\DK4AO$R:H$;Z0%YV/X%%$O
MD5QP@ID$9\#A_6OJN50UVFS6>#7LAL4TB:=IVX#>J#U@DH,LW"/:8:KO;-9N
M8GU<O&L!1S'W@QBC1CE)J-=29*'K*4;8 NW\C+LC6<<7@((\/D)!CE"0_>\J
MV)'8%J,B;X10VS#94<1*;/K KN-"BB_.#ZOO,I"$<!5\WKVJ*5MW/EH'WL8O
M2Q&[*P7P5U^I/5BJF]:JNQ)*7S".E@E%$4Z96Y=%2_E*5S:/VS^HV$]1$566
M&8;B9#0S.T$1Z;+ Y"?2ZH0O0;FRP3>A=59OD1ZD7I;7$<L?CTL+3L-$/8:R
M"BZ)9<X<'^DB5/?DA'4) =13N_7Z==Q0K 95\UPX</!E5O2.N%JRY4(Q=^UT
M9JZX;!V:N$&/K]DN&4-P+]W?J,>-/CTPE_CP"A_;];/.61;(3G]UD 5%%@9E
M)!KB+?0%Q5CG0P=5U!D/2X>Q'D+*X-6RHHV#0!% '-13"E)MAR#P9VI>@G"7
MBF(;;MAA5E<25D8&K"-V/191;O3WOKF/F#&_&+>S">Y+>:'BOO:0Z]>^_$ ?
M<0-P!&XI;#8SST$!#@4&Y^%7?*4M3R<]:Y,;@(*#*$0E]ASK 4?H0@>R-$K7
MM+!T%7]F.HV3+L.3L492<-%BML51K1#_C]$<!EMPI7_" DMOM6+,ZK3H[<!N
MPX?)#3Y.&OZ*8^NNTXJ*WV!LL3Y_G.YZ,#LWRZX$S%01(3C.=2A2XLPZ[N+!
M[*)A5SGNVL'L6@SPEJ@D^!L#OMUQ<P]F<V]@1Z+@=I#BA.OAMDO]N.L'L^M7
M9=[R<'3VZ>=2@!%/G"FWI$>SG2($I(F][N]OB%>/F[T_FUVY15NG%$])GVVB
MI1I3#.-XK-^I@&<<)Y?ZR%SI#R7\"E>==RZ7Y3SJICT:^T,2EI!CH'2JSX[:
MC(/ *E NXO ^UA%E==SX0]EX(5?D5! A WNMD+6,7L%VL>G6^41[7T/B&47O
M#<TI35AD"&1ZZ8J90$)"4Y]D_B01U"E(VWP4%[\1+VEIZO"L[(1X:9:P+)=+
M3VV=TH1*;.8AOJ@;@!^!\F&2U"GVKJ$N#ZVU-I<Y!HTR/6_A<J?)\X[_AQB3
MJ^RRK#CE*7$ F@%D?4)T!!$S18N#-@977'*N]#0TS1+K P8#P)_FE/]/S]\D
MEVTV)W*IFJCIX:L$P#%L7VRY JU)G,*%S<.,HNPWLL^%847-'4MD@[@7S?#K
MK?SW"( K"!>%OPR"6L8&O_*RW0QP^>%G%FB_2!;Q\LVO+RZ^Q27TA(B^)62,
M<9816)[Q]?KWJ,-I\6"PJH);%2H'61-(_0B\Y C7+94='%K*36!M+2EG ;68
M++E@E1BLQFR!*DVX5%ZR?,H>F6>B//T $XD',V:$FX\9D*O1JH0_%BP0H"M"
MXSBW<0VX: @S8WK=26#W[C#!V50ZBU+G6(X"_0QL;R+D,2="'B-[B!9!0'U>
M$'QOJM4Y$1+^!0AGW5_\0OJBA6U!)XK-O6/)\.@>9X[LZ%56*XXYN@*]#\T"
M6))Z72\W->;VV;&1;Z.BY)9-;#''9NP)/2"HW7I697;&V9R>GCKJBZ''/!4"
M)&%KX%(L<^,W5=LL%VTN>"@0P*Q&8#HC] SN6DB[:>VN,VGLS>K&CS$D&+ML
M5']LU8@<D+#UZ!$6;DZH+H(D-@R];;*3#]GL ]IJLXE+AXLXPS=95&G+^CZ=
M(A @3Z\%'K 6!EXYAT%H4<-%E@^;&E8E_J61.5C%):S>C\,L#J/]U_[QXFDE
M,;#7?-M4=T"G4_,UJ]I^?:T;%@<J:OJ8SVE.=J_$31+.:/LL]L1DMJNRIBGQ
M7-6FX,W&67$X1CAF?UN2>T^VY;5V-*K;%<N4AL+JLX&ME]9/I 6HI3V&2IJV
M=^(+Z_QW3 W1]3AE7G/?I ^4=]59&Q,2A@$/Y+(F UJU WT6PBI4"G#4?BV+
M 8:3VL7WZP[V&9 SIKX0(0@M16$H6M>/C%8'P3E*=>U+TW]8HEF&LP_NMS2@
MD;ACRT]W^\-10/XXQK?S7HO(9JLI-N\Q1&14)A%GS<2F:,3PR/.VR'A*^B?C
MQPF68O5R!WJ\3?)I%&8&IZY2M1)F%-EK46CCX<VFN5G^/G!<S.V[TU8F=FC-
MA;H>TR//VFW M4^.X-HCN';_-:E&KYY)P15$R92:8S_>1M/!2DWBWA@<#%"X
M0>7C^:X^RWUEOIJ\"WB4XW<,K 7DIBO5EN%:D/S*J%_:6'[.H9%RHG.]F@Z:
M=K:%;EZIA'6UV$WI8:>4:7NSHY,VZ(+=(TZ&G3@"."(+WB,%+Z%=*V:H4[?6
M&78M9AY!,=7$0U-.-)":^"AJ3D0T'G)(2\T6D4<@75/3.7QLR73V#=.[\,AZ
MAR2R:5U[8-[$U.M,)*8SYB>@L.!%,+I$IG$>.8$H18XNO!,.CGW=Y&Z:E]<D
MUHB]Y@%^0J+H< ;F&)5>L3%OTUFIJ%M3\-'QW?"-LM6$6I%IZEB&,3FF"RLD
MQ>N-P^1$)>95+CU<L3<RR+=G4Z#<H[*:#,O\8)0RP6:H);+$<"I&R,(P+L-,
MS"$2*-VE-[<['5398EB=$QT%XS^L;[QMC$>V\.F3P)0E;!$^719:-37BNL)C
MM$XW.M[!WS#<S(\Y47TXD3$E$AW]/C'1@73]OMH*=.Y8FHE2-OK(DV&PWO!0
M&,[-?[B)""/1$LA6 >J(37>2E.RWMO\:J6"E%X%U40=9?*\*C7R4*(J499R=
MA+*Z3(OLWYI[&*"IX ;>A93#<%P?0:V7CIGV(OY,>%AE9ES+?%O_KM)"&A=[
M0DLEMF4R^:H+.2)[]]HUC2\25)*=C ;9ES0T+XSZT$_'*\PMJK[A%)=7GC@-
M^59_2<QJ^%?(0K4$@]=HDTJA2XP(=V9+-"#%9?S<7&6SPU +:=:@9&N7'+QV
M%5&"W,?&>TN^X944Y=\RG"$1ZA?Q'J)'T=923<PW(1EM'($P4>:&HM:6XSQU
M?@B5Z^Z9KW!Y<C1[;./GU8N%V;C8H\^SHS@AZQF"6$1R='=K.U21DK8Z (=?
M&#[* YC *A?JT3+/_$H:F@=J:+?N%=X[H2&J2G9%9)W(^LH8*N'3!Q]0-:Y4
M5IA]A:$XD@;# @">3=C4LF*7*&)(8-O<4\92/<#M(@^,IO@IO1QW77DY'.H+
MH[9NCD.D"XK5=.UFTEX2/85H;Y)JXEM<U2'$Z66;Q9_8)O%I8!#FJ_GB[!=.
M;?_L+K,Z3\W'#!$V'RRC*8>K)/3J7#B&MULP2]AFW"[W9BC[##<X^_-RK?ED
M9@PT#\CN]X*;"84/HN_C;5?9R45@UO)4MPXIDVBYZ>!30U)PK7L);7% #AYD
M8D8>*D$4&\Q^%MKB#*9&^<^[C:9AQ!X-'3$X@MXUE^4UMV'JNNHFP>4+5O!X
MKF/2;@(#(P])T?@*K3X-:6_2)3U'@/P5F=M+#A]7.UTJBGG!V6<?I9D79*A'
MAV&_\U0XZA!IZ^:7KKG/58[=@[4 8YIF9<?']-1*Q'1[TX"D&(DSA*&A,KEZ
MR:$<R:5.?X#]M/;43X0'T?Q>.'2WI,XH^Z*%1@G>?Y<TU;Z""%_%J\V8C1B<
M&575^Q(0@F%<3+."<J+G605"@7,O:6R$_N@1:+P%O<%DL;.)T0ZFJV:PLN4J
MS'+J>@^3#A\1D0KV00=#B(*)3;EILH@,4QHB-KW4!:(6_JZH!13=%MNKWP<A
MH[D&JS71(O:1!Y/8GE+TR]X%^CM\6."OEU4:Z!C]I<.X:])B2N?.N]:Q;(PL
M8,2)9Y\:/\9]>(?LHEG6-3P>36)$QVH6Y>A 88>@'WMC=;TZ^19B,&IT7+FG
M8_.UTXC@]/W20CX(Y1*H_@;HI&6:1+3L,MYU4>:<'!SOI3V6$WOEQ*?'<N*Q
MG'AG%/T^6[]#A-"_O\D,H>%89E,JTPQ9'N2,X P:H[KR7)A@$.LAI(L;^F]-
M7.N-PG;!<+OLBALP5FVA0_MHN"Q%Z3RL6%(F1+#'?/(,]73RC[*:RWTPW*@@
M=+[4L4$4G H'/7_#T:?H*]HI:"-V\!Q7C)2C<",.']C;_X5B2$2;\;^R^220
M[,I"(HZ&?+U>EHLL,.4C:TZ,8<)7QXI[HD,VP2D-?,=_T$M)57;JFFO\<,?B
M=IA&A,2[P*L7<\FS"!P4K9>N2N7SYRLPNM5&Z*3-)?"](#16!"IG*RA.-XS3
M_"I8UW(?:3J%NKRFXD7,@/#04PRZA$>8ZFH>"[9:H4\?8/_"&FF A<RQ%]TA
MNBP^%V(*BZ2 12NO<_! WGAWA:&I/$BL(W-F&)66$9E)"/<$]GUNQ%(7DF5;
M%E(@]<3O@I5.Z[+:0&96P:N U&6$M-SHQ 1F-ME(R!S>D80QO"%/F P.F&*C
M,,B!$'Q&#T(-##)1CJ+K*J/ 6\(<?S&_"3KP(\;.>H!E=Y*V4*T3HQ+.9S7(
M!YW:).3B5)E%_9"[^:6?I:YRCT\C8\IXF=G+II%FCA#HA9Q4O2*NKA!BAM%G
MITE(5J1<I;64\LK\;#((T>"+SA"U&[UR2C+#6[>-S&W+:WH5B@':G&>!X3.(
MPD*/O.Y>F7&T/])WG^.GZ^1B=E-ZX&@R]]!D#N]DL)E,3M8],"1YP7"B1L&_
MB!%#?CJ!64R=_M'-_2BWH2C("EVZ60GCF<]V*"I_2%S+JOL\J_0#@4CEXQ1:
MK>1\IE<EFKRYD_GOA/X%2T<!<5).<\4[4&@'UP(CM!E_\M/DG3"S=@Q:%[I_
M0B9TYML30M2J%L(FY#2V701<"*TS1OY\]%TH'-+D*4T$^!8%; :9-<8^D"X-
MG^,^!<Q\ZENI?>]6)D%K"\AKZ\,OS-;SPL]8H(33SC=+31TS&&*&:;$XH5Z*
MP%J-%D_A!Y7.W02-F/$,]W^U6=*D*XMNP8PY+%9+XGH)MKANAL4VY#MO$'])
M#!3IRFO]3LC.326^AZ6<@>7P:E*>YJ@/]^WY;M:'?V5O^I4?L/2FK'QQ#S?^
M8D981_W5!6/;SYX]>TS]'NF*W:UO_OKJS<7%MQ/I7*U#IPE5Y$GL0@L('IVQ
M.,1])/=1 X0&!W@JBHW_AKD=\,R6H.,8OJCYO"&PFIYRNMK8/?'X@L#1344[
M4L*S8GP"$T[;VAVZ[MS"QYJWV-@9AUTU3-YR48COYC46-IL*K=\D,88 5F<R
M#+OK>4??^ZE?'8U-OE#2=8;VT!O\K_\\>_S@2W$W'#7'Y]4<=,BC<R_U?J]&
M0F/A^S#0!8_[2S@!Y4K:TGV7MWQ/M,KY@P?/4).\?_G\K]_ZO'=6A3DWG'T(
MA6VO;20H#?Y,U%P7T*Q*]=D2W+I:23\=1AEKC?D@Y+ILT\K/MI5,]R0>GB.C
MLVIE,<+:!G@K+2.N9%8T)2(\0BPLCA88+-9$T&7_EMBF8-V#PZ?PG!+F3)%J
M<D6<VU='JF*6NQ35%5R\%KS&4"7%=NKQ"H?1)SIR._18XF/W*[L<F.L:M;7.
MI#23E6^S)$?G8=^>[V;GX4>:-_N"^O_Q5)?URD$T0,?YFQ]?/+_X]J9D)-7B
M(:YI-+.#-C6KIU7*W$$X?X-ZH*G2*W 0&>-UE)A]>[Z;)>:--L0G;]C9J9-W
M+=9]"X=2PSH?XYI1C:]M,YT$JLC)1(5CXGE08MDA5BD_%H517[OFC%%8GR^S
M?%ZY C?B[,GW]8 #S?XF%V5E 'K!*E!\M.=4XN.P4V]%#ZEW@QA;E.PWSW]Y
MATZU,1U5F/6UUC4,P3=9I84LR56:<P^^Y2'H]=>;^CK9-:3ZP%5?EO4:\2%Q
M8W=Y7<!'E]E:*!(,(A(G\"!&;^ER<@S"78<;^XTY,I8>=XJ*]"25L'&8M#X>
M]KU[ON'#?@$A7WF)L N&6E!6IPM'E!+]7T8Y(*)T"J,SPA@U7V>)FH!\DMWZ
M?4.M4V86631&C%L0(D117,EA*B1ZI.#[&'$>2EU[Z-ET0T%B#[(24T!P'DA;
M";ZW:VC[K[NYMY"HZJ.>NI]5J(=78(&FT9 -!"HD#]@ O>.N$-#5^9A2.*W:
M_#(U$. 1 $BHO@DZ3W K7I?9VLX*1V-B_#BF-%BGA-:<RH'NPQO*&(;OMXEA
MM*1"]62-"I(]()B2U7C<3V<;]X.\=(?<1G? N(.R!9?9(M+946F+#2!)DBIP
M>>5Y?R46CL*/5&@T-5#X/NFV!?9%B+?T,C2W]-# <B+@[3FC37 8N'; 47$S
M8\1_H*@@1NI*N.1!VYT!JZ&6F%6S=H6H3CK JX@8Q+(0$ V5TOQ$,$-$F_":
M+AJ$1LD\<7AVS!^Q6$KXVBS;6J1XQAMJ1%K@Z@?8?G?#J Q4*KQ+TI<AL&@S
M]-(H.U$?VG[$O<NF.3/@9XU$#IXRZ3R6,JYEM"-$/]%-=:"#Q/J#Z^6+NG'1
M3\1#4\_@\W&E'/%\)7>/T$=(3B*X_[@>B"Q+6X^ WZS$&5H=0UJ)F<Y)G/WL
MC'PPWYNGJ_32,=:??L[JR[+B/9B8\!G=X2JK2]&@[B/<KO9UX/"&)XN6LC(#
M((:0/!AT.2>V#]V0;85\2A>]BV,YL+11KN+Y%K"MU;H4*)Y.WDXO\1Q*]8KW
M)?R*X8LD'E3[2?V08!RR,4R!PTZ!VB;0,\A=J#<@H](JIT[9E2\=,[XN07M2
MPQ -*RI7O;'I%MTP-,Q#>] T<$  A\XJ9 'UC_K[D1Q]_CF_1Y3DS2C)9T>4
MY!$E>2!#M&]DKACHJ<NS#Q 0+"GC5Z2-L/C2+.0F[NVSB/!@6BOT]LE<^?;"
MT Z&!KLW%TD*@5R+HA#-9>KY]=O*\1+3JDSGQ,$"7T9>6A<ZDH@5-0O0GO=5
MNUIW&[P#:K]C!BC5H1CY7U,DK)J,7P81@CC&MO!C;+OO$OD,Q,!6URW9.!H-
M%Y!Z+_T77U=S ;+[<<K*$FR<$@@WYXX:-SJ!EBE/RA3F'U]<^"#0X.C!G%$_
M=I& (#:8F+,T&#&7;K".ZEQ$>3NI%0:ZX:J%/U+)=!*]L<:1$S%KGJ#4MO]$
M['F> AYI\K G'1M,BN1O$,"E&-QB4?'A@TER_N#LR21Y Y:2Z@^R7WAOXA#N
MKN^DPS."L#RS=\+9W-T\6,E)ER -?Z*.>8Q8X#!)4[WO^0A+08">K(C(6]3Q
MY>=$&K6LGLDX9'DG2IWC VT0G '/*066#?*G(786SNUU&7@:(X^WY&:[-?B)
M"%1JBYQS*)RLYV@)_!9M:8E9,+E5%N)LP;WR+&7*5CWX'NYY N]] JX0_>;L
M>T.8*DC:SJ)K/@@+P]QXEQ00@\*Y09'TW^ZM,.Y00RF-&3^;Q!1TAK##$80H
M3CO1EW#Y['K:W=0EL=^;R'(5);/N4?D"1.??KBHG OW$:VN2*0IF61N9N]5X
M_Z<DW%.W 7>.=[*[)'Y,M><)1T"K[G O>I%V9/_XF!U;+&K'P*#!!>HL3SAN
M'[,5=]SK^DKG-8)1,>=E:H3,"BHR'E^.W/#>8A(VE3+%V2IDCT3,)7'T&OOR
MZ;"\ZJ13W@9%=+%8I)G OP;M0;C*+P21]DBF'UC"X)(_NFD5M,7YQ!ZL6*$K
MP[.9IKZ+N)N@DGI2"\&'\ZF-1 PSE<05U0DRY;-^J>8ER!8>0S.*M?\JCVZM
M^$3@J&$?=U/N2_ :?!Y*)\748U06+FF9F9QZ1J=C\&--6G](B)>43 SFM?"C
M@\J)4VH?7 ^>S9,M1>EF*E^8T24&*I]=7)5SSV2EL1XFD;(9DCU1\H[]&IS?
MVO05'+5'6PIC.%G"JCI73+L"7CS1]Z;_-?$DQ$(,VMJ/.%RT=E3R&B*I"R%N
M07$Q;%>XZF:4J> +Q(![W:+,CNM?329*G<LKI75(5F 2D4WY%@QVD?_WI8/M
M9WL:#KS77#ZE=#%)HNQ-_VS!J9]KJS##?9G01;P:6F57I#,&?06OUN2:[$YU
M.E#85Q)>:F&EP*-@LEOUIL86(.PBQ?RO\8V'FT1KK&)&G(9*9X*M)Q>$4)#Y
M":B"I,H@S .#=H;R[GGMKK'11B<X8[>04>):&A76&,3]8JI0!C3 +WMO9'#-
ME&J?0WPEQ-O"CM(I/I&-)O0E6A_X&W6H,%3ISQ0/K052D=+T[TZ4--R+OZ5\
M%+J@NM0O:_ .TH 7?"/MPF]"\PK!2C'-/B<W^SD^/Q?_QW!ESS5=^=*W1[]U
M"-2$C>4?/8+L[$'R#8YJ9B*AG"]S\1RAJ:2KAW$H.G@7G9B%<]1.I=44#6)]
M:<A,J-'HD@ KSC=M<2]00*[PZKO>/)9HOH/-M9*18I(OFO[<:@&R<E/V0TI_
M;Q-YVXXUE,. 6_<T]$R058 G*Z6CD,2,KIHR#:%N(ZQ@! / 9D"XH9+[R'8-
M1L,,A'!,^BBV>LMM3I-W&7HZ$LJ-.#(H?GC$T->%**<;)IOJ&C,.8.E*7!EV
MCPWYN8:LOK[@<P:]20_P?'%8S<[^%1%GE0$]WQM\85GBR)%C2&*0='KSYR#2
M.HM^@C_1-M'+&JXLFSGAT3%"9FD6V<E6ZWI3?UDES'EFK7\CNICH3I3Y@4/L
M>%Y1Y9;(5GZET86]_806'YLJNAQ#XXO:I!]=;5H3<$F#G,H&@<8L?0":O$\_
M2IL"Q8DU3S:7J)"?BE(*@3],A>>,'.%GK,K@SB?3E @7L)N!3/H:EU7L@^*O
M51F$G2$TICQ_J,K :5B6?HRX9QF3WL"@H#L\??%.I!S3:\,/=U72I*.Q"-N4
MA42(3C7TN/!V-<Z').<<W3SM'R19\-12=E$UIE48:L"H9CK!KY.->,J/3T=*
M(O/Q_8?E//'"C[JVFTVIRQ.D+82_R@L_3^<@8>E,WQ+VT6[($KP5#FN%S;8Z
MH6TM*Q(D/7 "EJ7HC@!9>'._U_9ZW:,:( <L/9X4A>5HPD&7YQJ-4(J8'T ]
M(<^,!2UP^E?KIH=F#/$<7N6'C,JN-3B#$K &"_<T^88^\L/%MX/&C&QH'=3V
MMF-1*JFB)&>_>X"(WYE$-T_,3VC:2Q#QDW)Q0N0[:IB\[);73G!?6UJ=\<AX
MYB>J$8:"Y!L\$R\XY$&Z*$QN4GE/S\]ENL8OK'"S_;<(N2&[N\/QF9=%BZ%?
M'H[-JR)Y ?:,O%,^)<]_><=#2>LENZ[H%W".KLUID!:V,E#GEW"8J<^A$6S
MLY0,::)!#>$,B)K(?+667\% MHT$4MA>=;4F>-\?P-AB>&&M/S?ATQ%P"CDL
MVV8FYDDA.8Q^FI&_7#66^3B*LT%.(1:=TXH0IIQL)Y.5$BUCW7V.T^2U6<^S
M1ZIYTN0]^)LU!Q,O].[/Z>Y_0QFGM9V'% N^8X8O[5MXV6%!)=S4Y)]5KMGX
M_KJM.E+W^IJ<%TE,@;!ZTP>_M]91;,YI$O72W_0*DPZRGAQ"3MM1E!G3R1:\
MK&3]Q,WW+P]K05RPF%2@#Q2E 4=*G&I&K+HP#FCN9F0:)S(6#!80VP(DW8')
M$/\!A&. JT*Y,;J&%-59H:AW%SPXZU+H%M$CFEP'_HZNL34AL5>1+E.<=0EZ
M*\/UP"H+.1>D&*1,M+T UL[?L8%?/W3L-9Y@/Q6<_(VH-(&81?Q-XG=3)GEB
MGBJ,KO*7X_"#!,KX5P&\H+5[I#U/JTMET%5[4%.AQWZJ7F+(0T-E>' <&*U>
MH*$5+WE0.BG/HW@C*RC3&.A$V0+SVG&NP'JXQFD?CMVFE&X@S 6AGV%1?.[2
MK.-$ZTH"9O2,8X&B(\+TF<@L4%Y92B[)*_7#KPZ3)2M0 J/+=$#:&79MCT14
M.R>B'CTX0BS^D!"+/3050XD.G^"7&F9(7RX&2H#/2(></SA_X/F.U97T6HMY
ME*LR#\EKD^&<AMRJX68--Y_); P_M*8/O(A(#Q<V(1AN6(JWVW/3V5^%OQ?N
MLF2R@L;RQZNSRW8H[JSA:_PPD1H[.":4/1%2P.B:837BBV0ZWZ%,7,YS1S@-
M2E&94DK1J)5L9B9IPLU.LH*\8='K2"4<!<ZCJ2S$P%,(F*JC^4/>.GBXHO'!
M:9DP18-];C873)+5DHNY+F<80'I2:V.L11QJFR6/4N$^8HN,%.9J7)/Y;>6/
M2.F(UI*<"7HVLSL:#@Q"1C$15R#&X]_=ABO_FHP-JINP[UR<BSB;#8WWEO<W
M27EL@II2MV[=(GW':?+7O[[CD<HYO-A\@Z)2-9)L\,*^,)QE&-[/J:,$-L[D
MYG#=5+A3++^+PUU#V(RHE!C"PO21(G@4=?BYEUJC R>HFTO_)=U(@(W^O19=
M;03IY=Z?B(LY=E=@E/N&#Q8NEF?09IJ1NG%K\DS3-7=5\S$2Z9G"P2ZH,!#%
M^></X DYSV=3E/Y%[&IH0X4Z9?YOY.0/C*R*FY:I5DI'R^<<3!I3,R0CF"FL
M%6'I.8Q3YL1"TZ^LULY]H)B\XWS_N0\DLXI,M2D)FZ#/&9%B=F9&U6-'H9E7
MZ=%,;4FZXI33L<P*SSKR B=L+I2$[M /F^(4CX6BJ0/,MW_OFA!><1C$ADAC
M+-I=@A=NNE7WH/9L[PT[\ (_2'RO4:^(-O'R;L'7,>G\EG$Q7:UD\Y3#TX=X
MUTG9:8?+P 0:?^(]%'Z@@B-#B'0\5>IY/J*K^R234._Y,49E)?'%0!X63:38
M&(E/Y(3XYS$K:6<BK$DN:<PQW6_J2 \*5*XKO:A8M8IB!D80I\IJA;@'GKAA
MJ['W4.!]'DI\F]X<&RRU1'D$;0(;ZX"V52S5: -D7-K_'#BZ0R0<]1PR<Z?&
MN+' 4N:MPLH&=Z=P)7+2(PDW%3.Z$Q>9)YWV.!(]0Q'A:30T9(],$6%1,3E)
M<%2JMZ:!_+ [AY%>N<T_&-)1FHE!B%=?;XB\:GIR+?KPK+%Z8.@ -5-7OE?/
MO'A'E=]E#)SF0&3H6TS=B/UY9&7-@;33) 66K!+F&[;[0L;NPS2;ZZSQ&:B1
MJIO-934Y0O#.^ ]NGZ_"#!^/W>04%WE^G1KX:/>W95?5@7SD*"+A(X$0YVXE
M?*>=B=W(U4@ ]9K)1HI()7M!MXI?$51YQ"#^&3;MOBDM*41A1FTRA$H#T1/'
M")&@L'9J+BGYG#9IA)>R,Z-A.UFAX$">=.&$2L<A-@^[1A'&*CX6)1\IUTB(
M!<:W6JP)-8EB0%)6IKF-/%NP+@A?=#+$RG:=1D:\".ZN6'BZ>:8@(#UC H;$
MYCHF1F[@0313"!'AG!D1[#@BZA-#YT9FN4GLK9@?[\7XQ77%559Q@Y\_6XOT
MJJPX45)!"!)^[#>_>P42A2*I.#>:^2392#TD,1[9$\#V%E_/CODBQW8Z4J&\
M,=1Z"=K\[('FHHE1;;!UQ-R].V.&2!)KAEATIWYV1*ZG&\TK#8A'2O,?''<?
M>S&QU "4)R'MPONJ Z^TOYD(DN,#@,?>1@+W[^SW$ 08RDHCQ5/-C&08NS<@
M[<4\QX+UCV##/R2_0)R7.0AJ)\G?$-L%WYW]# $IB\8OX TNX<E^@$^ 1DW>
M4@<)"/+[:F-JV_^WO3=O;N-(TH>_2H=G9W]R!$@1I&[/.D+686M6EC2B_'KW
MKXT&ND#T".C&=#=(83[]6WE59?4!'I(L@*Z)V#5%]E%=1U96YI//\Y!RV^V_
M?H_'K5YPB/VA/R_ :7MD_>4@Q\QN. 8D:XF\4YP6#@/AH1P=%_>G5V^>^TW'
MIU*P)M40JO$=T$DGK]HZ0J[\GS1"[?O/2J(( ,842;5",V ARM([3'[#2,-
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M3J%@ #88[ ))988-&24]U?@.U]+;..\_T1<:='V(E0)C58O!>KL@:47IU8_
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MO:<C[Q!M <G+6L,#^Q6JIZ=]<$=>AG-YTO?)>@5U,932=U*S+4!0W_ZF, &
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M([12/@-"+3J%*:M'R$)]2K.?JKLFC \N4F29=@T$'-; +5Z'/)T!Z P?X8.
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MEHYLGS4PW#!!ZB2(3> .PU2#WJZK1J(HAZPZ1 JFMF]ZR1+0:#(E6>WSBI*
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M"R^$/:ORT9<<H7)\MGIFF,WU4TI']0H?<=.68UW(?A%N!=#,3JPQR"%]EKK
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MNRNS$BRU_<HGVXUICA&&)P?'#^T K #;6YP=+,S,GCYA#EQAFH21E0<[.G'
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M0 7R=3"LZ--QEFV@;9Q7:]*/5"$.^?E%_M'0YHU\1'U2 DK#BHE <"E;>^R
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MX0C^K!%GXZZU[WJ64O3Z@&D(]21*%%6J+H P@*F>.W0'*G3A@<<FQP-N6"Z
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M71Q-!^'5Z74DONHLS^B@CDZ[YPM3$408I %_W6>^@C"C$)OU316=HJ#($1K
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M(K@@B:A5FF<DN-TTR*H=]HT@SYC&PE%;?#0A;C/=+)E<1.<HN*P\M!03!@N
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MS?9U1M5,. ,J42Q"QG@^7K@RIQ)K.-U'HL8L8KW757I&=WC"5T9\5UPX1?K
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M9BJO:W=Z6@8A(F3\#XP>-&#[^[7!RL1$76ZYOH?="5CGN?MGZX4=HT8$/E=
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M)XT6HP .K,:WX]0'MY[2$AT_/CE!QX*[?22]^>(3GPOLA0[73%\'J\]W;N#
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M_TY6OK2*OUN1?,[]MH6^D/R7".>?_@]02P,$%     @ Y8)F3_;"))#B%0
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MJ>%66(>G1<]V7)TT^C-" R?RU?@SSN9U3%S >C6>XY2^,P@N66E=8 9H=&A
MN)C7"G>8"OH@Q/JCGCW)L0G00Z-%+XIOX#=>XKCDI[;>%%D"0T?QC;8F,R]D
M84)G)4P&3*;)GN,*CH=G_MW5?$@W8I!R#HD\&983%*:]RRR0O\,4CR[S8E16
MX:#NP\-U&[;2]4T2F/V'_J57>[GK/1R?$\CO1T:_8)E,\>)S[^$+SEY\H:%
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M=(EUI\8P4-FQ8FF!2L+31)CNJ>FOW4$YCN6W4&Z+O)HIC.>_+ERB >H@N.7
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MZ5!T42S[U;C6Q*[5L4>P4YVY.YZX?W^'[H!7\EA4C-D5;GD&K7D(WGE'GAQ
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M2?ST?/YQ,EWD(0EM2C V,@R+5M= LZ%5F6(<6VJ5U8"=LM</I\M-DAS^6.+
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M%>D\!:C%.M.DX<J6.!_R&4^_1FJP<= 1[K/SZ;0>FPN5*,CTM=F# )H;-3)
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M-,F"5FN#% \'##YX7[+D1>6!4JJ$D"-36:F:8\3K);O I*<Y($#*0N[*TMM
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M4X>[.C&7U)W@C0CT!FPWT4U]0+<H2-$#-XCZ&=SU063".S(].2Y1R.'D;B5
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M>?(!2911,+:^4QCW[:"XKH(??(_+=;N!#Q;/N$?PL2$,/F5%L<O%T2&7L6U
MD2K1@DD1SN4*8.Z[7\0/002$%<FV??]$<,7O+PP_:]D*_+2_URHH0WGR"_ D
M=B*0Y*C):_S2[(-@U_+6U3 #;*^);<ZOEB[8E<GP%4OES(5A!OA5I*2$;D"^
M0BT\GU5O6S2CW,]"BR3K?N3"^>-9.5\$.4)P2YFBHK8"=O9SAW]:8(6J1.=@
MC7GR%V!(5%1X&#LHES@-#+QGRN.3IH6DLA_\V .%=6=]C$<R.F6%Q5EA9DW0
M\UKF5'Y)SIC$>S<_ ?>DS ]:?8023SKM-O<U7KO.JN+RGO'/)G\41\BT:D.7
M-FG*+>Z,7FBI/* Q7M,3^N+U0/4UX+^"\T!T&;^T5NE10&;&C*!\D'V1&L/
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M;9LJL[A R/ +/4UY$S791T4M@0IN!A^3<%$O4OPCG6TWAJ[OT1^!9E$!ZL*
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ME%>68;NB#$5:].]_O%!PY\DGKR1/WLXGS-)-KE$2__ QVYL4,./W"NKD_PO
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M))4 $ZS-;^\55)#X:IJ8V:*0 AT79.1:S.F.])></8UJ2'V5^%F*WL]&SM&
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MJ-_UN0JZS[FOCR#P].:73(D9MRUSB]7V^"D?I[)*$#&5(!S'@R^4#G+Q+B'
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M.V179/KP3$Q"9@)EMDJF])"+7PO%VR@=30^A!F13-I3^>L672BD,"G\%6@(
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M--1&BQKXWKE/!;->MB Q3WNL2/4]M\PYJHKUAS/,;(ATGSTE*HB0>3Q#&R-
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MRW:3,W<[N1[-TU17-2UT,4NE)\%+*OE9B(KNH6E:W<'.:;"1A?P*+4<1%AC
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MKW">D20+$EOM8E+O39($RP30P]K-F]#ID&VIX\R"XY%9J52\T6S/56*Z<<&
M,*ND)YU<M'42+P22",/+JE!GD?]WYO(?3BJX#-F4GH0.-(>GR>^O]S,F8];V
M_8\SE0)_DJCNQF(6KK6L=E2?K[N2V&4O-@=OM(/]-@RFUB"?'#/5N0UV_R%/
MIAYW?VCR_5Y"!=*H<_J2/(/5R:7'48YZQFIB6O4%#TZ-E=@@IK?4<RBOO::!
M5YZA!_SZ6ASM)PE.@H7+AXFY8('5<7.%@"<LY2C$.AZ<VU46?(MT\RW)B2&U
M-W/R(5N\#SQN2J=N;>'S(#]* V[R857/1N8G2;2KV!Q$=Y?OX4N62KITL:IC
M#@YN6]Z^$>$@#&=>/647^@^[S1\OIGV2!\8.#*K/*O.Q(4I/M*%)>EE+D$(&
MO=A\W@E?J)."MC.\@<;QJT%87:L4F"UZPRBZ'B8U:AN]AGZTSV?'##QW*KZZ
M',"#"N>E<B4*L^.B"V!%AMRN--#A4_+&(C,'N:(G0N#>9>R#LA^[0%W7M*YJ
M4K6OETH.ZZWYOXNI_Q,B@Z72@0&;(UZ@? X'<H$/_/>XSSO(3LK1QKS3A#&Y
M.I55O9D-Y(*MVC,*PSA-Q-6.?SL32]2V&([+P8.9U)>UT32NC\TXL_$HX\M'
MM#1*RV,/*GNFGF0@TZK%,#\OR,-$KD2-!<F,E63R UH3P)*<*QG+B5B\%C1:
M2R<M$<N(!T)B"Q*Q;+KBXLJ :.\IVG@C88WV!UF<6"W(ZZ"TY-\SXAR07P^\
MQ/()Y]O9!;R['?T+ ")5/:;.G*5P['@'3S;QO2/0G4)AZZ[*KBJ$H,-P=8"Q
MZ2'[.O<B]]&?,P,6^D))<82Y[DK$_#,=66I&9FT1_HS*%,8#BSHOEV)6-\*3
M;#=#9_>9I"<F9OESCF:@:EN@UGN](Z!8;;S?'-<#K1 Z?C_>0EL'\)A9@\R\
MV5UNXG)(;ASL#MF%&_G?46TSLFWQ3(=\;E1).YPVR:=#FD@[; Y-G-'VE_@9
M2"*7K X6K!"O<*_NZGS\QP84+5D<^%J/>W$9L54/95 :>K#8%A2_XP9)@2.(
MB^59HW4Q^E"'-<<!-^XDP<ZH-,^#*-LM0E<(@I^9M!15KD/ZL<#R[HP?*RT3
MS=*S;RK7]((R;'(ARW.TV]<%])-QM1T-6U5J@N8R#=/E'<N'7H<=RQI9G+X"
M9[.KXWI3TR),!P/P.,"+JQ+/[*\OQAA![@G/7@P>B6KJ'#)OFEOHG=045,)'
MEP^\POEYU]0Q]<\#WF_/BO>7&I^!VNUMBTT7ICL.L_WYS$;B?^Q)VFR-6EQ(
MPIKZ73MH"7N14]\#/4Y.?V1'#"8U>+76%DMDI.J_KO'F;I(=R@ZCJS=AB:A%
MZ(GMX!(>*XX9TAL+K2"$:7D6[=B7QK/Y_0P9,OB_V:?NXL9WTIY<6V/W@Q_?
M@&17P"O\G9"JSP=N,!X^G7C]-^7P]B"NU^^7;FU^)3G1IKU4KO)R:T+_)&&7
M6.O=JF2AGJ[5"MF.I5/2C^V&&'>[]J<)"+P8ZA)S;#.%"9URY;:GI.JZ$$;#
MZJA=X^/7 ^0#=OSO?9Z%[#OLR3GF9Z!!1:[&FWJFL(G\Q4((IBS1@J=3#$R=
M:/[Y&K!Z4[VNS8I.X4";8N4C=AP?[] ;LX_)VD?:/)]'U?.VE?20.B4@(Q<[
MXLC7J '5USG>N;K"4E4(=BX9O/"K);;74DJ5H]&+_I7H;TN!]H;"-F714(0=
M%LKV3R&H$TZ464NFCM0:;ETY_'2+;7Y,@NK(OKI:H(K3 5C64#9.;^S!047(
M6^T90">4>X#9[PI$<$B9$;J1FH>T.6);LUN [TF\,7+E Z#2%Z=-0<Y#8YFE
M#LSO4#WPAQ>0@D4N]35YQQ'_+8FMWH =W?6XI$?C&:LDE%MM^^K>J:*9'@IA
M>\3OE&7+,]ZA:<8RH_UUTUA$W<P($!AO8V,[]I:H$[6\)(%A:L%U2%SFU^M*
MSB^7+,,_8.Q6;HX0$V9N"-B 6]80-_4(%=,B3_M6L?/VV"AWOI%/Q;+6X1R"
MVV8VFH_K].Z,B(1>_?#UN<M O5!N8Q6BE'-D])0Y@JJ+]3G60">HW ^:2&N3
MY0C+N!!6YOY7M+$S6:QV*W0[UUCU+5_GU^<N38V$1= R#;0&9?A'&ZKT6N9=
M\W%BY1^8]652BZ"<&='B6_;%I8+C%KE_SRKSRR,032$.PQC4O(5Z\9KVDE].
M7@;/=8:.^2&%%<WPKP37ARWL>^J>_%%LK,DP3F]4+A<%;U@>X-022U)539P
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M!ND.URC LU0B3S)N-@VV?WAM-H77K0E.TJ>A&?4#KRXZ5)9\QU=T/%"KM:S
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M2.KL2%,LH_!NV^6.YPU:P3'#A..X[#E[;W:B0S#9_#/;Q%JA92ECB9(MO0S
MFUJVC.T4DQ.*2$3I('V$M'S,!L,,U+Z/O\)T"U1DRJN[(;O4L89C"Q8T2/ S
M6\Z/6FK*[3K)?]LJ<- O%9V<Q+?^92XJ5+#NB-G1PS!U(1W4UUT!UY<"^J@V
M4@==0&W)NA#Y.N51UG>2%6)$]C,NZWRB:P2<S6;1\AG 0B]AO4U5%FM@E&AK
MALR9FML*GRRH5WOXV<KA+R9D-[Y+CDQ.CS'K/IXU-2@OP&A_F,+>>RKPM3TF
M_]/+;E3APW[/-]DX'WQ57]60J/Q#SUD.#OB27AP7K]35=@E',HY".WQZGU=^
M9L/;W6HD^'H>]+_8>ZNHN+IM7;3B) 1("*[!W=TJ?X)6X85[\!10$-PA@FLH
M* @>J"K<H7 )'IS@4+B[N][\:Y^U[][[O*S6[CJMG8<['^;3?!AM]CY&_[XN
MWY"6K\XU91.)2!57#U3TT7'YH)4-YJEJ\3%H^VIZ;_,%(+')>HE%TK;N#2EA
MU76()Z$("9\$4M%5!9$6.8FOS0M_2X[L;0Q]E7?I E;HO2358"N\R3N[75C=
M$SY]P[7^N':H TT*U9;\V,JUTVA]"QOXG$4V2:7^;U3I</7;G$[:BM9'2LTD
MV])'AFT5VD:I=!WF=QGI;.[3,;'9"XK^NDUJF1HR+Y3Y^C)3XX@9^(^J<%PJ
MXXBV=1=E'Z9**'*N> J6VB2G=1(^]1L-QJV$[#C$F1*EK(GLF^)T0Z#,O55U
MX4?E9NY/E\=,&LJE$[2B"!&1FQ%X77+74OZ%6V@%IZC("G1[IU';L*\SS(+A
M-W.'=)YJ8":TPI;]C^]:_]KUE_?20QX'6V!W8")<B@-05R-.ZO8V^( (%B[*
M"@D_@7:P+7'VG2O(^:H!I.X 6.M/R:35Z<Q\D2PAESO,Q ^ZNZIHVNWYI A,
M;'.<#&3CCME&V 53DG;:B9Y]L&'RZCV#5SWETXL[XM?(VE1D7_9)**36^WTI
M56:["Y/F,E+Q&"ZO<GCB^'&\.1J?/47*:_B:C#E>B FG1YU+(!LS3HLQ?H+&
M< OAOAP7QU)]#E^,>Z'0]Y+CQX]K"-,O$YUM6,%*89=S%A#=E2QT9B&)J5T<
M\Q:,T];JHA*:3@[7G:D]F5V9)D8[%LR.(?0Q3%@V-Z9NWK 6WH"/$71D+6QR
M;-Q]Q(+_R4.(3_>$9M)82$KK@,*.6_31+'!R2[/O/?QAH<KUA>11$_PMV&_H
M#/S*R,@8G5_JX[Q@EKREG&QQ!4C&JZ%WH@<^X0:M,ZQ7]-*'<UZ:V:FQS(I%
M"C'TTN&>%P3U&-&C <G%N*6BVL5(,"2B3\[*RE<&'7P  )",;ZM.U8VHASNG
M?ZO>\%HJ+'?MI"+<?160 Q./IJ+N<7X,A@0VT24\[;7$IY.9PA,..;.^MRPO
MYD9_7C2FOR[SO^9S 8]L;I#XU'6E+K/D/?7BY0-=QV&_@[=1[5$(<,EHHE0F
M\$F5YX=WRXT1# +)@\D@#W6278TM?NG'9O^8N3%"\P:@/]W;GGW@= =@77C"
MO"^U(J=A/2CMZ[':TT%7'<#!,U85W:&BJ !W52[+/;C12WYVI ^?XER0A_0.
M@D%#BL2?-?>M8D69'</L>GF()CRXICECG_<=7*9DDS86ZQ518XBGF>TXK/F6
MP%1OWQ ?)V9 %2/S\[3C<B+":1/N2R/^:87[$A?-4^-!U[<YB,.%0O/FB;3,
M:7;8Y&>O-)[*G-_DC-/,HS',SW\E2MD)APR.X%97?M0#C\ $L4$JS/^\::%Y
M&+_6E18U_O)&M\'I]Y&82G>C$(PENO"\OFLHUL=PO3ME%E<P:7Y#8R#=.O][
MO;Q$P9K:NYAN7Q:\<536EK%ZWX5ZARTAHM'>2K^1;U*WB>:5@DXR$+$EVH:U
MN@YH!9V_"H;,_D/BV %T/>NRE0,D2:BVJ.#J8XQ7#.U<QC#U/!/AX=2(75$I
MR^8TUA6/#O^43>F80&6Y.C9<R*5<.QP*H8*UL0Y53K\+B0O,D+&PL)"3DZ8Z
M";,!@;E$,<VQJ=@'I?YT-0?TP=9V1-@/45S (\AX*6SS6LSM5Q&T(_Y82CY*
M%]UD$BF&H03]LD3.>VP>Y,+3MO!EQ#;4$"H\ 03<KIU]S(,;,NSK7O+!>7NH
MI M)IO-\3\F/[JX,F]6-;UB^'J!*(/M()K5J[>&9F=HKPH.H?/SL[.Q6#7J&
M(]X^Q9 BZLKU67)ISBS.@LQ;B\Y8:RM[R2'U-Z\K76LO3^$A!10^?*_SN;I3
M<1;N (O];NL2Y@5 Z%F#LMPB6C&!G$E_MXBWO PURXX0C->=3_Y8A4H%1U/
MUR!Y&>,?;]>HONU*E88S846>=IQ4OA$[PV1]ZV!6Y'SU, (E09W;GS''-ITO
M&/MRA=ER>L2K-6L1&S6MX&<H5V*CA9 /7YEVU4#>O)Q,I?A]*_M#XP"3-PA>
M/<TSEG)OKB[@T\S)B@?S>FH_[1O)34(A47*^(?_.-$E#DUG_KV+'YEI[XZ,'
M+P(*3X3B639N-+R)^6>&U*;!(Q%-+%%55,&'V1;=OQ8[!+ETMX ;8 Y2HA"Q
M$=:5<^>3QH4> L%&:X;Z5)4TE]U%D[P8>Q%W-0^.\6MEEH'E4K^*4O#"OF(S
M:+1BO5N2^;] L7]SDH1@B5G0,V99.I$Z49V)?QNJ;E$1O-05=4DT?+#,NZDY
MW%L_%,GQ+F0(E1B3\!=WP)J*#5IX"<(E.-R<59V5M)CDDXC(=MFE[)IO$G'G
MC@Q])F/WR/U)VL8D 5%@IE56WVPL-+33QC"3Q2ZU?03"BNZZC%;-_6:Y?HQG
MI&N1'&UM.K,;<$)!#=F(2JYE!REJ[U_CMI4LN,JRCL*X7VKYX7G(EZ7JTDL&
M6(__?##74'(1+O+E>G188J,+0M%B9A1/7;D@;^FDTJ.QRF&5S4\?\AL]"5]'
MYM9Y*#.!#B:T.QDVTPE5P!K[J^@)G^3"&W'T*'>2C8&ZK)2*9KVMW"RY?<Z2
MN*3)PZP#I/"%1BYPFCROGJVD8$&FM"B!I*6QA=.SA*7EVTB.ABD82M">0*B!
MZQC*9U&RJ(T-@7RK8(V(^-4Q.+^BK\6JB:#X'<?Q3H4_(E:%2Y(">J ,Q .R
MI7_ _6.P@C6,UK'7QL":@/$?U.V)SU?4D'3F=R15NBRQXZU^6SCM*Z+*BL.+
M7_[I89D;WZ6.A_/!@,#M*[M[0@0V3=:F^[2"_N^3HU='_!#VT&-A>8(_)V2^
M*H:N1P331(X)?E6:_X;^*D9,,5';HQ47G"I7-%K.P9FIT_=6/!C)P#@!V3*.
M:GH&WV1CK/25DG*TSP[0)(7N%C-0WA?O/VV<&R_I&)?/6%!S2.BVC\M<KGY_
M+>&J#G(3'[3$ZW@ZJ@8X7GON,>?>TZ_YH5%$K?8/L#%YKSFH/RGW(=TOFC!,
MU6A-CU*)',U/&FGJZO:JJUP0?F/08F7DA1B,\F0]2P_95#G";.RVC;JG#D$"
M U&;<ESSV5H+SXBPVP<<X%1);P$S6[ZOIJ)%F)8#*<^OD):._5Y**G1;*?C9
MZG6.X,2IE!%-7EH9NWAB+.^\+*SB1$ =[I68F/A]"@5O=A+%R[-QOQS[$]9M
M$)8&D-I"<8R-8D0V!)62S;+A!$O)T?SYCQU#C]LH_Y+N<*DJ;?'K?4RN-RE(
M!S2G/P36.^CGD/(V +IIR;[ PB 6'.P_4\H#1BP2Z2:WPC ODQ4V\#RLLZ[&
M7PW.ZM0&:F3/& _GC29'1>?VZ4X7^.$;A,H)9AW,U[-OQDW7Y-ED&C+V=@95
M[/P".*>:EI8UO"GCQ2O],G#.(SB6F":0MNC&K @QM=!%]$IL0O&%L9%<8P;I
M]\KUGX(.D'E>E[(:T,4:I$[1AS'*<-FZ02$%CR38#D:?V'Q.I8!:##WP)%[U
M2?"3MG&.M[O/';YYR4,<.*6@VD*5)[-T)7F4+$_'Z3JZUQ<,J2W0'FHHE3PW
M"%+A'1Q1>:7XY_TR!I8YDHFJ$?0')I?;S^Y0#^3 ?&7]BS;.$(5KD^%H,6G^
MV^=P2/ABBCZTHA]+_ 8(('IZBG*A<#T3$>HX+@Z*9Z_!RWF?.:3.KR V.8N,
MZV=R6DQ3?>>K9$HBVN.7[@8'O4P/;I'][$K%C)Z-*O<DG8G6V8C<'2ODM%V_
MC"@K\-4GA8X&X_?:RJV<O7$G+%LB._T%,!29%)EY1,NY,D"]V@.)6J+^*2(G
M]*2M&)<I<E)W_J*M[&W.H W<4UOR*S\]_Z%B;CHRR[*@NOIJ3?SZ9J?@E-+;
M Q)=7FC<CZJ[5NAH>+3GH4,PQYTI@&_SCSIBDQ=LT(NCDH>K[/M0@S&6=9PE
MERT4GRN71W':[:1VR"FC.BI,)H=(3+ K(%,P28.L-SKW15A%V9##H.]PC_;4
M#73+;ZXTQ;$JP_.PYA15L,#Q?6D];J.%]C0F06&,N@<( L>C,IX*<<F!_M&Y
M#@:&@B%&2KV]-P\?48+,+B@2=XL$F9] \3ZW"[^FZYI(?V#G:B0C/-C[Y1K:
M+!C=[''5OF4+H?4DEZ)RC[3]F*(1N'1$6'Z$"V6]Y6#9]SMH2<4T&)GP"B>?
M.ML@.K8B1^:(S_/.:O*XJ1("Q3@)F[G)]><MXX2L77_>OP/<]KBM<RY]\290
M4X[/AKG8'S38/U0EC/O^W;@[*[][HS=4\<U]U.KS968HB-"WBQ8MEY%NR_E^
MW%F,:PT)\[/=3$U;0%.QVB09"@ OQX81;+>CI X;9R6<C?RJ1'_#,>O6G;]V
M^0<D I9J6Z@&^)MD/_3RT*8_C ^,,ZP32W4NV5XF9^Q3+K)B\Y610[B\P64L
MSLDD(^6A^.[.4)0F[[:V6A2C/<XN_VRJ*%<?93D'#C!U(-[3RC:)1A>U5/WQ
M!5T U''[9CUN?7?\4E@FA^G)ZQF-PYF=F)>"RBEHJ[&FQPM'<46A!IT<>N::
MX /6QFR9!$TTLS>'QPJJ;NY56".L2F.&VG&4[JE5Q3 =N".=QOBYLW8T$C<)
M<>Y]C67^KN29\W_\8N1_HSC*OY;,&3*47VP<70VZ XQ?NP]C_!KBK84MIO-!
M7 W[-+01+?2Q<*L:R2P(,C!ZR3748#?]UGS7TW%"$6YLB9[!J>EA7_7CR9'8
M>[M1.50W2QF5900<(\LI$!C+.== @H"N[(HX1;\*K)DSR$$V&JWV#)OV! ='
MCY;Z4_-E#/V) A))J_8ZHMI/_9.4H\G%N'T1]<W^FX?/PY0LDFISE=O"L"_)
M&.4B6C],O7OVLKN&BFOSC9KK;?;N5N%<]>J*NR,GG;+PQB"2Y%J<Z \X3G(8
M%A/3C!=(0=W(<;]Y_G?R7,'$5CR>@S(\Z((0S[C!ME"XD//+?B7H1/]Y-E'J
M\RZ++YY@D3+Y2W@<E$<^(*1/SD/'-D)ON/BUCA!+E3MU\JGF'LRJ82HNK_U2
M3"-Z;IM=F __R[\:7?]]ZASD5U?OI$:!KMYZNXP?KL/'1/=0AR($?+_85L^W
MJAY/%+#0@^.G0W8IM<E4 %M1K44\B@*<OF:FE'W,#T)^5N<G+D?G155ZRJZ_
MV:3Y4ONY9GVA7DB<HSE;:+^0R[*=DY9LK*@D565"HTMUOFLTO%"A0RH+0/TY
M#V/O7><F]RKGQ$W(-&&;*S1FS*PZ7DSWBV:^1+C>TVCJ9X[M])*BZEURQXFJ
M7-4'#,)+ UQXPIBL7#%)4@'U8MM:E<G?1>Z/Z_1)+F53R;7R(89('$X3=%4W
M7YA32E*$1BQH\RGV255:TTY71Q*7ZKLD;%\JG)E&M=Y-\D-'J%BC6W4WDVPH
MW6I2?(3$"YMW\Y .B &C/ MC845W IN]W8:&YE*P [2UL=K57WN+^22_>,8:
MG:G>@4#4^; .=B8K!D?JH<6'=)<X7R=GJR1!!!F!PO_<8_>>-6"O"I8,7[<P
MVQ1JF1OY=J<,?4^0?Y@<:6F4F\NI,#CK&M_NDAJQ4]?K@5#4/M3:PH=;=+UM
M>V> \#&/)OV%]/!&XY5%(!GZRB1ZFWCJ,5UE*4ECKJO2WV958JP=71VMZ;K<
M2-S<"*?=E+K*&6O1U8LC-I#HW-"0@>8_#/W!-F8JXU;3$G.-F!.]C.VXIEFQ
MCC2/CRC$VRWHR%AB^NM0N2/%V61)8"BVS&,HB]-2V'7CB#"Q438VGHJ4?[UH
MZ$"IK-=-/YHZ:\(T:+#G.7] 10]G!5P:)CCUE!56.0AG1(6$A-2^"*B__<]<
MQ&)-/W&$70H/UWABH9+W]!NQCMT#JLQX/?(.3.<A^Z20\#[-?B(7*^*Q_N]%
M$#QV/)><_.4G ?4UGE>'C21.)F8??!+Y4>-#JN?F]W]9""NHF!39S_A>*S+
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M>,XD9U2-!2Y8/\[J#HLE0@I@@6I!:02F(_'E<I'DKZ+JGE\&*ES,ML2?EC^
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MKQ!S/- *:VT7ULR8">"*^^>2[W_,ZZG&-3@[7X;47VU!-DCX2T?3!D/0/IW
MT6]7#&XWZP,K)DF_4]K*__EO]P&8[-L3;\[F_K3Q"%K/&OR/"!JUZK6;6SF9
M(IN$$AJG/JY\\]O@Z<@6P?V+M:C;ZX]<Z#SCLI]A39=(\PAFM:R3YC9L,_=2
MS+=97U7RQKKARMUB9!W/'OK+$;=[AWB<6OCZ8+-U%R?NE+4F[0IY:?^A:> Q
MR'_HP9IT3;GH4VA/]IQ8]EII8;I?<8!NW6B]L*_N2:/NANLF$,G=H_SHR$[&
M!';(5::;^=1#U_N&8YV"SZ3X*'\XDTUA9L)*FL^JSUF<31>M;:(SSM+W^2CY
M^(C!QP99;F.O'3TX.-A=M7LKX;ZE ^?2TD*0Q0-9XE7OQYN0JGY4_:@\?>\
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MI)Z:=ER/G>Y?*;O]M)F^!=P!F(DFS9?PA'> 3,_ILS_I'_ MWVY>G=\RH^\
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M/GO#/YI";@GG:,)IQ-'<$:2E?N\G*<:-C7(<5\1OTSSV[.I.F(]EKTG[;>X
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M7&%M7*J39:Z<R]M#'WX4.IRDJ"UV=I;Q!M^F+"P#=P:E":N=>NX.VZ-$"?U
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M'3#)3;6YX/'9?>\=A0_AU88VKPT'Z^E?V^WF)#-7]9-B>5X-0/[Q2_@5B9E
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M9TB:ZMYVM.#\[9K+57)(K($:LM3GD_4GV?\^:2+#!=)/8H2 1NO2=)-(.+E
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M]6&LZ#24E5G-K+PB".3&':Q7)>FFTUQ_5:1O#X7RUO>?>:8\]$*<I<WP9%Q
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M(%8="4CTGI@#"P]I2?0@0).LH$T7%9KPY),P%/05837O6 3-/^&7B_LBYW?
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M'G[L???QA_GMJD$N[<W 5N&W;(PUAL'!=<H*MB1$^57[.4E3E49.!\(&61"
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MPQ38%44>X,X-41V.!#R_SY+SBRMIW+5@6'/V(*E3T]GT'I,7I9_Q_D/,/D1
MZH!/)[E#W2LOM=J$JM>*H5YPPII!.1"<P#I4@8^,DC:CC^]7* [B9<SMYS[-
M6I&5R]]\WS]^F_.J8=4%N?(SUEU;5R@5F6Y?VN:V9<RBT\5X1S2'+0O)55(P
M^Z*T*(&BJ:&)U[.$HRD:GZME#H"0M":0:A'#0@0M2^9T)X+!T16<X>$=;2WS
M4$,=3NUXFA]P'@604'@<B$^&!K(+E'L@QY7^EO@?D;4$PC/-/*GQ?N<1>TOG
M:DD/[?WLU.A% UU%R:1Q0V[#81UF:(#_&)&:?5DWY)J@7DTS%JR<Q2PE%MNZ
M)T:C&X^V2XI_P*B2 5[6KD;3N*"UPN#+DC(L5*TP:./XT@EUFWO$UC5!ZO&C
MT7W1I89DFQ 8(T$':]K=$";PU]XQ-YVM>@JQ@=''*2_<4Y)%X\!K>=//Q37(
MIP/CU8RV\LT,RW-W3#/&&/G]3$6*HE9^#(MZ-,WGBKOH1>GY9T&I6:<PM7,E
M&@&&Z'E#M:3L#/)[S#<'OQ$0&+17-)8OINX%%-A$R[1'Q-CVR:IQZGFD8<U!
MN(W>;N.B6.:NI+E.8<Q60[DJ:Q<X.ME;(MOF@:"AFVQP)\IA<2>G2=YEE]+L
M8G+5B$;G* IDI7Q-X-XNPCU9QP&UX0>J[#CPLYQ/^G ['44BLZ380DY;I\C\
MZ],.3<0^#%$%<GE6P,8I,NRVA&P7OR$+FN=>1JW'.+H%U+&SBP<]+]6&=[];
M8 9>#I;)FO/6))A^F7ZQUA3:57W,(+OZ7M$K>8G#%%WK>AX6:DAO6Z1'$S\,
MZ2K7N$O\5K681K.9N6M>(312A;.J+3EC1K3VH]/G].2[N]O18Q=A'CHXMN('
M(R)LS D&=J.Q>#^)+X'L8&192T#Y+'2=VD$=^V4"FJV>$U+A\<X&K,,@)(4>
M!,7:^\5!&).P 9DYNA"/$?)GJ;W-)AC;G\GZ<T,2G.#/T*84F$<'R4WI:X)]
MC2#NO.;]]2!/1>0LNXS"]Z/XC?F>W;4E(!=[B4DNEL^)J**BZ=&@)I2FNM <
M[L'2]KJ_#:Q5+/'.YXU/7-XT^ R"M]+2Q$$*29S5*.?'F^0>J,J-'U6UI91Z
M5'*#(E15YR6[8UR+[A]#9MWES=N*\$;D5'V#A]J-5D@Q,_2;6B&I$%0MFTO\
M6BIWOD1Q* *>PPI62_NRF?008(&&_-D;H*]]:,8PGR2KN7(77 ,$ZU0^2"[.
ML&X2QX[E3<A)\.YUH10T&!X7TCAHT$5"Q%0]HD_^3C89$]Q_[6S<Q'SB;4O:
M/.*SZH-*^# L*=D(JFGW>%1,!_%H@<U>[;,<V3ID"1&G&%& L[2T)N@MK]I^
M9.^AVLT7D4W&X#XGC7N<9*MFT+:>7S5,+1+B,-\EZ>AB?.IQ\04'R9:S3!?S
MM5MC9DV\'URGRPI]W4\4"B<@QIQ+31::#LZ;FK35)?4L+*9XU#HX<(=H/%U0
M&S+ )Y:OSZNPI1=T\QKQO?D>I#/T,H+"GD*M*?W&O3Q^B836'5YU%OY_1IB%
M?QQ];8BUE5],U[MRW2C]Z+HI.U\LI^+7NG;I[GS*\Z9ZGNKH&8'1_AC/)=.^
MXYQUY/EI^1VK'$GO&9_EJ/1K@H%SBV7Q1M+1VD<]DBE_'_3&X,5'G(<-JTCD
MT, $D7C![(3-G8X2;PP3@B'^1O+X<:9R;0'7/2.@B<4^'+_"G^CZQM(M14.)
M-1RL"0X+6^C_ >7K1=OW]IO7'(18X5W.\UQG6U$<A.RSO!)5VI'/DBXX :H[
MUH#S0>!2G>=DLK3RAO[+S\EKX1-,W\O$#, )C]?O^[6>$)44>D*>=Z$Q$&17
MX.YCMI-BL5FO)XI:K'.39B+NUP1V#K+"[IO=]#^R5/O5&S$YILD^>%LE-=X$
MR[F)\/D3(:"<BG8H[<]?W_,OU@[X)0J-7FG#F,O6"AY*PRM1W_><(CT\1E U
M.Z;AI^7).C)C7;7XA&&2PMP"A4X&\X=#7='(2A-[?YI4:][$/&-1M$?,[#H+
M;MK0:]THJ[9P?&TOY4@.Q:FPQ24I):1QSV0PM+42*);7)F,+=KS7]0Z)L!^3
M$XXQ-V"[HD\ &\P;Z/(XVT0N5!WBQ=>+.(O1UO4F4$W('P#:&**F&A]W:D\4
M$A'TR-(*'UB=G4:2.'9.NRX+ZHK,RAD*L",ZF >GOA3E!)$!7J585DET\8F,
MW$GCF"6B_O-&)^Q^_[.1,7I=BX]6GNR/$S1?'M:HYSRJKV@KD_+TNRV^+JH'
MQV48C'3L\ [.6^%Y,A)=#T*S!UN=GV'HQ4%#&VN0<4P];:%<7I-+OH(H5Z\[
M@ P<GI"1'=(_OUT1-!D'T&O*ZMX#.G>$2KQ]X=;O-$=2S&G-K(M"\RU1T3>0
M.YJ+FO*GE=KM9*7*WAW)<$D2)V?ICZKQ=';W%%YI6RKD*92*6(IRY1=8<$WP
MG[EZX*'KK[<#\5";9-6C.\(*<Q;$.FT]L!!WDH$CI]HE;]B%"3D16MNY?"G'
M2W[JC&?)(/,SSXT:G)?/93LUVHS:2J>ONR;8O,SNTU\]SZSGM.A"^=O629=&
M3#'(I<C.AUHS#%NO);7 ?]+)#(WVQ$L_G9/^8C]9+FD>J+T&8G&RP,W7[':"
MRCIIC U-+%,U8T/X8CQ D9M'K#:KTW\>]7(IK4V$GM4]T\\3P^>*[<Q_3E4+
M)_.)T[C]O;(G[$K)_63+KB,8\:1[ZE4%0L Z:"(N$G;.Z&A:D.S+/E9)*Q8O
MS#0N^"@0@8P1]XD5DLO;Y8RU>I(_E.! /.#;;N,)_$7;T<3QV6I:#9^!VHWH
MO4B3 W".[<GN_/.S9_K1,S80&W<+N;FE-M?Z>F0U!84;PFE!H[0TG6](GMO^
M%)?BIE[M9&J(F(_D4C/\W22DA2/K[:L,.V6*X8$ :2^89O@;N 45ZE/XFQ)5
MMN^L)6HQ!W_""?BM-@:=\[\D#FU<L2Q4R6E5GTQ]PE5+W9E)M83+MU/X*MCN
M7HCYMG9W.K*WE$&B976SXQ/(K0PN64JC:U:V*AF%QIW?W]B-FI2L7]9"U4OA
M-LWQM#QY- [[-?D(W9BH!TI+IFQOFXAW72%HZWP#%"CG7F_>8'B.T_<OSOY_
M]3<R@I/MSQDY/$BZ"@482 L<]H"*,9.S.Z_@:*?]#<+[&W1_<'&]\ -;+7E4
M4,#+6,"ORH58Y)^/@27156<D:!<--S^DJ]GSR7*$FJU4A(1N@BO1R<2(7PKG
M4+(:!FGU2%3%^S>\Y=_<2%N]-;1FJN,DY,(BOB]S_G"P:F,DF14=+'46<-',
MH4[N1;'@;9#\L%2 LV/ 08^)2PALS)1LQ_!01;#N8LO=[-U;:2EXPVT,RJXF
MQ*UK+C-+33R;>SK;=));[$3$Z*M5RNE???+D4;I+D^LUP;L:8!81M;A9PT$D
M>:P^"$#(@$EX7<9[B$EQ30]17B_9E7'P[_6+<MK3&IP\E/7M:LJ675DOCMGL
M.'2('AK(4Z,9!^48IEA, 6HB>LPRI# \.]O H_@6JN6R7PSBD./> ;A:M+M/
M?,6JW4W)K6]20DXREHS5>IW*=FNNIW?Y:7!47C[L7AS2Y>#QJ6D<\T%8!MV@
MYK;-K%=RC6[GZE9YS2  $YEJBI+QE!JCR6(\UTEAV4Z:P$[88R=XL8%)D'O0
M[&2%5Q/0#%:XV#CI"S@3(?-?A-;B]!R>D@Q/=G*DF('L__%7[OROE;'^+W*W
ML5;[DK6._LK:56#9ZEUL0D54C4]"L?R;\ZPUM>+.ET,?H \?_$\IAG^W%,-O
M.=N;4TJG4"?<S>K]+";]@UT1T>WTICN,#2/,+/)EF\V^D?Y(]ZTAA?+O4[?P
M<.)5/!J M,7%1>A7# *SDSRRD^:2?+2,M82]MN/'I\T(CF?M9<W5>);*ZZ %
MO*X7@=3@G^L^K3/Z975XK72-X*SR!_[\5D2I.WE 33YD<M$W^,\1/=1L-_E:
M>3F#7LVR1KZTQKYRM:Y\L9>)1-NL^$X19P$+<571\/2CXD!)VUD.A.CK8/Y'
M#+_HWA\;#'T:K@L+A]J7]:>WXSAV(T-9T//L9N[/0MRK+MAUF'63DH4 9T6#
MC)&X!8LK-NKZ&_S/-?SG7T G)[RJKOB-SQ_:>':LL)16H8>FLA0O004)R]S/
M3%'*.WHQ:CNV8EFP*2VB8KI#.NB%4)_'A_^T&V]<I/M^Z:EG5^M5B:+/8?0]
MGE14+^E^*4[ON6PLDH%-5@ "P.'!P35?*)6%4N!/DY,]6*NP,ZP)=M;>OL?2
MWWJ7_+SEPU/>=R!5YM*P#4;N[CK%?'#'NJ4D0T+))ZT9[\]2W<-&E80S(E8<
M["[MT]CR\9HD9J98=X1<SI34YJ)9=SU_,N39]#DVU/OH*.&;/T*>*4-T8\2U
M5;^QO3N%Y>3+SSH]<+4BW9$$@6_NJVP#]1 3$U+M<\*]+P%_W&*GCQ>R[P1E
M!)<R*YD_E&?73I@$T$()P<.8QX^IOSP>R@<%2.H6<C:%,R]RJ2(S8UNQ,[=B
MYR9^QGBD]?KU7\JA;2@7&:5*]27O#!K:[3VP^NI@:.LG7UCW,LC"*,Y^]"'6
MWL3^Y5;"P9,MSVBN\#HGPM,V^+>^+,>@IG2Y^2\,%A?CQNM[Q:5>!J;:+@(!
MH*6K!VVH?HFNU(JX-HI-KR$$66$7-=>;M?VK,]G5H^)'A8LPC8@J79- ^XM
M?]3,WEVAEH*\MZNK&Q8H[@BD87VQ[4.(#\Z2U'*&-;TPW_V,:C5&H&6!>Z1@
M=H>EO_'B3D[7#*+P;J[;[DQMW]+TLF*6'I';$]LVYY2YT^DJU:X(\:#O7_?P
M>0U/)KE^YFD^/+LZYJZKZMP+R[>/8^VP7S:961 ?%N87$."'LM:*]4W/C7]?
M)=O8V+"6J32+W@]S7=9%\2EG"5/1G338:$/Y^.SY(*.CN!SEKG 6(I?55H5'
M_F!-?Z8GO^N]95$A8U79/IX^M22X._%1SE?[1#?>V6IX;+@[0JZF[59"1O]'
M.=J.&%)[+MCP9'#97 >47VS>%C!0$1MK::E\RQ4"KD)QD\]3#Z086U&SSG-B
M/H?'_1PTIO&A^=E-^XYQ_,6B'ATY\./>)Y$&'5N)K99@]TK=EY_K!6WQ2=2P
MM9YQ!3TR.<Y>+D<Z^X_\0,0J6QDF= ;?F0.3V$D@/\^)."M>Z#;?%M72&=V+
M_%QEZ,C*DM164(WBYHFX;THL6OOJ4^L)68P+ ZT[Z9R\#"RN?AX[@FZL#2(7
M<I*%^/YL.\IF-:'9)_?UU_">)=?#KK?\,%"0Q A( 12%4L#:2HE$T4DGO$O]
MFF>R>(9X,Y\$#WUME!V7.6B),1R3WS\V'-J=?#LJ2"8>_+TK"<@P29DN]%=;
M([HZ5_!1MX#M@FJC1Q<-9--WL4-B%,5MEB-"_5I63IDZB^]2U+@X6"DD75R/
M.HP"D8J!+8>/*5-0Q*MU#+?+C(DD",,(_M Z%W;B,G;9NI%MTU\B(1$YFG05
MW1,"?BBB9VXOSJ+0QO!E+6IH(LR@Q$*KR[6=^%N@@9F6BAD--*F-S:+GQ[T_
M7_XS3O7_0T&%WY*5@.%HNB9HF<(4>#8&ZW#5T->2LJ,G')6M!JWE.EOR3+SO
MUB=M?P1F*^M]&*DFB)L#O"QM25<TRA-NJ@E\ '1+?;['AT_O,_([SZ:)4'<X
M.)7.?S'>.J&3I/,SP95[3T?Z_3@C'7-HPGW%F6\$__H=Y"_AV9RF+3TB[G^I
MFSRBE,I>M8B!.JLFL.L%UMZ?*N&>0^>Z5#=E/2O/[\EJAU8=CBS$,\:.,X/4
M8@;I3R0.<[G3B60XCC6,/=WVY?-<LI%BV-5=1Z_WDG6D)SH%*(ZPU/MF39D3
M3FC%((HUL*T#+#^];0YW;A152\:,/\^_T>E:U-K*ED>_Q ,?J38SISO+[T@D
MMYD/L=-X_<.S9+D%=J)E@190<6U#Q*?=# MK,J8>KJ^M=J&?ROHQ<C0T13O%
M,"?15,AE';:M@14.FY4 *K]#"*98L/X89@[\CWOR/SQJ3=TX%BBEV36A]/D,
MVXJ[L/8W?3*X:0S,.2+=L"B*6RRG?6,^R;0(,?+BZAG0/F]B7T8S3A9:TV2#
M4M":._ESK]BX;G"3 :&5G['"C\AO ,-VS'G?&JDAQ'683U3EY&XQANXT.<3"
MX@8$(E,<<1<:^-'AV($OHKHWBV%N<)CM.JXRVV!,+C#./'K!;4][$Z$8.\$%
MS]->=9 Z;WB2T_)2X5'*2=LS XN.!<3NM'?<>[O#8['U&K1[_HB/%3^1H/YB
M#HCXWF#.?5/]YYP%1LT4$]N/8:=_[P8FY+#%\E4M;')V\4Y8%*$H?E1NNHN$
MU!^.OM5V,ZY#V:*8;%:34HGG3H==SYEWG/ QN]5 6Q[2J;<=YSZ3=5Y^N)Q-
MP[":4CXY!<'7Z<V8QNXXR!\?K/E><80'!.%^C3]86^H&YV,:WP[#Q)IGBPZW
MMO&)FTRTX!)-/FZ&3=!54GV9HUP592%(UJ#G.8MD\L^MOZ-HHR )$= @"S:%
MB(NORQMCQG<0=G92NV6?VND:V?PA.F;+\X;Z;I(B:A_@^RM_";_:C+;KZNS7
M!)$I5C,P<Y2S:-I$IVAA"N+5BSTNMP9>O8):00@8V!'#=^@,%)]C(P/U"FD$
M]9J%4:SZD/,O><]W@!;<DMN-QN/9 J2GY%)[M!;3AHN4$U!-BY5!H@\E%O4U
M?5ZGJOS:#1T-/0\#09W+2ZI5&V^XNB*E5C>2CK#F3Q'!I]/ML$)/%>I^4A].
M]12Q0588-\LNZ3PR.#R\5U+L1UNVPX)'=__#=2\!U=S-+J&F>7T\I$FM(:#&
MG<SO\.U$@:0YQTK[\Y@T)Y&_K<R_EG+_7T3V<CQGE>WG]KXP^KTTCS^\'ND[
MN%#O>4XYQ0@V\0,H%]Q\^^X7F+[O*B:^2BQ]L@CW/4\1)4F6SYRB/9#-Z47[
MO$QY]FJ,X/:B;USZUF&W_(08V6GT3B_FT*S&:;M_Y&*F\JJP\-3%B-4J[=:_
M^!<=!\]8[YF>BWO+U,0%6_>+HZLA[^4$GWG?3[;IDF5G.BRJSTLE6O[Z]D]2
MCS#R+WU83Q+K_*[L!(/<^^2N"::E+!9N'L@MG_8FM%1SWWG6%T1PJ\Q-\$S/
MPWFW7_B*S/Z&*(EMHXWY#J/(^]?)44MXOW@'R(&8"LF'/ZJG\8P_,$H7/6O7
M!+VR7P2W?-,;O"D[MB>4S-#\[WGL;9"BRZ8?;B:NI^,H"'>[*<^/;^DX*U<:
M7)*X[]LVDBJW6CB\E_JKDF\L@_1AWKK.',_MY:2W:# :S>5GKBWJ)VB(N'[V
M<W(E'KJ>7;0&4XMB!\S;+2F>&@!(=!G(-E,LG?)$34B@VWD6_-I?;Z>ZY]"6
M]7M QQ-%:0%?%CT6\H$[:.5,X]6AS[ $]E)P6/@\-6_9:41+?7Z3G(+-I-O$
MX96R2N HS9J Q;-];<]A1LEVO?!EC^9B5\DG!G1W+EIB$FLI%$Q"3YG5W9.5
MB]Z]0^CU;%6"W*\^XZ<R('5B![OEU4'-GR%] 6]GYU[E)7 -)MP=XUQ$TYE+
M5"[=@)Q_(+@,]WY:WU*\LE=@.MW-T E+#NWY3-^8\^72M9Y^4V28-X]OK8"Y
M$/W,/M^>16R?1 Q9-9@+^(T_Z*J*K$474449$-VFLQ0> [T<;E>N7BZ%=RG&
M-H1*<RAJ)0SK\ .QQ R!^[7-W8N-=@W:T)?NHA(C(E7I;0\:X4N'_ H?JK")
M8M3Y0OF39$ZO<!)Q ?+4G85H6N,32YQ1,09ZD@\5-/;?2/7GL4'.S"*=.- ,
M)I"#\R+#AP'@5,"4Z,AA-T#;)KPT0FI$.\.TS]G8 IS"/B0Y'P$ "8.==5B(
M'X5_;O_YGV ZV/'M=DU!A%U4_^;EUSW1UKYR0VO&!82.)E>;U9P''U[9:FCM
MBU!6DK'MLEQA=*(XNYI*G/*\9G@J,*REC:W5F#*(P3?G3Y]D%P::H4FIREK.
M)=QF'B8'G-2J4WP'7X1,EW@5VZWRN:T&?D7RF>[ BTI%X\/-384 H2Y+P-I*
M;,ZH!KR%\Q'3LPUTG#7 ];Y2""G//=BI$+)A[M7$6P "DQL<W/,MLM#0A:L+
M U%^8D[)!0"R/4'P84]8$RAF;H4=N(EO)&NVAGO3+[ISEW(>T:4U!H?)$/_1
M&$9C;')#C4M.PIDQL%$V;L(M)CPEALD,IUFVG"<"[#Q$Y<L%T#4^]*N<E)1=
M"NKI;3NO*RS!TC<'MF?Q8M8'H=*G11 YDH48'Q8&G?%=MG 9D8)1(0W25/DZ
MESN(A:(;-OF5?14MV+2[T!].L ML(7JC'>Z/YAW# U4Q-HJN3^!^+U8$5+Y\
M3]>=4CU38B-G\T=P7E*,3-4F6-D.C+BA-EL#\S7B 6 8U*W-+MSV^=43#FH%
MDU(K)<_#C?J)$?JEMLWS1.X]QI#.=''?="B#:)V+AX]:R(=-'FI>O3'DI#SQ
MH[);K4909&^WRK!E3 AX IN^27]W53Y-VFN:(F*HUI$H1Z"/8L"!9-!TF*M+
M1J++19C]]%7HG':_/>02E>F<GVI3_>Y^L<'RZ'F#"98G44L=61D9SP6QUK)7
MAY0E&CU+%E6!?Z^F4?.E& Q['AOU.(?R\\]^O[>T80I3AB:RCM"IB>E54<2S
M?&7;=[[K3TY4G>!6_IDGJAS?UF&*+@0$=]F:]WD;32T/$K&WX0OZ(*L(D&T_
M?=>N=#*=-TMFJ24<J)%;BXXA[:HQ@AC$2'0'ZRD*K0_TZ(BE\20&Y*[6^!5;
MZ*D/Y6I6#^8KM:&X2R( SF'+U$V0-K6!0:6,J@>;$EL1ABXU^RGZ+1';G\76
MG_VH$F3G1HM3R!,W!<9N;C)K&838>^R^&E=KL=&T+B:+K.>V2*/H9T_M22#<
M50D\*UV(@MHU\)?BSM8!0S2."_'&.39@XQW_*W(CMVN"(_RILLAJ@0&L[YDS
M681/]W?-DJHI;*EO@O*X ;"%>^RA0A?,P!&)#]UH)L'8/@2&@?0^FMX"AG;*
MQ>Y3:T4DZ7K&I%B7AK4LBYVL#A^LMN4>1"SGC)35>"S 8^.YT7[D-#^<<G1E
MMT@]S0A9=U50K>USO^FS1+9G@,4$Q]T>UVFC>P4PXVV*QN:RET0[+LE*L4.
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M21#7$7Q.^Y->"#=S.YR-T4#$Z]C>]:;%-@!0A!^J.+_0\GP[DB,5]E! EDV
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M"1K"J1*K9D (E*_W < 0*< SY!! XYR#0,9%-<6_E?& &7BXE_&^_T<U/;Y
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MYFG0YA[4Q7^^\5I:KQR7]:;X+2I+!?\Z2G=+\*.;*I-"9!D)K[)U9SNUEF:
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MHXR3\_Z$AD:8WQ]1KL$PQ.M(,DXP'AM@&8'CIP%Y:S /+^Y93&0_'+2OO_4
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M]ATC?C)6K,>5TD.T8Y.L2W3K*S ,STNQX 8D%2D_[WAPD1@3K34O(MH5J"K
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MC>V_7PBM PL9$4TN07Y!)IU>FGW3&9'H5,D(+0J+[G)39N&*=(815#BXE0:
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M,H HJ&K0EQGYAT&:@F:[9(A-<)H;J#(:L>E@P&;U]>2R;&"'WFLKU#X!Z=/
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M4GIG$<T1,?,=QJ[=C:UPG8N",.\=QJ7H]X[*2?>#B5_O_X*\MR<\/_;R[S#
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MDT0QR,"=O/--4K'#WH%!R$^2;FGYZV#RLMV_WD*1-)V<7RQ_]),$Y_;FQWV
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MBRD2[=R12GW]CD;SSOM56];^.<H=YKM[TH5J)8^]AED(M6Z7/>8= <>&L.#
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MU&J"?HQ<N-54J&U:4/=X_221IV_<OPA>6Y)TM5]=O!#5><1[C26OO<>N@,T
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M_$&[)$7YAE"!%O6RW&P'IL KH9DKF?F6,A.-BMG]HJRR1W<Y1)BE8153=T-
M; +^)KHN.O2PA2C/J<C0X^(L^F*(V"HQ#]UX>PU>G#&M032L\R5"\5P\&.>D
M-2D!+5PJ'4AL>G6@/8)KBCR>6:;36;JS.P1$R&S# ^8<FIG5W;_&Z<<PG>*R
M4JQ7<5"%(1L\1V?G)>F;@C</SM3C6[O!DG6N=!KL"/ZLA$$MV"MD=IOH1<;W
MGR27+:G7\6]^DLA^_4FB?\VR2_A)<LWZD^2'TT^2_>SB^E^2E <#+J'S BRK
MI8?RAVM%UX@F'3]W,\[YD.;PI]=,5QY7CC])MLT.;$=D_*JW?@UHQE4<O^L5
MMG%^,>8P8;DAYSG:O-OZX\/6?-Y/DARS K.$73G8H5F?/.B@03SVTWXSPZ)-
M*U?P?NG*EZ]/;)-B?R4[T7Z#:QCT][<N=+>6!AAK?ZL1G?5+&8WF%Q.R9TI-
M0"'I -?]T7-*?8YJYW'N&O55=OO<HLX?&2LE,*-HC@2%>VVY,[RA6*T>VK&[
M&^.QII$[LGK9>D;-GD@I-Z(1O!F'OM9#JZPH!);MS^2>?TU1E3HL!BRWB@>2
M]WW#^764^\\X^=HFU0UXK'7N7%17\\FV%0*-M_3$3GM[Q=3SC(_T)06NK77%
M=I'NCC_XO+?OMRQJ+[[/I [45CUZV,Q/BG9":'A:3;?17G2OSXT,U7DC&]P<
M8[.1E:);HV2I6"-XE5::2R"8)S3\2=;&>,3C5BE/'X,5%"W1_5F""R,)">G<
MV?">2,P^/,]1#%.I8[],P$2 <<L&C;CG>CJ7[N1E,0(TTONYUNG*KBF^,8WW
MUBPJ):O9_PB8LI)JG2MG:8TRK=+T9]$_M<47\Y_Z:N%A&PU7FB/UAOUX*4KG
M@&)>91 ,BKJG$@CFR/PVD@>K4<%TR=@;%'O$S+K7\3B<%LD&[?E!QGBZ?I(P
MMTQZDS9E4,5:4R?;*,DX<4Y?!(F$];D5"H"(ROF>UA0\G%<4,5A-2H5"4UY:
M[Y\D>IL/GDD]7O@X9[QAR.\3]L-T:DXK+WT?.9*-5"G4SS6/M,^U;143#)/'
M#\N.?5>VI68A[Y^_,DD6T I6&1*^.6\OT[8Y;-VELPY#$PRRJDA9.1*T#JA=
MNC)!E?PWH<\2#RI2[7^D5NA.F=PZND,<NQ!]G>R&LRAO?M!:GTZ,I#J'$SV=
MHF@ 5^2F('%_@?+)_/IKV9G@6]6?3L&^ I3=OK:(MA3;2"V/)4N#:Y[:YW_.
MM7PV[XT7]E&QZ/5]?T:S*[&7 XGNGL:H=RD >C.,ONC+&S .'K&L+!YE2!%E
M]523U0I#O.'M$9"#7(4B0).F26;Z-!21 0>F"&&14(KN5TIK'_ZX(65ZF#2[
M&E2\:]D]\\#0>2_V<N]VA_,,5$P^Z&7]&<I"/YG:4ZKC3BJ;K)CT,X+>\)@(
MFT^UF>%CZWM&_84V*D1 2E/%:EY%HMKL,5/(X<(P<R(J^=%75Q,G)SOW!"+*
MJXAH?TI;:=^7GW"@X<J#P"V/($*=G6YBEV,^WO<O*ZT=-#2<F_.9-D*9P(H<
M"OGYB/)2[=WM;BPP'H>+(VN)[?A8&XBKAM16*&+&, (J(B(".#C1JW'6<QW,
M0->Y\GI[J"0WRBHL"H4CPBT?CR6$6]*\@W!@(2_C;KIUYGX445L9E[YHC7!G
M6SXEBW3AQ>,>P^Z(5VMP*0<CG%D<1RU&/E3JGG<A-P_RPKWNF[;!'.6-$"UL
M'4$]W.&]5L#,)]%*,45):XO@L%;Q-YD[JIIU>L-D<^%V7L35Z:_VFZYN;<D&
M8RFI2)[R?%YZ%SQD!$\GJ8V;QF5-Q\8Z.S%S$OPM,,8DH+?S>L9GID/3J3'&
M/6/&'V>E.H(<)I"AO9H,XSZ9DX^=D43]EU[S)-4\L^81RZXE/'#KLL1DUB/K
MNT>XRQ7!O&1X"I.K#J1/+*VU8D,0GVS[,3$.O?Y#?.Q85NQ[[GTZ;#YB2;VJ
M,%FEL<W#IC97 Y%BY! 3R;_2_;%&^>%9BT-B@],KQI\DO&,-;JMGW 5E/B(/
M=%W<QO1ZT3UA+8Z!=#K:MY>1V'*N03:]%CKR.(*2ZC<1O>\WG[KFR;!S1=5Y
M<>56F1I?0C*GMXQ:'>Q>E-;6[#_90-*Z6B]:X35 <'V^$A_O?950QI=MIQJ4
M[2DRYMX)JX[*-4(4@%R,;V&T@17580_#;.RS/Y=.)$=[K_*\B_N[;"97*(%R
M._X]1N6TY9[V8+Y>![:$4,3:VX[D ]_TS<1Q_9&J68G!Z6IZXJR1(28K5X5V
ME'<D^:X*#A$!IM<0TE[$OC- ?&9:%9 7L/U),I\=+_-YA*GWC/:W'$^]+IA9
MP+A%@N]E 9?1'G]:P&()T!#%:.KJ/WH^)X33U5:.L31G=9+)FH2F>+;QFVAG
MB'PJELR+X!PZTZBX0&QT:)P]4#K>,7JU+L5_FBT=5LDS+J8[FM>ELEI@0404
M@F Y;1RE'AQ88\I=%IOI6K^IR7H7!PQ+;&*B)=HG"IRCVS=T(3 [X"RSQV&S
M1?G^??QU4U%MSW:1H&Y?D##!,?VS8F<(I>BI(-6]+C+P/%JG:H$K"G/T0'*6
M>OJ2<ZYD\W[GL,,VWTZ>3\)A,I'T-:A&Q^-K#8Z[_6$[&),!JECA,@S'M)"1
M186W)A$M?V3M7#2*<H8MT32%S4K;JDV;[20U59T.:SDXM!I/S.JIM$[AZ6]5
MS,BMIL!PW(>:O8J:(#N%'X.4+)F6QMWPT.ZI16^7+L[AJ>GBUUN$[]FPX1->
M+T-?D(*X[K$C^SVI/DD%<!H8 /Y<$8MZR^H;4277.NU;6--<XE;D&;\]<_;D
M G7N+3XAJ;QJ&S=[1=,940W1VV]2B^DOJRT[%TNHDGE^[=)S:-&!SGR-O@>!
M/*N&B+<=?,_N]/FZ/J4ROY55FVDG1AB3@K'$>+SFWU"(>&PSO,/%A]MH?QJ)
M[-8B4.IW(V(7IX$XJ,_-S1^CM>!QYDH5[WJQ,64&FG'#<<;DV!4];%WQZ#<%
M*&+&#A/S QQ8F=EA&'*;72E[5=TWBQZ:A %)07(*!K#BB2A'%$.S6<6TM%]X
M_A9=90841^= G)KG;@%)]CM]:Z'$90[!XM>/S!KV9.K#=E;L^V4-T!1F^<[&
M;V?<]=8C&'=F?*.2.[#9["T:GIA ?@,5=+1QAZ#094[_%=GC]]$S[KI3*XW%
MR<@1#U7J^ICQE/@+](:>JMO9VNP\&<..6P0-8O7RY-GT5U1XPUW=*QWZ5S[L
MNFKM<>(2N3R8#8?42E4/#3%+D8M'7(J.O6S\'+IEWL8#QCOD&F<OAY5#F+I0
MC>498PQ46]9C;"F FNW<!PI.(_3 W!517$%W)-ZN8$+DN$K6\W"G4="\?"%O
M(TZ'IZ<ED"',OJ0ZT8D\)KFO@9^8_"V#1GQ1AEH[4:GNU&[OI,IH2D*<5K(O
M0?"EN>1L +FB\5X!'B(S3=Z]S:@N16J"]\)"#[?UGI088;2<1.-LS?B/:X75
MOO:A@OGI]QC+5^8\CWK?X&9_6]<SVB..=0]K50;D&^L/GX)SE2T1;K]H6FV^
MAD3/YR#J304!T07Z#SQQSH!LX7^D^O>SY@FZHE.\KZ='-!-UT#JY56"\"=$A
M^]O$V,3GUEUKA=3?'?3H8^\[2/(#VY/1$",4!,2IHF2!/3&K<3HETHM+9\.J
M:P+LC49&^)>XNT J<+S=7U?\9R6@1<<H7MEXR69?]/5%1,S8OI^0:UEE 94W
M" *GP:.US*SQSF1HJ_/&'\Z;.\;&9 5^>P+)6JA[CF)X!LVR1?(AU>'<A^-#
M2;-*B1Z6<ZYKQ<D"&RD1@WVM>4@&=X7*D?6-0[S4B ,_2">;[^OYBUQ2>))9
M%K_(<TRI1+^G>,H%LV+P*Z,$ S=V7Y?0%8_B1YZ F"6 G"12*HJU0YA>5O[#
MY-#\BUE=>=KNE-64;EX$6W?DEE.';T7-%#8S!H]G?AAKO&^[=PFWM<TY44,C
M+P-Y7+=YMRY]I2KR5$2R$4F[Z^VO-Q4@[:^2C,(S.):XJQ*0N))MKMXFLUWF
M52F7WZ>3"I8)PY\+A62;.0?()Z8';%?/D\-#^\QC)W2;I9FZRL*D/)WT!B*G
MMT'MVEDI"KJQ0$J ^=>_YHOVSH8VC+^>STYT3_>*S*\^9J)MU0YL2X] >3/8
M@RV(+AK"\%P-G TN?<8J=C%1TU_T-\ :\,_?HU.&BOD\8>F>PWE"3*Q=Z)\D
M60=JS)S?:IF"A/*J.=O&/QQ?!9E^FSO![F4A%B699!WRXW4J*=EK06C022D-
MH4^%\!724IN4(9H^I?\F8&,<.^M?*JZGYG1",9"^(86_ E\>+^EN]L\M9B+S
MU0 \]J[(?BBI5A).JYL($BV-;>_T32C?WK)SZU\D>)>+J%=;V$K2<L5!.D5D
MMMAK>IQ[)BFK_#!F@.])H=?6@6V)@]^4D &@,T*F\-!#%0B$TFH0/0P[DK%=
ME88,5<A5H:9T0]!.ML3!FLS<P30-ZMQGTO94]M0;.2V@KEHP=2FZ"8U]Q2''
MAG@TI;,2!:K0E')58<^4Y&\^G@-9?IFA8R]I!^LN3]0=,:=&]\PPS)69''<;
MJ[)G%^)=>*K2.=R!_$2Y*K:RR9RAJ7L2>B*_UM-([<%^LM2A48D;Y^8&^CJM
M]MB$"]$<U&R:9#]K,#VC'0%&6@)A&H627<^@+MA03VTB)T'88YKK+8!9\<.^
M46"MFXFO"][:4^^1QUK,\H6<*E+JB+7SD*%//MA@ULS,Q*"9IWMQ=;%;JPP(
MC=Z*ZO1MDUC$_2)O.N+A;/,RE-\T\B<G-V81,W5^J=!D,E+ZZS0-/ \F'#2<
M358W&"CU*A0>P$J=\;B-NQW$@54M"%S[=K=CCS?5UK"YRIW79=8VP;IN3[(#
M(Z.B(1__R^KM0 +\>6SYOM>%X+"5]B/>75[FF-^-"OC590+YXW3]1:#AD5)]
M>>@BV^F&F@TIW=JQOCO0L9W"/=&Z<1H=*'BCI1!$1)M"-)*5N2$@($=F"@57
M'[N\_;6)^[.*84G=B\!^ 0O9XJ=]40&;]1>Y*W('VNOQNI\Z1,(S&*'I[,((
M+>,?CHTET'FC$([&E2<A*FL99BE%QI,IC\_*"_%UOE\W&;!!([F5IXMC @[Y
M)EI1J_5\1?A&*'4>9M_7FC?40YEKWT7N,6;0OZJ9U71%]:9$;4,!'U-E9]FL
MIJ))HH'<X;*\O/D"%_OO$[')F''F-VWB8NU<#4J+8PM ZT5$5%Z4I8;!1^*Z
MQ,98<AI3R"C,'37X+MO6Z0U"VX) *G924NQ$\T[MVV ^[!7$HH:CAGF!+O4I
M3^&.N(N[(^:(=NDVX6MBL*4]^32X4T0V[</<9M(:YW@MW**&^-I8ZW%NJF_(
MI+;1\XY#7I_TKA5%<3Q@4G2G9I'"H2QS<::O#4@[++NP')LE_<;=;"LQSG5C
MS"LR'JT24?G8Y$4V1JTMGTNW8$FCP/86(@FD!?6P@1>,F%)A79>&K_)VU0HO
M!CJ8^&L]8WL@(M:[<R+7X@NG,_$SXB-'F)TXIZ+#JAS!K9553;U^>T=^?$5;
M@'CTDA^PKC4@G7TK"J"M0VTU#Y[R^DF"<9 +1\GRC[D+S$PG^HDN9=F;4M@A
MJW!K](2O-9F;6MAT(AU]15)NG^@^'/MIF-HADIN$Y#?]5*1WTK1@A)?W'QN^
M-!4NR5KEI^UHUV0SZZD>D>86X<L^SV*4EK[VFGOXA,Z,4G%/F4]IL&QKEUH;
M=,N>'9(31;_J"%(1O#W@Y G:< MI%*<MK'6'111>!YNC2!\27522[85K:@@.
M%SPJ+YR)4%P<36M[F/$KWITI_[HW//O];S!=R1?=*0IH_F<IJP6;!<-T4XGY
M%FL?$F$.64Q?2J\BE77-L5.C"NXT/07YVW1/$[@,(YA&L"&\!LRR/&4ZM#93
M9YK&KD=IT@\0&V+E_-D?-VBE@X8F9^'Y*%LGA7RW/IU<&#1" I)7D8%(")*0
MA/X/QMXZJJVNB1=.WWJQ"JZE;7 I[M"68L%*<"]% P2*.SPM5C3%BZ9(@."6
MX*2%XJZ!X 1WMT#X^KSKN]^ZZ[OKKGO/O_N<L]:>O><W\YO9LX>?%"P<Q/ L
MYCD H.V%@R[? ( U;"=X*L6H9=FCD1.QRW3^JN;BL6D'6:P(5D^@^EY.!QQ*
M0M'%B3=4A]%>U4@>ZM6\G(F+\[W'U(>@XRDMNZ]X%>\8D-1PBJYW:7 /X ?7
M(0JUHH$>D'=+'Z)RIJ.!1ADSVOY&ZFSG66S;YK/.WPW.)"O)-'O,%'9EJDM\
MR,Q\&U!^!0ZV#/^AIJER9+%I,S8%4UM[N'LX+V.A5+=#6;KEUS[WEM/E2Y*)
M?BCF.5=!IQX/"F?>Q8EE\M9A3_EB"B"7<S"Y)-5ESQK>%2,<9\?JLWT+TIX,
MEMCJ3_B%'@&\6 RQPZ?[Z^. G]>5-<<8)\<4\=%&_H_VCL,Q?TF40>])OG7<
MQU1YD0GJA'3XK9)@ZJHBM!/EZI"*3X[W]XTG3[]UA="0=61Q+AS(2*W0O!FJ
MY3=8A_C%]HQ^&&6&>[ KKL9('F?DTJXD%.@)A@EL>W]JI) F"$T/>CIG<>R5
MP'R<F KJJ^@#WS6J:OFA3LF-*_GL-Z*,%XXB\QM&^6OKTN]5Y/=Z[+$B$.4B
MX^5M2UJI(SAP(D,"="D0,]""G9;2#H+H^9EK5(Q"N>PVW4)+F[F]04$<Y8R'
M,;3O!)-UDFW2?P-C'U*_I[L?_>M?-X?T5[W20,M"M!M%G 'Y_;X6"_GH0:#G
M*DN8Q3GFQ9DTAXN!L]TR9=VN6.R(WJI:>P1=6/>/RA>=4%[T5WD[E2=/R!S7
MM*546IQ1F:V3S3P;C)<>N9NXLNGIJO1A*+=>J;YF-103/YKY;_B-%WW>XYH
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M8\PI;:MRE"'@]I-(>A <JM)&&W(<(2R30'#>EOWL6@[H=SR(>G!E/R*!(G=
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MWP#N?'9)U9SJG#'_O';?4!9;JW^2H'T)=9OZ>K2ZK.XU>,E1'W4@]HC(ZW!
M%60UB/$Q(?A-PR5*CXU6% D0NY?+^G:[>^<9XJ#4[XNE=K/=43XJH)5:A\+G
MVR:';A^,M;C[4Z#1V@;ZB(<OC7HL$,S;(P*<G2)TY?[K_$:UMIM>/_BR[*F
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M45)&E%8G076N']T^3XVZQG\5Y8[K@MH>M\\/V%_Y,/:1V0'DE6JHCN4/YV\
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M8N\<NFB(L=;?>#03U)W52A1S6; T(BCM!AS[F0_"IL@SKZUJ+ZE_FF_;9OP
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MT6!X<,O#YSW4WG,K!+FZ'?'REP'*:ZT!R2'%)\JW[)D&^.M,8+EON@YO)X6
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MY9L0D$ __CS+#:.W:#0(.#XD^ ,CT3X\QO?"E6U-H_Z%[_MYWH<&N2T.;E$
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MWZCJF=P#J$+<=U:>O!-3-999Y7@/7YUU9F25Z(,K61+VN0?T)\\$$S<%^9:
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M$EF94-U:BF4:/7[&+C7&GDK;S7_*\FR3"$B\B=QQ9'#WHXE>!!(!WAL&^D3
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M:4$R%&MF9<@I ,M*ZM18LU6Z.0;?4[L+(W)C33OH[;C1.Z"!&? RE@$.U)Q
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M="479AG+4EQD!4R5=JA1BC&D7##(,I8S7(BLX-@MY&U$[:<7.[=1$?P(N,E
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M>3^HIMOL[1,MY^9C?K-<U=WB9I'@N3(=2 ILJK$(F4$B< JC0F#"A5(1=:+
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M:59$>%BH^Z&HJ<TXFY!L^Z+]%GC:309^4 I,WCLQZXNZ_%NGY@UXW],]XHI
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M4D54A"&.HD*OXY(,4I0ALU\5H11SA*E3G,]925/C@U8M8.J?MSF6PD\WN7V
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MGUCKT&SDF&F@>O'MN )J77$REB*)8QI#1C(!D=FA9X1@J#"CG!/%\LBI'F
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MDA22*)&((Q+'A+AY V<D38T&VCE.:POVU6T[W[IZ!.< MO4)/, VCE?@CM@
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MZK9W9H$)PIQ'"NHOV[2(H;$)8*$P4SGG"F$J,Z=2$@-TF)J3U6EI]C,.\DA
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M\B[C;^=_>$4U,/ETN@+SO8!=>'>C_;VF5]MAXSFO^H+0L1.J[3 XD4EM>>/
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M9JT(U]\5R9NJ#W1NTA-_IM__/E]]-?N>\\6C_L69>O1">V\44@EP021 "C&
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M1ZNE-I>C3G3]C,=21:YP>2U<9-WYN&6,7#$Y*FKDW("WREW;?,T8)FD>DP3
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M<Z^^I?/R;_1I+>^K:OW<97EXD5Q;2'];:D.IWA'[J VF]N+D+*,Q*2"G0/N
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MCR^G)]]]QL5R.I_]^Y_XG]F?OL-9FN?I[,.__^FO[W\"]Z?_\1__\B__]O\
M_.\?WKW^[M4\G9WB;/7=RP6&%>;O?I^N/G[W]XS+?WQ7%O/3[_X^7_QC^CD
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M5Y7^8I&^FR\R+FA[.2<@+-(M %R']O83WW\*"WH0I(_3DWS^VW6?&4*?J_G
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M1>HRB5J"1HLEL*C"70E5QV/J3FK&:6/2#D7'B[P#W*R1?TG^\E=<G:\ ZV)
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M(T3<P<'S]OR]ZXYNZ_K*JPW=,HDBDP4&6M99O"I&B-$)<#RS+$,J,K2J2WR
MK'%C <<H_'8MXE#2[P!+5UH#WF)%,$DV6%:@C7?$2A 0?%# C!<N1CI:[QI=
M.$ 9]?TTC>O:#XBBH>3> 81>Y+Q.!@PG;\,T_SS;QB4F@B<RY>BPE4KR>NQ*
M\-E[H(V9.$Q6A[N&B0R0=7(W/>/:-P-"9PAY=P";]PL,R[/%U\LU,&%!FJ*E
M!A8=<< (\Z'F#@?/.&;'$_(FC3]NDS*NN3,@6(Z4\OXX\1N<S/!#[;KT?C"X
MO,-5F,XP_Q@6,]HDER]2.CL].ZDO>85EFJ:KB?>UZSEAWYJHZO"4##$G#IRY
M.H0^A<2;%,]_F[1Q_? !X32P%CK8AM8+X^/\A%2PW AJ8DV)RI%3P84D?U'S
M!,Z;&IFPQ;)L&+--0CBW21GW&G] W!PIY0Z\\JLNZ"S?P8^R3%ID%J2HZ2LI
M,/!*(IW&(COO="FQS9W8-PCK)@8X=%SG>#4,!JO';;SX=BWYC[B:)C)KK_$R
M5!?&ZZ]XC):,#S#UF/T9K<]%AR"!I9KS7QO!U#GSX!PK'(-3+#=9Q8_1G_%Z
MY(($_F:Q?FU>VX5O<;$>#C#)"H-!+6ACCK0H$R\0@J>CG.OLHV39FR8M*G<C
M[PGT<]P'0P]'EP;140=&UG6N-C,H7IRM/LX7T__"/'&81.+6@PPQ@L+$@+X)
M4#3CDHX'S^\:!S,TXFZ2]03*+H=#VE$ZZ11A/R^79\0)ZIBY=A$\DC&@0A$0
M4XY@0@FFR!QS:!)5N)^D<4-1HR#K %UTBJIKP7[E!&972R84;<-!DOO"A8%$
MEE9*+)7<IDC\&W2-&[T:!5^':J4#D%VY"KCWO-<V,Z,\!V&L!963KDT*,_G>
M(L84=,ZL207G#K2-ZU\V!]O0VND+<+>.?9^R*[$X2"ED,BQ+[=/+'1CKH@S6
M:]?FTN8!FL8-@CTFP([21H_ VI[Z1HJ@I'00LB\D'H/@13*04V'<"2>Y?QQ0
M[6%^#3[0:CQ ':"%'L%T]8BW+$2FF0;F>,UQUP'JE"9PY+(HSKA2_'$0M:_5
M-?A<K/%@=:@^#L;69US$>8O;YPT_D^)\%IFD(ZT@)HPUX"UQH@4F2ZLC.]8D
M#'$'+3MA:? A6H^&I6.E_W0F)EV(<CDOV[**6J$T5-#^GL<W"MCOPLQ P?I-
M'\J+%UY>0M8&&):Q.H"M#NLJ&9PL!HSQPGCCI1%-2JSOH>?XV^?M ]^O>]$7
M&XN(*&A-U>Z:*C*HH\E %/2N,*W0WS'$=L#;A_<[]_UO%F(?0O.WKY\/%O.(
MEM!RL:K=H/-96I'?B8O/TX0OODR7M0V,8H$VR!+(-U#<.HBUVY[-.C-K,ZJR
M2S2 GG\%(O2WF_"XCX!.[F .4.9\0,GV@8SU-?B&@^6K^6F8SB;>Y^094R#7
M31&<U1!DME!,8CQQ%\I.%WC[P.,V%>-@9!C%WD;)D5+NP)U:%ZG_@IN9V,IS
M5DNOG# U14L:")Q,MRRX<]EPLK>:5!M=H6%T>!RKT?DPXNT &:])!)NI2EMY
M;-E@$JW6FIRXS HH(6G)J.R)%Q0.8S F-TG_OX>><:YCVR%F"+%W@)Z+TYB<
M"_R9OB5/SA;EI$5(S@M0GGPZ$D0&PTJPTG%DJE'^Y$U2.KG"/]Q0&4C*'>#D
M'7[&V1G^1%(BEW)MTO]]NOKX\FRY(G-_05;_R5D-)=4.XO3__#Y\(1:#K0TK
MP"F1B$52>6#*@C4:#4G+Z#:UU ?0VHE)?" \;F5YM]55%Q' +9/+B7%*E2(L
MB%J#KFB3A1@B[;H9M<](?J5LTM3TG(!.-JE!H;.?5#O8GBY:GFQG3%YF*SMG
MHK*T8SO-<SV/R:Z3F0&3M5F%"(Z<B1;PN)>B3K*'AL'+,'+O $#O2 U$0!V%
M^XK6P,E\/;-KR]5$!N8LG?\@0PU>H1'@BV*@I.1,:ZZ,:))6_"!5XYY9 VG^
MUOXSE!HZP-1?<$8R.B%>7N33Z6Q:Y;.:?L9S=HP2)NLDR8ZL>2>,'$TGR< ,
MV0;#M?.Y-+FP^@9=XQYH;7 UI"HZ0-8M(4VTK,D!/D%VL7HGWM:CNH"(.A3M
MB@NZ2?'D+4K&/=[:H.<X<7=0_7;!P.9VYO5\64.JWFA>"A3N<3L;M:0 6D<=
M@]?1Q2;QH3MHZ23A=6"3Z$!9=P"77^>S^74NSD>WGZ\F%J1GEI%_&&-=3=&"
ME\C !^$RLUYDWR0I_YN4=9+..@R4AM5##^=6'<!]+U<3EB3MT(&!QG5YJ4G@
M&>W1,CDM?8G2ZR87&P^3-:Z=/3 &[IJ(/HQ".H#7S[//N%S5];=AX^<9/9M^
M,O$V&6&L!QUH):J 8;/_%F8Q%72>\R8]M>XC:%P3NRVD!E%"%V#:T'V^%I1Q
MNHCB 2WYG:J.*7!<%. J2ZYSP*2;1+-OT#&N?=T:.H>+O)]6-_=OIREGG\C@
M@YSJ] QG:PL.7D"R:#,K6F;9)/OMN*.M?6U&8VMI+[EW8'Y?.@[G5SC3V1DQ
M=9FS^0.6^0*O#/O^\0NM/M+7=!867]>BK(UUZ^7/_.1D+8_M)NQD=":1@ VJ
M.NF5MF/'A")Y9.8S2]J()C&GACQU4@\R#(A[T7TWRX!8W"[C'W"&9;J:8&!*
M&5L@NUQGV"L&3I%E&GV*EFG+36X2ZKJ'GD[J1H:$WW$R[^@DQM65( RF;$-*
M"KACD:P):< K4C.&&AF,7 K?Y";P&A6=5(8,=.(>+-\.MI?S'GCG9< _A.4T
MU7NGZ<D9H7#"C27/-W.(3!@R9,D"#5JFFG?*M"XN!]$DF?\;=.T6C6!/!$%#
M*J$#G_'O./WPD>A^\9E.ZP_XZUE-"7Q3UJQ=J;>[R66-HY1$4"@994TMT^""
M0G I"RYE(I$V.=$.(W<W!#Z59*E'4-D3+'>;ESLZ$5YC9XBJMSO?TKKX[=NL
M#=^P[O8;+^(EOB2)0B7((B,HA@5<+<9,/A4L7A7:\YIFVSY$W=#U<8D9H6H6
M68EK*Y+6*2=7Q(LH>>19I-#$ NNI/FYX5'RK6FX/H7=PA%Y0OY'(R_GII_FL
MUJRNZX L%F;0%"CKMF:6&7#5'A F.Q.M06N:W! ]2%4G@#I W?<AYVC9=P"D
M&SQL2SY0!I>-\Q"3*J!2-2WKV*H4."O*\)1"PW$\-ZCI!#C':_O.^3S'B+X#
M_%QIF+$M[8DZ*K1$MG6Y-B9S$0*+!K+G7GFM2FF32GR+DAZ&\1REW?M[DQP@
MZ@ZP<L],C_.2,&<RL\6!=,2"<LE#"%P "JO(S"3Y^";7/@]2U<,HGB$Q-)P*
M.L#3M08K6Q9$<CF7&,BU]9PV9%/'(Y*GFXW0W@:>8FP2C[J#EAYF\0R)G6/%
MW0%B;D[VV')AM.(V60729E.'24>22A808E;16,.<:M)HZVYR>AC+,R1N!A!Z
M!]"Y(Z"6<I*))P8>,8'B69([05]TSLIEB:GP)CWD>R\!'L*W.DS*'>#DYUFJ
M^R2^PLV?/\]N!S#>S4].?IHO?@^+/%%TJ(8<-)@4B3T6>6T6G8 9J7SF&()N
M4C2U)YV=.&$'PN+V_6TS'74 P3L&QA0=/;FJ$8Q  :J(!-Z0GYI+22D+LNUD
MD]3. R?UM.R[U4[SWQX'M8\:#@;2)UQ,YS62OUBU[U%*1H%-M<V]CE'6?JL<
MO*PAV"22DIJH:I/O>72/TF:GX6-";##5= .V%_G_.]OD12_?S^_Q5M>LQK"^
MNCJM"3AKW;Y#$NURNL)MIYFW:\K>89I_F*V?LAD,*:S)6>@ WDDR.[W/$#RG
M<T/P)#D+@8E& UO;,C:NM_F8H.\*(KT<]YOVUZ_.%K3R-VQM-H1WN%PMIFFU
MG2/QHDK_5ZP];^>+@M/56>U*ZYDN,1<.F?, RND$(=1K-25)3X7V"]ED\,+1
ME(_K*C^Z,?%H2NX7U>L5NA._&8T*W# 0W.6:[H(0I..0;-"!%Q>E;M1F]CC"
MQZW-[ #3;53<+Z0W:_C'TT\G\Z^(FR$L9XOTD:3_]B3,EI-:D\\,YU!$G6D0
M0@8?BP*3,:+(.6/#4;W[TSMNN4P' !Y4H?WB=KU.[^5RXLAFRLE$",XZ.F^X
MK>F&%FQ@/&MO?6PS8?,@:L>MCND LP,JLP/$7G$1WN%Z</O[^?OPI?;WJT(E
MKDF4YZG4UWV$29W'P(K,(&N_$I6U R^<!B9<8L%BYJ;)N+LC:!ZWN&8DWZ^I
M8ONISMD<)M6Y)<YV956$0JO5>^"2U^ X<G#%&RC$L&=<.MLFE^(08L>M]7G4
MK;>U*OM![:_X^XN4YF>U,//#V\5\1M^F34+OXN7',/M @K[Z@>DL33^=X(^E
M8"(C_T6>?ZK<_Z^S0!\HT[21A;&:<VD4,"DT*(6UTR8CT<3HHDXZEM@D3M&$
MFY%+E!X3^..CH0.;Y'H9H)4D3BT1%,8 *HH"OO (2EHI),\B8I.^8ON76;:K
M47I<"!XJ_0Z@<\=-8B3NT;K:,416@SP$<,8K<,AB%H6%4IJT%COT0O=97+<=
MJ8<C+]E^G.7V][G!%):=YF05\W7R#K%2M()<N$X*34BB=?;V8?>Y_%G<;0VF
MFT&Q]J@#!%^&Y<>?3N:_MYD?>/GT1Q@?> \KPU=.7KSHHC0.E9>:"4E++=72
M.!8A:$7&D;+&1&2^N$;GP_U$#6!!U6>2 ?EY2N+[X>M?2?8_SRY:B;Y(J^GG
MZ6IZI9^MCJ9H+0-H7R.M5B'4'J/@E2J.W'XM6).\I_U)[23![E@LW6%WM=19
M!\;9#<LR8%32.9!(J%#H X0ZS]'J4*R5V23;)+WD +N^%99:J_QARWX/^7<
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M@\BL@U#A;V=Q.<W3L/CZ9K&9#/0+KC[6'(Q:<8'X\NST[(34\AG?XB)5%7W
M-[_/Z/T?IY]>%"+DQ<G)^T68+<EXVWB#6;,H2@"><VU/G!@$GAW9<R(K+IAG
MI4E\<7!.NC" #@36K0NV,;4\]M;V"RX^$ >76_]G)/&NEN]Q<4J"K@S]A'C>
M)D8K4[PL&:PS9"9P68.QVD+)";EC7@=K=MKT]GIM%]OA<6!K+.LN(T<_A.5T
M.2]7W=M# D9W/>;X.-$WB>LJ/,2-<'36"G#:9U J!@CU*#:)"<$U5PF;U =W
M$?)>J^I-N9PI.Y%6>6&3(-,SU'H>;\$;5R ZYTUF HML(HY;E#R'H-(^V+IY
M=AZGFBYWK=^F'V;KL<2SU94IQB3:5'/V#]B_'G[@\3O9'@0/M*?=?LT%F"+Z
M;#4=6@4+!Q54!&\C)TO(AU2X+DRX%BOS?I*.=@(>$N][DN@/)[7,JR R[Z0#
M8IX1XTE"L$4#"TXXQ0(3O(UEOQ-Y(X\X&@8OMPSWX37S]':D9CO38^U08^U4
M/-;NP*J EB[10:4%1#J[@%E91)92-AJJTVZG^FLM/?UQN9J>TAF_G"BK'2]T
MD.=,7"IA OD/,D'16GDCK>"JR8YTG8QN=YY]]']SYSE"TAV$M:Z9BFNY?+W<
M+8-(EF>!8&4M##6VU,+05)/[7)%<!-VF$]%#1(T\"*T-A@;30@>(^BE,%W\+
M)V=XQ=/X>49".EN[&AON)B4I4^J,EY+6E?#D&D0C.3'%;4+%34ZJ!;1VHF[D
M,69M,#:\7CH &RV<&H7=)%B]FR[_\9)HF*[J=Q.4FG.."3@C+I1-M!/K;&L;
M:^1D5RIMFC2;?("FD<>.-=N\!M%!!W"ZM[';K3TY%QUY*6"<J#=A48'W00 W
MAK9F5K+V33H*[$K@R*/!V@"MB78Z0-VO^/L5B2WF,_HVX95=^29_&KUSV9&-
M68H#Q6,"QV4F(19%8A1:FB:S%?<E=-RBT$8H;*JM#M"X;<I?)_J1IWZW0<JR
MRBQ"'?,,*G%9EU<&= J5UH(;T:3V\YN4C5OUV0AOP^KCZ06UCD@OW^FYC4-:
M+=/-'T"<JY7$MK:L-Q%!*900N+* LFA, 1WZ)D=$NXA6':!<+\<?;F9UT0+E
MY=FB+MI?:A7&MKU^#DXP68#;4$5B-="VG" Z+3$P5ZV#%B(YEO!NHV;[8.SF
MKO:HVNS@5"4Q;E*',.\RN_[^#M,EL:03!L"4:WS1TF;O CE8=9^/&95QNR0P
M'[*P!V&@V_C=,6@>1;L=H/JW]!'SV8,MT3>9H\D*])@5&%''@1KE(#!=:DF=
MY*KD(-HD:>Q*8+<1OV-0V40[':#N7FY^^/J>'K&N82@R<NT5@G'9@BHQ@M<\
M IG$-IA88M%-:NAVH&WDMB)-0+%KI.9 #?4,NLK0MBB"V2RUD0C%T1:N"GT7
M0G) K*2@76'./6Y4\)*V<4$W.!YVQ=N!RND ;R_GIY_.Z'$7K&Q+93 R49(B
MN02K:I(, \^- I>DBR$[HV23C>T>>CK%U:%ZOW6U<;P2.L#23?*=+Y@3+^!+
MH@T]>P>><0.%2$<6A<RBR>7K(=AIY@JTQLXQ0A^[$.3E?+8V/W\)L[-"?Y+3
M/?MP-</XUH(P3-NZ;QM3 YS<"1*4I?4ABU=!Z))N9CS>4PNR[YO'-=Q;8:B]
M$L8NV*[=B=?'OK79&!X=84'6=HB^0!#TQ6BF@O:%-MI=6O7N5I!]_M:1>[.U
M-,$/EVX/D-@BV4ACE? *BJ*C5?&BP6/"Z@1KQ@.*R(>KTK]\[XB%UX=I[*;.
M#Q#?R%K_93J;GIZ=;@D7C "?2@3MPWHNLP2?&>V5WG/K',O&[1*BWTGOU]X\
MLN8/T=M\""$>K/W/N(CS(?0?OEPAG02 Q65. H@2E%,*Z.2J,7[F4LY6&3G8
M87#MS>,<"(/I_V ACJK_;UI1KR_*;,E\X5IF#275=A,L:K)J:I*U":7XR)/A
M38::?YNTD3MRCAK-.TP_'3C$]W+TUR66LY/7TX(3+YP4V6JRH;6JQ8L(D7D.
MR7,AE _2RB8U(3O0UFG0Y4 X[(JV W73 =RV+2!G'];WVZ^G(4Y/IJNODU)K
MSK)D4+CVM4^N!Q>(%^G(]BN,-O&=FE'M7\E]-SV=QF.&@=40.N@.2N^F'SZN
MWA1:&2^62UQ-$CD)T9H$6=>>@*+&&D3.A /&F<=8;)L4EP>IZC1$TP)6Q^BC
M W"]VK[V'8GG'1F>T\_5=EBN)P-X692+C)3/R"TMV4#PQ8 L+ O:BA%SDPO\
M^TD:MY:B,:P&TD27V9[;A-:#,CHO?O?XK,V[R1@H,W/[\-K$_CR,^_?IZN/+
ML^5J?HJ+B_2.VER:E3K]A0X:\M6R@)!K/IO+*2MF3!9-;HQWI&^@7/+[7G.9
MPIR=9:'V3<JB7OZR&, 'YB';B :M="(U&=BV*X'C6MPMT'1/FOFPJNIZ_SDB
ML?SF(X;;C5JFB^\*(V]1),\BI%"'KB(:TK 78$MT/BD;=6EB13[2IO27^6=<
MS#9-US9ON3QA)\RO3VWR+(VHX7>AP!F'P!67AGLL1C>I;7F(J*>Q^>R#FIN;
MSV J&36>N;ZUO<W*BY069YA_.XMI^Y/YXB?$FO%40D:9P(8Z0]E*#BXF!UB4
M"3EQ)^1NE^:[OW-<%[\EE%H*O\MC[/4TX6R)83V $HFXCR_G)X3&^:80^Z*S
MY$$'W.X//_[H.Y"1KGHR,DYN%R^6K* Z73GX# X)5^BER89)EUB35F==]&2\
MHJ[/^&*QJ#=:]06OILMT,E^>+?#2>F3:6^M< <<368_:*3)1!8>8B@C61Z=R
MDY#G'C0^ASZ.^^#Q=M)C&W4^Z5WT"&=AWU<\WH[:_R@D%KAT7F60VI/M1X8@
M>/H6?(I&)Q4]JC8![1[VU<L@X-ILNK(4-VGSFYM=YXPR& V@51J4##6_4$A
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MZ,!^NMX02<8B=<("3G$B/CH)H0@+6(3AL5Z5F2:.Q;/L@;87$A[L@;:/6CK
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M!7N'P]L7UW,71_:97+_ZL?\#F\%=28O <RF J$@O3$3PJ@Y>D25;*9DA<;0
M?4.>IMT!4X)UV2=N.LCP[N?D0_B*;Y:UO_8L:N^\(0:<\>1L:8;@:S,(%KEC
MY'#YX)MT4GN.L&G!W V"CD+V0'5V ,^WY.$N?R!N/,:/F\8DN\%H)3IR^BG
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M A0J5V]4Z_S5Q,C-$8:U><)V$I7G&J&C%KNO[N4QYH@U&JF96Z4M;0_/(E"
MH@H&$8MODBPZC<QI_?!V*'MLQAHJKWUI]NX7]8\8UOCO?_T?4$L#!!0    (
M .6"9D_>LHSD" @  .,L   :    ;FQN:RTR,#$Y.3,P>#$P<7AE>#,Q,2YH
M=&WM6FUSV[@1_MY?@5.F%WM&;[0DVY$<S\0O=Z=.FJ09==)^N@$)4$(- CP
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MPNIJ1;(EN5%Z(3F;\F98;L-A/1UA&B96&FHI3$&%(E0M2:&<*3B8!]75%UI
M!"49/!E!)4EI J\,T9EPQ.D@MR&@>,*MI6:)(AF]X3!O;4P+[Q@H U-*7Z5A
M#A1(A(&J#&(*NH,FC!NRF(ED1FR!'W?](3OQ<A T(!-60OE&)K 0;@8&VIPG
M7D$<-P?5- ,SY]"-D7A9=\,+AG3O.X$T)ZE0 !K$WQU(FH!G$(=F4VL7*H5D
MYY,9?$]DP6!, &(-$4T L3!R27+ $88 AH:4=Q@OX67O30UAQ#S+;:)$(4$
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M@*$J<RPN3S@>DMV(AT6=N)IR581D2FB!-$5R+:>XSFX#24;>M$59B(^;&7-
M/@[$E.XB+Q^9PG]Y[FT*%U_T!MITI%_?=[)1M9T)P0S1!]49"TWP-,$K=@.\
MBV0>P;$.,CI,*0EO:+F%X7LD;V(L)DD*2R!:H@<K\C+C/+ZA<VF4XA(4\5>!
MO *%[JUU3C$",)7>ZE>JB3M4"*<^=""DBX4N^U&3"7<+_D1).$0,B%"=@O5E
MY9@S):]!E4= M_K7O\$A]XR/Q[;I[>U$?'S+IC<<4(LJKNHWB9+R]C+.;W(F
MX?4>1&J-X:->'/F]-]8M6$MX@<*R3'H/L+$2C0PR(FH1$G4*P_<P#C#Q.RHL
M^#_M+ZJ A;\*B2J'$"UT$@Z%]K_O9Q\XE&]XRBN%E!7=+!&P="1!AQN)!(17
MR3@6^\H9\&NB$)'"!A(1R'<X.J\.!.\%VG(+& ^$-J18+G"@@T6&W0#PDJQC
M9\0J<NIZ9# .Z8LK,H0,.BB845:PC8>F3YR=[-A6\Q62D-1B)JLC?B!D7D1@
M^,FDA&H]5G6IIT9-@4J[YN/REQ];)FO(<F7F@*VSB8GIF:\$ @+W&UE.<Q=^
M/;]$GX5TS=ZA'=D(33FJA_LGVU^:6(7Y482Y#SOM<DC9(RPD+[RIAH3Q\<T(
MHQ<L>4+QW$&_^K(<5S3^=#D6R4BLJKGB\[[4P;PP;WF[I7O4/.SVV@<OPAT7
M;_%/5"J5]U^:\?Y+RXOUQN-FIWMR<-3[<H\[A]_9>'+2/.EUC@^W%=X*VD<+
MT#4NY_IE[;!6C:A"Q9N\?Y!_7H1.N2;T:DNXW7;WE%@-4NKR711X*S27\F%<
MT4[$P$.#?+SL]'J^@9]4*[ SOEUVZU=\<+<#5YV]I26U\Y^?=8]/7?B\??]F
MX=DO O?HNW/O=.Y=#MT,TBH+:J/A[J3QT'W_,)/&Q41"RMXLJOS[N,,+W/(W
M2"QX;N=;IY3OJ_7_7:V]#_','!=J;<GV_P>KU HL8XW9W7UE,#?Q-G$__BHW
MA>4[N'=>S5V3P$?.J,+#:;GX[7M?YRT_X\7A<(7Y_+]02P,$%     @ Y8)F
M3\^5<,Q !@  S"(  !H   !N;&YK+3(P,3DY,S!X,3!Q>&5X,S(Q+FAT;>U:
M;6_;-A#^OE_!.5CJ +9D^2V.[1IHG'3UD*5IXB+;IX(6*8N+1&HD%<?[]3M2
MLN.7Q'76%DU6!XA@D;SCW?&YXY&G[L\G[_O#/R].4:CC"%U\/#X;]%&A[+K7
MM;[KG@Q/T+OA[V>H[E0\-)28*Z:9X#ARW=/S BJ$6B=MUYU,)LZDY@@Y=H>7
MKF%5=R,A%'6()H5>U[3 DV+2^ZG[<[F,3H2?QI1KY$N*-24H58R/T36AZ@:5
MR_FHODBFDHU#C:H5[PA="WG#;G'6KYF.:&_&I^MF[UW73M(="3+M=0F[18R\
M+K!/E4\>B.%"0]:J]#2BKPLA-=S;]4:B.Q-&=-CV*I5?.@4[J-<-!-? 2P)E
M]C-CL,9&TSM=QA$;\[85US P!+/^$?9OQE*DG)1]$0G9EN-1L=IHE&;_J.)4
M#CI9WU[%_G4,@W* 8Q9-VZ^&+*8*G=,)NA0QYJ^R7L7^H2 Q"&]?)YDVAT <
M,4[+N79>U:IT^L>[P?%@B&I5QUO69PM-'K#"PU0^+ :5S]( _=/+X>#MH/]F
M.'A__G1=MC;!7ZG2+)A^7QO4'[;!12I5BD$H+9 .*9+T[Y1):EQ((44U"H34
M(6(<7:8115X-E[UZ<72 1&#'7U$_E1 "0([3.S_$?$S1&U^;;N^H5B\AK! &
M;@1<NF@(]O=:U6JELSC8-GF= QC,B>%H(@I,U:@8-OT0)V!UU*R9MZ'Q:N2U
M9O-_Y,Q$BRL-04-!?" 4%:'WHW/E]!V8S&L>=BPKX'XL,4&_.>A"3*A4)?0K
MY53B"*A2KFAD6((MSQB_L5V:^8:C3(3$5J)%^?LB3C"?+HO>QS)"UPXZ \TD
MY260G=$ O64<<Y_!3.^#@/F@2ZZGI!K+Z4R5G&4)4>R'**22CJ8(1@-VC'EU
MB'5IMDPCJJR-0Z;0#1>3B)(QW=]KM#K_ 9!; )G! G+=+M>: *L$$P+!N1S1
M0+=MRPL!N^?,M'QFHBU9M-IRS/93Z WO06%PYAUV%/J08@G>$$W1)05@ @@X
M>BMDC+Q*^8-Q5@N/A$HF",K<[HJ"_\0C@%VM4K(;IX71)&0 ,VT0U,] YF<P
MAP:L-6 0:+%QZY"-F+;;Q)(+7-A)F)]+<N\*01J!?#Y('AG@3I@.UV,+@/?>
MTXL8 HJ\;V@4R3S"+$>*QE''>,^C:'T*-G\8W%=?'NX9!RS'&2!]8(.!E)AM
MR$!B!7DHP,QX1"*I,M@JF7$XBA#0PTB(N]"1 +:@QY '\W@,G(G-7VU$AE%I
ME$%3@ ?9R=5*=';6\+()2\\JZ?$:!@L#CJZ9YE0I=&WV&!$\0VQDHF:K!3+
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M+FAT;5!+ 0(4 Q0    ( .6"9D]]]Z.)A38" ,,7%P 1              "
M 3TS  !N;&YK+3(P,3DP.3,P+FAT;5!+ 0(4 Q0    ( .6"9D^C(A$WZ0H
M /YG   1              "  ?%I @!N;&YK+3(P,3DP.3,P+GAS9%!+ 0(4
M Q0    ( .6"9D_VPB20XA4  %;;   5              "  0EU @!N;&YK
M+3(P,3DP.3,P7V-A;"YX;6Q02P$"% ,4    " #E@F9/R%^9ITX^    J0(
M%0              @ $>BP( ;FQN:RTR,#$Y,#DS,%]D968N>&UL4$L! A0#
M%     @ Y8)F3[E!^/P>& , !+X# !0              ( !G\D" &YL;FLM
M,C Q.3 Y,S!?9S$N:G!G4$L! A0#%     @ Y8)F3_OBKSR&EP  #(P& !4
M             ( ![^$% &YL;FLM,C Q.3 Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( .6"9D\G*U!T;EH  ,T^!  5              "  :AY!@!N;&YK+3(P
M,3DP.3,P7W!R92YX;6Q02P$"% ,4    " #E@F9/WK*,Y @(  #C+   &@
M            @ %)U 8 ;FQN:RTR,#$Y.3,P>#$P<7AE>#,Q,2YH=&U02P$"
M% ,4    " #E@F9/#(,.1PH(   =+0  &@              @ &)W 8 ;FQN
M:RTR,#$Y.3,P>#$P<7AE>#,Q,BYH=&U02P$"% ,4    " #E@F9/SY5PS$ &
M  #,(@  &@              @ '+Y 8 ;FQN:RTR,#$Y.3,P>#$P<7AE>#,R
;,2YH=&U02P4&      L "P#K @  0^L&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797667488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June&#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed to develop treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NewLink and its subsidiaries (the Company) have historically devoted substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements as of September&#160;30, 2019 and for the three and nine months ended September&#160;30, 2019 have been prepared assuming the Company will continue as a going concern. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s cash and cash equivalents as of September&#160;30, 2019 are expected to be adequate to satisfy the Company&#8217;s liquidity requirements through 2021. If available liquidity becomes insufficient to meet the Company&#8217;s operating obligations as they come due, the Company&#8217;s plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position and may materially affect the Company&#8217;s ability to continue as a going concern.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Proposed Merger with Lumos Pharma</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, the Company, Cyclone Merger Sub, Inc., a wholly-owned subsidiary of the Company (Merger Sub), and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as a wholly-owned subsidiary of NewLink (the Merger). Following the Merger, NewLink will change its name to &#8220;Lumos Pharma, Inc.&#8221; and Lumos will change its name to a name mutually agreed upon by the Company and Lumos. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the effective time of the Merger (Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of NewLink&#8217;s common stock equal to the amount determined pursuant to a charter amendment to Lumos&#8217; certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock.  Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately 50% of the aggregate number of shares of Company common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and the stockholders of the Company as of immediately prior to the Merger are expected to own approximately 50% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by NewLink and converted into options to purchase a number of shares of NewLink&#8217;s common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for NewLink&#8217;s common stock.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company's and Lumos' conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger.  Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos.  Lumos stockholders approved the Merger in September 2019.  The Merger Agreement contains certain termination rights for both the Company and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company or Lumos, as applicable, may be required to pay the other party a termination fee of $2.0 million.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split, with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time. The Merger is expected to close in the first quarter of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812942272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Blank check preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Blank check preferred stock, authorized shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Blank check preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Blank check preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">37,426,844<span></span>
</td>
<td class="nump">37,343,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">37,314,076<span></span>
</td>
<td class="nump">37,251,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">112,768<span></span>
</td>
<td class="nump">92,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795333568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Authorized Increases of Common Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Jan. 01, 2015</div></th>
<th class="th"><div>Jan. 01, 2014</div></th>
<th class="th"><div>Jan. 01, 2013</div></th>
<th class="th"><div>Jan. 01, 2012</div></th>
<th class="th"><div>Jan. 07, 2011</div></th>
<th class="th"><div>May 15, 2010</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember', window );">2009 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Authorized Shares Added</a></td>
<td class="nump">1,490,048<span></span>
</td>
<td class="nump">1,484,382<span></span>
</td>
<td class="nump">1,166,546<span></span>
</td>
<td class="nump">1,152,565<span></span>
</td>
<td class="nump">1,119,233<span></span>
</td>
<td class="nump">1,062,920<span></span>
</td>
<td class="nump">839,407<span></span>
</td>
<td class="nump">823,649<span></span>
</td>
<td class="nump">714,285<span></span>
</td>
<td class="nump">1,238,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nlnk_A2009EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803885024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Fair Value Disclosure of notes payable and capital lease obligations</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,929<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember', window );">Contract Manufacturing Organization Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property, by the lessor or lessee, respectively. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77913719&amp;loc=d3e40879-112712<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nlnk_ContractManufacturingOrganizationEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6810097664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: </span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"/><td style="width:61.112392%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.887608%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"/><td style="width:61.112392%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.887608%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,004&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>nlnk-20190930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nlnk="http://www.linkp.com/20190930"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nlnk-20190930.xsd" xlink:type="simple"/>
    <context id="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc0e4827406f4f73ae9067857e0f0115_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i9ace74c0019743fe88745f618d835f4e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2743af692cc2469faa69ffc8ef0a9673_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4664525312404d1b94728c50760da2a4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if704753e5c8a46528426b0f8ea5dfb41_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8c515a2dbfdb4d1595a67d09c00d6655_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d82dd02a58c4c18a9a60caa4785696e_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9151d1bccda84d16ba78784a7225722a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a287cf3281c476b98eed454958f2277_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i98ebbfa104374f4d9aa9a287ba8b999e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7cb50f6d464f41209ad8d692ff7fbf39_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i03d751ee6c76466fb5eb60f4019c30a5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic25aea5b67dc4615836b71f7ec170110_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i505afb318e1146129e9c7d51a2e1dd64_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaf470515d3af40d1b502950814a2820d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i743bdaaa5b21446bbc814722f648cd49_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id59db6466a5d48b5a06237c225e6a257_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if9d41031c4b440719ab7602de06c798e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i83f04576fbb64c32a7733ec82cee0caf_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5d697c19fe5e4fa58ef31272011cf521_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6330f627e2f84026b002dd0309e55153_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2f28d90376cb4de3827920363100e946_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i53d872755c9d49bead485135d03d139a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8de8dfc9265f4814a10af285b763d500_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iacf3bbd0ea44455a821a356b26309749_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie307d6d5bcea4b01bff357ad51555c41_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i183f47689ec84868ab9f6b72e3f7e433_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8364331140614060a05ae248ab045408_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0ea5410251564fd6a62a198b8e5f4009_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifab97d107e9549eb8b271ae98baea406_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i24b974929d044217aed5ac3c4be73ea8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a3dd401368e49a4ad4de2abc0db6cb6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id52ffe662b424bbb88ce5417c24c5166_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic5715e9adfac45a8b83e8d40a69664d9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7a75e769cc224d6298f34cd36e25d43a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i351b47f7af6542ac9248452c834d8455_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i45a81768f87d40cca900412fadac8d87_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i118a4632bd23467da06fa77e0c2bb1f1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0a4c804c8dac4cfd990183466fd9ad56_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9acd99c8b887434880292fb731fadbdf_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i72e1400b763c49568b5cacb45201ccaa_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if05c8243e3884438adf343cadc3e292d_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if5a22af9c5264e37834b47db5e74b120_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4d603373292d4142b02b4ad42398d206_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i288a43aa7f8440249689de817a189731_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i7d85a484cbcd4b0abfadd3bc26932841_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="idf5534a41e53449b97133e968328f9a5_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i140b485706b14058a26125a6cce6a765_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ie5a934ace4c946c28093a195503e156f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i63cdc44a40d049039d180bc48b94bf7f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i3a400765af1e4295a589ad235b0bb229_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i0e7921dfa4bf484fbd69745528d65347_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i8d417601e8ed469ba93c08f508e5c6cb_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ife35f142e8d74a338ff0bcaccfa25ad0_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i8ef502f9d9d44723b54dcbb9a8c41982_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i29c7d068b9374823b5c5345eb272ce77_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if7d6f7ba47da4441ace39e0c4364b8cd_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ied703d3a9b144f7399e282419ab70c09_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="id64eda74baf5476a8141082fd8f23afa_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i088d0c7eb2e542868a81a509f658724c_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ie18061ceabd14d7cbfa7e44c6aa37ff3_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ie8fe32be617d48f8b264cb18a8de74d1_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ida83887e682745b687c7e89ab3d035f6_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i11f2bdb36ed64cb5b8001849d4dad9df_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:LumosPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib799a2a817e04b59aab49144acc02919_D20190930-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i75260a9b71b248a180be746c764bb685_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibf9fcb41ebd843cfa2f5be0b9a6e54c6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2c5dd96d6f28439094a7f5c566181c4f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc3288156e044e1ea7072638951290c4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nlnk:ContractManufacturingOrganizationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if42832590af241ccbfc792218e48761d_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ib8f327bd7ef245e79de2f37014c6d665_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i09d3bfeeceed429b9919afe16c36b882_D20150201-20150228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-28</endDate>
        </period>
    </context>
    <context id="i12a8e9aa761347babed3658ff5c9a4d6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4778bd47a7ba44e880bf6a0a6262fcd0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie0068a8d71d2412c8b3c5bc4e29bbc32_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i1af278cb3284478691a305bda935ae58_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nlnk:MerckSharpeAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i93f6713f23084b77b9f014a1385b3370_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie54c7721636a4a35b6a388e0c9fa5e67_D20100515-20100515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-05-15</startDate>
            <endDate>2010-05-15</endDate>
        </period>
    </context>
    <context id="i3bebf0fb283644b1b4fa4191fa81d9e9_D20110107-20110107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-07</startDate>
            <endDate>2011-01-07</endDate>
        </period>
    </context>
    <context id="i614cfc319ae4417e821a813bf2a85f20_D20120101-20120101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-01-01</endDate>
        </period>
    </context>
    <context id="ieab1db675dee4e5da76fe81774a8552b_D20130101-20130101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-01</endDate>
        </period>
    </context>
    <context id="icd0760fc05764fa1a60a9c9d11289a14_D20140101-20140101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-01</endDate>
        </period>
    </context>
    <context id="i1c98279781c9463f806811bc0a673a4d_D20150101-20150101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-01</endDate>
        </period>
    </context>
    <context id="i6ff1b4bb134b4e37a54c3394f117eb6b_D20160101-20160101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-01</endDate>
        </period>
    </context>
    <context id="if33b56d22b074f6897659805507c8fd1_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="i4016611a1eab4f25b572395001428c52_D20180101-20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="i4f210ec5feb14d6589ee87904ff50298_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="ic06e3556e29342f9b22ed68a8c5b9967_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36cc09bb5c5d4dd48310b49ce7bfd13b_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="i107fa001f84543fa888d506c91a7babb_D20190509-20190509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2009EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-09</startDate>
            <endDate>2019-05-09</endDate>
        </period>
    </context>
    <context id="i7ba61dd7590642d3b68ea5be9247b3d3_I20111110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-10</instant>
        </period>
    </context>
    <context id="i5db880b71be843cf9fa1297dd718c0fb_D20130509-20130509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-09</startDate>
            <endDate>2013-05-09</endDate>
        </period>
    </context>
    <context id="ieb329194fab14e95927fc78307847e9a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010NonEmployeeDirectorsStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i019744478ea04e56985668e5cb38d38d_I20111110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-10</instant>
        </period>
    </context>
    <context id="i5956af200be14c239393954a2fd95c97_D20130509-20130509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-09</startDate>
            <endDate>2013-05-09</endDate>
        </period>
    </context>
    <context id="i7a1bc3c99884466aba07355633ce5f0e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nlnk:A2010EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1e7f9677e03e45f3a98571e955061cad_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2ef382a4e2574d5795c997701aaa5ba2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ief1b201dcccc48339b02bb8bb2870d0e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id22dbb1e99d54346b14b3c0916a4c37a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f55c0e897664d23bff3a32fd6ca9f5a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib4a2953b237a4956bb04a2ba877036e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i57817203713c4925802ca15e17d5adaa_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i257055a317c4463eb42d9ef38312b06f_I20190620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-06-20</instant>
        </period>
    </context>
    <context id="i2e071305c5974ee088653329c9314097_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia6344520fdce4afb87589a3d00b3e720_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i370c9ff0ce304ee3974eceb8f6074b8c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i35f4cfa3cbf241ec8c3640a53481c862_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib0476f147a0a46768f18d7f62d1b188a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5acd55e388054c249dd813ea270ac6b8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibe1655708734471499ed19001400af44_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i169a1b92c3e548cc86648a4bb5aae559_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4d00499345b541a7874a4e149b9f52ef_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nlnk:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i008f25566c8b40b295668c906960417d_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="id606702fb4024e63b1d691ef77f26589_D20190731-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ia903a4bd9a7147489f1eee7dc6293440_D20190731-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i9a2c4b2e6e974786a12caa1d58429adb_D20190731-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i0db96647bdad4850a6a856796387bea0_D20190731-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea28de91b41343fda8f542de215d493f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i531e62c5dc1b43ee9e14641d30401d86_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b905d67ed264c328656baba2a4db384_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b3f948dc1734160ad119b9960b9d13b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i39cb87fc9300480f802ea9c680a0f776_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie7ae389b9e2b4cae9570b2523f80048b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i347cb4a8f93f4834925abbdb2c22d273_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i79f20a25e4d646fdb0ce1a7190c7639a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia14e8601ef3249db99d27585927dca67_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55705cb9c17045b2b56549f7969a9968_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ia427f2113ccc4110bc882b22d38777fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic490d40b023c41d2b5ba726dbee45eb8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001126234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>nlnk:employee</measure>
    </unit>
    <unit id="director">
        <measure>nlnk:director</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl80LTEtMS0xLTA_ae96c667-4000-4373-a343-b0d149184c53">0001126234</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl85LTEtMS0xLTA_84d1eb4c-888e-432e-8671-e24b2e9e49f6">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl8xMC0xLTEtMS0w_b697d582-3e1b-40da-9003-2874a268d0a7">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGFibGU6YjEyYjE0MTVlZjBhNDU1MWJlM2QyMjUxYTQyM2ZiMmYvdGFibGVyYW5nZTpiMTJiMTQxNWVmMGE0NTUxYmUzZDIyNTFhNDIzZmIyZl8xMS0xLTEtMS0w_81354d4a-49f3-47a2-ad97-3fbd1d5e9d7d">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80L2ZyYWc6MDgyYjJiMTJlOWU4NGY2ZDlkYjAwOWU3NmQyMWI5MDEvdGV4dHJlZ2lvbjowODJiMmIxMmU5ZTg0ZjZkOWRiMDA5ZTc2ZDIxYjkwMV80NA_2d11377e-78a7-4fce-87e7-d4966c3dcf4d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i75260a9b71b248a180be746c764bb685_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia903a4bd9a7147489f1eee7dc6293440_D20190731-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjQ5OQ_eda0d1de-291e-4724-9f3d-24d63817ed19">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9a2c4b2e6e974786a12caa1d58429adb_D20190731-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjUxMw_1e2e5b28-e0fd-452d-9a2f-63613413e197">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iea28de91b41343fda8f542de215d493f_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i531e62c5dc1b43ee9e14641d30401d86_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentType
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN184OA_057c0849-3215-4b5a-b475-4a1e0073015e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN185MQ_5f0a777d-8c7c-4367-8d87-7100b78462b9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18yMTQ_786563e9-a092-4dd2-9975-d146dd294e92">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18yMTg_36069a74-a99e-42cd-a13e-88aa55d396ef">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180MTI_954e0cab-83df-4d1c-bf7a-f12f0e734c40">001-35342</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180MTU_e82b6d8b-afd1-4542-86b6-3e601d234df4">NEWLINK GENETICS CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6MjQyZmJiMzU3NmRmNDk1ZmI0ZDIyYzExZGViMzFlODkvdGFibGVyYW5nZToyNDJmYmIzNTc2ZGY0OTVmYjRkMjJjMTFkZWIzMWU4OV8wLTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDBlMGJhOTRmMWQ0MTkyYWNkM2RkNTJmNWM3MmJmNV80_101d97f7-d03d-4aa4-b26d-2c4d7740ed3b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6MjQyZmJiMzU3NmRmNDk1ZmI0ZDIyYzExZGViMzFlODkvdGFibGVyYW5nZToyNDJmYmIzNTc2ZGY0OTVmYjRkMjJjMTFkZWIzMWU4OV8wLTItMS0xLTAvdGV4dHJlZ2lvbjphMTdjNjM5NDdlNzI0NDRkOTU5Yjc2OWNmNGFhMTcxM180_7e8c32fb-bb1f-4a6e-b33f-74879cb5a2e6">42-1491350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODI_f49a11fd-a75e-48a2-9fbc-642c8c6a1bd8">2503 South Loop Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODU_9e1d4694-4354-423f-ba4c-cbfd7142c8eb">Ames</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180ODk_b1c1e337-9ca9-4669-9844-81b2bf679e40">IA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180OTI_539a481b-0071-4c34-b807-3ecd58f70eb9">50010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN180OTY_ad53cc04-50b8-4286-8954-a0fa3d72c495">515</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN181MDA_1cb88d34-ccd8-4483-baaa-6d0fbf075cf8">296-5555</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTAtMS0xLTA_123b3026-40df-4b59-b00d-ecfc4f635565">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTEtMS0xLTA_c9282f43-eb44-45b1-9be5-99dc394a7e0f">NLNK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6ZDExN2IxZTZhMzYzNDc3ODk1ZGZhODdlOTUxYjRhOTkvdGFibGVyYW5nZTpkMTE3YjFlNmEzNjM0Nzc4OTVkZmE4N2U5NTFiNGE5OV8xLTItMS0xLTA_de200377-a321-4b96-8e5a-9ab920fd60cf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xMDE4_e59935c2-e044-40a7-bcdc-979aab08d256">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xMzUw_3c016da0-3c73-4ea3-974b-9c0331b26860">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M18yLTAtMS0xLTAvdGV4dHJlZ2lvbjplY2M5MDU4ODk5N2I0MzZkYTkyMWIxY2NjNzc0ZGQxYl81_e4b8d901-fd23-48e6-8f32-9531b45e162f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M18yLTItMS0xLTAvdGV4dHJlZ2lvbjo3NjA5OWM1YTI2YjA0ZDNmYTZjYmU0OTMwYmJhYjkyMF8zMQ_caaf73d4-b620-4cbb-987c-886d7e4262d9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGFibGU6NDQwMTk0YjlmNWMxNGMwODkxNzFkMWM3MjA1M2I2ODMvdGFibGVyYW5nZTo0NDAxOTRiOWY1YzE0YzA4OTE3MWQxYzcyMDUzYjY4M180LTAtMS0xLTAvdGV4dHJlZ2lvbjozOTA4ZWIyZmFjM2U0YzU3OTVkZjYwMzcyNWQ5NTg0OF8yOQ_8f7b466a-7116-412c-8e64-a56afa5d8cef">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xODQz_5938f2fe-c9ae-4f8d-ab25-913599d261ae">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="idc0e4827406f4f73ae9067857e0f0115_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xL2ZyYWc6NmYwMjdiY2E5MTEyNGFjMjliYWVjYzA5MjNhZjlhMTcvdGV4dHJlZ2lvbjo2ZjAyN2JjYTkxMTI0YWMyOWJhZWNjMDkyM2FmOWExN18xODc1_41bd5ac8-1a9c-4a87-bd59-58c03b2e5073"
      unitRef="shares">37314076</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNC0yLTEtMS0w_a97d6fe0-7685-4927-8596-f1fe8a0cc240"
      unitRef="usd">98527000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNC00LTEtMS0w_7a73713b-358a-40c2-9d02-7699c03f2b12"
      unitRef="usd">120738000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNS0yLTEtMS0w_7358e081-2bdf-4fee-9d7e-b7afd81836c3"
      unitRef="usd">3311000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNS00LTEtMS0w_1c857512-41af-4330-8a9e-515e67a9b686"
      unitRef="usd">5536000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNi0yLTEtMS0w_03df40c9-435c-41d6-9014-ebc5b28ad3c8"
      unitRef="usd">76000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNi00LTEtMS0w_29fbef5d-6678-4e5d-bcf1-0bf69539ced4"
      unitRef="usd">339000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNy0yLTEtMS0w_2d5fca32-20ba-42fd-a2d5-9cde82c8e28c"
      unitRef="usd">740000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfNy00LTEtMS0w_9caba568-b883-45a8-b02f-689123e3ab80"
      unitRef="usd">459000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOC0yLTEtMS0w_567d871e-a3b1-4a19-898d-5558eabff548"
      unitRef="usd">102654000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOC00LTEtMS0w_74be43cf-afec-4fe8-aa41-286de32dd13f"
      unitRef="usd">127072000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOS0yLTEtMS0w_3bec1613-92f0-4869-97f9-614265e7c1ad"
      unitRef="usd">2889000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfOS00LTEtMS0w_1c11f8b6-d0d6-4548-9c41-a120bca83df9"
      unitRef="usd">3727000</us-gaap:PropertyPlantAndEquipmentNet>
    <nlnk:OperatingLeaseRightofUseAssetNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTAtMi0xLTEtMA_902fd70e-a1ef-4f66-90eb-fdf20569a47a"
      unitRef="usd">1042000</nlnk:OperatingLeaseRightofUseAssetNoncurrent>
    <nlnk:OperatingLeaseRightofUseAssetNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTAtNC0xLTEtMA_1fb90ff8-970d-4bd8-8d40-d98e4ca5052e"
      unitRef="usd">0</nlnk:OperatingLeaseRightofUseAssetNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTEtMi0xLTEtMA_98026d21-42fe-4dcc-97db-0c05363c5e2e"
      unitRef="usd">69000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTEtNC0xLTEtMA_2c3b0a5a-4a53-4155-9143-f12cd453fd08"
      unitRef="usd">140000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTItMi0xLTEtMA_0b7e53f8-055f-4902-8d1d-cc17dc686dab"
      unitRef="usd">4000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTItNC0xLTEtMA_49bd4e3a-429e-4ad8-a443-cb23aaeb0166"
      unitRef="usd">3867000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTMtMi0xLTEtMA_cb4d42d5-2d7c-4a44-ae6a-2f0dce64fa2f"
      unitRef="usd">106654000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTMtNC0xLTEtMA_a3737d1c-cdb8-4680-baeb-0dea63b13e64"
      unitRef="usd">130939000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTYtMi0xLTEtMA_32ffb52d-d196-426f-8912-c17afe4e5702"
      unitRef="usd">145000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTYtNC0xLTEtMA_a9063ea9-0610-4b64-9a24-a19f67fd2233"
      unitRef="usd">555000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTctMi0xLTEtMA_04f85039-56c4-4330-b068-fffbd94d51f1"
      unitRef="usd">12125000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTctNC0xLTEtMA_932e94d6-4bdf-4192-8431-42218cb2b03b"
      unitRef="usd">8139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTgtMi0xLTEtMA_df91dcaa-3a29-4bcb-a9b2-46a82468ff0a"
      unitRef="usd">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTgtNC0xLTEtMA_260c3992-600b-4a29-aac8-3b87ce63b38b"
      unitRef="usd">92000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTktMi0xLTEtMA_6efe1618-df48-408d-84ac-5bfa9d1fa07b"
      unitRef="usd">1712000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMTktNC0xLTEtMA_284305a9-c7fd-4f2e-b054-ed93e5804ac8"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjAtMi0xLTEtMA_868ca264-9214-479b-b13b-1fd3e94eea76"
      unitRef="usd">58000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjAtNC0xLTEtMA_3bdaac86-f97c-420f-92a5-609406452911"
      unitRef="usd">61000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjEtMi0xLTEtMA_c03dd1ad-6bad-4612-88fb-ab368901ee96"
      unitRef="usd">14040000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjEtNC0xLTEtMA_46a09fe6-65fd-4631-a50c-e3629025bfe5"
      unitRef="usd">8847000</us-gaap:LiabilitiesCurrent>
    <nlnk:DeferredGovernmentGrantsObligationsNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjMtMi0xLTEtMA_c9d6f984-f5fd-43ac-95ff-42d92f892151"
      unitRef="usd">6000000</nlnk:DeferredGovernmentGrantsObligationsNoncurrent>
    <nlnk:DeferredGovernmentGrantsObligationsNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjMtNC0xLTEtMA_e4d79779-c7a1-4139-bc9c-6dc40fa16258"
      unitRef="usd">6000000</nlnk:DeferredGovernmentGrantsObligationsNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjQtMi0xLTEtMA_f614ada9-cc9e-42c9-8b23-5ff39345343d"
      unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjQtNC0xLTEtMA_3ae0ea51-da3e-4d98-879b-955995e2f7a6"
      unitRef="usd">43000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjUtMi0xLTEtMA_617ab977-d0fa-4d6f-87d7-375ced9ae339"
      unitRef="usd">217000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjUtNC0xLTEtMA_77cbeeb3-c4bf-4593-9096-c4af74781fe0"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjYtMi0xLTEtMA_48fb031d-d58b-4abf-8f05-2f894ec12bdc"
      unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjYtNC0xLTEtMA_0c713400-13a5-42e8-b375-a40d2a7e61b4"
      unitRef="usd">906000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjctMi0xLTEtMA_bc3c972d-16bb-41e2-ab15-bf14ec789c5c"
      unitRef="usd">6217000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjctNC0xLTEtMA_c73086f1-1c34-40ad-b92b-7961d98db85c"
      unitRef="usd">6949000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjgtMi0xLTEtMA_c680154c-1efe-47c0-8850-04b942ae2735"
      unitRef="usd">20257000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMjgtNC0xLTEtMA_51fb7a5a-fe95-4f19-b68b-724f5c23071b"
      unitRef="usd">15796000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzMz_42fad464-df06-4379-bc0c-b26079661a3c"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzMz_6f025580-02a8-41f9-ae68-f91a7a8a411b"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzY3_9583e963-dcee-427c-8367-6eb4d7aa503c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzY3_abfd3526-6244-4b2a-86bf-e512096d0f13"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_07203fca-5f4b-4b67-8016-156ff32fb0a0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_277a4d77-0b09-4539-b378-707f302fd32d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_eb4eae3d-ab03-4420-b0e8-c4de0dd713ea"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmIwODlmNWM2ZjJkMjRlMmFhYmM1MTJjMTQ4ZWY3NjhiXzExNg_f2a42bd5-cd5e-4744-a8c7-e8b172c16bb1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtMi0xLTEtMA_d03b6518-68c0-4958-a685-33088794dae7"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzAtNC0xLTEtMA_1a8ca786-5896-4601-b34b-370719bb2e9c"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzE4_247d4070-9988-4d18-96d2-0a6647912d72"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzE4_3d3537ed-16af-4633-b9d8-291472098d40"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzUy_145e4182-7cd4-4445-afd1-b32e613a385d"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzUy_efaeac2c-adfb-46dc-a856-f1f0a09676a1"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzc3_9cc90d49-9384-4169-86e2-5486924eec90"
      unitRef="shares">37426844</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzg0_d7b3ca37-88a4-4fde-85b9-aed9a9fb5087"
      unitRef="shares">37343547</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzEzMQ_15d9c2d8-5834-4b5d-9ca9-3e352397fc7e"
      unitRef="shares">37314076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjNjNjJmZjM5NTIzNzRhN2RhZDEzMDJjYWFkYmNlOWQxXzEzOA_138638f9-3215-4628-ac22-85ac2d1ba38d"
      unitRef="shares">37251220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtMi0xLTEtMA_317485e4-7cf3-46d9-9de4-b299929bb1f2"
      unitRef="usd">373000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzEtNC0xLTEtMA_2c1b7861-d594-4129-a5db-8b46f4b81fda"
      unitRef="usd">373000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzItMi0xLTEtMA_78122dd8-e1d9-4499-a439-63a127bb4c6a"
      unitRef="usd">413205000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzItNC0xLTEtMA_dc9ee810-342e-4236-b90e-1f4b27f7e12a"
      unitRef="usd">407199000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjcyMWYzZDc5MTIzNTRjYWQ5MTQ1ZTQ5ZmM0ZmEwNmJhXzI5_4109de0d-cb02-47aa-99aa-957911885022"
      unitRef="shares">112768</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjcyMWYzZDc5MTIzNTRjYWQ5MTQ1ZTQ5ZmM0ZmEwNmJhXzM2_cb7af4bf-c85e-407e-aa3a-a520287e414e"
      unitRef="shares">92327</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtMi0xLTEtMA_6722ec88-da6f-4b7b-a1ae-61c618014a06"
      unitRef="usd">1451000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzMtNC0xLTEtMA_0f6794a7-5878-4bbe-ba02-a03cd3227e78"
      unitRef="usd">1417000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzQtMi0xLTEtMA_28b953c7-1e5e-4bd6-844c-e4e01d4d096c"
      unitRef="usd">-325730000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzQtNC0xLTEtMA_83680215-c588-44d9-be5c-e89d62d547e4"
      unitRef="usd">-291012000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzUtMi0xLTEtMA_143db1bb-5275-47c1-9da4-10e9b9faf899"
      unitRef="usd">86397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzUtNC0xLTEtMA_fe92ea36-8a89-4483-8c46-6c481bb052bb"
      unitRef="usd">115143000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzYtMi0xLTEtMA_141fbb7c-076b-4682-83f0-fc7aa5ada5fb"
      unitRef="usd">106654000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xNi9mcmFnOmRkMmNmZjRkODE0MTRkMGU4M2NkYWJlZGJlZDc2NjQzL3RhYmxlOjg0MGM4ZTRmMjc2ZTQ3N2M5NGJiOTRmYjNhNWJjYzY5L3RhYmxlcmFuZ2U6ODQwYzhlNGYyNzZlNDc3Yzk0YmI5NGZiM2E1YmNjNjlfMzYtNC0xLTEtMA_2278f784-845d-4f4c-b06f-067d0ff3664b"
      unitRef="usd">130939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4664525312404d1b94728c50760da2a4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC0yLTEtMS0w_961e0965-4eae-4152-944d-7bcc839f834c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if704753e5c8a46528426b0f8ea5dfb41_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC00LTEtMS0w_c16cd805-e68a-481b-91d8-5b1e69d554b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8c515a2dbfdb4d1595a67d09c00d6655_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC02LTEtMS0w_30c908bc-616c-4aea-a95c-5b79ad1c3923"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0d82dd02a58c4c18a9a60caa4785696e_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNC04LTEtMS0w_82300e1e-58e7-4242-87a8-cb99bebd1705"
      unitRef="usd">11268000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9151d1bccda84d16ba78784a7225722a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS0yLTEtMS0w_f09389a2-b24e-491c-a402-aae8ecbfc6ac"
      unitRef="usd">246000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4a287cf3281c476b98eed454958f2277_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS00LTEtMS0w_2edcd898-48dc-4eea-a0b9-89f360bb7ad6"
      unitRef="usd">120000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i98ebbfa104374f4d9aa9a287ba8b999e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS02LTEtMS0w_aca19417-a0d4-47ea-9357-27ac5555366f"
      unitRef="usd">503000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7cb50f6d464f41209ad8d692ff7fbf39_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNS04LTEtMS0w_61cdc5b6-ecb6-410d-886a-217db6624895"
      unitRef="usd">1004000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi0yLTEtMS0w_16dfdfa6-4006-4ce1-b442-755f30ff58ea"
      unitRef="usd">246000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi00LTEtMS0w_795581bd-8f82-42be-9733-82963c2b55e7"
      unitRef="usd">120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi02LTEtMS0w_47f85e2c-69df-4854-9a77-c61739d2d5b6"
      unitRef="usd">503000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfNi04LTEtMS0w_f4cfcaba-d1ef-426d-9649-ed7c200e6ba0"
      unitRef="usd">12272000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC0yLTEtMS0w_e834b7e6-2447-4cd7-b2bd-505da46ed03e"
      unitRef="usd">7024000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC00LTEtMS0w_61a9461f-36c9-4068-96bd-cc4fc253026c"
      unitRef="usd">7570000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC02LTEtMS0w_32f01945-7daf-4d40-b726-e400e26c731b"
      unitRef="usd">17464000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOC04LTEtMS0w_9df71db4-313e-466b-aa5f-499e1fdc6379"
      unitRef="usd">39972000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS0yLTEtMS0w_5796c384-ab5c-49bd-bfdc-d7d023bf7425"
      unitRef="usd">8279000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS00LTEtMS0w_15188fde-ea5b-4c33-9052-2e1e596c98d5"
      unitRef="usd">7588000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS02LTEtMS0w_a562928c-b584-4242-8b30-ba4b87409862"
      unitRef="usd">19484000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfOS04LTEtMS0w_c0e64456-396e-4596-b2f9-2f2b98550e6f"
      unitRef="usd">23792000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtMi0xLTEtMA_34605658-a766-45d5-b00d-31b4894ce644"
      unitRef="usd">15303000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtNC0xLTEtMA_75553869-3441-4b2c-8551-f10e01489ad0"
      unitRef="usd">15158000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtNi0xLTEtMA_d6faf758-920f-4401-b43c-28148b99304b"
      unitRef="usd">36948000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTAtOC0xLTEtMA_7deb6121-9f5a-4f19-be25-b3bc0cfceb06"
      unitRef="usd">63764000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtMi0xLTEtMA_2d75d787-1afd-4125-bcc7-f98c55ddd8bc"
      unitRef="usd">-15057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtNC0xLTEtMA_e80e9497-8eb6-471a-b9dc-dd70d3ebba24"
      unitRef="usd">-15038000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtNi0xLTEtMA_ff6ad30c-f621-4efe-8a08-d11506a2b415"
      unitRef="usd">-36445000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTEtOC0xLTEtMA_7aa30459-aa77-4416-924a-89f521411353"
      unitRef="usd">-51492000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtMi0xLTEtMA_1dbb652d-0c2a-44f6-be5a-2f71894182f7"
      unitRef="usd">-33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtNC0xLTEtMA_e0601d3f-2433-4d67-bb3a-41686bd83c2d"
      unitRef="usd">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtNi0xLTEtMA_92b3afae-75c6-4c7b-a362-2651958a39c3"
      unitRef="usd">-38000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTMtOC0xLTEtMA_2eabdff4-a8f5-4931-85c4-4c50c70b199d"
      unitRef="usd">16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtMi0xLTEtMA_3a21c4c2-b6a7-495b-b70e-4067e4b0ba05"
      unitRef="usd">567000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtNC0xLTEtMA_15bf0ac1-1918-4e05-b2b1-3ce5cc8a2a75"
      unitRef="usd">664000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtNi0xLTEtMA_bd77a1bf-4821-4379-8643-62efa42ed4ef"
      unitRef="usd">1815000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTQtOC0xLTEtMA_6133990d-7f42-43ce-95d9-0b6353e67db4"
      unitRef="usd">1510000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtMi0xLTEtMA_5e2be3cf-e906-4e43-a26d-9f3c1759cde4"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtNC0xLTEtMA_d037e612-24c9-4801-a33b-c8ced4b0057a"
      unitRef="usd">2000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtNi0xLTEtMA_47627166-e627-481a-a109-e488a073127b"
      unitRef="usd">50000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTUtOC0xLTEtMA_9a08049a-335b-4f0a-92fc-5df5584dc595"
      unitRef="usd">51000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtMi0xLTEtMA_85df196d-9c84-4711-bba2-d82a66aa7c38"
      unitRef="usd">509000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtNC0xLTEtMA_9f09afb8-3b69-4114-a018-2e3430b9d2cb"
      unitRef="usd">644000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtNi0xLTEtMA_79f33ec3-6680-4239-b069-23a018786b81"
      unitRef="usd">1727000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTYtOC0xLTEtMA_f36a11d1-5ed4-493a-9faa-1770f3aee096"
      unitRef="usd">1475000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctMi0xLTEtMA_55b27c29-e45b-41cc-8b92-495d741b9ea9"
      unitRef="usd">-14548000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctNC0xLTEtMA_3096e8bd-4f29-4574-8199-831b9b8d0ac8"
      unitRef="usd">-14394000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctNi0xLTEtMA_159b92d7-0f5f-4fe9-90ef-ad7533b8700f"
      unitRef="usd">-34718000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTctOC0xLTEtMA_6336e805-8cdf-42a8-b56d-65d4dccc28bd"
      unitRef="usd">-50017000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtMi0xLTEtMA_e1f41d77-d93e-4cbd-ac7b-8e019da6c696"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtNC0xLTEtMA_743ccb91-3b4d-4143-b89f-73632c679a53"
      unitRef="usd">-6991000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtNi0xLTEtMA_29e8703a-17da-4a7b-8204-f7ab4f0ee844"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTgtOC0xLTEtMA_c420623c-5ab5-494e-8088-12f36a094740"
      unitRef="usd">-6991000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktMi0xLTEtMA_791d6f8d-9d5c-4825-99da-c43cb2181f91"
      unitRef="usd">-14548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktNC0xLTEtMA_2421aac9-4c68-473f-8c5b-6fb4864d2ffe"
      unitRef="usd">-7403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktNi0xLTEtMA_df87f03e-3e39-4454-8ea0-6ae404dcd8da"
      unitRef="usd">-34718000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMTktOC0xLTEtMA_6e43ff13-f2ef-4324-8eb9-84afdab08289"
      unitRef="usd">-43026000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtMi0xLTEtMA_6ef84dac-0210-4a9e-bac9-4258e112f043"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtNC0xLTEtMA_bf30ac39-a4ca-45ff-84ec-6496da96b13d"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtNi0xLTEtMA_a77b6794-3d71-4daa-ab63-d9d9db8bf8b7"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjEtOC0xLTEtMA_2ae379cd-1dd6-4509-9c45-6bd0a0a8b0f5"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtMi0xLTEtMA_6db34284-c1ad-4043-a12e-3b5beb96f78c"
      unitRef="shares">37308523</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtNC0xLTEtMA_e31637be-08d8-424b-80d3-d501fd60b5f0"
      unitRef="shares">37214363</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtNi0xLTEtMA_3df268bd-f687-4755-b621-45f84ff9a757"
      unitRef="shares">37286930</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8xOS9mcmFnOmI4NGY4Y2FhMzdkYTQ3ZGVhMmNkNzhiODM3ZGEzYTAwL3RhYmxlOmY2MzMzMTZkMWVjMDRjZmZiNTNmMDA3ODg0NTdmNzY2L3RhYmxlcmFuZ2U6ZjYzMzMxNmQxZWMwNGNmZmI1M2YwMDc4ODQ1N2Y3NjZfMjQtOC0xLTEtMA_b80621c3-79fa-42c4-bbb8-8f159c298d54"
      unitRef="shares">37178542</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i03d751ee6c76466fb5eb60f4019c30a5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0yLTEtMS0w_89a42cea-3ae0-4732-b4ca-9b3d70ec368b"
      unitRef="shares">37251220</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i03d751ee6c76466fb5eb60f4019c30a5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi00LTEtMS0w_04e2f332-c570-4370-bb9f-30fafad2d37d"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic25aea5b67dc4615836b71f7ec170110_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi02LTEtMS0w_a32c42f0-e637-43d6-8454-d65a3316cc22"
      unitRef="usd">407199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i505afb318e1146129e9c7d51a2e1dd64_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi04LTEtMS0w_58aa5524-7324-4dec-baed-40da2116dd3a"
      unitRef="usd">-1417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf470515d3af40d1b502950814a2820d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0xMC0xLTEtMA_789b72c4-8568-4f92-b05d-69cc54b0d4c8"
      unitRef="usd">-291012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMi0xMi0xLTEtMA_4cfdd5be-d949-46ce-8314-147830e83b29"
      unitRef="usd">115143000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i743bdaaa5b21446bbc814722f648cd49_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMy02LTEtMS0w_0b599ba4-4d07-459c-a52b-661a41b4570f"
      unitRef="usd">1944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMy0xMi0xLTEtMA_65f2d8b8-cf81-4eeb-9f53-58bed5afa43b"
      unitRef="usd">1944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNC0yLTEtMS0w_2316d60d-b458-4669-9eb3-5a9bf9dfc527"
      unitRef="shares">44329</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNC0xMi0xLTEtMA_4d5e7fcb-25f2-4325-9a52-ec5132742b24"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i13820eacd2d445c8b7eeba2fa794975c_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS0yLTEtMS0w_6d7c7491-a3c4-4945-a6ef-0bc417f27908"
      unitRef="shares">19447</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id59db6466a5d48b5a06237c225e6a257_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS04LTEtMS0w_a36a1947-2d3e-4660-89a2-ea0a06e285af"
      unitRef="usd">32000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNS0xMi0xLTEtMA_6e0f0dd8-6231-4563-a12f-9cd0c8782995"
      unitRef="usd">32000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="if9d41031c4b440719ab7602de06c798e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNi0xMC0xLTEtMA_bfb093ca-de09-4023-84d7-4e1f379b8a91"
      unitRef="usd">-10036000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77b44dcf24140da9b508e4b9d182966_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNi0xMi0xLTEtMA_1f035e10-c831-4cac-80a0-825fe9d328cb"
      unitRef="usd">-10036000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0yLTEtMS0w_fb6625cc-26d4-428b-80a9-ef883a92f8cb"
      unitRef="shares">37276102</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5ee35d2fc43e4532b7ca8591d5e012ed_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy00LTEtMS0w_3ea60361-ab95-44c1-b622-13cab90c4fc8"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83f04576fbb64c32a7733ec82cee0caf_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy02LTEtMS0w_546c531a-f6e4-4540-beda-a1206a70bd78"
      unitRef="usd">409143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d697c19fe5e4fa58ef31272011cf521_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy04LTEtMS0w_4a862771-a037-4311-aba8-16b98778a86c"
      unitRef="usd">-1449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6330f627e2f84026b002dd0309e55153_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0xMC0xLTEtMA_2c79d6e6-d1e6-4933-830b-9616f10dbcf1"
      unitRef="usd">-301048000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f28d90376cb4de3827920363100e946_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNy0xMi0xLTEtMA_f42670d6-c890-45cc-b9ca-97175a00d239"
      unitRef="usd">107019000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i53d872755c9d49bead485135d03d139a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOC02LTEtMS0w_b437204b-d93d-4656-b7d3-426eaa5834cb"
      unitRef="usd">1773000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOC0xMi0xLTEtMA_349b4a4d-6679-4c85-b992-b28a86471964"
      unitRef="usd">1773000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOS0yLTEtMS0w_02066f0f-6e93-486a-986d-2373e2e12f5c"
      unitRef="shares">1250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfOS0xMi0xLTEtMA_a03f9362-d1f5-4f0c-9c80-886740eeae67"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtMi0xLTEtMA_1def31c0-ba5a-425b-91e2-9b7255fa29e8"
      unitRef="shares">23967</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i53d872755c9d49bead485135d03d139a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtNi0xLTEtMA_e2a88841-56d5-42f0-b7a9-b27c30e20206"
      unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTAtMTItMS0xLTA_ce501dd7-80b7-4398-a045-80bbe560e640"
      unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ieb3292ff02dc422ea60c99c8b835b2b9_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtMi0xLTEtMA_a2c2148c-7d85-4c99-826a-57c802f5d129"
      unitRef="shares">359</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8de8dfc9265f4814a10af285b763d500_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtOC0xLTEtMA_6bc5b4d3-6367-46a1-8425-766348371add"
      unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTEtMTItMS0xLTA_a9ebe739-0844-43b9-b337-9249d5608aee"
      unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="iacf3bbd0ea44455a821a356b26309749_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTItMTAtMS0xLTA_65d28398-b690-40d9-9c3a-759b48e1e5d0"
      unitRef="usd">-10134000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7397a26596a645c8b1f49ddf254ed158_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTItMTItMS0xLTA_5d1a278d-758d-4e0d-af1c-142779ae7972"
      unitRef="usd">-10134000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie307d6d5bcea4b01bff357ad51555c41_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMi0xLTEtMA_24f2d8ef-8739-43f0-87f4-260cf9d7fe90"
      unitRef="shares">37300960</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie307d6d5bcea4b01bff357ad51555c41_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtNC0xLTEtMA_80ac4c74-4e2c-450e-987b-21b971e68e3f"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i183f47689ec84868ab9f6b72e3f7e433_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtNi0xLTEtMA_3cf44a63-eea7-4de0-8fb4-a91c1b8cafe1"
      unitRef="usd">410946000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8364331140614060a05ae248ab045408_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtOC0xLTEtMA_21c2e083-89d3-41fd-a908-78e3cd4c5053"
      unitRef="usd">-1450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ea5410251564fd6a62a198b8e5f4009_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMTAtMS0xLTA_a903b938-742b-4e8d-b23b-94ee5059f776"
      unitRef="usd">-311182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifab97d107e9549eb8b271ae98baea406_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTMtMTItMS0xLTA_e562dd51-b6f3-4fef-981e-ed345e438d50"
      unitRef="usd">98687000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i24b974929d044217aed5ac3c4be73ea8_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTQtNi0xLTEtMjE0_757433af-8b87-4893-86e4-4d53dc6a2a67"
      unitRef="usd">2259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTQtMTItMS0xLTIyMg_4f3aa305-6b0e-4e44-829c-8f46f256c3bf"
      unitRef="usd">2259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTUtMi0xLTEtMjE2_14eaf1cf-4d54-457e-a84c-5d05938e1f5d"
      unitRef="shares">13751</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTUtMTItMS0xLTIyMg_0b1854ba-4ae3-4518-bc38-241a18c5f752"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ic18e2738c0134ba4bbf2230281d21f19_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtMi0xLTEtMjE2_3d271f36-717e-47d7-a00c-3c53a4905241"
      unitRef="shares">635</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4a3dd401368e49a4ad4de2abc0db6cb6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtOC0xLTEtMjE4_028ac407-018b-4d40-8360-de816312572b"
      unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTYtMTItMS0xLTIyMg_b706814b-822d-43b4-b572-d07991849eee"
      unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="id52ffe662b424bbb88ce5417c24c5166_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTAtMS0xLTIyMA_54b5bd50-9b71-43ae-ba99-7a9b723a3f1c"
      unitRef="usd">-14548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTItMS0xLTIyMg_35beae7f-621b-4264-a043-da0b512d8e98"
      unitRef="usd">-14548000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMi0xLTEtMzYy_98d2095b-f964-46ff-a556-003014917b40"
      unitRef="shares">37314076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i234b88f8d9e549b1ab1694a9852d6c3d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNC0xLTEtMzYy_92d0cddf-3ab9-4d6d-8e6c-716311f14a36"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5715e9adfac45a8b83e8d40a69664d9_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNi0xLTEtMzYy_db9ace65-7e83-44d9-9588-c27b4522cb45"
      unitRef="usd">413205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a75e769cc224d6298f34cd36e25d43a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtOC0xLTEtMzYy_c5a9d045-1b1a-4cd6-b7ff-6bbd5b58970d"
      unitRef="usd">-1451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i351b47f7af6542ac9248452c834d8455_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTAtMS0xLTM2Mg_56f4557b-0080-449d-b1dc-2f8547cc0852"
      unitRef="usd">-325730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTItMS0xLTM2Mg_77207ce1-75ed-446d-9b0e-4a5d0cfbdbc5"
      unitRef="usd">86397000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i45a81768f87d40cca900412fadac8d87_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMi0xLTEtMA_160e9ad7-f492-4a36-b3d2-e4082dcc9af1"
      unitRef="shares">37109556</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i45a81768f87d40cca900412fadac8d87_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctNC0xLTEtMA_66a275b2-6f87-4aaa-9bb6-24cd4ae0c9f2"
      unitRef="usd">372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i118a4632bd23467da06fa77e0c2bb1f1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctNi0xLTEtMA_6d988a71-09d8-4d55-88e4-1e60628f553b"
      unitRef="usd">389786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a4c804c8dac4cfd990183466fd9ad56_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctOC0xLTEtMA_789d5b5d-1a70-45f8-99d0-a327b6ac4cba"
      unitRef="usd">-1142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9acd99c8b887434880292fb731fadbdf_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTAtMS0xLTA_28a62ab9-2ddc-45f2-8b54-91b8afc680aa"
      unitRef="usd">-237459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72e1400b763c49568b5cacb45201ccaa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTctMTItMS0xLTA_89587139-a40c-4607-a77b-e0f7086c6207"
      unitRef="usd">151557000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtNi0xLTEtMA_fcd98943-541a-482b-8b25-3bdb89fea808"
      unitRef="usd">4820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTgtMTItMS0xLTA_36666084-475c-4a00-8be6-1fe3f4bfbfe0"
      unitRef="usd">4820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktMi0xLTEtMA_b43ef4d9-769a-4557-9456-1e7be73ce47f"
      unitRef="shares">84262</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktNC0xLTEtMA_5825748f-ce96-478a-9973-10c7225b328c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i47a9b7a0934546df830fca2941e5c980_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktNi0xLTEtMA_53a7ab9d-0307-4814-9ff4-cf69995196ee"
      unitRef="usd">105000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMTktMTItMS0xLTA_e76e7236-aeda-4c62-a223-eba28223ef60"
      unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i20ca9fb453e24817b4bf73be4f765ef1_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtMi0xLTEtMA_52cbabf9-cfe4-49a4-baa1-b619ddad52a2"
      unitRef="shares">28720</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if5a22af9c5264e37834b47db5e74b120_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtOC0xLTEtMA_445f6508-087a-478f-96f5-73d26a07d904"
      unitRef="usd">261000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjEtMTItMS0xLTA_14b860c0-8fbe-46db-92a2-1118a7174399"
      unitRef="usd">261000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="i4d603373292d4142b02b4ad42398d206_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjItMTAtMS0xLTA_c209171d-39ba-4c32-9b22-e6a3c8ee047a"
      unitRef="usd">42000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
      contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjItMTItMS0xLTA_3926f0ef-a8b2-4bad-aece-c5b92096dcaa"
      unitRef="usd">42000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
    <us-gaap:NetIncomeLoss
      contextRef="i4d603373292d4142b02b4ad42398d206_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjMtMTAtMS0xLTA_51148b01-3d05-4fb7-bbdb-e11afb297659"
      unitRef="usd">-18310000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if05c8243e3884438adf343cadc3e292d_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjMtMTItMS0xLTA_b97ded4c-036c-4fd2-b282-1d93aa458245"
      unitRef="usd">-18310000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMi0xLTEtMA_6f1f754f-c49d-4daa-9260-11fb52d24697"
      unitRef="shares">37165098</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i18ff9bc8e64f4694b7d2cd7c335e5b97_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtNC0xLTEtMA_6d3548f6-f83a-4967-852e-f06e1ecc839f"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i288a43aa7f8440249689de817a189731_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtNi0xLTEtMA_13a1a603-068f-4b56-b144-0a00aa522b62"
      unitRef="usd">394711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d85a484cbcd4b0abfadd3bc26932841_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtOC0xLTEtMA_d85d3ec8-3e3a-4cf8-8822-5596612df2ad"
      unitRef="usd">-1403000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf5534a41e53449b97133e968328f9a5_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMTAtMS0xLTA_3f7b1ba5-3e36-4c8d-b74b-1afd586c9300"
      unitRef="usd">-255727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i140b485706b14058a26125a6cce6a765_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjQtMTItMS0xLTA_b9488613-9544-4afe-9283-ea3b9acefb7f"
      unitRef="usd">137954000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie5a934ace4c946c28093a195503e156f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjUtNi0xLTEtMA_6f71d937-d14e-4608-99bb-f7cedab09318"
      unitRef="usd">4177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjUtMTItMS0xLTA_35cba31f-9aaf-4f48-a3ff-fb4d5c3d3b96"
      unitRef="usd">4177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjYtMi0xLTEtMA_b695e660-01f9-439a-a3b7-03c97546452a"
      unitRef="shares">1250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjYtMTItMS0xLTA_72e17465-bd58-410a-ab17-5bdb75afc62d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctMi0xLTEtMA_b5eb31cf-cc59-4ed5-870c-a1dd178baaf5"
      unitRef="shares">32111</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie5a934ace4c946c28093a195503e156f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctNi0xLTEtMA_85928f76-0e6f-4ee6-94fc-e7c4da449194"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjctMTItMS0xLTA_6ce47119-cdca-42f4-a40c-47ddb6d64af7"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i5dd9668e08894a02ac6eede663ba0772_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtMi0xLTEtMA_702639e6-ab8e-4396-ab50-1576de206245"
      unitRef="shares">359</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i63cdc44a40d049039d180bc48b94bf7f_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtOC0xLTEtMA_9d2bcae8-1919-450e-abeb-efd05983e8bc"
      unitRef="usd">2000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjgtMTItMS0xLTA_3048df6e-a92c-4ead-82d0-2becdc270eb6"
      unitRef="usd">2000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i3a400765af1e4295a589ad235b0bb229_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjktMTAtMS0xLTA_be20f1c6-09da-434d-8f3a-0501b40fc4f3"
      unitRef="usd">-17313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85bcbc2d7fb04eaa8fe2d212b40dd0d6_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMjktMTItMS0xLTA_a27b7e94-4ec9-4ec2-be2f-778d23ec3921"
      unitRef="usd">-17313000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e7921dfa4bf484fbd69745528d65347_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMi0xLTEtMA_18a14fba-b892-4bf6-a3b8-e8f8c96dac7f"
      unitRef="shares">37198100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0e7921dfa4bf484fbd69745528d65347_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtNC0xLTEtMA_36fb9740-480b-41f8-9e1f-afecac413f48"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d417601e8ed469ba93c08f508e5c6cb_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtNi0xLTEtMA_99c03a28-b4c9-47ee-911e-e9855ebe47bb"
      unitRef="usd">399018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife35f142e8d74a338ff0bcaccfa25ad0_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtOC0xLTEtMA_b5821424-0224-4ebe-a7ea-52a3e134e0ce"
      unitRef="usd">-1405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ef502f9d9d44723b54dcbb9a8c41982_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMTAtMS0xLTA_42c07f9f-c54e-4a63-9d64-90a50c98e377"
      unitRef="usd">-273040000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29c7d068b9374823b5c5345eb272ce77_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzAtMTItMS0xLTA_f4e33a45-a10d-41d1-be9e-d39783571f69"
      unitRef="usd">124946000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzgtNi0xLTEtMTI2_a21488f5-44a3-459a-b2c4-d9bba9b49b68"
      unitRef="usd">4623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzgtMTItMS0xLTEyOQ_80ec0655-4800-451f-b08e-cdd20f92006f"
      unitRef="usd">4623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktMi0xLTEtMTMy_58f5e719-3314-48ee-b08f-2335c6c8588d"
      unitRef="shares">19881</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i10c2e464d85a441c8e040eda11e4fc15_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktNi0xLTEtMTM1_53aae108-5071-4f2e-8dd8-f59a8b2cfa75"
      unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfMzktMTItMS0xLTE0NA_b9df6bfa-6921-483a-8021-38f9bb61ea72"
      unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i46b246a7d9ae4c61ac85d964da2c40d5_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtMi0xLTEtMTMy_bcf69310-f09d-4739-8c4b-4c280c77d894"
      unitRef="shares">1089</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if7d6f7ba47da4441ace39e0c4364b8cd_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtOC0xLTEtMTM4_28f7895c-795d-4110-b6bd-d4b3174fff67"
      unitRef="usd">4000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDAtMTItMS0xLTE0NA_d65e1c89-ed61-4ce9-8010-6c9650fdd547"
      unitRef="usd">4000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ied703d3a9b144f7399e282419ab70c09_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDEtMTAtMS0xLTE0MQ_690e87bf-baf5-4770-afef-ef450b10c083"
      unitRef="usd">-7403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDEtMTItMS0xLTE0NA_a520592d-5415-427e-ae0e-78eadbd3de30"
      unitRef="usd">-7403000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id64eda74baf5476a8141082fd8f23afa_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMi0xLTEtMTU3_7c48cc5f-fcd5-4af4-9de3-803cf08af7b8"
      unitRef="shares">37216892</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id64eda74baf5476a8141082fd8f23afa_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItNC0xLTEtMTY3_69323396-8151-4c38-93b3-c6cc3e82c7f4"
      unitRef="usd">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i088d0c7eb2e542868a81a509f658724c_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItNi0xLTEtMTU4_c63e26dc-e1c0-4c52-aef3-41527050b5b5"
      unitRef="usd">403674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie18061ceabd14d7cbfa7e44c6aa37ff3_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItOC0xLTEtMTYy_1cfa278d-a3af-4946-809a-cf51d44f8cd6"
      unitRef="usd">-1409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8fe32be617d48f8b264cb18a8de74d1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMTAtMS0xLTE2NA_4b9b573e-d6e2-4c2c-9350-0a3ac45aed4a"
      unitRef="usd">-280443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida83887e682745b687c7e89ab3d035f6_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yMi9mcmFnOmU5MjQ3NmNjN2VlYTRkOGM4YzE4MTU4MDk2NTg0ZjllL3RhYmxlOmQ1NTEzNTQ3M2I2MzQ5Zjg5YTU3ODgwYjIzYWFiOWMzL3RhYmxlcmFuZ2U6ZDU1MTM1NDczYjYzNDlmODlhNTc4ODBiMjNhYWI5YzNfNDItMTItMS0xLTE2Ng_3c89e55b-31bb-4fa1-8aef-6e00bdd28b31"
      unitRef="usd">122195000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMy0yLTEtMS0w_f3144681-f8e6-4c50-b69a-c207b84695a6"
      unitRef="usd">-34718000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMy00LTEtMS0w_dcd8eac2-cf8a-4eae-82dc-01c974c8a537"
      unitRef="usd">-43026000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNS0yLTEtMS0w_abb7789e-39b8-405e-a81a-e5a91f07ecb8"
      unitRef="usd">5976000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNS00LTEtMS0w_c34612f5-21fc-4802-bccf-054d861b79af"
      unitRef="usd">13620000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNi0yLTEtMS0w_53275e3b-c9ff-4a7e-83f9-28dc0c6943f2"
      unitRef="usd">432000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfNi00LTEtMS0w_4b913b3c-4108-4706-82af-bc3c56e31c8f"
      unitRef="usd">901000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtMi0xLTEtMTg5Nw_60e5c012-bed0-4201-977c-5be6cc1b32c6"
      unitRef="usd">351000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtNC0xLTEtMTg5OQ_b5198b63-c01c-456c-a0b2-1d928a0e81c0"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtMi0xLTEtMA_645c0dfb-d09b-4956-921e-374497528a39"
      unitRef="usd">-40000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTAtNC0xLTEtMA_a33f5a99-065e-4930-a4e8-905c61d75001"
      unitRef="usd">16000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTEtMi0xLTEtMA_99c8260d-7dc6-42ba-8998-dc72ef44be10"
      unitRef="usd">111000</nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability>
    <nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTEtNC0xLTEtMA_48f879f5-7cae-40ff-9e18-b331576aae2f"
      unitRef="usd">0</nlnk:FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTMtMi0xLTEtMA_b2d5c8a7-178e-41ac-a9dd-5d3cc3e90a24"
      unitRef="usd">-2225000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTMtNC0xLTEtMA_df5ad0ce-53af-4aa9-b225-41caa00cf25a"
      unitRef="usd">-842000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTQtMi0xLTEtMA_f6fb8171-81dd-4993-b507-18dd80139383"
      unitRef="usd">281000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTQtNC0xLTEtMA_25c95f8a-baf6-4cad-aaff-cb48ff54794d"
      unitRef="usd">-9982000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTUtMi0xLTEtMA_a62d3c8f-2fb2-4d00-9ef3-8d0c6cd41efe"
      unitRef="usd">3576000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTUtNC0xLTEtMA_2944365c-71a9-45b4-a326-97c34e0b2794"
      unitRef="usd">-11749000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTYtMi0xLTEtMA_4c2238cc-88ae-4a61-89dc-43a64675232b"
      unitRef="usd">334000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTYtNC0xLTEtMA_d750b88f-06e7-42f2-a917-6045f9d14cea"
      unitRef="usd">-7042000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTctMi0xLTEtMA_ae304bfb-df48-4b82-8933-b51cee4f38d0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTctNC0xLTEtMA_1da9ce14-0fbd-47e9-8d84-91e8bba860ea"
      unitRef="usd">-56000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTgtMi0xLTEtMA_b44ac86c-ed2a-464a-bc81-53b450da4b92"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTgtNC0xLTEtMA_884aebb1-a519-4cff-893a-75f1773758f6"
      unitRef="usd">78000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTktMi0xLTEtMA_9819c2cb-c50b-4395-b471-01e2904beaad"
      unitRef="usd">-22176000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMTktNC0xLTEtMA_11cced94-5ab4-4880-a07f-8654f1788bef"
      unitRef="usd">-36622000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjItMi0xLTEtMA_0beb2d2f-9489-4be9-bfb7-33e21d5d6095"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjItNC0xLTEtMA_2a97e964-b85d-4ace-b143-aed569223e5c"
      unitRef="usd">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjMtMi0xLTEtMA_671d8732-595a-464e-82b7-26fc487ee30e"
      unitRef="usd">15000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjMtNC0xLTEtMA_4beeef64-6931-4945-bbc2-67fa26397bef"
      unitRef="usd">118000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjQtMi0xLTEtMA_4fadd540-8006-494e-98cf-8fc1a32aa8dc"
      unitRef="usd">15000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjQtNC0xLTEtMA_b45bd8f0-a0e4-4e68-8d18-ab619a642716"
      unitRef="usd">111000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjYtMi0xLTEtMA_c85e087d-1dff-42ab-807b-fcca2a34f3df"
      unitRef="usd">30000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjYtNC0xLTEtMA_09420667-89ef-4540-b5c9-2593cb6100ab"
      unitRef="usd">269000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjctMi0xLTEtMA_d0be3166-905c-4df5-ac23-fb33b0acd63e"
      unitRef="usd">34000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjctNC0xLTEtMA_601041f3-210c-4d92-b24d-4d13e95db4ed"
      unitRef="usd">267000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjgtMi0xLTEtMA_82130cfc-4a76-4f1d-88db-e795ded9daa7"
      unitRef="usd">46000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjgtNC0xLTEtMA_86977fa1-1115-47cd-a4c8-9ef6d0f6c3d9"
      unitRef="usd">138000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjktMi0xLTEtMA_4d53f9f7-c096-4bef-a553-2db2bea4b801"
      unitRef="usd">-50000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMjktNC0xLTEtMA_4dc34977-7d9e-463d-b8ff-57b3db9427fa"
      unitRef="usd">-136000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzAtMi0xLTEtMA_42e49c90-0e94-4d56-90fd-d32735e93f94"
      unitRef="usd">-22211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzAtNC0xLTEtMA_d1cba743-16f2-49f8-bcfb-e62574139a43"
      unitRef="usd">-36647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzEtMi0xLTEtMA_933dffef-74fc-4032-bd32-60212f2e61df"
      unitRef="usd">120738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72e1400b763c49568b5cacb45201ccaa_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzEtNC0xLTEtMA_dbdd46e6-6481-4261-baa1-16d6fd7d33b4"
      unitRef="usd">158708000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzItMi0xLTEtMA_32cbc8ad-2853-4200-8481-42af56ad605a"
      unitRef="usd">98527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida83887e682745b687c7e89ab3d035f6_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzItNC0xLTEtMA_81d9393e-e751-4fc4-a7f8-38f0473787af"
      unitRef="usd">122061000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzQtMi0xLTEtMA_4184ab28-82c6-4152-ad60-2b605bd4af11"
      unitRef="usd">3000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzQtNC0xLTEtMA_f47ba431-31ea-4420-bc0c-7936c818b1ff"
      unitRef="usd">6000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzUtMi0xLTEtMA_361672c9-f8ab-414a-b544-417165f75484"
      unitRef="usd">14000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzUtNC0xLTEtMA_86b6431e-106f-4af0-8edf-7c06c088a855"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzctMi0xLTEtMjAyNg_af3d6fa9-0aba-4c1c-a298-c19e5bbfc0fa"
      unitRef="usd">348000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8yNS9mcmFnOjEyYmY4NjgxMGI4NDRhNWU4MWI3MjY0MzM1NDYwMjhjL3RhYmxlOjU1Yjk4ZjEwZjNlZTRjZDRiZGU3MWJmNmVmNDA0MzFjL3RhYmxlcmFuZ2U6NTViOThmMTBmM2VlNGNkNGJkZTcxYmY2ZWY0MDQzMWNfMzctNC0xLTEtMjAzNA_c833fc9c-832b-4743-9d76-c2d9c702f5e6"
      unitRef="usd">4000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:NatureOfOperations
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMjE2OA_4229ec4b-89a5-43e9-9385-fa8fc358a6c3">Description of Business&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On June&#160;4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed to develop treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;NewLink and its subsidiaries (the Company) have historically devoted substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements as of September&#160;30, 2019 and for the three and nine months ended September&#160;30, 2019 have been prepared assuming the Company will continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s cash and cash equivalents as of September&#160;30, 2019 are expected to be adequate to satisfy the Company&#x2019;s liquidity requirements through 2021. If available liquidity becomes insufficient to meet the Company&#x2019;s operating obligations as they come due, the Company&#x2019;s plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#x2019;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position and may materially affect the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Proposed Merger with Lumos Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 30, 2019, the Company, Cyclone Merger Sub, Inc., a wholly-owned subsidiary of the Company (Merger Sub), and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as a wholly-owned subsidiary of NewLink (the Merger). Following the Merger, NewLink will change its name to &#x201c;Lumos Pharma, Inc.&#x201d; and Lumos will change its name to a name mutually agreed upon by the Company and Lumos. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;At the effective time of the Merger (Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of NewLink&#x2019;s common stock equal to the amount determined pursuant to a charter amendment to Lumos&#x2019; certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock.  Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately 50% of the aggregate number of shares of Company common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and the stockholders of the Company as of immediately prior to the Merger are expected to own approximately 50% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by NewLink and converted into options to purchase a number of shares of NewLink&#x2019;s common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for NewLink&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company's and Lumos' conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger.  Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos.  Lumos stockholders approved the Merger in September 2019.  The Merger Agreement contains certain termination rights for both the Company and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company or Lumos, as applicable, may be required to pay the other party a termination fee of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split, with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time. The Merger is expected to close in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="i11f2bdb36ed64cb5b8001849d4dad9df_D20190930-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMzg0ODI5MDcxOTI1MQ_f2c3ceca-13be-48bc-aa84-beecb8f21474"
      unitRef="number">0.50</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="ib799a2a817e04b59aab49144acc02919_D20190930-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfMzg0ODI5MDcxOTI1Ng_eddbc7b8-eff9-499e-a889-75f7664ff924"
      unitRef="number">0.50</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <nlnk:MergerAgreementCovenantsTerminationFeePayable
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zMS9mcmFnOjJjMzEwYjBjZGVjNDRkZmE5MDkzZWMxNWEwZWNlN2I1L3RleHRyZWdpb246MmMzMTBiMGNkZWM0NGRmYTkwOTNlYzE1YTBlY2U3YjVfNjU5NzA2OTc4Njk5OA_52d51892-05e9-4da6-a0bc-71cddcd27dc3"
      unitRef="usd">2000000.0</nlnk:MergerAgreementCovenantsTerminationFeePayable>
    <us-gaap:BasisOfAccounting
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNC9mcmFnOjBmMGY1OWI5MGY3OTQyN2E5MTJmZDBiMGZmNGVlNmI2L3RleHRyZWdpb246MGYwZjU5YjkwZjc5NDI3YTkxMmZkMGIwZmY0ZWU2YjZfOTcy_f789a966-e633-443d-8301-e5ad25f310f6">Basis of Presentation&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S.&#160;GAAP) and the rules&#160;and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management&#x2019;s opinion, reflect all adjustments necessary to present fairly the Company&#x2019;s interim condensed financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2018, included in the Company&#x2019;s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc4OA_e80e562b-246a-43db-ab21-3a1fd536c414">Significant Accounting Policies&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated financial statements include the financial statements of NewLink and its wholly-owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Financial Instruments and Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable was $58,000 and $104,000 as of September&#160;30, 2019 and December&#160;31, 2018, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#x2019;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.6 million and $7.0 million as of September&#160;30, 2019 and December&#160;31, 2018, respectively.  Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e"&gt;three&lt;/span&gt; to five years, lab equipment has a useful life of five years, and contract manufacturing organization equipment has a useful life of five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases, to improve financial reporting for leasing transactions. The Company adopted the standard on January 1, 2019 using the modified retrospective method, as required, applying the new standard to all leases existing as of the date of initial application. The Company has elected that the date of the initial application, January 1, 2019, will be the effective date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to apply the use-of-hindsight or the practical expedient pertaining to land easements; as the latter is not applicable to the Company.&lt;/span&gt;&lt;/div&gt;Upon adoption of the standard, the Company recorded a lease liability of $8.5&#160;million and a right of use asset of $7.5&#160;million associated with these leases. Included in the right-of-use asset are lease incentives that were previously recorded as deferred rent liability of $1.0&#160;million as of December 31, 2018 on the consolidated balance sheet.  There was no material impact to the consolidated statement of operations. Refer to Note 7 within for additional discussion around the lease liability and right of use asset as of September&#160;30, 2019.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc4OQ_87a45c6c-e8e2-4fa7-b629-4ccde171dbfe">&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5MA_819eef65-f47b-4580-8963-060acb5d0d72">&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated financial statements include the financial statements of NewLink and its wholly-owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5MQ_6429bbf9-f059-4c77-adb2-ac9980db14ec">Financial Instruments and Concentrations of Credit RiskCash and cash equivalents, receivables, and accounts payable are recorded at cost, which approximates fair value based on the short-term nature of these financial instruments. The carrying value of notes payable was $58,000 and $104,000 as of September&#160;30, 2019 and December&#160;31, 2018, respectively, which approximate fair value using Level 2 inputs (computed in accordance with ASC 820). The Company is unable to estimate the fair value of the royalty obligation based on future product sales, as the timing of payments, if any, is uncertain.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMTAzNg_68f7f60f-0e00-4eb4-b71c-ad73f269b654"
      unitRef="usd">58000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMTA0Mw_89001efe-b645-4f02-b4fc-75b9ab8d6bea"
      unitRef="usd">104000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5Mg_11c15605-dcc1-4aa2-a05a-cf33c3eb8ffe">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#x2019;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5Mw_6c424b86-6dca-4765-af68-2cee799a05fa">Property and EquipmentProperty and equipment are capitalized as the Company believes they have alternative future uses and are stated at cost, less accumulated depreciation of $7.6 million and $7.0 million as of September&#160;30, 2019 and December&#160;31, 2018, respectively.  Depreciation on all property and equipment is calculated on the straight-line method over the shorter of the lease term or estimated useful life of the asset. Computer equipment has useful lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0MA_80d6cd09-2ad8-4d84-b517-c642f119361e"&gt;three&lt;/span&gt; to five years, lab equipment has a useful life of five years, and contract manufacturing organization equipment has a useful life of five years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjAwMA_df463cbc-3289-4426-a4a2-88055cb0e17a"
      unitRef="usd">7600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjAwNw_c3147c5d-b632-4e0d-90b8-fcd7ab2d6c1b"
      unitRef="usd">7000000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibf9fcb41ebd843cfa2f5be0b9a6e54c6_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI0Ng_112c86f3-6b5c-47b7-8afd-a974084b8ccd">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2c5dd96d6f28439094a7f5c566181c4f_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjI4NQ_f4fd105d-187a-4055-b0c1-239a50c6e651">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idc3288156e044e1ea7072638951290c4_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMjM2MA_adbe12bf-6a71-469b-8c52-fc3e1120b28a">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzc5NA_4271b550-36be-4882-8ad4-63fccc32ee21">&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), Leases, to improve financial reporting for leasing transactions. The Company adopted the standard on January 1, 2019 using the modified retrospective method, as required, applying the new standard to all leases existing as of the date of initial application. The Company has elected that the date of the initial application, January 1, 2019, will be the effective date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the "package of practical expedients", which permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to apply the use-of-hindsight or the practical expedient pertaining to land easements; as the latter is not applicable to the Company.&lt;/span&gt;&lt;/div&gt;Upon adoption of the standard, the Company recorded a lease liability of $8.5&#160;million and a right of use asset of $7.5&#160;million associated with these leases. Included in the right-of-use asset are lease incentives that were previously recorded as deferred rent liability of $1.0&#160;million as of December 31, 2018 on the consolidated balance sheet.  There was no material impact to the consolidated statement of operations. Refer to Note 7 within for additional discussion around the lease liability and right of use asset as of September&#160;30, 2019.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="if42832590af241ccbfc792218e48761d_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzQ3Mg_e4a8f51d-37d7-4d05-95cc-1556eeaa2a60"
      unitRef="usd">8500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if42832590af241ccbfc792218e48761d_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzUwMw_9a933d31-590b-4b3c-a071-c49d90e5d47f"
      unitRef="usd">7500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF8zNy9mcmFnOjdhOWY0ZTNkNzhiMzQzZmQ4NjMwMGIxMDMyN2FkMDc2L3RleHRyZWdpb246N2E5ZjRlM2Q3OGIzNDNmZDg2MzAwYjEwMzI3YWQwNzZfMzY1Mg_e11cb3d6-a75a-480d-bc44-d00cd9017b47"
      unitRef="usd">1000000.0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTgyNA_70e080fc-941e-4548-a99b-02249f21334b">Revenues &lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Prior to transferring the government contracts over to Merck Sharp &amp;amp; Dohme Corp. (Merck) in June 2018, the Company received payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services (HHS). These agreements provided the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues were recognized over time and measured using the input method. The Company used labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. Under this method, the Company recognized revenue generally in the period during which the related costs were incurred, in an amount that reflected the consideration the Company expected to be entitled to in exchange for those goods or services transferred to the government entities due to the government entities' control over the research and development activities. &lt;/span&gt;&lt;/div&gt;The grants and contracts with government entities were fully transferred to Merck as of June 2018. Accordingly, during the nine months ended September&#160;30, 2019, the Company recognized no grant revenue. The Company had $520,000&#160;and $309,000 of receivables relating to the government contracts on the balance sheet as of September&#160;30, 2019 and December&#160;31, 2018, respectively. The Company had $24,000 and $54,000 of accrued expenses for subcontractor fees incurred under the government contracts as of September&#160;30, 2019 and December&#160;31, 2018, respectively.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTgyNg_3863987c-d78d-41e9-a44e-aefe49d4dd84">Revenue Recognition Revenues are recognized under Topic 606 when control of the promised goods or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Prior to transferring the government contracts over to Merck Sharp &amp;amp; Dohme Corp. (Merck) in June 2018, the Company received payments from government entities under its grants and contracts with the Department of Defense and the United States Department of Health and Human Services (HHS). These agreements provided the Company cost reimbursement plus a percentage for certain types of expenditures in return for research and development activities over a contractually defined period. Grant revenues were recognized over time and measured using the input method. The Company used labor costs and subcontractor fees as inputs to measure progress towards satisfying its performance obligations under these agreements. Under this method, the Company recognized revenue generally in the period during which the related costs were incurred, in an amount that reflected the consideration the Company expected to be entitled to in exchange for those goods or services transferred to the government entities due to the government entities' control over the research and development activities.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:GovernmentContractReceivable
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMjc0ODc3OTA3MTI2OQ_38e07065-e991-498d-a523-5a5787d161ee"
      unitRef="usd">520000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTU3OA_840f6006-1183-460c-95b1-f42864b2d3bc"
      unitRef="usd">309000</us-gaap:GovernmentContractReceivable>
    <nlnk:GovernmentContractAccruedSubcontractorFees
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMjc0ODc3OTA3MTI3Mw_92be670d-d4f7-4534-a18c-35ac98deb3ad"
      unitRef="usd">24000</nlnk:GovernmentContractAccruedSubcontractorFees>
    <nlnk:GovernmentContractAccruedSubcontractorFees
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80My9mcmFnOmFiMDcxMzU4NTExMjQwNWU4OGRhZDhmMDhiZDYzMDk1L3RleHRyZWdpb246YWIwNzEzNTg1MTEyNDA1ZTg4ZGFkOGYwOGJkNjMwOTVfMTcwOA_e32f7ccb-7733-4a16-bf23-b701d932249e"
      unitRef="usd">54000</nlnk:GovernmentContractAccruedSubcontractorFees>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjkwOA_3aade098-2ce3-4c70-a650-cc90eea3b573">License and Research Collaboration Agreement&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Merck Sharp &amp;amp; Dohme Corp. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2014, the Company entered into a licensing and collaboration agreement (the Merck Agreement) with Merck to develop, manufacture and commercialize rVSV-ZEBOV-GP, an Ebola vaccine the Company licensed from the Public Health Agency of Canada (PHAC). Under the terms of the Merck Agreement, the Company granted Merck an exclusive, royalty bearing license to rVSV-ZEBOV-GP and related technology. Under the Merck Agreement, the Company received a $30.0 million non-refundable, upfront payment in December 2014, and a one-time $20.0 million non-refundable milestone payment in February 2015 upon the initiation of the pivotal clinical trial using the current rVSV-ZEBOV-GP vaccine product as one arm of the trial. In addition, the Company can receive escalating royalties on potential commercial sales by Merck of the current product candidate ranging from single digit to double digits on the rVSV-ZEBOV-GP license agreement product sales and escalating royalties on potential commercial sales by Merck of products other than current products within the Company&#x2019;s patent rights ranging from low to high single digit, on increasing levels of annual net sales worldwide. Merck is expected to lead the development of rVSV-ZEBOV-GP and any other rVSV-based viral hemorrhagic fever vaccine product candidates in order to create a marketable product safe for human use.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Merck Agreement was amended on December 5, 2017 in connection with our entry into an amended and restated PHAC license on December 5, 2017. The amended Merck Agreement absolves our subsidiary, BioProtection Systems Corporation (BPS), from any future obligation to negotiate or amend the terms of the PHAC license, converts the scope of Merck's sublicense under PHAC&#x2019;s intellectual property rights to be non-exclusive in the Ebola Sudan field of use, and requires Merck to reimburse us in certain circumstances where we may be obligated to pay royalties to PHAC as a result of Merck&#x2019;s product sales but Merck would not otherwise be obligated to pay a royalty to us. On April 26, 2018, the Company entered into an agreement with Merck, the U.S. BioMedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA) to transfer the government grants from BARDA and DTRA to Merck. The transfer was completed in June 2018 and Merck has replaced the Company as the prime contractor on all such grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:23pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September&#160;30, 2019, the Company recognized revenues under the amended Merck Agreement of $246,000 and $503,000, respectively, for work the Company performed as a subcontractor of Merck under the government contracts that were transferred to Merck.  For the three and nine months ended September&#160;30, 2018, the Company &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;recognized license and collaboration revenue under the amended Merck Agreement of $120,000 and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; $949,000, respectively, &lt;/span&gt;for the reimbursement of costs not covered under government contracts.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="ib8f327bd7ef245e79de2f37014c6d665_D20141201-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfNTM2_580cbd69-8f08-41fd-a024-a178f2e2ec3c"
      unitRef="usd">30000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="i09d3bfeeceed429b9919afe16c36b882_D20150201-20150228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfNjA0_8e72a101-7a8e-44a8-87a2-a839c1a2e2b7"
      unitRef="usd">20000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i12a8e9aa761347babed3658ff5c9a4d6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjU1Ng_eaeb206a-2b0c-4e00-a0a5-ecc360b4e66c"
      unitRef="usd">246000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4778bd47a7ba44e880bf6a0a6262fcd0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjU2Mw_1ea5f80b-3f60-44f4-a0a8-efbfe5cbbe13"
      unitRef="usd">503000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie0068a8d71d2412c8b3c5bc4e29bbc32_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjgxMw_b76221e3-26c1-40df-a21c-3a19d35007d3"
      unitRef="usd">120000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1af278cb3284478691a305bda935ae58_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80Ni9mcmFnOmY4MzM2NmNiNTdjNjRhZGE4MjE1MDU3YzkzOTY2MWQxL3RleHRyZWdpb246ZjgzMzY2Y2I1N2M2NGFkYTgyMTUwNTdjOTM5NjYxZDFfMjgyMA_6a7683a2-a5e2-44d7-8752-d5f521dea23c"
      unitRef="usd">949000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxMw_782106b5-43ab-4eb4-b108-2eb284f904d2">Common Stock Equity Incentive Plan&lt;div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2009 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan (the 2000 Plan), in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan (the 2009 Plan), and in May 2019, the stockholders approved to amend and extend the Company's 2009 Equity Incentive Plan (the 2019 Plan). Following the approval of the 2019 Plan, no additional stock awards will be granted under the 2009 Plan. Shares that remained available for issuance pursuant to the exercise of options or issuance or settlement of stock awards under the 2009 Plan became available for issuance pursuant to the 2019 Plan and all shares that would have otherwise returned to the 2009 Plan became available for issuance pursuant to the 2019 Plan. Under the provisions of the 2019 Plan, the Company may grant the following types of common stock awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Nonstatutory Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Awards under the 2019 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of September&#160;30, 2019, there were 12,400,653 shares of common stock authorized for the 2019 Plan and 5,271,904 shares remained available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the authorized increases of common stock under the 2009 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.199488%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.078772%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.521739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Date Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Authorized Shares Added&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;May 15, 2010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,238,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 7, 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;823,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;839,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,062,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,119,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,152,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,166,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,484,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&#x2019;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2019 were made pursuant to an &#x201c;evergreen provision,&#x201d; in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On May 9, 2019, the Company&#x2019;s stockholders approved an amendment to the 2009 Plan which, among other modifications, included decreasing the automatic annual &#x201c;evergreen provision&#x201d; from 4% to 3%, in accordance with which, on January 1 of each year, from 2020 to (and including) 2029, a number of shares of common stock in an amount equal to &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2010 Non-Employee Directors' Stock Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Company&#x2019;s 2010 Non-Employee Directors&#x2019; Stock Award Plan (the Directors&#x2019; Plan) which became effective on November 10, 2011, 238,095 shares of common stock were reserved for future issuance. On May&#160;9, 2013, an &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;additional 161,905 shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of September&#160;30, 2019, 268,902 shares remain available for issuance under the Directors' Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2010 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Company&#x2019;s 2010 Employee Stock Purchase Plan (the 2010 Purchase Plan), which became effective on November 10, 2011, 214,285 shares of common stock were reserved for future issuance. On May&#160;9, 2013, an additional 185,715 shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September&#160;30, 2019, 29,542 shares remained available for issuance under the 2010 Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Share-based compensation expense for the three months ended September&#160;30, 2019 and 2018 was $2.3 million and $4.6 million, respectively. Share-based compensation expense for the nine months ended September&#160;30, 2019 and 2018 was $6.0 million and $13.6 million, respectively.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, the total compensation cost related to nonvested option awards not yet recognized was $4.7 million and the weighted-average period over which it is expected to be recognized is 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Options and Performance Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the stock option activity, including options with market and performance conditions and options granted and forfeited in conjunction with the option exchange program, for the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.090909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.818182%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.636364%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.727273%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;of options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,978,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,753,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,696,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,318,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Outstanding at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,716,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,165,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.139535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.962791%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.697674%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;1.8% to 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;77.0% to 86.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;4 to 7.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;No options were exercised during the nine months ended September&#160;30, 2019. The fair value of awards vested during the nine months ended September&#160;30, 2019 was $2.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the nine months ended September&#160;30, 2019, the Company&#x2019;s Board of Directors approved and granted 650,000 shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $1.24.  The equity awards vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2017 were met during the three and nine months ended September&#160;30, 2019 and 79,849 shares vested.  None of the targets for 2019 equity awards have been met.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock and Performance Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the planning committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September&#160;30, 2019 and changes during the nine months ended September&#160;30, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.235828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.954649%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.140590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number of restricted stock shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Unvested at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(59,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Unvested at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, the total remaining unrecognized compensation cost related to restricted stock was approximately $124,963 and is expected to be recognized over a weighted-average period of 0.3 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Option Exchange Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 20, 2019, the Company commenced an option exchange program (Option Exchange) for its officers and employees to exchange eligible stock options to purchase up to an aggregate of 5,849,059 shares of the Company's common stock that had been granted to eligible holders, for a lesser number of new stock options with a lower exercise price. Stock options granted prior to December 31, 2018 with an exercise price equal to or greater than $2.97 and held by eligible holders in continuous service through the termination of the Option Exchange were eligible for exchange in the Option Exchange. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The eligible shares were exercisable for a reduced number of shares based on the following exchange ratios:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.559105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.598722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.559105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.598722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.284345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price Range per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Outstanding Eligible Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exchange Ratio (Surrendered Stock Options to New Stock Options)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.97-$10.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;2 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$11.00-$24.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;720,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;3 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$25.00-And Up&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;468,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;4 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Upon the expiration of the Option Exchange on July 31, 2019, 45 eligible employees and 5 eligible directors had tendered an aggregate of 3,914,856 options, representing 67% of the total eligible options, for 1,720,341 new options to purchase shares of common stock (New Awards). Each New Award was granted on July 31, 2019, pursuant to the Company's 2009 Plan, with an exercise price per share of $1.77 per share, the closing price on the grant date of the New Awards.  Each New Award has a maximum term of seven years.  The New Awards will vest in equal annual amounts over either &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjQ5OQ_eda0d1de-291e-4724-9f3d-24d63817ed19"&gt;two&lt;/span&gt; or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjUxMw_1e2e5b28-e0fd-452d-9a2f-63613413e197"&gt;three&lt;/span&gt; years, depending on whether the tendered eligible option was vested as of the exchange date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As a result of this transaction the Company will recognize additional stock-based compensation expense of $1.0 million over the vesting schedule of the New Awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i93f6713f23084b77b9f014a1385b3370_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTE5OA_ddb87518-895c-490f-a5d2-3437a53467e1"
      unitRef="shares">12400653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i93f6713f23084b77b9f014a1385b3370_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTI1Nw_19dd09d5-1282-4739-b05f-8df625846a76"
      unitRef="shares">5271904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxOQ_d0c3c9a3-afb1-4f2a-aefb-f2b9552adf55">&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the authorized increases of common stock under the 2009 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.199488%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.078772%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.521739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Date Authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Authorized Shares Added&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;May 15, 2010&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,238,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 7, 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;714,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;823,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;839,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,062,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,119,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,152,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,166,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,484,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,490,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ie54c7721636a4a35b6a388e0c9fa5e67_D20100515-20100515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMS0yLTEtMS0w_129689f9-466c-47a7-940b-2b4499bc94a8"
      unitRef="shares">1238095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i3bebf0fb283644b1b4fa4191fa81d9e9_D20110107-20110107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMi0yLTEtMS0w_7e043fa6-ef8d-4b94-b0fb-3ea755d9a381"
      unitRef="shares">714285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i614cfc319ae4417e821a813bf2a85f20_D20120101-20120101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMy0yLTEtMS0w_ce20a08a-e788-4c57-8df8-1d0eacbb8a8e"
      unitRef="shares">823649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ieab1db675dee4e5da76fe81774a8552b_D20130101-20130101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNC0yLTEtMS0w_b884b7b0-5e59-40e8-8655-0fae47f50e51"
      unitRef="shares">839407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="icd0760fc05764fa1a60a9c9d11289a14_D20140101-20140101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNS0yLTEtMS0w_5ace90c9-6c9d-4db5-a29d-56f1f7044cb7"
      unitRef="shares">1062920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i1c98279781c9463f806811bc0a673a4d_D20150101-20150101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNi0yLTEtMS0w_9a0fe44e-95f7-4698-8c13-f15a368af234"
      unitRef="shares">1119233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6ff1b4bb134b4e37a54c3394f117eb6b_D20160101-20160101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfNy0yLTEtMS0w_590a2225-778a-45ab-9cc1-ec0be06e5c1e"
      unitRef="shares">1152565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if33b56d22b074f6897659805507c8fd1_D20170101-20170101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfOC0yLTEtMS0w_f66c05ca-1272-4c19-9495-426e886c111e"
      unitRef="shares">1166546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4016611a1eab4f25b572395001428c52_D20180101-20180101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfOS0yLTEtMS0w_82a333c7-54d7-4489-8d54-12037fbfe3c1"
      unitRef="shares">1484382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4f210ec5feb14d6589ee87904ff50298_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjU0YWZiM2ViODE3NzRiMDc4NDM1ZGU2MDRiNDlmNDNjL3RhYmxlcmFuZ2U6NTRhZmIzZWI4MTc3NGIwNzg0MzVkZTYwNGI0OWY0M2NfMTAtMi0xLTEtMA_d0e1c683-a069-4c86-9eca-9d59f9eb067c"
      unitRef="shares">1490048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum
      contextRef="ic06e3556e29342f9b22ed68a8c5b9967_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMTgyMQ_ab8f9186-6639-46d6-9ff2-c6c06c3fdd62"
      unitRef="number">0.04</nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum>
    <nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum
      contextRef="i36cc09bb5c5d4dd48310b49ce7bfd13b_D20190508-20190508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjI3OA_80fcd86f-302f-47f9-bbab-aa6096ec31e3"
      unitRef="number">0.04</nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum>
    <nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum
      contextRef="i107fa001f84543fa888d506c91a7babb_D20190509-20190509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjI4NA_4c240825-08c7-4b94-9a19-26eefaf3da6b"
      unitRef="number">0.03</nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum>
    <nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum
      contextRef="i107fa001f84543fa888d506c91a7babb_D20190509-20190509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjQzMw_46028a64-7b6e-4588-8c01-af0f8de775fa"
      unitRef="number">0.03</nlnk:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAuthorizedStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7ba61dd7590642d3b68ea5be9247b3d3_I20111110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjg5OA_83189ce8-fe56-4a6a-a790-5685b9e95622"
      unitRef="shares">238095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i5db880b71be843cf9fa1297dd718c0fb_D20130509-20130509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjk4OQ_07f0bbd8-c565-43b7-b67a-9bc21bbc6c47"
      unitRef="shares">161905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ieb329194fab14e95927fc78307847e9a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzEwNw_d56db801-4ddd-4737-99a8-17e5ccd218be"
      unitRef="shares">268902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i019744478ea04e56985668e5cb38d38d_I20111110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzM0Ng_476248dd-1e39-4bae-b443-4601b5502aa1"
      unitRef="shares">214285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i5956af200be14c239393954a2fd95c97_D20130509-20130509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzQzNw_080bd796-df32-4ab5-a7cc-c6b22b76d2ff"
      unitRef="shares">185715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7a1bc3c99884466aba07355633ce5f0e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzU1Nw_356c0136-2d5a-4515-8f9e-a3fa17dc088c"
      unitRef="shares">29542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzcxMg_e9483250-9fac-4319-b0ae-401f0ba799f8"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzcxOQ_24416c29-828c-45fc-9a86-41e946aacffd"
      unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzc5NQ_12988dbf-8a33-457d-9457-83dce3110eb4"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzgwMg_ad07f4d9-432f-4df5-8dca-65431d642f94"
      unitRef="usd">13600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDA5Nw_5a280458-4909-474f-994f-545228ac8f20"
      unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDE3OA_e7fa6aa0-c3c8-4521-942b-8ce5377be17e">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxNQ_c16fa813-c833-4569-9190-79766a523041">&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the stock option activity, including options with market and performance conditions and options granted and forfeited in conjunction with the option exchange program, for the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.090909%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.818182%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.636364%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.709091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.727273%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;of options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;remaining contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,978,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,753,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,696,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,318,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Outstanding at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,716,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,165,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2ef382a4e2574d5795c997701aaa5ba2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS0yLTEtMS0w_38ec3652-fa01-4e54-beda-17c16d8cbadb"
      unitRef="shares">7978030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2ef382a4e2574d5795c997701aaa5ba2_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS00LTEtMS0w_02de2141-992a-4c03-a0c1-6b5665db8afd"
      unitRef="usdPerShare">11.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ief1b201dcccc48339b02bb8bb2870d0e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMS02LTEtMS0w_f3c760cb-e93d-42fd-b053-4db5cca61795">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMi0yLTEtMS0w_b170c7dd-5ab3-4dce-9382-66dfdf51fc26"
      unitRef="shares">3753274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMi00LTEtMS0w_4969e104-db12-44f7-b2da-d501b66e08c5"
      unitRef="usdPerShare">1.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMy0yLTEtMS0w_23b1a739-2586-4277-81ca-dacca0319521"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfMy00LTEtMS0w_c8a5a35f-897b-4d94-ae8b-95b6a54b50c9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNC0yLTEtMS0w_b26e1944-5b94-4e54-a67e-f247cae615f8"
      unitRef="shares">4696520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNC00LTEtMS0w_7688f324-0aae-4683-bb67-2eb78db0a106"
      unitRef="usdPerShare">11.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNS0yLTEtMS0w_2f7dfc2b-b91f-4a35-afb8-6856986d0a6f"
      unitRef="shares">1318698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNS00LTEtMS0w_1563ae7d-b8cf-4f4a-9684-f4d90701b0be"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi0yLTEtMS0w_a1227383-00bc-4c8c-a9a8-bc1355223bb5"
      unitRef="shares">5716086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi00LTEtMS0w_2f7cf03e-9d8a-46a5-9687-5679db366bf6"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNi02LTEtMS0w_9ce66dca-e36c-495c-b62f-3aba7bb25950">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy0yLTEtMS0w_41fae093-e51f-4ea1-8d6c-4690814db13c"
      unitRef="shares">3165770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1e7f9677e03e45f3a98571e955061cad_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy00LTEtMS0w_d52b6e2c-5692-465e-bdbd-3ad29a608ef6"
      unitRef="usdPerShare">11.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmI3NzA4NWNhNTBlNjRiNGI4MTEyMzVlOTQyNDc1MGY4L3RhYmxlcmFuZ2U6Yjc3MDg1Y2E1MGU2NGI0YjgxMTIzNWU5NDI0NzUwZjhfNy02LTEtMS0w_65a6c936-b3fa-49fa-9680-e9582b7b49ee">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAyMg_087646f1-8c89-470f-be93-ba809da87740">&lt;div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.139535%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.962791%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.697674%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;1.8% to 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;77.0% to 86.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;4 to 7.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMC0yLTEtMS0wL3RleHRyZWdpb246ZDg1Y2M2NjdiMjE5NDBlZmI2ZmEwMTA4ZDc4MTJkM2FfMzg0ODI5MDY5NzIzNg_8a4e8a7d-d8fb-4297-9350-26220b3a6929"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMC0yLTEtMS0wL3RleHRyZWdpb246ZDg1Y2M2NjdiMjE5NDBlZmI2ZmEwMTA4ZDc4MTJkM2FfMzg0ODI5MDY5NzI0Mg_d2cbd2c1-b772-44a7-aaad-d5360bf7d9a2"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMS0yLTEtMS0wL3RleHRyZWdpb246MTdjZjI0NTJmY2E0NDllNmE4Yjg5NjdmYTcxNGZlMjVfMzg0ODI5MDY5NzIyMw_b0e91ee4-4e66-444a-ae88-ea666fa3d1d8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMi0yLTEtMS0wL3RleHRyZWdpb246M2JjOGRlMGViNzBkNDcwYmJkMTFkYjcyMTM1YmU3NDVfMzg0ODI5MDY5NzIzOQ_db8c456f-e21c-43b3-88ab-e3d72e287d76"
      unitRef="number">0.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMi0yLTEtMS0wL3RleHRyZWdpb246M2JjOGRlMGViNzBkNDcwYmJkMTFkYjcyMTM1YmU3NDVfMzg0ODI5MDY5NzI0Ng_b39536c2-fa71-4336-9ebb-2ffe444250b2"
      unitRef="number">0.863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id22dbb1e99d54346b14b3c0916a4c37a_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMy0yLTEtMS0wL3RleHRyZWdpb246ZmFlNTkwZTM4ZTVmNDMwN2JiY2QzZmY3NGQ0NmE0M2JfMzg0ODI5MDY5NzIzMw_42fe548d-c48d-4b1a-84ed-ad3b3eb90d88">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8f55c0e897664d23bff3a32fd6ca9f5a_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfMy0yLTEtMS0wL3RleHRyZWdpb246ZmFlNTkwZTM4ZTVmNDMwN2JiY2QzZmY3NGQ0NmE0M2JfMzg0ODI5MDY5NzIzOA_2c98eeca-2096-4e88-aed5-a7c0bcdd89d6">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmM0OTNiMTc0MDJhODRiOTc5ZDhhNmZjNWU0NTIzZWU4L3RhYmxlcmFuZ2U6YzQ5M2IxNzQwMmE4NGI5NzlkOGE2ZmM1ZTQ1MjNlZThfNC0yLTEtMS0wL3RleHRyZWdpb246YWI3NWVkYmMyYjkwNDU1ZTljN2Q4OTVmMDZhOTNjZmFfMzg0ODI5MDY5NzIyOA_b17eb2b1-8956-4041-a0d7-c95fc9e13d69"
      unitRef="usdPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDgzNA_62b22035-7b82-46a0-938d-2f004da9df61"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i922a5931f9a14f6ebdf2a8561ec32eec_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNDkzMQ_257c8e5b-f066-4c85-a257-76b650124b90"
      unitRef="usd">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTAwOA_90f0dd70-c55e-43c5-8aad-4c672b517b79"
      unitRef="shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTE4MA_f78f04e0-3e23-46e4-bf94-744d4f45252d"
      unitRef="usdPerShare">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifa4dcedfbf254a60bd61f6c82b03ad8b_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNTM3MQ_b0819eaf-20a4-4b65-be34-a54f886c4078"
      unitRef="shares">79849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAyMw_cc7e6736-cc8a-4c1d-8c00-cd534964fce1">&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September&#160;30, 2019 and changes during the nine months ended September&#160;30, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.235828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.954649%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.140590%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.933787%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Number of restricted stock shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Unvested at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(59,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Unvested at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib4a2953b237a4956bb04a2ba877036e8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMS0yLTEtMS0w_f94ea5e0-313d-4856-8a59-a56be583aea7"
      unitRef="shares">68585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib4a2953b237a4956bb04a2ba877036e8_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMS02LTEtMS0w_4e89d319-7df5-4cd6-9dd0-fa9d430b4d17"
      unitRef="usdPerShare">37.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMi0yLTEtMS0w_dff0b695-6346-4f36-b44d-8f3f3e25263b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMi02LTEtMS0w_d6382a13-eddb-4da2-a677-0878dc2aab92"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMy0yLTEtMS0w_cca3e44f-1655-46be-8c1e-d0b99fce17fe"
      unitRef="shares">59330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfMy02LTEtMS0w_e3d139f6-0d54-4508-b26d-bb4abebacfad"
      unitRef="usdPerShare">38.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNC0yLTEtMS0w_28b29d29-3ff9-477f-bd2a-48774f624dcb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNC02LTEtMS0w_48e75f3d-38d5-4357-a7ce-dd983f2b989d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i57817203713c4925802ca15e17d5adaa_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNS0yLTEtMS0w_fcc22245-8905-4e1c-be9d-3eb44f985c9f"
      unitRef="shares">9255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i57817203713c4925802ca15e17d5adaa_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOmU1ZGMxZDA5M2JjMTQxOWY5MWYwZGQ0NTU0NzkxOWU1L3RhYmxlcmFuZ2U6ZTVkYzFkMDkzYmMxNDE5ZjkxZjBkZDQ1NTQ3OTE5ZTVfNS02LTEtMS0w_a540286a-dca6-4854-abda-a5299e046b26"
      unitRef="usdPerShare">34.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i57817203713c4925802ca15e17d5adaa_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNjQ3MA_36b01d89-938f-4959-a784-1c3bc18b1f60"
      unitRef="usd">124963</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i650044a8fd7a4954b1544468244a04c8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNjU0MA_f621e33e-1077-41a5-bf58-b73a72f027c1">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized
      contextRef="i257055a317c4463eb42d9ef38312b06f_I20190620"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzAyOA_834d6d81-6eb7-490c-a968-dc4cc22a484d"
      unitRef="shares">5849059</nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit
      contextRef="i2e071305c5974ee088653329c9314097_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzI3OA_4729c96e-9da2-4da6-9a7a-690706da9f39"
      unitRef="usdPerShare">2.97</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfODAxOA_f5de9e73-8aa0-4f60-8a16-c27e801d2ffb">&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The eligible shares were exercisable for a reduced number of shares based on the following exchange ratios:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.559105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.598722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.559105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.598722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.284345%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price Range per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Outstanding Eligible Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exchange Ratio (Surrendered Stock Options to New Stock Options)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.97-$10.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;2 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$11.00-$24.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;720,373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;3 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;$25.00-And Up&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;468,671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;4 to 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeTableTextBlock>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit
      contextRef="ia6344520fdce4afb87589a3d00b3e720_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0wLTEtMS0wL3RleHRyZWdpb246Mzk2YWIyZjVhNGIzNDMwYzgwZjYzZGIxMjYwMWNiMDBfMzg0ODI5MDY5NzI1OQ_9dc416fa-b18a-484b-93ab-23d7f7d8c02e"
      unitRef="usdPerShare">2.97</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit
      contextRef="i370c9ff0ce304ee3974eceb8f6074b8c_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0wLTEtMS0wL3RleHRyZWdpb246Mzk2YWIyZjVhNGIzNDMwYzgwZjYzZGIxMjYwMWNiMDBfNTQ5NzU1ODEzODkxNw_ff5c334d-57f6-4b02-a834-f5bffcf19935"
      unitRef="usdPerShare">10.99</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit>
    <nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding
      contextRef="i35f4cfa3cbf241ec8c3640a53481c862_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS0yLTEtMS0w_81af62f4-85b6-4d48-9304-a6536a5b56ab"
      unitRef="shares">2725812</nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio
      contextRef="i35f4cfa3cbf241ec8c3640a53481c862_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMS00LTEtMS0wL3RleHRyZWdpb246ZTIwMGIxNDg2OGEzNGVjYWFmOTk4NGYzZTZkZGM0YzJfMzg0ODI5MDY5NzIyNw_55f960f9-101b-4d8a-bd9b-df448e859fe6"
      unitRef="number">2</nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit
      contextRef="ib0476f147a0a46768f18d7f62d1b188a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0wLTEtMS0wL3RleHRyZWdpb246ZTE5ZjZmNmVjOTcwNDdkYmE0ZDg5Y2NmZDI2NDA4MTRfMzg0ODI5MDY5NzI0NQ_4c640541-61e5-4642-931b-162f35f1ac9e"
      unitRef="usdPerShare">11.00</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit
      contextRef="i5acd55e388054c249dd813ea270ac6b8_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0wLTEtMS0wL3RleHRyZWdpb246ZTE5ZjZmNmVjOTcwNDdkYmE0ZDg5Y2NmZDI2NDA4MTRfNTQ5NzU1ODEzODkwMg_6fe39c81-cd2d-4f4d-a437-bf31bb862583"
      unitRef="usdPerShare">24.99</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeUpperRangeLimit>
    <nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding
      contextRef="ibe1655708734471499ed19001400af44_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi0yLTEtMS0w_b920d6b5-0374-470e-b98c-fc437bdae4c3"
      unitRef="shares">720373</nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio
      contextRef="ibe1655708734471499ed19001400af44_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMi00LTEtMS0wL3RleHRyZWdpb246M2ZlNTIwM2NhZWRhNGIxNmI4M2I5NDc4NThiOGM5OWZfMzg0ODI5MDY5NzIyNw_7c09c6a4-f806-4339-82e2-d309a1a0f105"
      unitRef="number">3</nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit
      contextRef="i169a1b92c3e548cc86648a4bb5aae559_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy0wLTEtMS0wL3RleHRyZWdpb246MzFmZGJiYTE2ZmM1NGQ1Y2IwZTkyMDA0NzQ2ODhmZWVfMzg0ODI5MDY5NzIzOA_50cceb2f-3d59-4a45-9369-2214de682c85"
      unitRef="usdPerShare">25.00</nlnk:ShareBasedPaymentArrangementOptionExchangeExercisePriceRangeLowerRangeLimit>
    <nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding
      contextRef="i4d00499345b541a7874a4e149b9f52ef_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy0yLTEtMS0w_fec5a7c6-cf13-4db9-8d49-c97ae8fa9af2"
      unitRef="shares">468671</nlnk:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExchangeOutstanding>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio
      contextRef="i4d00499345b541a7874a4e149b9f52ef_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RhYmxlOjhhNTM5YTE5M2I5OTQ2ODQ4ZDgzMTZjYTViZWIzODA0L3RhYmxlcmFuZ2U6OGE1MzlhMTkzYjk5NDY4NDhkODMxNmNhNWJlYjM4MDRfMy00LTEtMS0wL3RleHRyZWdpb246ZGYzMjc3OTJlNzQyNDIwNjk1NjU1ZDJmMjgwZWE2MGRfMzg0ODI5MDY5NzIyNw_9d4e40bf-f76d-491e-a0d0-e0076b347fb3"
      unitRef="number">4</nlnk:ShareBasedPaymentArrangementOptionExchangeExchangeRatio>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
      contextRef="i008f25566c8b40b295668c906960417d_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzU5OQ_2fbbc09f-266b-469c-8f9e-9f8917bd1c7e"
      unitRef="employee">45</nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
      contextRef="i008f25566c8b40b295668c906960417d_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzYyNQ_c5361e68-ceca-4e57-8b8a-3f6337b6b78c"
      unitRef="director">5</nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeOptionsConverted
      contextRef="i008f25566c8b40b295668c906960417d_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzY3Ng_baf36305-5233-41c1-8594-6637ea700809"
      unitRef="shares">3914856</nlnk:ShareBasedPaymentArrangementOptionExchangeOptionsConverted>
    <nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent
      contextRef="i008f25566c8b40b295668c906960417d_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzcwMQ_54c126d4-f6b3-46f7-9f6e-333f17c68fb6"
      unitRef="number">0.67</nlnk:ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzczOQ_57a3646e-827d-4f17-9411-571801e51abf"
      unitRef="shares">1720341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzkyNw_76095ca7-7445-4e6a-b37d-86464115e4e1"
      unitRef="usdPerShare">1.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id606702fb4024e63b1d691ef77f26589_D20190731-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMjE5OTAyMzI2NTU1Mw_f1c4a09c-4a06-40cf-bcaf-4828dd482911">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0db96647bdad4850a6a856796387bea0_D20190731-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfNzE0NjgyNTU4ODgzMA_f0760bec-7876-40ed-9825-4b23f2b963c2"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyMw_1f06a6df-aeaf-47b7-92aa-4cb448de2699">Leases&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has certain facility leases with non-cancellable terms ranging between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7"&gt;one&lt;/span&gt; and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6"&gt;three&lt;/span&gt; years, with certain renewal options. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records lease liabilities based on the present value of lease payments over the lease term using an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. To compute the present value of the lease liability, the Company used a weighted-average discount rate of 5%. Certain lease agreements include renewal options that are under the Company's control. The Company includes optional renewal periods in the lease term only when it is reasonably certain that the Company will exercise its option. Prior to September&#160;30, 2019, the Company had asserted it would renew the lease terms through expiry of the lease renewal option periods. At September&#160;30, 2019, as part of the Company's efforts to reduce costs and conserve resources, the Company concluded it would not be seeking renewal of the leased facilities in Ames, Iowa and upon termination of the lease agreements, it would identify a new space for the Company. As a result of this decision, the Company remeasured the right-of-use assets and lease liabilities using the shorter term. The weighted-average remaining lease term as of September&#160;30, 2019 is 1.0 year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not separate lease components from non-lease components. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The Company's lease agreements do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyNA_b44eaf83-70a3-4a42-ab9b-ba173c1871ef">Leases&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has certain facility leases with non-cancellable terms ranging between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7"&gt;one&lt;/span&gt; and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6"&gt;three&lt;/span&gt; years, with certain renewal options. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records lease liabilities based on the present value of lease payments over the lease term using an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. To compute the present value of the lease liability, the Company used a weighted-average discount rate of 5%. Certain lease agreements include renewal options that are under the Company's control. The Company includes optional renewal periods in the lease term only when it is reasonably certain that the Company will exercise its option. Prior to September&#160;30, 2019, the Company had asserted it would renew the lease terms through expiry of the lease renewal option periods. At September&#160;30, 2019, as part of the Company's efforts to reduce costs and conserve resources, the Company concluded it would not be seeking renewal of the leased facilities in Ames, Iowa and upon termination of the lease agreements, it would identify a new space for the Company. As a result of this decision, the Company remeasured the right-of-use assets and lease liabilities using the shorter term. The weighted-average remaining lease term as of September&#160;30, 2019 is 1.0 year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not separate lease components from non-lease components. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The Company's lease agreements do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfNTAy_f08a6a18-de9e-464a-ab3f-3524bb1f6f00"
      unitRef="number">0.05</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfNzkw_b7ce93a1-679a-4df4-a2d8-de787d456f26">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyNQ_261af0cc-cf0a-4b50-af60-df637c5f06aa">&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMS0xLTEtMS0w_06ed2892-dea2-4cc0-995c-c718026f7160"
      unitRef="usd">255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMi0xLTEtMS0w_25d4df09-d1da-4b4e-bed5-a546c202da46"
      unitRef="usd">599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfMy0xLTEtMS0w_2926fea9-6124-4b5f-aca2-268a4629599d"
      unitRef="usd">133000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNC0xLTEtMS0w_bb3e0d83-d468-4d10-98da-80070b0433ef"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNS0xLTEtMS0w_dc7b0c24-41de-428c-bb30-d2012d3ecfd2"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNi0xLTEtMS0w_92e014b1-9c63-4448-8d01-4589f2b7cab6"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfNy0xLTEtMS0w_cb2525a0-f093-415f-aeb0-54665ea1f0c2"
      unitRef="usd">987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOC0xLTEtMS0yNTAz_a788e669-1966-4b2f-bf0d-ea68e1e87aaf"
      unitRef="usd">9000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nlnk:LesseeOperatingLeaseLiabilityUnamortizedIncentives
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOC0xLTEtMS0w_3cfab903-66aa-4945-b42c-c06c74328c9c"
      unitRef="usd">951000</nlnk:LesseeOperatingLeaseLiabilityUnamortizedIncentives>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOmJlYWFkMmU5ZGNjNzQxNDBiZGYyNGJiMWZkOWEwZGZjL3RhYmxlcmFuZ2U6YmVhYWQyZTlkY2M3NDE0MGJkZjI0YmIxZmQ5YTBkZmNfOS0xLTEtMS0w_1a5e9915-12ad-42c8-892e-5f5d6628c594"
      unitRef="usd">1929000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTUyMg_fb6583bd-a227-4635-b501-cd162d44f7c9">&lt;div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.112392%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.887608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMS0xLTEtMS0w_d4b95915-8944-4cbc-9bc4-b279dd709a06"
      unitRef="usd">1105000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMi0xLTEtMS0w_40afbc18-7b24-4ab8-b3c8-85b97afb0e4a"
      unitRef="usd">1004000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfMy0xLTEtMS0w_fbe9cee5-ee5d-4a57-af27-6e55992f3abd"
      unitRef="usd">923000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNC0xLTEtMS0w_0fc01f16-32ae-4c8b-a56c-c5ff1c0ff557"
      unitRef="usd">906000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNS0xLTEtMS0w_09a14ea1-05d1-444d-aa7f-17039bd3ac22"
      unitRef="usd">909000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNi0xLTEtMS0w_ff296c89-3d78-4fc2-8bef-4f2511750fc6"
      unitRef="usd">6570000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RhYmxlOjAwNDE0NWU5NGQzYTQ5YzhiNDhjZTYwZDVjMmJhODFhL3RhYmxlcmFuZ2U6MDA0MTQ1ZTk0ZDNhNDljOGI0OGNlNjBkNWMyYmE4MWFfNy0xLTEtMS0w_1cdd4f0f-cbd1-448e-a587-c706988d53ef"
      unitRef="usd">11417000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMTg0MQ_bed0fedd-8ae1-48d6-846f-b9c089f6d187">Income Taxes&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September&#160;30, 2019 and 2018, the Company has recorded&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; no and $7.0 million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; income tax benefit (expense). The income tax amount for the three and nine months ended  September&#160;30, 2019 and 2018 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to a full valuation allowance recorded against anticipated net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has an income tax receivable as of September&#160;30, 2019 for $140,000 of which $71,000 is recorded within short term receivables and $69,000 is recorded in long-term. The full amount was recorded as an income tax benefit in 2017 and is for the receipt of alternative minimum tax (AMT) credit carryovers. The Tax Cuts and Jobs Act of 2017 (the Tax Act), provides that the AMT credit carryovers are partially refundable beginning in 2018 as an offset to a tax liability.  The Company expects the amount to be fully refunded by 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September&#160;30, 2019 and December&#160;31, 2018, respectively, due to the uncertainty of future recoverability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has a reserve for uncertain tax positions related to state tax matters of $653,000 as of September&#160;30, 2019 recorded within Accrued Expenses in the condensed consolidated balance sheet, which includes the accrual of interest and penalties. The Company does not expect the amount to change significantly within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfOTQ_1c77e909-2ed6-48a8-9863-09f8d529ed29"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfOTQ_f9620ce8-1654-471f-9af1-aac7f77a01f8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMjc0ODc3OTA3MTU2NQ_27d6aa96-b945-4e9c-95f2-3b02d752e1f4"
      unitRef="usd">-7000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMjc0ODc3OTA3MTU2NQ_5c82f50e-7f6b-42be-9a5d-0916eccba5f4"
      unitRef="usd">-7000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNDcw_49a79479-7434-4f11-af72-9903917021fa"
      unitRef="usd">140000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNjU5NzA2OTc2ODc0NA_ad78badc-bf21-4246-8266-18da6d426d97"
      unitRef="usd">71000</nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent>
    <nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfNjU5NzA2OTc2ODc0Nw_ba73b9b5-d2b4-4a92-9d7d-05297b4659f0"
      unitRef="usd">69000</nlnk:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81OC9mcmFnOjZkMzk4OTI3ZmUwZTQ5Y2NhMDgzYmQ3MGQ3ZGJhNTY2L3RleHRyZWdpb246NmQzOTg5MjdmZTBlNDljY2EwODNiZDcwZDdkYmE1NjZfMTYwOQ_e2c6d5aa-d2bf-4477-b99c-d0da41d67f0e"
      unitRef="usd">653000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTA0Mg_be064e5b-3ea1-40a6-b6a2-719eee029365">Net Loss per Share of Common Stock&lt;div style="text-indent:22pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic loss per share is based upon the weighted-average number of shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.709389%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545156%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545156%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.141282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.588376%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,308,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,214,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,286,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,178,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;All common stock equivalents are excluded from the computation of diluted loss per share during periods in which losses are reported since the result would be anti-dilutive. As of September&#160;30, 2019, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 5,716,086 and 9,255, respectively.  As of September 30, 2018, anti-dilutive stock options and restricted stock awards excluded from our calculation totaled 8,371,005 and 89,053, respectively.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTA0MQ_f495fd7f-a86c-4ed0-981a-d432c6749e0f">&lt;div style="text-indent:22pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.709389%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545156%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545156%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.141282%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.588376%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.667660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(43,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted weighted-average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,308,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,214,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,286,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,178,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi0yLTEtMS0w_220d9085-7098-408a-8737-31697a1f0950"
      unitRef="usd">-14548000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi00LTEtMS0w_866f45f0-911e-4571-ae57-08b55078db42"
      unitRef="usd">-7403000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi02LTEtMS0w_df87f03e-3e39-4454-8ea0-6ae404dcd8da"
      unitRef="usd">-34718000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfMi04LTEtMS0w_6e43ff13-f2ef-4324-8eb9-84afdab08289"
      unitRef="usd">-43026000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC0yLTEtMS0w_d21695bd-2fcd-4457-8ad2-7736de49452b"
      unitRef="shares">37308523</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC00LTEtMS0w_4388f019-a622-449d-9afe-841fe86303e9"
      unitRef="shares">37214363</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC02LTEtMS0w_3df268bd-f687-4755-b621-45f84ff9a757"
      unitRef="shares">37286930</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfNC04LTEtMS0w_ba5a2b49-5a0c-4d2d-a0a9-48240caa8cc1"
      unitRef="shares">37178542</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC0yLTEtMS0w_357bbf5e-7072-4c80-b190-acd605957fb8"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC00LTEtMS0w_117269fe-ab92-4075-98cc-dd11b7d4e00a"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC02LTEtMS0w_c40223a4-f031-48c0-978c-7208d7793929"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RhYmxlOmM2MGE2MDZlNDc0MTRjMzdhZTAwNmE5MGE4MmFiYmRjL3RhYmxlcmFuZ2U6YzYwYTYwNmU0NzQxNGMzN2FlMDA2YTkwYTgyYWJiZGNfOC04LTEtMS0w_6d39bcb0-653e-40a4-8726-caddfa77b11e"
      unitRef="usdPerShare">-1.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if9e8020da2d04e2191d918eac49f6ae6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfODg0_e981bf8b-ba7c-49fa-8276-b21014b2f9b9"
      unitRef="shares">5716086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b905d67ed264c328656baba2a4db384_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfODkx_dac8aae1-ec57-43a3-b9b7-9f3f1126574f"
      unitRef="shares">9255</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b3f948dc1734160ad119b9960b9d13b_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTAxNg_90d86741-8aa9-4720-bd5c-23d52c5d810d"
      unitRef="shares">8371005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39cb87fc9300480f802ea9c680a0f776_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82MS9mcmFnOjkxZGViOTVlMWNiOTRiODNhMzc2ZmViNTZmMTVmNTE4L3RleHRyZWdpb246OTFkZWI5NWUxY2I5NGI4M2EzNzZmZWI1NmYxNWY1MThfMTAyMw_82948ac8-bff5-4c3c-acf4-c67aa8142b0b"
      unitRef="shares">89053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfMTEyMQ_a29f0a51-d639-4366-b218-76a79d4656da">Restructuring and Severance Charges&lt;div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&#160;restructuring&#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, is recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&#160;activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 30, 2019, the Company adopted a restructuring plan to reduce its headcount by approximately 60%, which consisted primarily of clinical and research and development staff, and made several changes to senior leadership in order to conserve resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the restructuring, Charles J. Link, Jr, M.D. retired from the Company and the Board of Directors, effective August 3, 2019 and Nicholas Vahanian retired from his position as the President and member of the Board of Directors, effective September 27, 2019, and will remain an employee of the Company through a transition period ending November 11, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the restructuring and departure of Company executives, the Company recorded restructuring and severance charges of $4.5 million during the three and nine months ended September&#160;30, 2019 of which $2.9&#160;million is included within general and administrative expenses and $1.6&#160;million is included within research and development expenses. As a result of the restructuring, the Company also recorded an impairment charge of $351,000 relating to fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#x2019;s estimate of market resale value.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2018, the Company reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September&#160;30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows the amount accrued for restructuring and severance activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.838407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.205152%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.824356%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.205152%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.526932%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Employee Severance Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expensed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Cash Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="ib799a2a817e04b59aab49144acc02919_D20190930-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc2OTc5MQ_de822ffc-551a-4bd0-961e-e2204d1f84ba"
      unitRef="number">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzMQ_be89cc4e-83ee-407b-a819-97b03c215086"
      unitRef="usd">4500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzMQ_eb2bd911-601c-44e6-a88e-059de32a7f66"
      unitRef="usd">4500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie7ae389b9e2b4cae9570b2523f80048b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzNg_269366a5-844c-49e6-acba-0c202d915d72"
      unitRef="usd">2900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i347cb4a8f93f4834925abbdb2c22d273_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkzNg_7ccf361c-f6d7-4736-a947-98eafb538d6c"
      unitRef="usd">2900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i79f20a25e4d646fdb0ce1a7190c7639a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3Mjk0NQ_47bb69bd-642f-4c2b-a842-a51f2642236a"
      unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia14e8601ef3249db99d27585927dca67_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3Mjk0NQ_4a29fb1c-d025-432c-83bc-db1d285aae23"
      unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i31282c57bcdb494faf04bea0de3977c3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkyNQ_95f3af01-623c-4f8f-b19c-02fe925a609a"
      unitRef="usd">351000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNjU5NzA2OTc3MjkyNQ_aec1ce3f-1d30-4489-a4e7-1bdee8f44f0f"
      unitRef="usd">351000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i55705cb9c17045b2b56549f7969a9968_D20180701-20180731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzAx_a03eb44e-7818-4610-93fc-1eba8e1c30dc"
      unitRef="number">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="icc91753e9f7e4a75a7b58c7a5b974b97_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzE0NjgyNTU4NTE3MA_22a1643f-391e-40b2-a4d1-7845b24f084d"
      unitRef="usd">1300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i621f2e3f2b994b61a004a4cd8edcc42a_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfNzE0NjgyNTU4NTE3MA_8aae1a5d-6418-43a5-adde-67da7c8c8f84"
      unitRef="usd">1300000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RleHRyZWdpb246MTgyNzBiOTY3OTA2NDUzODk4ZWI3YmMzOWE3ZjhjZjZfMTEyNA_b33f9428-b2f3-46a3-88d8-2a10f30e79fe">&lt;div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows the amount accrued for restructuring and severance activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.838407%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.205152%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.824356%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.205152%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.526932%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Employee Severance Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Expensed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Cash Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance as of September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ia427f2113ccc4110bc882b22d38777fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMS0yLTEtMS0w_9d76a60d-a1cc-4013-9ce2-f671c73984e7"
      unitRef="usd">649000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2743af692cc2469faa69ffc8ef0a9673_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMS00LTEtMS0w_b5f9eba7-be2d-46a2-86d8-b30617c1bf83"
      unitRef="usd">649000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMi0yLTEtMS0w_6d8fc247-ca45-4a7d-98eb-8c29bdbf74ea"
      unitRef="usd">4489000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMi00LTEtMS0w_ff8baa24-5801-403c-ae16-170ad666eaa6"
      unitRef="usd">4489000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8f87b8aa6fb145d78087f6e94c8ff5f1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMy0yLTEtMS0w_cdaf2dfa-dd65-4df2-a241-99e5be296956"
      unitRef="usd">554000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfMy00LTEtMS0w_76edc7d5-14d7-4b90-8503-dffe12a12415"
      unitRef="usd">554000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ic490d40b023c41d2b5ba726dbee45eb8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfNC0yLTEtMS0w_b6cf3094-d6c9-4681-b25a-1b82670175d0"
      unitRef="usd">4584000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9ace74c0019743fe88745f618d835f4e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF82Ny9mcmFnOjE4MjcwYjk2NzkwNjQ1Mzg5OGViN2JjMzlhN2Y4Y2Y2L3RhYmxlOjI3NTVjMWI2YzMwZjQ4NTBiNzlhZTQ3YWM0MGNhODgxL3RhYmxlcmFuZ2U6Mjc1NWMxYjZjMzBmNDg1MGI3OWFlNDdhYzQwY2E4ODFfNC00LTEtMS0w_eb1c06d4-eaa8-4490-bfa3-0b8b5a6c47fe"
      unitRef="usd">4584000</us-gaap:RestructuringReserve>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7ee15b9d149740259f0dff8fcc1a8fa9_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF83MC9mcmFnOmNmM2JkNzE5NGNhYTQ4Yzc5YzU2M2Q0Y2U0Mjk3MTc0L3RleHRyZWdpb246Y2YzYmQ3MTk0Y2FhNDhjNzljNTYzZDRjZTQyOTcxNzRfNjAxNg_05fb5ce2-3753-4706-905b-8b8e0eb0e4fe">Commitments and Contingencies &lt;div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York (the Court), captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545 (the Securities Action).  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp;amp; Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company&#x2019;s Chief Executive Officer Charles J. Link, Jr., and the Company&#x2019;s Chief Medical Officer and President Nicholas Vahanian, (collectively, the Defendants).  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#x2019;s investors.  The Defendants filed a motion to dismiss the amended complaint on July 14, 2017.  On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company&#x2019;s investors.  The lead plaintiffs do not quantify any alleged damages in the second amended complaint but, in addition to attorneys&#x2019; fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#x2019;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018.   On February 13, 2019, the Court dismissed the second amended complaint for failure to state a claim, with prejudice, and closed the case.  On March 14, 2019, lead plaintiffs filed a notice of appeal. The briefing on lead plaintiffs' appeal was completed in early July 2019 and oral argument before the Second Circuit Court of Appeals was held on October 21, 2019. The Company intends to continue defending the Securities Action vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#x2019;s Chief Executive Officer Charles J. Link, Jr., the Company&#x2019;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth (collectively, the Morrow Defendants), captioned Morrow v. Link., et al., Case 1:17-cv-03039 (the Morrow Action).  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#x2019; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#x2019;s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs&#x2019; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action has until March 15, 2019 (30 days after dismissal of the Securities Action with prejudice) to file an amended derivative complaint or rest upon the current derivative complaint.  By further agreement of the parties, dated March 15, 2019, the Ely Action will continue to be stayed pending the outcome of the appeal in the Securities Action. If the Securities Action continues to be dismissed in its entirety following its appeal plaintiff in the Ely Action has agreed to withdraw or dismiss the action, with prejudice.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6796293856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Severance Charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Severance Charges</a></td>
<td class="text">Restructuring and Severance Charges<div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee severance costs are accrued when the&#160;restructuring&#160;actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits, is recognized ratably over the future service period. The Company also records costs incurred with contract terminations associated with restructuring&#160;activities. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, the Company adopted a restructuring plan to reduce its headcount by approximately 60%, which consisted primarily of clinical and research and development staff, and made several changes to senior leadership in order to conserve resources. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition to the restructuring, Charles J. Link, Jr, M.D. retired from the Company and the Board of Directors, effective August 3, 2019 and Nicholas Vahanian retired from his position as the President and member of the Board of Directors, effective September 27, 2019, and will remain an employee of the Company through a transition period ending November 11, 2019.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the restructuring and departure of Company executives, the Company recorded restructuring and severance charges of $4.5 million during the three and nine months ended September&#160;30, 2019 of which $2.9&#160;million is included within general and administrative expenses and $1.6&#160;million is included within research and development expenses. As a result of the restructuring, the Company also recorded an impairment charge of $351,000 relating to fixed assets which management determined had no or limited future use. The fair value of impaired fixed assets was determined based on management&#8217;s estimate of market resale value.  </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In July 2018, the Company reduced its headcount by approximately 30% as compared to June 30, 2018 and made several changes to senior leadership effective July 26, 2018 in order to conserve resources to advance its clinical development programs. Restructuring charges of $1.3 million were recorded during the three and nine months ended September&#160;30, 2018.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table shows the amount accrued for restructuring and severance activities which is recorded within Accrued Expenses in the condensed consolidated balance sheet (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.426901%;"><tr><td style="width:1.0%;"/><td style="width:44.838407%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.205152%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.824356%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.205152%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.526932%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Employee Severance Cost</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expensed</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Cash Payments</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance as of September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795697328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common Stock Equity Incentive Plan</a></td>
<td class="text">Common Stock Equity Incentive Plan<div style="text-indent:22.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2009 Equity Incentive Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In April 2000, the stockholders approved the Company's 2000 Equity Incentive Plan (the 2000 Plan), in July 2009, the stockholders approved the Company's 2009 Equity Incentive Plan (the 2009 Plan), and in May 2019, the stockholders approved to amend and extend the Company's 2009 Equity Incentive Plan (the 2019 Plan). Following the approval of the 2019 Plan, no additional stock awards will be granted under the 2009 Plan. Shares that remained available for issuance pursuant to the exercise of options or issuance or settlement of stock awards under the 2009 Plan became available for issuance pursuant to the 2019 Plan and all shares that would have otherwise returned to the 2009 Plan became available for issuance pursuant to the 2019 Plan. Under the provisions of the 2019 Plan, the Company may grant the following types of common stock awards:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Incentive Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Nonstatutory Stock Options</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Restricted Stock Awards</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock Appreciation Rights</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Awards under the 2019 Plan, as amended, may be made to officers, employees, members of the Board of Directors, advisors, and consultants to the Company.  As of September&#160;30, 2019, there were 12,400,653 shares of common stock authorized for the 2019 Plan and 5,271,904 shares remained available for issuance.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the authorized increases of common stock under the 2009 Plan:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:57.163743%;"><tr><td style="width:1.0%;"/><td style="width:40.199488%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.078772%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:54.521739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Date Authorized</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:700;line-height:100%;">Authorized Shares Added</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2010</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,238,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 7, 2011</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">714,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2012</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">823,649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2013</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">839,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2014</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,062,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,119,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,152,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,484,382&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,490,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The increases in the authorized shares of common stock under the 2009 Plan in 2010 and 2011 were approved by the Company&#8217;s stockholders. The increases in the authorized shares of common stock under the 2009 Plan in 2012 through 2019 were made pursuant to an &#8220;evergreen provision,&#8221; in accordance with which, on January 1 of each year, from 2013 to (and including) 2019, a number of shares of common stock in an amount equal to 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </span></div><div style="text-indent:24pt;text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On May 9, 2019, the Company&#8217;s stockholders approved an amendment to the 2009 Plan which, among other modifications, included decreasing the automatic annual &#8220;evergreen provision&#8221; from 4% to 3%, in accordance with which, on January 1 of each year, from 2020 to (and including) 2029, a number of shares of common stock in an amount equal to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or such lesser amount of shares (or no shares) approved by the Company's Board of Directors, was added or will be added to the shares reserved under the 2009 Plan. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Non-Employee Directors' Stock Award Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Company&#8217;s 2010 Non-Employee Directors&#8217; Stock Award Plan (the Directors&#8217; Plan) which became effective on November 10, 2011, 238,095 shares of common stock were reserved for future issuance. On May&#160;9, 2013, an </span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">additional 161,905 shares of common stock were added to the shares reserved for future issuance under the Directors' Plan.  As of September&#160;30, 2019, 268,902 shares remain available for issuance under the Directors' Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2010 Employee Stock Purchase Plan</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Company&#8217;s 2010 Employee Stock Purchase Plan (the 2010 Purchase Plan), which became effective on November 10, 2011, 214,285 shares of common stock were reserved for future issuance. On May&#160;9, 2013, an additional 185,715 shares of common stock were added to the shares reserved for future issuance under the 2010 Purchase Plan. As of September&#160;30, 2019, 29,542 shares remained available for issuance under the 2010 Purchase Plan.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense for the three months ended September&#160;30, 2019 and 2018 was $2.3 million and $4.6 million, respectively. Share-based compensation expense for the nine months ended September&#160;30, 2019 and 2018 was $6.0 million and $13.6 million, respectively.  Share-based compensation expense is allocated between research and development and general and administrative expenses within the condensed consolidated statements of operations. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the total compensation cost related to nonvested option awards not yet recognized was $4.7 million and the weighted-average period over which it is expected to be recognized is 2.7 years.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options and Performance Stock Options</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the stock option activity, including options with market and performance conditions and options granted and forfeited in conjunction with the option exchange program, for the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.409357%;"><tr><td style="width:1.0%;"/><td style="width:39.090909%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.818182%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.636364%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.709091%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.727273%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">of options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">remaining contractual</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">term (years)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,978,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,753,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercised</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options forfeited</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,696,520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options expired</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,318,698)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.93&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Outstanding at end of period</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,716,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Options exercisable at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,165,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.9</span></td></tr></table></div><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company estimates the fair value of each stock option grant on the date of grant using a Black-Scholes option pricing model. For stock option grants issued with a market condition, the Company used a Monte Carlo simulation valuation model to determine the grant date fair value. </span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the range of assumptions used to estimate the fair value of stock options granted, including those options granted with a market condition, during the nine months ended September&#160;30, 2019:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:62.865497%;"><tr><td style="width:1.0%;"/><td style="width:66.139535%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.962791%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.697674%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">1.8% to 2.7%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected dividend yield</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">77.0% to 86.3%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Expected term (in years)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">4 to 7.7</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Weighted-average grant-date fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$1.89</span></div></td></tr></table></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">No options were exercised during the nine months ended September&#160;30, 2019. The fair value of awards vested during the nine months ended September&#160;30, 2019 was $2.7 million. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September&#160;30, 2019, the Company&#8217;s Board of Directors approved and granted 650,000 shares of equity awards to certain executives with either market or performance conditions. The equity awards had a weighted-average grant date fair value per share of $1.24.  The equity awards vest upon the achievement of certain performance conditions. Certain performance conditions relating to the equity awards granted in 2017 were met during the three and nine months ended September&#160;30, 2019 and 79,849 shares vested.  None of the targets for 2019 equity awards have been met.  </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock and Performance Restricted Stock</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Restricted stock is common stock that is subject to restrictions, including risks of forfeiture, determined by the planning committee of the Board of Directors in its sole discretion, for as long as such common stock remains subject to any such restrictions.  A holder of restricted stock has all rights of a stockholder with respect to such stock, including the right to vote and to receive dividends thereon, except as otherwise provided in the award agreement relating to such award.  Restricted stock awards are classified as equity within the consolidated balance sheets.  The fair value of each restricted stock grant is estimated on the date of grant using the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's unvested restricted stock, including restricted stock with performance conditions, at September&#160;30, 2019 and changes during the nine months ended September&#160;30, 2019 are as follows:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.473684%;"><tr><td style="width:1.0%;"/><td style="width:54.235828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.954649%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.140590%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.933787%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number of restricted stock shares</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Weighted average grant date fair value</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">68,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(59,330)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">38.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Forfeited/cancelled</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Unvested at end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34.73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the total remaining unrecognized compensation cost related to restricted stock was approximately $124,963 and is expected to be recognized over a weighted-average period of 0.3 years. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not have a formal policy regarding the source of shares issued upon exercise of stock options or issuance of restricted stock. The Company expects shares issued to be issued from treasury shares or new shares.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Option Exchange Program</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 20, 2019, the Company commenced an option exchange program (Option Exchange) for its officers and employees to exchange eligible stock options to purchase up to an aggregate of 5,849,059 shares of the Company's common stock that had been granted to eligible holders, for a lesser number of new stock options with a lower exercise price. Stock options granted prior to December 31, 2018 with an exercise price equal to or greater than $2.97 and held by eligible holders in continuous service through the termination of the Option Exchange were eligible for exchange in the Option Exchange. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The eligible shares were exercisable for a reduced number of shares based on the following exchange ratios:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"><tr><td style="width:1.0%;"/><td style="width:23.559105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598722%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.559105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.598722%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:45.284345%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price Range per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Outstanding Eligible Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exchange Ratio (Surrendered Stock Options to New Stock Options)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$2.97-$10.99</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,725,812</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">2 to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$11.00-$24.99</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">720,373</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">3 to 1</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">$25.00-And Up</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">468,671</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">4 to 1</span></div></td></tr></table></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Upon the expiration of the Option Exchange on July 31, 2019, 45 eligible employees and 5 eligible directors had tendered an aggregate of 3,914,856 options, representing 67% of the total eligible options, for 1,720,341 new options to purchase shares of common stock (New Awards). Each New Award was granted on July 31, 2019, pursuant to the Company's 2009 Plan, with an exercise price per share of $1.77 per share, the closing price on the grant date of the New Awards.  Each New Award has a maximum term of seven years.  The New Awards will vest in equal annual amounts over either <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjQ5OQ_eda0d1de-291e-4724-9f3d-24d63817ed19">two</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF80OS9mcmFnOmIwMDE1MjQ4OThjYTQwMTk4NjAyN2ZiNWM2NDkxZTg3L3RleHRyZWdpb246YjAwMTUyNDg5OGNhNDAxOTg2MDI3ZmI1YzY0OTFlODdfMzg0ODI5MDcwNjUxMw_1e2e5b28-e0fd-452d-9a2f-63613413e197">three</span> years, depending on whether the tendered eligible option was vested as of the exchange date. </span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As a result of this transaction the Company will recognize additional stock-based compensation expense of $1.0 million over the vesting schedule of the New Awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6796016336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Restricted Stock Activity) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(59,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited / cancelled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares) | shares</a></td>
<td class="nump">68,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares) | shares</a></td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">38.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 34.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6658808672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Net Loss Per Share Computation) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to common stockholders</a></td>
<td class="num">$ (14,548)<span></span>
</td>
<td class="num">$ (10,134)<span></span>
</td>
<td class="num">$ (10,036)<span></span>
</td>
<td class="num">$ (7,403)<span></span>
</td>
<td class="num">$ (17,313)<span></span>
</td>
<td class="num">$ (18,310)<span></span>
</td>
<td class="num">$ (34,718)<span></span>
</td>
<td class="num">$ (43,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average shares (in shares)</a></td>
<td class="nump">37,308,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,214,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,286,930<span></span>
</td>
<td class="nump">37,178,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797855696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time, claims are asserted against the Company arising in the ordinary course of business. In the opinion of management, liabilities, if any, arising from existing claims are not expected to have a material effect on the Company's earnings, financial position, or liquidity.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On or about May 12, 2016, Trevor Abramson filed a putative securities class action lawsuit in the United States District Court for the Southern District of New York (the Court), captioned Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545 (the Securities Action).  Subsequently, the Court appointed Michael and Kelly Nguyen as lead plaintiffs and approved their selection of Kahn, Swick &amp; Foti, LLC as lead counsel in the Securities Action.  On October 31, 2016, the lead plaintiffs filed an amended complaint asserting claims under the federal securities laws against the Company, the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., and the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, (collectively, the Defendants).  The amended complaint alleges the Defendants made material false and/or misleading statements that caused losses to the Company&#8217;s investors.  The Defendants filed a motion to dismiss the amended complaint on July 14, 2017.  On March 29, 2018, the Court dismissed the amended complaint for failure to state a claim, without prejudice, and gave the lead plaintiffs until May 4, 2018 to file any amended complaint attempting to remedy the defects in their claims.  On May 4, 2018, the lead plaintiffs filed a second amended complaint asserting claims under the federal securities laws against </span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">the Defendants. Like the first amended complaint, the second amended complaint alleges that the Defendants made material false and/or misleading statements or omissions relating to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L that caused losses to the Company&#8217;s investors.  The lead plaintiffs do not quantify any alleged damages in the second amended complaint but, in addition to attorneys&#8217; fees and costs, they sought to recover damages on behalf of themselves and other persons who purchased or otherwise acquired the Company&#8217;s stock during the putative class period of September 17, 2013 through May 9, 2016, inclusive, at allegedly inflated prices and purportedly suffered financial harm as a result. The Defendants filed a motion to dismiss the second amended complaint on July 31, 2018.   On February 13, 2019, the Court dismissed the second amended complaint for failure to state a claim, with prejudice, and closed the case.  On March 14, 2019, lead plaintiffs filed a notice of appeal. The briefing on lead plaintiffs' appeal was completed in early July 2019 and oral argument before the Second Circuit Court of Appeals was held on October 21, 2019. The Company intends to continue defending the Securities Action vigorously.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">On or about April 26, 2017, Ronald Morrow filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Southern District of New York, or the Court, against the Company&#8217;s Chief Executive Officer Charles J. Link, Jr., the Company&#8217;s Chief Medical Officer and President Nicholas Vahanian, and Company directors Thomas A. Raffin, Joseph Saluri, Ernest J. Talarico, III, Paul R. Edick, Paolo Pucci, and Lota S. Zoth (collectively, the Morrow Defendants), captioned Morrow v. Link., et al., Case 1:17-cv-03039 (the Morrow Action).  The complaint alleges that the Morrow Defendants caused the Company to issue false statements in its 2016 proxy statement regarding risk management and compensation matters in violation of federal securities law.  The complaint also asserts state law claims against the Morrow Defendants for breaches of fiduciary duties, unjust enrichment, abuse of control, insider trading, gross mismanagement, and corporate waste, alleging that the Morrow Defendants made material misstatements or omissions related to the Phase 2 and 3 trials and efficacy of the product candidate algenpantucel-L, awarded themselves excessive compensation, engaged in illegal insider trading, and grossly mismanaged the Company.  The plaintiff does not quantify any alleged damages in the complaint but seeks restitution for damages to the Company, attorneys&#8217; fees, costs, and expenses, as well as an order directing that proposals for strengthening board oversight be put to a vote of the Company&#8217;s shareholders.  The language for such proposals is not specified in the complaint.  The plaintiff also contemporaneously filed a statement of relatedness, informing the Court that the Morrow Action is related to Abramson v. NewLink Genetics Corp., et al., Case 1:16-cv-3545.  On May 19, 2017, the plaintiff dismissed the Morrow Action without prejudice.  Also on May 19, 2017, plaintiffs&#8217; counsel in the Morrow Action filed a new shareholder derivative complaint that is substantively identical to the Morrow Action, except that the plaintiff is Rickey Ely.  The latter action is captioned Ely v. Link, et al., Case 17-cv-3799, or the Ely Action.  By agreement of the parties and order dated June 26, 2017, the Court temporarily stayed the Ely Action until the Securities Action is dismissed or otherwise finally resolved.  Under the terms of the stay, the plaintiff in the Ely Action has until March 15, 2019 (30 days after dismissal of the Securities Action with prejudice) to file an amended derivative complaint or rest upon the current derivative complaint.  By further agreement of the parties, dated March 15, 2019, the Ely Action will continue to be stayed pending the outcome of the appeal in the Securities Action. If the Securities Action continues to be dismissed in its entirety following its appeal plaintiff in the Ely Action has agreed to withdraw or dismiss the action, with prejudice.  The Company disputes the claims in the Ely Action and intends to defend against them vigorously.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632661568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has certain facility leases with non-cancellable terms ranging between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTAx_fdab0ed5-414f-4e14-a6e1-1ee3417f10c7">one</span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhNzcxOWQ4NzYwNDQ2MjJiYzY2YWViNGVhOTEwMzE4L3NlYzpkYTc3MTlkODc2MDQ0NjIyYmM2NmFlYjRlYTkxMDMxOF81NS9mcmFnOjBiMzA3MjU2NTg1ZjRjMGU4ODdkNWM5NDY2NjUwMTAyL3RleHRyZWdpb246MGIzMDcyNTY1ODVmNGMwZTg4N2Q1Yzk0NjY2NTAxMDJfMTA4_699cda23-c0df-477d-afe3-0c19057a25a6">three</span> years, with certain renewal options. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company records lease liabilities based on the present value of lease payments over the lease term using an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. To compute the present value of the lease liability, the Company used a weighted-average discount rate of 5%. Certain lease agreements include renewal options that are under the Company's control. The Company includes optional renewal periods in the lease term only when it is reasonably certain that the Company will exercise its option. Prior to September&#160;30, 2019, the Company had asserted it would renew the lease terms through expiry of the lease renewal option periods. At September&#160;30, 2019, as part of the Company's efforts to reduce costs and conserve resources, the Company concluded it would not be seeking renewal of the leased facilities in Ames, Iowa and upon termination of the lease agreements, it would identify a new space for the Company. As a result of this decision, the Company remeasured the right-of-use assets and lease liabilities using the shorter term. The weighted-average remaining lease term as of September&#160;30, 2019 is 1.0 year. </span></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company does not separate lease components from non-lease components. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The Company's lease agreements do not contain any residual value guarantees or restrictive covenants.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Future minimum lease payments under the non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of September&#160;30, 2019 are as follows (in thousands), excluding option renewals: </span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"/><td style="width:61.112392%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.887608%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Less:  Imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Unamortized lease incentive    </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,929&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior lease standard as of December 31, 2018 (in thousands), including option renewals:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:50.730994%;"><tr><td style="width:1.0%;"/><td style="width:61.112392%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.887608%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">For the Year Ended December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,004&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">906&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6603541744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Range of Assumptions Used) (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate, minimum (percent)</a></td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate, maximum (percent)</a></td>
<td class="nump">86.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793911808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,991<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax', window );">Income tax receivable</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent', window );">Current income tax receivable</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent', window );">Noncurrent income tax receivable</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812789536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,718)<span></span>
</td>
<td class="num">$ (43,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">5,976<span></span>
</td>
<td class="nump">13,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of fixed assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability', window );">Amortization of right-of-use asset and change in operating lease liability</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">9,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,576<span></span>
</td>
<td class="num">(11,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes receivable</a></td>
<td class="nump">334<span></span>
</td>
<td class="num">(7,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,176)<span></span>
</td>
<td class="num">(36,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on sale of equipment</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Principal payments on notes payable</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(22,211)<span></span>
</td>
<td class="num">(36,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">120,738<span></span>
</td>
<td class="nump">158,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">98,527<span></span>
</td>
<td class="nump">122,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash refunds received for taxes, net</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right Of Use Asset, Amortization And Change in Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813196288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 98,527<span></span>
</td>
<td class="nump">$ 120,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,654<span></span>
</td>
<td class="nump">127,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,889<span></span>
</td>
<td class="nump">3,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_OperatingLeaseRightofUseAssetNoncurrent', window );">Right-of-use asset</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Income tax receivable</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">106,654<span></span>
</td>
<td class="nump">130,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,125<span></span>
</td>
<td class="nump">8,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,040<span></span>
</td>
<td class="nump">8,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_DeferredGovernmentGrantsObligationsNoncurrent', window );">Royalty obligation payable to Iowa Economic Development Authority</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">906<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">6,217<span></span>
</td>
<td class="nump">6,949<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,257<span></span>
</td>
<td class="nump">15,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Blank check preferred stock, $0.01 par value: Authorized shares &#8212; 5,000,000 at September&#160;30, 2019 and December&#160;31, 2018; issued and outstanding shares &#8212; 0 at September&#160;30, 2019 and December&#160;31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value: Authorized shares &#8212; 75,000,000 at September&#160;30, 2019 and December&#160;31, 2018; issued 37,426,844 and 37,343,547 at September&#160;30, 2019 and December&#160;31, 2018, respectively; and outstanding 37,314,076 and 37,251,220 at September&#160;30, 2019 and December&#160;31, 2018, respectively</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">413,205<span></span>
</td>
<td class="nump">407,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost: 112,768 and 92,327 shares at September&#160;30, 2019 and December&#160;31, 2018, respectively</a></td>
<td class="num">(1,451)<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(325,730)<span></span>
</td>
<td class="num">(291,012)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">86,397<span></span>
</td>
<td class="nump">115,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 106,654<span></span>
</td>
<td class="nump">$ 130,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_DeferredGovernmentGrantsObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_DeferredGovernmentGrantsObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_OperatingLeaseRightofUseAssetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_OperatingLeaseRightofUseAssetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MDAN0&AM::C"HKJ%LV(#T83Q'&;N5*#/_1)W98**;G$KS((I6N&0O.@SBODD
MSF#LFYQJL^%(#Z=()0!G,-5-3L'9<&*G5@@#V^2DOP8 FZ[!:D(4.X.9;G(2
M8 -@W2UCXN'-8EK;G!38(G *05U:3^MBES X+0"GI0'$@A18>"%I#=/FI,#
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M&'@$@&?X*D 0>"1V1$CG@)?XA@L#C\!FT7 &D]P**HJ-YE\F2)?F)O:,F<8
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M#0]L=A34/IIO@VW'-1L=C]WT@MC\C(O?4$L#!!0    ( .2"9D_O02I5L@$
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M\4TXVVG,)L-C/_\@MGSC\B=02P,$%     @ Y()F3SV33J>U 0  T@,  !D
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M['^#Z,!+2>[\"'7^@ZV&@L:%XQM_-O.8S8;#8?E!;/W&Y4]02P,$%     @
MY()F3QW5BINT 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M?5-A;]P@#/TKB!]0+EQNJTY)I%ZG:956Z=1IVV<N<1)4""F02_OO9TB:95NT
M+X"-W_.S,=EH[+-K 3QYU:IS.6V][X^,N;(%+=R-Z:'#F]I8+3R:MF&NMR"J
M"-**\=WN ]-"=K3(HN]LB\P,7LD.SI:X06MAWTZ@S)C3A+X[GF33^N!@1=:+
M!KZ!_]Z?+5IL8:FDALY)TQ$+=4[ODN,I#?$QX(>$T:W.)%1R,>8Y& ]53G=!
M$"@H?6 0N%WA'I0*1"CC9>:D2\H 7)_?V3_'VK&6BW!P;]1/6?DVI[>45%"+
M0?DG,WZ!N9X#)7/Q7^$*"L.#$LQ1&N7B2LK!>:-G%I2BQ>NTRR[NXW1SX#-L
M&\!G %\ MS$/FQ)%Y9^$%T5FS4CLU/M>A"=.CAQ[4P9G;$6\0_$.O=>")_N,
M70/1''.:8O@J)EDB&+(O*?A6BA/_!\ZWX?M-A?L(W_^A,-TF2#<)TDB0_K?$
MK9C#7TG8JJ<:;!.GR9'2#%V<Y)5W&=B[^(CL=_@T[8_"-K)SY&(\OFSL?VV,
M!Y2RN\$1:O&#+8:"VH?C1SS;:<PFPYM^_D%L^<;%+U!+ P04    " #D@F9/
MLW?S"@D"   T!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6QU5=N.
MFS 0_17$!ZS!D*L :;.KJI5:*=JJ[;-#)H#6QM1VPO;O:QN64G;R$GO&9\Z9
M\<1#UDOUJFL $[P)WNH\K(WI]H3HL@;!](/LH+4G%ZD$,]94%=&= G;V08(3
M&D5K(EC3AD7F?4=59/)J>-/"407Z*@13?P[ 99^'<?CN>&FJVC@'*;*.5? =
MS(_NJ*Q%)I9S(Z#5C6P#!9<\?(SWASAR 1[QLX%>S_:!*^4DY:LSOISS,'(9
M 8?2. IFEQL\ >>.R>;Q>R0-)TT7.-^_LW_RQ=MB3DS#D^2_FK.I\W ;!F>X
ML"LW+[+_#&-!JS 8J_\*-^ 6[C*Q&J7DVO\&Y54;*486FXI@;\/:M'[MAY,T
M&</P #H&T"E@ZW7((.0S?V:&%9F2?:"&R^^8ZW&\I_9N2N?T5^'/;/+:>F\%
MC=<9N3FB$7,8,'2&B2<$L>R3!,4D#O1#.,7#$S3#Q(<G<_7='?T4)4@]0?I?
MB9M%B1AFBXNL4)$50K!;B" 8&N$B:U1DC1#$"Q$,<^>^-ZC(!B%(%B(8)L5%
MMJC(%B%8+40PS!H7V:$B.X1@V7@,<Z?Q=OB@+RA"*):MQT#)LO=D]F@%J,J/
M*QV4\MKZ63GS3B/QD?I'_P\^S--O3%5-JX.3-'9T^ =^D=* S25ZL/_#VH[P
MR>!P,6Z[L7LUS+'!,+(;9S29/A3%7U!+ P04    " #D@F9/*,&:3^X!  !F
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6QU5&%OFS 0_2O(/Z!.
M#$EH!$A-IVF3-BGJM.ZS Y> :F-F.Z'[][,-I8S>OF#?^=U[=S9W6:_TBZD!
M;/0J16MR4EO;[2DU90V2FSO50>M.SDI+;IVI+]1T&G@5@J2@;+7:4LF;EA19
M\!UUD:FK%4T+1QV9JY1<_SF 4'U.UN3-\=1<:NL=M,@Z?H$?8']V1^TL.K%4
MC836-*J--)QS\K#>'U*/#X#G!GHSVT>^DI-2+][X6N5DY1," :7U#-PM-W@$
M(3R12^/WR$DF21\XW[^Q?PZUNUI.W,"C$K^:RM8Y24E4P9E?A7U2_1<8Z]F0
M:"S^&]Q .+C/Q&F42ICPC<JKL4J.+"X5R5^'M6G#V@\GVW@,PP/8&,"F@#3H
MT$$H9/Z)6UYD6O61'NZ^X_Z)UWOF[J;TSG 5X<PE;YSW5K!XG=&;)QHQAP'#
M9IAW!'7LDP3#) [L0SC#PV,TPSB$QW/U^WN<($$)DD"0_%,B6Y2(86)<9(.*
M;!""9"&"83:XR!85V2($VX4(AMGA(CM49(<0I L1#/.?-TE1D?0C0;):B&"8
MY8]'9_^Y!'T)'6ZB4EW;,%UFWFF(/+#0)^_P80)]Y_K2M"8Z*>NZ+?3$62D+
M+I75G7NZV@V]R1!PMGZ[<WL]M/Y@6-6-4XU.H[7X"U!+ P04    " #D@F9/
MZ_W@(,,!   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6QU5.^.
MG" 0?Q7" QPNJ]O+1DUNK[E<DS;97-/V,ZNCD@.Q@.OU[0OH6;NE7P2&WY\9
M8,PGI5]-!V#1FQ2]*7!G[7 DQ%0=2&;NU "]VVF4ELRZI6Z)&32P.I"D(#1)
M#D0RWN,R#[&S+G,U6L%[.&MD1BF9_G4"H:8"[_![X(6WG?4!4N8#:^$KV&_#
M6;L5655J+J$W7/5(0U/@A]WQE'E\ 'SG,)G-'/E*+DJ]^L6GNL")3P@$5-8K
M,#=<X1&$\$(NC9^+)EXM/7$[?U=_"K6[6B[,P*,2/WAMNP+?8U1#PT9A7]3T
M#$L]&49+\9_A"L+!?2;.HU+"A"^J1F.57%1<*I*]S2/OPSC-.X=TH<4)="'0
ME7 ??,AL%#+_R"PK<ZTFI.>S'YB_XMV1NK.I?# <1=ASR1L7O98TI3FY>J$%
M<YHQ=(/9K0CBU%<+&K,XT7_H-$[?1S/<!_I^2T_^(Y!&!=(@D/Y5XOZFQ!@F
MC9MD49,L(I#=F,0PAQL3LKDX";H-3]:@2HU]:)=-=.V*!QHN_@]\;JDO3+>\
M-^BBK'L^X9(;I2RX5)([ETOGNGA="&BLGWYP<SV_Y7EAU;"T*5G_%>5O4$L#
M!!0    ( .2"9D]:$!90MP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;&U3VV[<(!#]%<0'!"_K--N5;2F;J&JE5EJE:OK,VF,;!3PNX'7Z
M]P7LN&[J%V"&<\Y<&+(1S8MM 1QYU:JS.6V=ZX^,V;(%+>P-]M#YFQJ-%LZ;
MIF&V-R"J2-**\23YP+20'2VRZ#N;(L/!*=G!V1 [:"W,[Q,H''.ZHV^.)]FT
M+CA8D?6B@>_@?O1GXRVVJ%120V<E=L1 G=/[W?&4!GP$/$L8[>I,0B47Q)=@
M?*ERFH2$0$'I@H+PVQ4>0*D@Y-/X-6O2)60@KL]OZI]B[;Z6B[#P@.JGK%R;
MTP,E%=1B4.X)Q\\PUW-+R5S\5[B"\O"0B8]1HK)Q)>5@'>I9Q:>BQ>NTRR[N
MXW23IC-MF\!G E\(AQB'38%BYH_"B2(S.!(S];X7X8EW1^Y[4P9G;$6\\\E;
M[[T6/+W+V#4(S9C3A.$KS&Y!,*^^A.!;(4[\/SK?IN\W,]Q'^GY-3P[; NFF
M0!H%TG]*/+PK<0OS\5T0MNJI!M/$:;*DQ*&+D[SR+@-[S^.;_(5/T_Y-F$9V
MEES0^9>-_:\1'?A4DAL_0JW_8(NAH';A>.?/9AJSR7#8SS^(+=^X^ -02P,$
M%     @ Y()F3X %DY>V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL=5/;;MP@$/T5Q <$FW72U<JVE$T5)5(KK5*U>6;ML8W"Q0&\3O^^
M@!W'3=T78(8Y9\X,0SYJ\V([ (?>I%"VP)US_8$06W4@F;W2/2A_TV@CF?.F
M:8GM#; Z@J0@-$ENB&1<X3*/OI,I<STXP16<#+*#E,S\/H+08X%3_.YXXFWG
M@H.4><]:^ 'N9W\RWB(+2\TE*,NU0@:: M^FAV,6XF/ +PZC79U1J.2L]4LP
M'NL")T$0"*A<8&!^N\ ="!&(O(S7F1,O*0-P?7YGOX^U^UK.S,*=%L^\=EV!
M]QC5T+!!N"<]/L!<SS5&<_'?X +"AP<E/D>EA8TKJ@;KM)Q9O!3)WJ:=J[B/
MTTVVGV'; #H#Z +8QSQD2A25?V6.E;G1(S)3[WL6GC@]4-^;*CAC*^*=%V^]
M]U+2ZR0GET TQQRG&+J*29<(XMF7%'0KQ9'^ Z?;\-VFPEV$[];P]#_YLTV"
M+!)D?Y68?BIQ*^:S2K+JJ033QFFRJ-*#BI.\\BX#>TOCFWR$3]/^G9F6*XO.
MVOF7C?UOM';@I217?H0Z_\$60T#CPO&+/YMIS";#Z7[^063YQN4?4$L#!!0
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M)7@R7DK3.<<)AY.VP]2,9=\^^HD6[= :R=B?\]]02P,$%     @ Y()F3UI
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M\Q;O,FECO)1YW7].7M[JIBR4ES:5(OLS?&]W_?=!^3^:P09,&;"3 1\WX,J
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MO# ?3IIRK_X,\$__2"S^ E!+ P04    " #D@F9/4ZBVF"(#  #&#0  &0
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MJ#FVK!+F-]B>A&2UM:)<J<F?[ELVYGNQ]M]E?@&T M@+U-R?"9 5H \!_E2
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MG4P5'9,,YD$9BO,$.N$]^$ (,$K=;>H%\W3J;I.-#P19GF#H#S+U!IE>!0F
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M6!*L"8)N,L2'"0*0(- $I$> K)I"&+NJ$":  R%@(&1 @$++R;+%A!I3:$Q
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M,'GRB#JT%8DQT$/B-WA2\#8P"K&91 T@I# 5!.06/J)_/&;-&DX9[E5EN?4
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M30H293;)CB]. G_"B> ]398 GMJ810KZ\DX1;+JB^E)OE>,%?\;1U#!(H7B
MT+F(H(I;V7L5,7BA1)KR-JWNX7(137[3;LHZN@',VB3(/_R[YYP9,+,=\&T@
M(3+(;7L78[#> - P>ER7L-:3\K$0"DMD>2>D5</\R'Q['--F[568X8#F/P $
M8,1UFB^#_"@ZHD]AF)2D 92?  X)<(Q[H'BD5A##14L&+$-FQI\^I*7%I9EQ
MR&/]+8R[;2L4".G:/ZZSQ3I&=08O.+&P9@TP!ED!=OL/.J"2MLH$"<4W9-$
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M75%0%"S"3!J=IX?/M,['MT(/@-<3G0MY*MX%K>_1IPSG-9FXMGFRZ&A,8BE
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MZK,5.XK^I8+B3ZCB/6*SKOH>"D/D)>!KS@Q)[02D*GM\H!F2#M:'P23\&4
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M^'JL[W;9UW8^MO,0I%<>WW9*9^-@*=NEJ]NJLR/5\FO7MA_>R3"FK =*8H@
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M<0-0V"1?LZC"^9<TKP$<+!P;&)Y@V09DEI:%@^N&<44"+K3/-'F9DA.:HU)
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M!W9B@HIC-Y&2"T')%&BO 621+%X=BY)H%5,)E"IA&X>2%AI^/E"J^U\'Q-'
M"'%W?['NZ8!?F+BT)66ZHVQGXC-LZDM5SHS")VEM[99%/27<&IG:BKBV4M=M
MP-CCZ-J);'M3TKY*6Q,G3&<KG0Q"JS/X5]MD\2GAT,8M!C:1H00%ZV6&B/F5
M$AVV&&W8N*2*TOU*JLV!:69]RZ=.ZI2)S24IV,C*/AG)).<2$?HDI!*"E'1<
M))8.R.?&QD$V)G;U22YS09LDE$)\HT7!'<<Z$>L,"#W9"4N5)>[M&[?;2"4
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MM3D4I&7ZSI;H@@F>[,]6>+0<9ZU'B@1/]A?(:<M7+N'TX$I_ %!+ P04
M" #E@F9/19Q<(&4#   '&0  #P   'AL+W=O<FMB;V]K+GAM;,692V_B,!"
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MFN'Z< B'J;\1YFHIOOT!4$L#!!0    ( .6"9D^F'')?GP$  ),7   3
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .2"9D^"[)J+[0   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .2"
M9D^97)PC$ 8  )PG   3              "  ;4"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ Y()F3Z8ED@PL P  -P\  !@
M ( !]@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .2"
M9D]AB[;>' 0  /H3   8              "  5@,  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #D@F9/.JW=,U\"   _"   &
M        @ &J$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ Y()F3\&GF,L9!   *1,  !@              ( !/Q,  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .2"9D_R8E/+P <  #,P   8
M              "  8X7  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #D@F9/+N=(S1X$  !X$P  &               @ &$'P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Y()F3S<&39NQ 0
MT@,  !@              ( !V",  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( .2"9D\W\ VVL $  -(#   8              "  ;\E
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #D@F9/[T$J
M5;(!  #2 P  &               @ &E)P  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ Y()F3SV33J>U 0  T@,  !D
M ( !C2D  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #D
M@F9/TX^0[[0!  #2 P  &0              @ %Y*P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .2"9D^!1J[(M@$  -(#   9
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M970Q-BYX;6Q02P$"% ,4    " #D@F9/'=6*F[0!  #2 P  &0
M    @ '[-@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M .2"9D^S=_,*"0(  #0&   9              "  >8X  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ Y()F3RC!FD_N 0  9@4  !D
M             ( !)CL  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #D@F9/Z_W@(,,!   W!   &0              @ %+/0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .2"9D]:$!90MP$
M -(#   9              "  44_  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ Y()F3X %DY>V 0  T@,  !D              ( !
M,T$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #D@F9/
M(&+BV,<!  "G!   &0              @ $@0P  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( .2"9D]ON+IDL (  '@*   9
M      "  1Y%  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ Y()F3\L!XW7( 0  5P0  !D              ( !!4@  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #D@F9/IDX[>8D"   B"0
M&0              @ $$2@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( .2"9D\A%IR3S@0  /@9   9              "  <1,  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ Y()F3QH%4\1B
M @  "0@  !D              ( !R5$  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #D@F9/:RB4L H#  " #   &0
M@ %B5   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .2"
M9D_SP#[20P(  *L'   9              "  :-7  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ Y()F3UI W/QN @  /0@  !D
M         ( !'5H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #D@F9/J$7O1'D$  "=&   &0              @ '"7   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .2"9D]3J+:8(@,  ,8-
M   9              "  7)A  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ Y()F3US;7+Y; @  K <  !D              ( !RV0
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #D@F9//*5T
MRK4"  !'"0  &0              @ %=9P  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( .2"9D\%2<ZY%P(  +H%   9
M  "  4EJ  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MY()F3V[E2_KN @  V0P  !D              ( !EVP  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #D@F9/T+8N6.E"   ;"@$ %
M            @ &\;P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M" #E@F9/G.W-,#$"  !]"0  #0              @ '7L@  >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( .6"9D]%G%P@90,   <9   /              "
M 3.U  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #E@F9/V=><1),!   D
M%P  &@              @ '%N   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #E@F9/IAQR7Y\!  "3%P  $P              @ &0
LN@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +@ N '0,  !@O      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795878288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government contract receivable</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nlnk_GovernmentContractAccruedSubcontractorFees', window );">Accrued expenses for subcontractor fees</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nlnk_GovernmentContractAccruedSubcontractorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nlnk_GovernmentContractAccruedSubcontractorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nlnk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118261985&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797879216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><div style="text-indent:22pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data):</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"/><td style="width:42.709389%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545156%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545156%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.141282%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.588376%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.667660%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Loss attributable to common stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(14,548)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,403)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(34,718)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(43,026)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,308,523&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,214,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,286,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37,178,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Basic and diluted loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.20)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.93)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.16)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803818928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Equity Incentive Plan (Stock Option Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,720,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,978,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,753,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,696,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,318,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,716,086<span></span>
</td>
<td class="nump">7,978,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price at beginning of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="nump">$ 11.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,165,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual term, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
